Prior Authorization Approval Criteria

Effective Date: 07/01/2023
MedImpact

Standard Commercial
Prior Authorization Guidelines
1. **Formulary Agents**
   Drug products that are listed in the Formulary as Prior Authorization (PA) require evaluation, per MedImpact Pharmacy and Therapeutics Committee guidelines, when the member presents a prescription to a network pharmacy. Each request will be reviewed on individual patient need. If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

2. **Non-Formulary Agents**
   Any product not found in the Formulary listing, or any Formulary updates published by MedImpact, shall be considered a Non-Formulary drug. Coverage for non-formulary agents may be applied for in advance. When a member gives a prescription order for a non-formulary drug to a pharmacist, the pharmacist will evaluate the patient’s drug history and contact the physician to determine if there is a legitimate medical need for a non-formulary drug. Each request will be reviewed on individual patient need. The following basic criteria are used:
   a. The use of Formulary Drug Products is contraindicated in the patient.
   b. The patient has failed an appropriate trial of Formulary or related agents.
   c. The choices available in the Drug Formulary are not suited for the present patient care need, and the drug selected is required for patient safety.
   d. The use of a Formulary drug may provoke an underlying condition, which would be detrimental to patient care.
   If the request does not meet the criteria established by the P & T Committee, the request will not be approved and alternative therapy will be recommended.

3. **Obtaining Coverage**
   Coverage may be obtained by:
   a. Faxing a completed **Prior Authorization Request** to DHMP at (303) 602-2081.
   b. Contacting DHMP Pharmacy Department at (303) 602-2070 and providing all necessary information requested.
   Non-approved requests may be appealed. The prescriber must provide information to support the appeal on the basis of medical necessity.
ABALOPARATIDE

GUIDELINES FOR USE

Our guideline named ABALOPARATIDE (Tymlos) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. Postmenopausal osteoporosis (a type of bone condition)
   2. Increase bone density in a male patient with osteoporosis (a type of bone condition)

B. If the request is for postmenopausal osteoporosis, approval also requires:
   1. You have NOT received a total of 24 months or more of treatment with any parathyroid hormone therapy (such as Tymlos [abaloparatide], Forteo [teriparatide])
   2. You meet ONE of the following (a, b, or c):
      a. You have high risk for fractures defined as ONE of the following:
         i. History of osteoporotic fracture(s) (broken bones) due to trauma (injury) or fragility (weakness)
         ii. Two or more risk factors for fracture such as history of multiple recent low trauma fractures, bone mineral density T-score (a type of lab test) less than or equal to -2.5, corticosteroid use, or use of GnRH (gonadotropin-releasing hormone) analogs such as Synarel (nafarelin)
         iii. No prior treatment for osteoporosis AND FRAX (Fracture Risk Assessment Tool) score greater than or equal to 20 percent for any major fracture OR greater than or equal to 3 percent for hip fracture
      b. You are unable to use oral therapy due to upper gastrointestinal (stomach and intestine) problems, you cannot tolerate oral medication, you have lower gastrointestinal problems (unable to absorb oral medications), you have trouble remembering to take oral medications or cannot plan to use an oral bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate]) with other oral medications in your daily routine
      c. You had a trial of, intolerance (side effect) to, or a contraindication (harmful for) to a bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate])

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
ABALOPARATIDE

GUIDELINES FOR USE (CONTINUED)

C. If the request is to increase bone density in a male patient with osteoporosis, approval also requires:
   1. You have NOT received a total of 24 months or more of treatment with any parathyroid hormone therapy (such as Tymlos [abaloparatide], Forteo [teriparatide])
   2. You meet ONE of the following (a or b):
      a. You have high risk for fractures defined as ONE of the following:
         i. History of osteoporotic fracture (such as fragility [weakness] fracture, low trauma [injury] fracture)
         ii. Multiple risk factors for fracture (such as history of multiple recent low trauma fractures, bone mineral density T-score (a type of lab test) less than or equal to -2.5, corticosteroid use, use of GnRH [gonadotropin-releasing hormone] analogs such as Synarel [nafarelin])
      b. You have failed or are intolerant (side effect) to other available osteoporosis therapy (such as Forteo [teriparatide], Prolia [denosumab], Fosamax [alendronate], Actonel [risedronate])

Commercial Effective: 04/17/23
ABATACEPT - SQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABATACEPT - SQ</td>
<td>ORENCIA - SQ</td>
</tr>
<tr>
<td></td>
<td>ORENCIA</td>
</tr>
<tr>
<td></td>
<td>CLICKJECT - SQ</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ABATACEPT - SQ (Orencia - SQ) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   3. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
ABATACEPT - SQ

INITIAL CRITERIA (CONTINUED)

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Actemra (tocilizumab), Xeljanz IR (tofacitinib immediate release)

D. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named ABATACEPT - SQ (Orencia - SQ) requires the following rule(s) be met for renewal:

   A. You have ONE of the following diagnoses:
      1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
      2. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
      3. Psoriatic arthritis (PsA: a type of skin and joint condition)

(Renewal criteria continued on next page)
ABATACEPT - SQ

INITIAL CRITERIA (CONTINUED)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such Humira [adalimumab], Enbrel [etanercept]) AND the physician has indicated the patient cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Actemra (tocilizumab), Xeljanz IR (tofacitinib immediate release)

D. If you have psoriatic arthritis, approval also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful) to TWO of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Commercial Effective: 07/01/23
Guidelines for Use

Our guideline named **ABEMACICLIB (Verzenio)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Early breast cancer (initial stage of breast cancer)
   2. Advanced or metastatic breast cancer (cancer that has progressed or has spread to other parts of the body)

B. **If you have early breast cancer, approval also requires:**
   1. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive (a type of protein)
   2. Verzenio will be used in combination with endocrine therapy (tamoxifen or an aromatase inhibitor such as letrozole, anastrozole, exemestane) for adjuvant (add-on) treatment
   3. You are at high risk of recurrence (disease returning)

C. **If you have advanced or metastatic breast cancer, approval also requires:**
   1. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)
   2. You meet ONE of the following:
      a. Verzenio will be used in combination with an aromatase inhibitor (such as letrozole, anastrozole, exemestane) as initial endocrine-based therapy
      b. Verzenio will be used in combination with fulvestrant, and you have had disease progression following endocrine therapy (such as letrozole, anastrozole, tamoxifen)
      c. Verzenio will be used as monotherapy (one drug), and you have had disease progression following endocrine therapy (such as letrozole, anastrozole, tamoxifen) and prior chemotherapy (drugs used to treat cancer) in the metastatic setting (cancer that has spread to other parts of the body)

Commercial Effective: 07/01/23
ABIRATERONE

GUIDELINES FOR USE

Our guideline named **ABIRATERONE (Zytiga)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)
   2. Metastatic high-risk castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and may respond to testosterone lowering treatment)

B. The requested medication will be used in combination with prednisone

C. You meet ONE of the following:
   1. You had a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin, degarelix)

Commercial Effective: 04/10/23
ABIRATERONE SUBMICRONIZED

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABIRATERONE ACET, SUBMICRONIZED</td>
<td>YONSA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **ABIRATERONE SUBMICRONIZED (Yonsa)** requires the following rule(s) be met for approval:

A. You have metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)

B. The requested medication will be used in combination with methylprednisolone

C. You have tried or have a contraindication to (harmful for) Zytiga (abiraterone acetate)

D. You meet ONE of the following:
   1. You had a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin, degarelix)

Commercial Effective: 04/10/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ABROCITINIB (Cibinqo) requires the following rule(s) be met for approval:

A. You have refractory, moderate to severe atopic dermatitis (a type of skin condition)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
D. You have atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)
E. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
F. You had a trial of or contraindication (harmful for) to TWO of the following:
   1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate)
   2. Topical calcineurin inhibitor (e.g., tacrolimus, pimecrolimus)
   3. Topical PDE-4 inhibitor (Phosphodiesterase-4 Inhibitors such as crisaborole)
   4. Topical JAK inhibitor (Janus kinase inhibitor such as ruxolitinib)
   5. Phototherapy (light therapy)
G. You had a trial of or contraindication (harmful for) to ONE preferred medication: Dupixent (dupilumab), Rinvoq (upadacitinib)
H. You will NOT use Cibinqo concurrently (at the same time) with other systemic biologics (such as Adbry [tralokinumab-ldrm], Dupixent [dupilumab]) or any JAK inhibitors (Janus kinase inhibitor such as Rinvoq [upadacitinib], topical Opzelura [ruxolitinib]) for the treatment of atopic dermatitis

CONTINUED ON NEXT PAGE
ABROCITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named ABROCITINIB (Cibinqo) requires the following rule(s) be met for renewal:
A. You have refractory, moderate to severe atopic dermatitis (a type of skin condition)
B. You have shown improvement while on therapy
C. You had a trial of or contraindication (harmful for) to ONE preferred medication: Dupixent (dupilumab), Rinvoq (upadacitinib)
D. You will NOT use Cibinqo concurrently (at the same time) with other systemic biologics (such as Adbry [tralokinumab-ladm], Dupixent [dupilumab]) or any JAK inhibitors (Janus kinase inhibitor such as Rinvoq [upadacitinib], topical Opzelura [ruxolitinib]) for the treatment of atopic dermatitis

Commercial Effective: 07/01/23
ACALABRUTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACALABRUTINIB</td>
<td>CALQUENCE</td>
</tr>
<tr>
<td>ACALABRUTINIB MALEATE</td>
<td>CALQUENCE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **ACALABRUTINIB (Calquence)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Mantle cell lymphoma (MCL: a type of blood cancer)
   2. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
   3. Small lymphocytic lymphoma (SLL: a type of blood cancer)

B. If you have mantle cell lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. You have received at least one prior therapy for mantle cell lymphoma
   3. You had a trial of or contraindication (harmful) to the preferred medication: Brukinsa (zanubrutinib)

C. If you have chronic lymphocytic leukemia or small lymphocytic lymphoma, approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of or contraindication (harmful) to ONE of the following preferred medications: Brukinsa (zanubrutinib), Imbruvica (ibrutinib)

Commercial Effective: 07/01/23
ACETAMINOPHEN DAILY LIMIT OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ACETAMINOPHEN DAILY LIMIT OVERRIDE will cause a denied claim for acetaminophen when the total daily dose acetaminophen exceeds 4000mg. The claim will also deny if the requested drug is being used at the same time with other acetaminophen containing product(s) and the combination exceeds 4000mg of acetaminophen per day limit.

**Approval requires the following rule be met:**
A. You will discontinue the other acetaminophen containing drug(s) that cause the daily acetaminophen dose to exceed 4000mg.

Commercial Effective: 05/01/20
ACNE AGE RESTRICTION OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAPALENE</td>
<td>DIFFERIN, PLIXDA</td>
</tr>
<tr>
<td>ADAPALENE/BENZOYL PEROXIDE</td>
<td>EPIDUO, EPIDUO FORTE</td>
</tr>
<tr>
<td>TRETINOIN</td>
<td>ATRALIN, AVITA, RETIN-A, TRETIN-X, ALTRENO</td>
</tr>
<tr>
<td>TRETINOIN MICROSPHERES</td>
<td>RETIN-A MICRO, RETIN-A MICRO PUMP</td>
</tr>
<tr>
<td>TRIFAROTENE</td>
<td>AKLIEF</td>
</tr>
<tr>
<td>TAZAROTENE</td>
<td>FABIOR, ARAZLO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **ACNE AGE RESTRICTION OVERRIDE** requires the following rule(s) be met for approval:

A. You are above [enter age on POS message] years of age
B. The request is for a non-cosmetic (not for appearance) diagnosis.
C. Approval may also require that you have tried preferred agent(s), unless there is a medical reason why you cannot (contra-indication): [NOTE TO REVIEWER: Please provide the list of the preferred medication(s)]

Commercial Effective: 11/01/22
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ADAGRASIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAGRASIB</td>
<td>KRAZATI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ADAGRASIB (Krazati) requires the following rule(s) be met for approval:

A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread from where it started to nearby tissue or lymph nodes or to other parts of the body)
B. You are 18 years of age or older
C. Your cancer has a KRAS G12C mutation (a type of abnormal gene) as determined by a Food and Drug Administration (FDA)-approved test
D. You have received at least one prior systemic therapy

Commercial Effective: 04/01/23
ADALIMUMAB

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ADALIMUMAB (Humira) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
   9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)
INITIAL CRITERIA (CONTINUED)

D. **If you have psoriatic arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

E. **If you have ankylosing spondylitis, approval also requires:**
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

F. **If you have moderate to severe plaque psoriasis, approval also requires:**
   1. You are 18 years of age or older
   2. The medication is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3 percent or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the face, hands, feet, or genital area

G. **If you have moderate to severe Crohn’s disease, approval also requires:**
   1. You are 6 years of age or older
   2. The medication is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

*Initial criteria continued on next page*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

H. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 5 years of age or older
   2. The medication is prescribed by or in consultation with a gastroenterologist (doctor who
      treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as
corticosteroids (such as budesonide, methylprednisolone), azathioprine,
mercaptopurine, methotrexate, or mesalamine

I. If you have moderate to severe hidradenitis suppurativa, approval also requires:
   1. You are 12 years of age or older

J. If you have non-infectious intermediate, posterior and panuveitis, approval also
   requires:
   1. You are 2 years of age or older
   2. The medication is prescribed by or in consultation with an ophthalmologist (a type of eye
      doctor)
   3. You do not have isolated anterior uveitis (a different type of eye inflammation)

RENEWAL CRITERIA

Our guideline named ADALIMUMAB (Humira) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint
      condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   6. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   7. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   8. Moderate to severe hidradenitis suppurativa (a type of skin condition)
   9. Non-infectious intermediate posterior and panuveitis (a type of eye condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count
      or swollen joint count while on therapy
   2. If you are requesting Humira 40mg weekly dosing OR Humira 80mg every other week
      dosing, we require you have tried at least a 3-month of Humira 40mg every other week
   (Renewal criteria continued on next page)
RENEWAL CRITERIA (CONTINUED)

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

E. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy

F. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy

G. If you have non-infectious intermediate, posterior and panuveitis, renewal also requires:
   1. You have not experienced treatment failure, defined as ONE of the following:
      a. You have development of new inflammatory chorioretinal or retinal vascular lesions (eye tumors)
      b. A 2-step increase from baseline in anterior chamber cell grade or vitreous haze grade (types of classifications on how bad eye inflammation is)
      c. A worsening of best-corrected visual acuity (BCVA) by at least 15 letters relative to best visual acuity achieved

Commercial Effective: 07/01/23
Our guideline named AFATINIB (Gilotrif) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic squamous non-small cell lung cancer (type of lung cancer that has spread to other parts of the body)
   2. Metastatic non-small cell lung cancer (a different type of lung cancer that has spread to other parts of the body)

B. If you have metastatic squamous non-small cell lung cancer, approval also requires:
   1. Your disease has worsened after using platinum-based chemotherapy (such as cisplatin, carboplatin, oxaliplatin)

C. If you have metastatic non-small cell lung cancer, approval also requires:
   1. Your tumors have non-resistant epidermal growth factor receptor (EGFR: type of protein) mutations as shown by an FDA (Food and Drug Administration)-approved test
   2. You will NOT be using Gilotrif concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [Osimertinib], Iressa [gefitinib])

Commercial Effective: 07/01/22
ALECTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALECTINIB HCL</td>
<td>ALECENSA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ALECTINIB (Alecensa) requires the following rules be met for approval:

1. You have a diagnosis of metastatic non-small cell lung cancer (NSCLC; type of cancer that has spread)
2. You are positive for anaplastic lymphoma kinase (ALK; gene mutation) fusion oncogene as detected by an FDA (Food and Drug Administration) -approved test

Commercial Effective: 04/10/21
ALLERGEN EXTRACT-HOUSE DUST MITE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOUSE DUST MITE</td>
<td>ODACTRA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ALLERGEN EXTRACT-HOUSE DUST MITE (Odactra)** requires the following rule(s) be met for approval:

A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by house dust mites, with or without conjunctivitis (type of inflammation of eye and eyelid)

B. You are 12 to 65 years of age

C. Therapy is prescribed by or in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases

D. Your diagnosis is confirmed by in vitro testing (testing outside of your body in a tube) for IgE (Immunoglobulin E) antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or skin testing to licensed house dust mite allergen extracts

E. You have persistent symptoms of allergic rhinitis (defined as symptoms presenting for at least 4 days a week or for at least 4 weeks)

F. You have moderate to severe symptoms of allergic rhinitis (including one or more of the following: troublesome symptoms, sleep disturbance, impairment of daily activities, impairment of school or work)

G. You have a current claim or prescription for auto-injectable epinephrine within the past 365 days

RENEWAL CRITERIA

Our guideline named **ALLERGEN EXTRACT-HOUSE DUST MITE (Odactra)** requires the following rule is met for renewal:

A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline
ALLERGEN EXTRACT-MIXED GRASS POLLEN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>GR POL-ORC/SW VER/RYE/KENT/TIM</td>
<td>ORALAIR</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ALLERGEN EXTRACT-MIXED GRASS POLLEN (Oralair) requires the following rule(s) be met for approval:
A. You have a diagnosis of allergic rhinitis (itchy, watery eyes, sneezing) caused by grass pollen
B. Your diagnosis is confirmed by a positive skin prick test and/or a positive titer (the amount of antibodies in the blood) to specific IgE (Immunoglobulin E) antibodies for any of the five grass types included in Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens)
C. Therapy is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
D. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
E. You have a current claim or prescription for auto-injectable epinephrine
F. You are between 5 and 65 years of age

RENEWAL CRITERIA

Our guideline named ALLERGEN EXTRACT-MIXED GRASS POLLEN (Oralair) requires the following rules be met for renewal:
A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

Commercial Effective: 05/01/20
ALLERGEN EXTRACT-SHORT RAGWEED POLLEN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>WEED POLLEN-SHORT RAGWEED</td>
<td>RAGWITEK</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ALLERGEN EXTRACT-SHORT RAGWEED POLLEN (Ragwitek) requires the following rule(s) be met for approval:

A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by short ragweed pollen
B. You are between 5 and 65 years of age
C. Your diagnosis is confirmed by a positive skin test or in vitro testing (testing outside of your body in a tube) for pollen-specific IgE (Immunoglobulin E) antibodies for short ragweed pollen
D. Therapy is prescribed by or given in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
E. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
F. You have a current claim or prescription for auto-injectable epinephrine

RENEWAL CRITERIA

Our guideline named ALLERGEN EXTRACT-SHORT RAGWEED POLLEN (Ragwitek) requires the following rule(s) be met for renewal:

A. You have experienced an improvement in signs and symptoms of allergic rhinitis from baseline

Commercial Effective: 06/01/21
ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>GRASS POLLEN-TIMOTHY, STD</td>
<td>GRASTEK</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN (Grastek) requires the following rule(s) be met for approval:
A. You have allergic rhinitis (itchy, watery eyes, sneezing) caused by grass pollen
B. You are between 5 and 65 years of age
C. Your diagnosis is confirmed a positive skin prick test and/or a positive titre (the amount of antibodies in the blood) to specific IgE (Immunoglobulin E) antibodies for Timothy grass or cross-reactive grass pollens
D. Therapy is prescribed by or in consultation with an allergist (allergy doctor), immunologist (immune system doctor), or other physician experienced in the diagnosis and treatment of allergic diseases
E. You have persistent and moderate-to-severe symptoms of allergic rhinitis (persistent symptoms are defined as symptoms presenting at least 4 days a week or for at least 4 weeks, and moderate-to-severe symptoms include: troublesome symptoms, sleep disturbance, impairment of daily activities, or impairment of school or work)
F. You have a current claim or prescription for auto-injectable epinephrine

RENEWAL CRITERIA

Our guideline named ALLERGEN EXTRACT-TIMOTHY GRASS POLLEN (Grastek) requires the following rule be met for renewal:
A. You have experienced an improvement in signs and symptoms of allergic rhinitis (itchy, watery eyes, sneezing) from baseline

Commercial Effective: 01/01/22
DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ALPELISIB-PIQRAY

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALPELISIB</td>
<td>PIQRAY</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ALPELISIB-PIQRAY requires the following rule(s) be met for approval:
A. You have advanced or metastatic breast cancer (breast cancer that has spread to other parts of the body)
B. You are a postmenopausal (after menopause) female or a male
C. Piqray will be used in combination with Faslodex (fulvestrant)
D. Your breast cancer is hormone receptor (HR: type of protein)-positive, human epidermal growth factor receptor 2 (HER2: type of protein)-negative with PIK3CA (type of gene)- mutation as detected by a Food and Drug Administration (FDA)-approved test
E. You have disease progression on or after an endocrine-based regimen (your disease has worsened after using a type of hormone therapy)

Commercial Effective: 05/09/22
ALPELISIB - VIJOICE

GUIDELINES FOR USE

Our guideline named ALPELISIB - VIJOICE requires the following rule(s) be met for approval:
A. You have PIK3CA-related overgrowth spectrum (PROS: group of disorders that cause overgrowth of parts of the body due to mutations in a type of gene)
B. You are 2 years of age or older
C. You have severe manifestations of PROS that require systemic therapy (treatment that targets the entire body)

Commercial Effective: 10/01/22
**AMANTADINE EXTENDED RELEASE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMANTADINE</td>
<td>GOCOVRI</td>
</tr>
<tr>
<td>EXTENDED RELEASE</td>
<td></td>
</tr>
<tr>
<td>AMANTADINE HCL</td>
<td>OSMOLEX ER</td>
</tr>
</tbody>
</table>

**Please use the criteria for the specific drug requested**

**GUIDELINES FOR USE**

**GOCOVRI**

Our guideline named **AMANTADINE EXTENDED RELEASE (Gocovri)** requires the following rule(s) be met for approval:

A. You have Parkinson’s disease (nervous system disorder that affects movement)
   
   B. **If you have dyskinesia (abnormal involuntary movements), approval also requires:**
      1. You are receiving levodopa-based therapy
      2. You have previously tried generic amantadine capsules, tablets, or solution
   
   C. **If you are experiencing 'off' episodes (when the medication stops working), approval also requires:**
      1. You are also receiving levodopa-carbidopa therapy
      2. You have previously tried generic amantadine capsules, tablets, or solution

**OSMOLEX ER**

Our guideline named **AMANTADINE EXTENDED RELEASE (Osmolex ER)** requires the following rule(s) be met for approval:

A. You have Parkinson’s disease (nervous system disorder that affects movement) OR you are being treated for drug-induced extrapyramidal symptoms (group of movement disorders)

B. Therapy is prescribed by or given in consultation with a psychiatrist (mental disorder doctor), neurologist (nerve doctor), or geriatrician (doctor who treats elderly people)

C. You have previously tried generic amantadine immediate-release capsules, tablets or solution

D. **If you are being treated for drug-induced extrapyramidal symptoms, approval also requires:**
   1. You are 18 years of age or older

Commercial Effective: 07/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named AMBRISENTAN (Letairis) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) (World Health Organization Group 1)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
C. You do not have idiopathic pulmonary fibrosis (scarring of the lungs for an unknown reason)
D. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named AMBRISENTAN (Letairis) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) (World Health Organization Group 1)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved
AMIFAMPRIDINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMIFAMPRIDINE</td>
<td>FIRDAPSE</td>
</tr>
<tr>
<td>AMIFAMPRIDINE</td>
<td>RUZURGI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named AMIFAMPRIDINE (Firdapse, Ruzurgi) requires the following rule(s) be met for approval:

A. You have Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
B. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor) or hematologist-oncologist (a type of blood-cancer doctor)
C. Diagnosis is confirmed by ALL of the following:
   1. Electrodiagnostic studies and/or voltage-gated calcium channel (types of lab tests) antibody testing
   2. Three clinical symptoms of muscle weakness, autonomic dysfunction (nerve dysfunction), and decreased tendon reflexes
D. If you are requesting Firdapse, approval also requires:
   1. You are 6 years of age or older

RENEWAL CRITERIA

Our guideline named AMIFAMPRIDINE (Firdapse, Ruzurgi) requires the following rule(s) be met for renewal:

A. You have Lambert-Eaton myasthenic syndrome (a type of muscle disorder)
B. You have experienced improvement or stabilization in muscle weakness compared to baseline

Commercial Effective: 11/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named **AMIKACIN LIPOSOMAL INHALATION (Arikayce)** requires the following rule(s) be met for approval:

A. You have *Mycobacterium avium complex* (MAC – group of bacteria that cause serious infections) lung disease with limited or no alternative treatment options
B. You are 18 years of age or older
C. You have NOT achieved negative sputum cultures (mucus tests) after using multidrug background regimen therapy for at least 6 months in a row
D. Arikayce will be used as part of a combination antibacterial drug regimen
E. Arikayce is being prescribed by or given in consultation with a pulmonologist (lung doctor) or infectious disease specialist physician

RENEWAL CRITERIA

Our guideline named **AMIKACIN LIPOSOMAL INHALATION (Arikayce)** requires the following rule(s) be met for renewal:

A. You have *Mycobacterium avium complex* (MAC - group of bacteria that cause serious infections) lung disease
B. You have not had a positive *Mycobacterium avium complex* sputum culture (mucus test) after repeated negative cultures
C. You have experienced an improvement in symptoms
D. You meet ONE of the following:
   1. For first renewal requests, approval also requires documentation of at least ONE negative sputum culture (mucus test) for *Mycobacterium avium complex* by 6 months of Arikayce treatment
   2. For second or later renewal requests, approval also requires documentation of at least THREE negative sputum cultures (mucus test) for *Mycobacterium avium complex* by 12 months of Arikayce treatment
## AMLODIPINE SUSPENSION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMLODIPINE BENZOATE</td>
<td>KATERZIA</td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

Our guideline named **AMLODIPINE SUSPENSION (Katerzia)** requires the following rule(s) be met for approval:

A. You are unable to swallow oral amlodipine tablets at prescribed dose

Commercial Effective: 04/01/20
AMLODIPINE/CELECOXIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMLODIPINE</td>
<td>CONSENSI</td>
</tr>
<tr>
<td>BESYLATE/CELECOXIB</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **AMLODIPINE/CELECOXIB (Consensi)** requires the following rule(s) be met for approval:

A. You have both hypertension (abnormal high blood pressure) and osteoarthritis (a type of arthritis that occurs when tissue at the ends of your bones wears down)

B. You are 18 years of age or older

C. You have previously tried amlodipine AND celecoxib

D. You have an adherence or other challenge requiring the use of the combination product over separate agents

E. You will NOT use Consensi together with any other calcium channel blocker agents (such as diltiazem, felodipine, verapamil)

Commercial Effective: 04/01/20
GUIDELINES FOR USE

Our guideline named **AMPHETAMINE SULFATE (Evekeo)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Narcolepsy (condition where you suddenly fall asleep)
   2. Attention deficit disorder with hyperactivity (difficulty paying attention)
   3. Use for weight loss or exogenous obesity (overweight due to overeating)

B. **If you have narcolepsy, approval also requires:**
   1. You are 6 years of age or older

C. **If you have attention deficit disorder with hyperactivity, approval also requires:**
   1. You are 3 years of age or older
   2. You had a previous trial of at least ONE of the following stimulant medications: mixed amphetamine salts (Adderall immediate release), methylphenidate (Ritalin immediate release), dextroamphetamine (Dexedrine)

D. **If the request is for weight loss or exogenous obesity, approval also requires:**
   1. You are 12 years of age or older
   2. You had a previous trial of other weight loss medications such as Contrave, Belviq, Qsymia, Xenical, phentermine, phendimetrazine, benzphetamine, diethylpropion

**Note:** The approval of Evekeo for use as a short-term adjunct (add-on) in a regimen of weight reduction is for a maximum duration of 12 weeks

Commercial Effective: 05/01/20
AMPHETAMINE SULFATE ODT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMPHETAMINE</td>
<td>EVEKEO ODT</td>
</tr>
<tr>
<td>SULFATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **AMPHETAMINE SULFATE ODT (Evekeo ODT)** requires the following rule(s) be met for approval:

A. You have attention deficit disorder with hyperactivity (ADHD: difficulty paying attention)
B. You are 6 to 17 years of age
C. You are unable to swallow amphetamine sulfate tablets
D. You had a trial of TWO of the following immediate-release stimulant medications:
   - methylphenidate, dexamfetamine, amphetamine, dextroamphetamine,
   - dextroamphetamine-amphetamine

Commercial Effective: 04/01/23
ANABOLIC STEROIDS

**Please use the criteria for the specific drug requested**

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ANADROL-50

Our guideline named ANABOLIC STEROIDS (Anadrol-50) requires the following rule(s) be met for approval:

A. You have anemia (lack of healthy red blood cells) or cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)

B. You will be monitored for peliosis hepatis (blood-filled spaces in the liver), liver cell tumors and blood lipid (fats) changes

C. You do not have ANY of the following reasons why you cannot use anabolic steroid therapy:
   1. Known or suspected prostate or breast cancer in male patients
   2. Known or suspected breast cancer in females with hypercalcemia (high calcium levels)
   3. Known or suspected nephrosis (the nephrotic phase of nephritis-kidney inflammation)
   4. Known or suspected hypercalcemia (high calcium levels)
   5. Severe hepatic (liver) dysfunction

D. If you have anemia, approval also requires:
   1. The anemia is caused by one of the following conditions: acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias, or Fanconi's

E. If you have cachexia associated with AIDS, approval also requires:
   1. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
   2. You have a documented viral load (amount of virus in your blood) of less than 200 copies per mL dated within the past 3 months
   3. Therapy is prescribed by or given in recommendation with a gastroenterologist (doctor of the stomach, intestine and related organs), nutritional support specialist (SBS), or infectious disease specialist

(Initial criteria continued on next page)
ANABOLIC STEROIDS

INITIAL CRITERIA - ANADROL-50 (CONTINUED)

4. You meet ONE of the following:
   a. You have 10% unintentional weight loss over 12 months
   b. You have 7.5% unintentional weight loss over 6 months
   c. You have 5% body cell mass (BCM) loss within 6 months
   d. You have a BCM of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
   e. You have a BCM of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
   f. You have a BMI of less than 18.5 kg per meter squared

OXANDRIN

Our guideline named ANABOLIC STEROIDS (Oxandrin) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Weight loss
   2. Protein catabolism (breakdown) caused by long-term use of corticosteroids
   3. Bone pain accompanying osteoporosis (weak and brittle bones)
   4. Cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
   5. Turner’s Syndrome (disorder where female has one X chromosome)

B. You will be monitored for peliosis hepatis (blood-filled spaces in the liver), liver cell tumors and blood lipid (fats) changes

C. You do not have ANY of the following reasons why you cannot use anabolic steroid therapy:
   1. Known or suspected prostate or breast cancer in male patients
   2. Known or suspected breast cancer in females with hypercalcemia (high calcium levels)
   3. Known or suspected nephrosis (the nephrotic phase of nephritis-kidney inflammation)
   4. Known or suspected hypercalcemia (high calcium levels)
   5. Severe hepatic (liver) dysfunction

D. If you have weight loss, approval also requires:
   1. Your weight loss is caused by extensive surgery, chronic infections, or severe trauma
   2. Medication is being used as add-on therapy to help weight gain

(Initial criteria continued on next page)
ANABOLIC STEROIDS

INITIAL CRITERIA - OXANDRIN (CONTINUED)

E. If you have cachexia associated with AIDS, approval also requires:
   1. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
   2. You have a documented viral load (amount of virus in your blood) of less than 200 copies per mL dated within the past 3 months
   3. Therapy is prescribed by or given in consultation with a gastroenterologist (doctor of the stomach, intestine and related organs), nutritional support specialist (SBS) or infectious disease specialist
   4. You meet ONE of the following:
      a. You have 10% unintentional weight loss over 12 months
      b. You have 7.5% unintentional weight loss over 6 months
      c. You have 5% body cell mass (BCM) loss within 6 months
      d. You have a BCM of less than 35% (men) and a body mass index (BMI) of less than 27 kg per meter squared
      e. You have a BCM of less than 23% (women) of total body weight and a body mass index (BMI) of less than 27 kg per meter squared
      f. You have a BMI of less than 18.5 kg per meter squared

RENEWAL CRITERIA

(NOTE: For the diagnosis of anemia, weight loss, protein catabolism associated with prolonged administration of corticosteroids, bone pain accompanying osteoporosis, or Turner’s Syndrome, please refer to the Initial Criteria section)

OXANDRIN and ANADROL-50

Our guideline named ANABOLIC STEROIDS (Oxandrin and Anadrol-50) requires the following rule(s) be met for renewal:
A. You have cachexia (condition with extreme weight loss and muscle loss) associated with AIDS (acquired immune deficiency syndrome)
B. You are on anti-retroviral therapy (therapy that treats a type of immune system virus)
C. Your viral load (amount of virus in your blood) is less than 200 copies per mL within the past 3 months
D. You have a 10% increase in weight from baseline (current weight must have been measured within the last 4 weeks, document date of measurement)
E. You have not received more than 24 weeks of therapy in a calendar year

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ANAKINRA (Kineret) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (a type of joint condition)
   2. Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cryopyrin-Associated Periodic Syndromes (CAPS) (a type of immune disorder)
   3. Deficiency of Interleukin-1 Receptor Antagonist (a type of immune system disorder)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

NOTE: Kineret will not be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
ANAKINRA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cryopyrin-Associated Periodic Syndromes (CAPS) or Deficiency of Interleukin-1 Receptor Antagonist (DIRA), please refer to the Initial Criteria section.

Our guideline named **ANAKINRA (Kineret)** requires the following rule(s) be met for renewal:

A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)

B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

C. You meet ONE of the following:

1. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)

2. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib immediate release or extended release]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Commercial Effective: 07/01/23
ANTI-OBSITY AGENTS

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>NALTREXONE HCL/BUPROPION</td>
<td>CONTRAVE ER</td>
</tr>
<tr>
<td>BUPROPION HCL</td>
<td></td>
</tr>
<tr>
<td>PHENTERMINE/TOPIRAMATE</td>
<td>QSYMIA</td>
</tr>
<tr>
<td>LIRAGLUTIDE</td>
<td>SAXENDA</td>
</tr>
<tr>
<td>ORLISTAT</td>
<td>XENICAL, ORLISTAT</td>
</tr>
<tr>
<td>SEMAGLUTIDE</td>
<td>WEGOVY</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ANTI-OBSITY AGENTS (Contrave, Qsymia, Saxenda, Wegovy, Xenical [Orlistat]) requires the following rule(s) be met for approval:

A. The request is for weight loss OR weight loss management

B. You have evidence of active enrollment in an exercise and caloric reduction program or a weight loss/behavioral modification program

C. If you are requesting Contrave, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
      b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus (a disorder with high blood sugar), or hyperlipidemia (high cholesterol)

D. If you are requesting Xenical [Orlistat], approval also requires you meet ONE of the following:
   1. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
   2. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus (a disorder with high blood sugar), or hyperlipidemia (high cholesterol)

(Initial criteria continued on next page)
ANTI-OBESITY AGENTS

INITIAL CRITERIA (CONTINUED)

E. If you are requesting Qsymia, approval also requires:
   1. You had a trial of or contraindication (harmful for) to the preferred medications: Saxenda AND Wegovy
   2. You are 18 years of age or older and meet ONE of the following:
      a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
      b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus (a disorder with high blood sugar), or hyperlipidemia (high cholesterol)
   3. You are 12 to 17 years of age and meet the following:
      a. Your initial body mass index (BMI: a tool for evaluating body fat) is in the 95th percentile or greater for age and sex

F. If you are requesting Saxenda, approval also requires:
   1. You will NOT use Saxenda concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug for type 2 diabetes such as Victoza [liraglutide], Ozempic [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])
   2. You are 18 years of age or older and meet ONE of the following:
      a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
      b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus, or hyperlipidemia (high cholesterol)
   3. You are 12 to 17 years of age and meet the following:
      a. Body weight greater than 60 kg AND an initial BMI corresponding to 30 kg/m(2) for adults

G. If you are requesting Wegovy, approval also requires:
   1. You are 18 years of age or older and meet ONE of the following:
      a. Body mass index (BMI: a tool for evaluating body fat) of 30 kg/m(2) or greater
      b. BMI of 27 kg/m(2) or greater AND at least one weight-related comorbidity (disease) such as hypertension (high blood pressure), type 2 diabetes mellitus, or hyperlipidemia (high cholesterol)
   2. You are 12 to 17 years of age and meet the following:
      a. You have an initial body mass index (BMI: a tool for evaluating body fat) in the 95th percentile or greater standardized for age and sex
   3. You will NOT use Wegovy concurrently (at the same time) with a GLP-1 receptor agonist (a type of drug for type 2 diabetes such as Victoza [liraglutide], Ozempic [semaglutide], Byetta [exenatide], Bydureon [exenatide extended-release])

CONTINUED ON NEXT PAGE
ANTI-OBESEITY AGENTS

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named ANTI-OBESEITY AGENTS (Contrave, Qsymia, Saxenda, Wegovy, Xenical [Orlistat]) requires the following rule(s) be met for renewal:

A. The request is for weight loss OR weight loss management

B. If you are requesting Saxenda, renewal also requires ONE of the following:
   1. You are 18 years of age or older AND have achieved or maintained at least 4% weight loss of baseline body weight after 16 weeks of treatment
   2. You are 12 to 17 years of age AND have achieved or maintained at least 1% weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after at least 12 weeks on the maximally tolerated dose

C. If you are requesting Xenical (Orlistat), renewal also requires:
   1. You have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment

D. If you are requesting Contrave, renewal also requires:
   1. You have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment at the maintenance dose (two 8/90mg tablets twice daily)

E. If you are requesting Wegovy, renewal also requires ONE of the following:
   1. You are 18 years of age or older AND have achieved or maintained at least 5% weight loss of baseline body weight
   2. You are 12 to 17 years of age AND have achieved or maintained at least 5% weight loss of baseline body mass index (BMI: a tool for evaluating body fat)

F. If you are requesting Qsymia 7.5/46mg, renewal also requires ONE of the following:
   1. You are 18 years of age or older AND have achieved or maintained at least 3% weight loss of baseline body weight after 3 months of treatment
   2. You are 12 to 17 years of age AND have achieved or maintained at least 3% weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after at least 3 months of treatment

G. If you are requesting Qsymia 15/92mg, renewal also requires ONE of the following:
   1. You are 18 years of age or older AND have achieved or maintained at least 5% weight loss of baseline body weight after 3 months of treatment
   2. You are 12 to 17 years of age AND have achieved or maintained at least 5% weight loss of baseline body mass index (BMI: a tool for evaluating body fat) after 3 months of treatment
GUIDELINES FOR USE

Our guideline named APALUTAMIDE (Erleada) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that does not respond to hormone reduction therapy and has not spread to other parts of the body)
   2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
C. If you have a non-metastatic castration-resistant prostate cancer, approval also requires:
   1. You have high risk prostate cancer (rapidly increasing prostate specific antigen [PSA] levels)

RENEWAL CRITERIA

Our guideline named APALUTAMIDE (Erleada) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that does not respond to hormone reduction therapy but has not spread)
   2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread and responds to hormone therapy)
B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named APOMORPHINE (Apokyn) requires the following rule(s) be met for approval:
A. You have a diagnosis of advanced Parkinson's disease (a type of movement disorder)
B. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
C. The requested medication will be used for acute, intermittent treatment of hypomobility (short and sudden episodes where you have decreased ability to move), OFF episodes associated with advanced Parkinson’s disease
D. Your doctor has optimized your drug therapy as evidenced by BOTH of the following:
   1. Change in levodopa/carbidopa dosing strategy or formulation
   2. You have had a trial of or contraindication (harmful for) to TWO Parkinson disease agents from two different classes: dopamine agonist (ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (entacapone, tolcapone)

RENEWAL CRITERIA

Our guideline named APOMORPHINE (Apokyn) requires the following rule(s) be met for renewal:
A. You have a diagnosis of advanced Parkinson's disease (a type of movement disorder)
B. You have had improvement with motor fluctuations during OFF episodes with the use of Apokyn (such as improvement in speech, facial expression, tremor [shaking] at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named APOMORPHINE (Kynmobi) requires the following rule(s) be met for approval:
A. You have Parkinson’s disease (central nervous system disorder that affects movement, often including tremors)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a neurologist
D. The physician has optimized drug therapy as evidenced by BOTH of the following:
   1. Change in levodopa/carbidopa dosing strategy or formulation
   2. Trial of or contraindication to at least two Parkinson’s agents from two different classes: dopamine agonist (i.e., ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitor (MAO-I) (i.e., selegiline, rasagiline), or catechol-o-methyl transferase (COMT) inhibitors (i.e., entacapone, tolcapone)
E. The requested medication is being used for acute, intermittent treatment (sudden and periodic treatment) of ‘OFF’ episodes (when symptoms return due to your medication for Parkinson’s disease wearing off)

RENEWAL CRITERIA

Our guideline named APOMORPHINE (Kynmobi) requires the following rule(s) be met for renewal:
A. You have Parkinson’s disease (central nervous system disorder that affects movement, often including tremors)
B. You had improvement with motor fluctuations during ’OFF’ episodes (when symptoms return due to your medications for Parkinson’s disease wearing off) with the use of Kynmobi (such as improvement in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair)

Commercial Effective: 10/01/20
APREMILAST

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>APREMILAST</td>
<td>OTEZLA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named APREMILAST (Otezla) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (a type of skin and joint condition)
   2. Plaque psoriasis (a type of skin condition)
   3. Behcet's disease (a type of inflammation disorder) with oral ulcers or history of recurrent oral ulcers based on clinical symptoms

B. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

C. If you have mild plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication to (harmful for) one conventional (standard) systemic (treatment that targets the entire body) agent (such as methotrexate, acitretin, cyclosporine) OR one conventional topical agent (such as Phototherapy Ultraviolet Light A [PUVA], Ultraviolet Light B [UVB], topical corticosteroids [such as betamethasone dipropionate, clobetasol propionate])
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
      b. You have psoriasis covering 2 percent of body surface area (BSA)
      c. You have a static Physician Global Assessment (Spga: a measure used to evaluate severity of your disease) score of 2
      d. You have a Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) score of 2 to 9

(Initial criteria continued on next page)
INITIAL CRITERIA (CONTINUED)

D. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of conventional (standard) therapies, such as Phototherapy Ultraviolet Light A (PUVA), Ultraviolet Light B (UVB), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
      b. You have psoriasis covering 3 percent or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting your hands, feet, face, or genital area

E. If you have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more conservative treatments such as colchicine, topical corticosteroid, oral corticosteroid

RENEWAL CRITERIA

Our guideline named APREMILAST (Otezla) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (a type of skin and joint condition)
   2. Plaque psoriasis (a type of skin condition)
   3. Behcet's disease (a type of inflammation disorder) with oral ulcers or history of recurrent oral ulcers based on clinical symptoms
B. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
C. If you have mild plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) of at least 50 percent or more OR a decrease in static Physician Global Assessment (Spga: a measure used to evaluate severity of your disease) by at least a 2-point reduction from baseline

(Renewal criteria continued on next page)
D. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You achieved or maintained clear or minimal disease OR a decrease in Psoriasis Area and Severity Index (PASI: a measure used to evaluate severity of your disease) of at least 50 percent or more

E. If you have Behcet's disease with oral ulcers or history of recurrent oral ulcers based on clinical symptoms, renewal also requires:
   1. You have achieved or maintained clinical benefit compared to baseline such as an improvement in pain scores, number of ulcers

Commercial Effective: 07/01/23
ARIPIPRAZOLE SENSOR TABS

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARIPIPRAZOLE TABLETS WITH SENSOR</td>
<td>ABILIFY MYCITE</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **ARIPIPRAZOLE SENSOR TABS (Abilify MyCite)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   a. Schizophrenia (a type of mental health disorder)
   b. Bipolar I disorder (a type of mood disorder)
   c. Major depressive disorder (MDD: a type of mental health disorder)

B. **If you have schizophrenia, approval also requires:**
   a. You are 18 years of age or older
   b. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
   c. You have a medical necessity for medication ingestion tracking

C. **If you have major depressive disorder, approval also requires:**
   a. You are 18 years of age or older
   b. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
   c. Abilify MyCite will be used as an adjunctive (add-on) treatment
   d. You have a medical necessity for medication ingestion tracking

D. **If you have bipolar I disorder, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)
   3. You have a medical necessity for medication ingestion tracking
   4. You meet ONE of the following:
      i. The request is for acute (short-term) treatment of manic and mixed episodes as monotherapy (used alone), OR as an adjunct (add-on) to lithium or valproate
      ii. The request is for maintenance treatment as monotherapy, OR as an adjunct to lithium or valproate

Commercial Effective: 10/24/22
GUIDELINES FOR USE

Our guideline named **ASCIMINIB (Scemblix)** requires the following rule(s) be met for approval:

A. You have Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: type of blood cancer) in chronic phase (CP)

B. You are 18 years of age or older

C. You had a mutational analysis prior to initiation of therapy AND Scemblix is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile

D. You meet ONE of the following:
   1. Your cancer has the T315I mutation (a type of abnormal gene)
   2. You have been previously treated with at least TWO tyrosine kinase inhibitors (TKIs), such as bosutinib, dasatinib, imatinib, nilotinib

Commercial Effective:04/01/22
STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ASPARAGINASE ERWINIA-RYWN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPARAGINASE ERWINIA-RYWN</td>
<td>RYLAZE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ASPARAGINASE ERWINIA-RYWN (Rylaze) requires the following rule(s) be met for approval:

A. You have acute lymphoblastic leukemia (ALL: type of blood cancer) or lymphoblastic lymphoma (LBL: type of cancer affecting the immune system)
B. You are 1 month of age or older
C. You have developed hypersensitivity to E.coli-derived asparaginase (you are allergic to an enzyme/protein that is from a type of bacteria)
D. Rylaze will be used as a component of a multi-agent chemotherapeutic regimen

Commercial Effective: 01/01/22
ASFOTASE ALFA

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ASFOTASE ALFA (Strensiq) requires the following rules be met for approval:

A. You have a documented diagnosis of perinatal/infantile-onset hypophosphatasia (HPP: a type of genetic condition) or juvenile-onset hypophosphatasia (HPP).

B. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor).

C. You are NOT currently receiving treatment with a bisphosphonate [such as Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].

D. If you have perinatal/infantile-onset hypophosphatasia, approval also requires:
   1. You were 6 months of age or younger at hypophosphatasia onset.
   2. You are positive for a tissue non-specific alkaline phosphatase (a type of enzyme) (ALPL) gene mutation as confirmed by genetic testing OR you meet at least TWO of the following criteria:
      a. Serum alkaline phosphatase (type of enzyme) level below that of normal range for your age.
      b. Serum pyridoxal-5'-phosphate (PLP) levels elevated AND you have not received vitamin B6 supplementation in the previous week.
      c. Urine phosphoethanolamine (PEA) level above that of normal range for your age.
      d. Radiographic evidence of hypophosphatasia [such as flared and frayed metaphyses (narrow part of long bone), osteopenia (bone loss), widened growth plates, areas of radiolucency (ability to see through with x-rays/ radiation) or sclerosis (hardening of an area)].
      e. Presence of two or more of the following:
         i. Rachitic chest deformity (chest bones are not normal).
         ii. Craniosynostosis (premature closure of skull bones).
         iii. Delay in skeletal growth resulting in delay of motor development.
         iv. History of vitamin B6 dependent seizures.
         v. Nephrocalcinosis (high calcium levels in kidney) or history of elevated serum calcium.
         vi. History or presence of fracture after birth not due to injury or delayed fracture healing.

(Initial criteria continued on next page)
ASFOTASE ALFA

INITIAL CRITERIA (CONTINUED)

E. **If you have juvenile-onset hypophosphatasia**, approval also requires:
1. You were 18 years of age or younger at hypophosphatasia onset
2. You are positive for a tissue non-specific alkaline phosphatase (TNSALP) (ALPL) gene mutation as confirmed by genetic testing OR meet at least TWO of the following criteria:
   a. Serum alkaline phosphatase (type of enzyme) level below that of normal range for your age
   b. Serum pyridoxal-5′-phosphate (PLP) levels elevated AND you have not received vitamin B6 supplementation in the previous week
   c. Urine phosphoethanolamine (PEA) level above that of normal range for your age
   d. Radiographic evidence of hypophosphatasia [such as flared and frayed metaphyses (narrow part of long bone), osteopenia (bone loss), osteomalacia (bone softening), widened growth plates, areas of radiolucency or sclerosis (hardening of an area)]
   e. Presence of two or more of the following:
      i. Rachitic deformities (rachitic chest, bowed legs, knock-knees)
      ii. Premature loss of primary teeth prior to 5 years of age
      iii. Delay in skeletal growth leading to motor development delay
      iv. History or presence of fracture after birth not due to injury or delayed fracture healing

**Strensiq will not be approved if you meet any of the following:**
1. Your serum calcium or phosphate level is below the normal range
2. You have a treatable form of rickets (softening and weakening of bones in children, usually due to low vitamin D)

RENEWAL CRITERIA

Our guideline named **ASFOTASE ALFA (Strensiq)** requires that the following rule(s) be met for renewal:
A. You have experienced improvement in the skeletal characteristics of hypophosphatasia (HPP: genetic disorder causing abnormal development of bones and teeth). Characteristics may include irregularity of the provisional zone of calcification (area on long bone for calcium build-up), physeal widening (area of bone that helps length growth), metaphyseal flaring (a narrow part of long bone grows), radiolucencies (ability to see with x-rays/radiation), patchy osteosclerosis (parts of abnormal hardening of bone), ratio of mid-diaphyseal cortex to bone thickness, gracile (slender) bones, bone formation and fractures.
B. You are NOT currently receiving treatment with a bisphosphonate [such as Boniva (ibandronate), Fosamax (alendronate), Actonel (risedronate)].
Our guideline named **ASPIRIN ER (Durlaza)** requires the following rules be met for approval:

1. **You have ONE of the following:**
   a. Diagnosis of chronic coronary artery disease [damage or disease in the heart's major blood vessels; may include a history of myocardial infarction (heart attack) or unstable angina (chest pain when your heart doesn’t get enough oxygen)] OR
   b. History of an ischemic stroke or transient ischemic attack (arteries to your brain become narrowed or blocked, causing blood flow loss).

2. **You have previously tried aspirin over-the-counter (OTC)**

3. **Durlaza is NOT being used for acute treatment (short term treatment) of myocardial infarction (heart attack) or before percutaneous coronary intervention (non-surgical procedure used to treat narrowing of the coronary arteries of the heart)**

Commercial Effective: 07/01/20
ASPIRIN-OMEPRAZOLE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPIRIN-OMEPRAZOLE</td>
<td>YOSPRALA, ASPIRIN-OMEPRAZOLE</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **ASPIRIN-OMEPRAZOLE (Yosprala)** requires the following rule(s) be met for approval:

A. The request is for secondary prevention of cardiovascular (related to heart and blood vessels) or cerebrovascular (related brain and blood vessels) events

B. You have ONE of the following:
   1. Ischemic stroke (arteries to your brain become narrowed or blocked, causing less blood flow)
   2. Transient ischemia of the brain due to fibrin platelet emboli (blood flow to your brain gets cut off for a short time due to temporary blockage)
   3. Previous myocardial infarction (heart attack)
   4. Unstable angina pectoris (chest pain when your heart doesn’t get enough oxygen)
   5. Chronic stable angina pectoris (chest pain when your heart doesn’t get enough oxygen)
   6. History of undergoing revascularization procedures (procedures that restore blood flow to heart such as coronary artery bypass graft, percutaneous transluminal coronary angioplasty)

C. You have a risk of developing aspirin associated gastrointestinal (GI) ulcers due to age (55 years or older) AND have a documented history of gastrointestinal (GI) ulcers

D. You have tried both aspirin over-the-counter (OTC) AND generic proton pump inhibitors (such as omeprazole, lansoprazole, pantoprazole, rabeprazole)

Commercial Effective: 07/01/20
ASPIRIN ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASPIRIN</td>
<td>ASPIRIN, ASPIRIN EC, VARIOUS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ASPIRIN ZERO COST SHARE OVERRIDE requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. A generic aspirin agent
   2. A single-source brand (SSB) aspirin agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) aspirin agent

B. If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ATOGEPANT (Qulipta) requires the following rule(s) be met for approval:

A. You have migraines

B. If you have episodic migraines (0-14 headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Qulipta is prescribed for the preventive treatment of migraines
   3. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
   4. You have tried or have a contraindication (harmful for) to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine

C. If you have chronic migraines (15 or more headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Qulipta is prescribed for the preventive treatment of migraines
   3. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention
   4. You have tried or have a contraindication (harmful for) to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, atenolol, nadolol, amitriptyline, venlafaxine, Botox [Note: For Botox, previous trial of only National Drug Code (NDC) 00023-1145-01 or NDC 00023-3921-02 are allowable]

CONTINUED ON NEXT PAGE
ATOGEPANT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named ATOGEPANT (Qulipta) requires the following rule(s) be met for renewal:

A. Qulipta is prescribed for the preventive treatment of migraines

B. You will NOT use Qulipta concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (e.g., Ajovy [fremanezumab-vfrm], Aimovig [erenumab-aooe], Emgality [galcanezumab-gnlm], Vyepti [eptinezumab-jjmr], Nurtec ODT [rimegepant orally disintegrating tablet]) for migraine prevention

C. You meet ONE of the following:
   1. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Qulipta therapy
   2. You have experienced a reduction in migraine severity with Qulipta therapy
   3. You have experienced a reduction in migraine duration with Qulipta therapy

Commercial Effective: 05/22/23
GUIDELINES FOR USE

Our guideline named **ATORVASTATIN (Atorvaliq)** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. To reduce the risk of one of the following and you are 18 years of age or older:
      i. Myocardial infarction (MI: heart attack), stroke, revascularization procedures (restoring blood flow to heart and other areas), or angina (chest pain) and you have multiple risk factors for coronary heart disease (CHD: heart arteries get blocked with fats and plaques) but without clinically evident CHD
      ii. MI or stroke and you have type 2 diabetes mellitus (a disorder with high blood sugar) and multiple risk factors for CHD but without clinically evident CHD
      iii. Non-fatal (not deadly) MI, fatal (deadly) or non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure (a type of heart failure), or angina and you have clinically evident CHD
   2. Primary hyperlipidemia (high level of fat in the blood due to genetic causes)
   3. Heterozygous familial hypercholesterolemia (HeFH: a type of inherited high cholesterol)
   4. Homozygous familial hypercholesterolemia (HoFH: a type of inherited high cholesterol)
   5. Primary dysbetalipoproteinemia (a condition leading to increased total cholesterol and triglyceride levels in the blood)
   6. Hypertriglycerideremia (high level of fat in the blood)
B. You had a trial of or contraindication (harmful for) to generic atorvastatin tablets
C. You cannot swallow atorvastatin tablets AND had a trial of rosuvastatin (Ezallor) sprinkle capsule
D. **If you have primary hyperlipidemia, approval also requires:**
   1. You are 18 years of age or older
   2. Atorvaliq will be used in addition to diet
E. **If you have heterozygous familial hypercholesterolemia, approval also requires:**
   1. You are 10 years of age or older
   2. Atorvaliq will be used in addition to diet
F. **If you have homozygous familial hypercholesterolemia, approval also requires:**
   1. You are 10 years of age or older
   2. Atorvaliq will be used in addition to other LDL-C lowering therapies (such as ezetimibe, fenofibrate) OR will be used alone if other LDL-C lowering therapies are unavailable

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

G. If you have dysbetalipoproteinemia or hypertriglyceridemia, approval also requires:
   1. You are 18 years of age or older
   2. Atorvaliq will be used in addition to diet

H. Requests for zero dollar cost share also requires that you are between 40-75 years of age without a history of cardiovascular disease (relating to heart and blood vessels) and you have not used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on your prescription claims profile or medical records:
   1. Aspirin/dipyridamole (Aggrenox)
   2. Clopidogrel (Plavix)
   3. Dipyridamole
   4. Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translungual dosage forms)
   5. Prasugrel (Effient)
   6. Praluent Pen
   7. Repatha
   8. Ticagrelor (Brilinta)
   9. Ticlopidine
   10. Vorapaxar sulfate (Zontivity)

Commercial Effective: 07/01/23
AVACOPAN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVACOPAN</td>
<td>TAVNEOS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named AVACOPAN (Tavneos) requires the following rule(s) be met for approval:

A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])

B. You are 18 years of age or older

C. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)

D. You are ANCA seropositive for anti-PR3 or anti-MPO (a type of lab test)

E. Tavneos will be used as adjunctive (add-on) therapy in combination with standard therapy including glucocorticoids (such as methylprednisolone, prednisone)

RENEWAL CRITERIA

Our guideline named AVACOPAN (Tavneos) requires the following rule(s) be met for renewal:

A. You have severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (inflammation of blood vessels) (granulomatosis with polyangiitis [GPA: condition that affects the blood vessels] or microscopic polyangiitis [MPA: condition that affects the blood vessels])

B. You continue to benefit from the medication

Commercial Effective: 10/24/22
AVAPRITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVAPRITINIB</td>
<td>AYVAKIT</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named AVAPRITINIB (Ayvakit) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable (cannot be removed completely through surgery) or metastatic (cancer that has spread to other parts of the body) gastrointestinal stromal tumor (GIST: type of growth in the digestive system tract, most commonly in the stomach or small intestine)
   2. Advanced systemic mastocytosis (AdvSM: group of rare diseases in which uncontrolled growth and accumulation of mast cells [type of white blood cell] occurs in one or more organs)

B. You are 18 years of age or older

C. If you have unresectable or metastatic gastrointestinal stromal tumor (GIST), approval also requires:
   1. You have a platelet-derived growth factor receptor alpha (PDGFRA: a type of gene/protein) exon 18 mutation, including PDGFRA D842V mutations (a change in your DNA that make up your gene)

D. If you have advanced systemic mastocytosis (AdvSM), approval also requires:
   1. Your AdvSM includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (abnormal mass of blood and blood-forming tissue that forms when cells grow and divide) (SM-AHN), and mast cell leukemia (MCL: an aggressive subtype of acute myeloid leukemia)

Commercial Effective: 07/26/21
AVATROMBOPAG

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named AVATROMBOPAG (Doptelet) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   a. Thrombocytopenia (a type of blood disorder)
   b. Chronic immune thrombocytopenia (immune system attacks your blood platelets)

B. If you have thrombocytopenia, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor),
      gastroenterologist (doctor who treats digestive conditions), hepatologist (a type of liver
      doctor), immunologist (a type of immune system doctor), surgeon, or endocrinologist (a type
      of hormone doctor)
   3. You have chronic (long-term) liver disease
   4. You are scheduled to undergo a procedure 10 to 13 days after starting Doptelet therapy
   5. You have a platelet (type of blood cell that prevents bleeding) count of less than 50 x 10(9)/L
      measured within the last 30 days
   6. You are NOT receiving other thrombopoietin receptor agonist therapy such as Promacta

C. If you have chronic immune thrombocytopenia (cITP), approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or
      immunologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to corticosteroids or immunoglobulins OR
      you had an insufficient response to splenectomy (surgical removal of spleen did not work)

CONTINUED ON NEXT PAGE
AVATROMBOPAG

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnosis of thrombocytopenia in chronic liver disease, please refer to the Initial Criteria section.

Our guideline named AVATROMBOPAG (Doptelet) requires the following rule(s) be met for renewal:

A. You have a diagnosis of chronic immune thrombocytopenia (immune system attacks your blood platelets)
B. You had a clinical response to therapy as defined by an increase in platelet count to at least 50 x 10^9/L (at least 50,000 per microliter), compared to baseline.

Commercial Effective: 04/01/22
AXITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXITINIB</td>
<td>INLYTA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **AXITINIB (Inlyta)** requires the following rule(s) be met for approval:

A. You have advanced renal cell carcinoma (RCC; type of kidney cancer)

B. You also meet ONE of the following:

1. You have tried at least ONE systemic therapy (treatment that spreads throughout the body) for the treatment of renal cell carcinoma such as Nexavar (sorafenib), Torisel (temsirolimus), Sutent (sunitinib), Votrient (pazopanib), or Avastin (bevacizumab) in combination with interferon

2. Inlyta will be used in combination with avelumab (Bavencio) as a first-line treatment

3. Inlyta will be used in combination with pembrolizumab (Keytruda) as a first-line treatment

Commercial Effective: 04/10/21
AZACITIDINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZACITIDINE</td>
<td>ONUREG</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named AZACITIDINE (Onureg) requires the following rule(s) be met for approval:

A. You have acute myeloid leukemia (AML: type of blood and bone marrow cancer with too many white blood cells)
B. You are 18 years of age or older
C. You have achieved first complete remission (CR: signs or symptoms of cancer have disappeared) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy (medications for cancer)
D. You are not able to complete intensive curative therapy (treatment to cure the disease)

Commercial Effective: 01/01/21
AZTREONAM INHALED

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZTREONAM LYSINE</td>
<td>CAYSTON</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named AZTREONAM INHALED requires the following rule(s) be met for approval:
A. You have a diagnosis of cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
B. You are 7 years of age or older
C. You have a lung infection with a Gram negative species such as Pseudomonas aeruginosa

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named BACLOFEN (Ozobax, Fleqsuvy, Lyvispah) requires the following rule(s) be met for approval:

A. You have tried or have a contraindication (harmful for) to generic baclofen tablets
B. You are unable to swallow generic baclofen tablets

Commercial Effective: 05/08/23
## GUIDELINES FOR USE

### INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BARICITINIB (Olumiant)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Severe alopecia areata (a type of hair loss)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You have tried or have a contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)

C. **If you have severe alopecia areata, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT: a type of disease evaluation tool) for more than 6 months
   4. You are NOT using other systemic biologics for alopecia areata or other JAK inhibitors for any indication (such as Xeljanz [tofacitinib], Rinvoq [upadacitinib])

D. **NOTE:** Olumiant will not be approved for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults.

**NOTE:** The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

---

**Continued on next page**
BARICITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named BARICITINIB (Olumiant) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Severe alopecia areata (a type of hair loss)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
   2. You have tried or have a contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)

C. If you have severe alopecia areata, renewal also requires:
   1. You have had improvement while on therapy (such as scalp hair coverage)
   2. You are NOT using other systemic biologics for alopecia areata or other JAK inhibitors for any indication (such as Xeljanz [tofacitinib], Rinvoq [upadacitinib])

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named **BEDAQUILINE (Sirturo)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pulmonary multi-drug resistant tuberculosis (MDR-TB: tuberculosis bacteria in lungs does not respond to multiple drugs, including at least isoniazid and rifampin)
   2. Pulmonary extensively drug resistant tuberculosis (XDR-TB: tuberculosis bacteria is resistant to at least isoniazid, rifampin, a fluoroquinolone [type of antibiotic], and an aminoglycoside [a type of antibiotic])

B. If you have pulmonary multi-drug resistant tuberculosis, approval also requires ONE of the following:
   1. You are 5 years to less than 18 years of age AND weigh at least 15 kg (33 lbs), AND will be using Sirturo in combination with at least 3 other antibiotics
   2. You are 18 years of age, AND will be using Sirturo in combination with at least 3 other antibiotics
   3. You are 18 years of age, AND will be using Sirturo in combination with pretomanid and linezolid

C. If you have pulmonary extensively drug resistant tuberculosis, approval also requires:
   1. You are 18 years of age or older
   2. You will be using Sirturo in combination with pretomanid and linezolid

Commercial Effective: 12/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named **BELIMUMAB - SQ (Benlysta)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Systemic lupus erythematosus (SLE: a type of immune condition)
   2. Lupus nephritis (LN: A type of immune condition that affects the kidneys)

B. **If you have systemic lupus erythematosus, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You are currently using corticosteroids, antimalarials (drugs that treat parasites), non-steroidal anti-inflammatory drugs (NSAIDS), or immunosuppressives (drugs that weaken your immune system)

C. **If you have lupus nephritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or nephrologist (a type of kidney doctor)
   3. You are receiving standard treatment (such as steroids, antimalarials, nonsteroidal anti-inflammatory drugs (NSAIDs), or immunosuppressives (drugs that weaken your immune system)

CONTINUED ON NEXT PAGE
BELIMUMAB - SQ

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named BELIMUMAB - SQ (Benlysta) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Systemic lupus erythematosus (SLE: a type of immune condition)
   2. Lupus nephritis (LN: a type of immune condition that affects the kidneys)

B. If you have systemic lupus erythematosus, renewal also requires:
   1. You have had clinical improvement while on Benlysta

C. If you have lupus nephritis, renewal also requires:
   1. You have had clinical improvement in renal (kidney) response as compared to baseline laboratory values (eGFR [measurement of kidney function] or proteinuria [level of protein in urine]), and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid dose)

Commercial Effective: 05/01/23
BELUMOSUDIL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BELUMOSUDIL MESYLATE</td>
<td>REZUROCK</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named BELUMOSUDIL (Rezurock) requires the following rule(s) be met for approval:

A. You have chronic graft-versus-host-disease (cGVHD: a long-term type of immune disorder)
B. You are 12 years of age or older
C. You had failure of at least two prior lines of systemic therapies (treatment that spreads throughout the body)

Commercial Effective: 04/16/22
BELZUTIFAN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BELZUTIFAN</td>
<td>WELIREG</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named BELZUTIFAN (Welireg) requires the following rule(s) be met for approval:

A. You have von Hippel-Lindau (VHL) disease (genetic disorder that causes tumors to grow in the body)
B. You are 18 years of age or older
C. You require therapy for associated renal cell carcinoma (RCC: a type of kidney cancer), central nervous system (CNS) hemangioblastomas (tumor in the brain or spinal cord), or pancreatic neuroendocrine tumors (pNET: tumor in the pancreas)
D. You do NOT require immediate surgery

Commercial Effective: 01/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named BENRALIZUMAB (Fasenra) requires the following rule(s) be met for approval:

A. You have severe asthma with an eosinophilic phenotype (type of lung condition with inflammation)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a physician specializing in pulmonary (lung/breathing) medicine or allergy medicine
D. You have a documented blood eosinophil level (type of white blood cell) of at least 150 cells/mcL within the past 12 months
E. You are being treated with a medium, high-dose, or a maximally tolerated dose of an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication which includes a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or oral corticosteroid (such as prednisone)
F. You meet ONE of the following:
   1. You experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months OR at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months
   2. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      a. Daytime asthma symptoms more than twice a week
      b. Any night waking due to asthma
      c. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice a week
      d. Any activity limitation due to asthma
G. You will NOT use Fasenra concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab]) when used for the treatment of asthma

CONTINUED ON NEXT PAGE
BENRALIZUMAB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named BENRALIZUMAB (Fasenra) requires the following rule(s) be met for renewal:

A. You will continue to use an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, tiotropium, umeclidinium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or an oral corticosteroid (such as prednisone)

B. You will NOT use Fasenra concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab]) when used for the treatment of asthma

C. You have shown a clinical response as evidenced by ONE of the following:
   1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
   2. Decreased use of rescue medications (such as albuterol)
   3. Increase in percent predicted FEV1 (amount of air exhaled in one second) from pretreatment baseline
   4. Reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

Commercial Effective: 06/01/23
**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

Our guideline named **BEROTRALSTAT (Orladeyo)** requires the following rule(s) be met for approval:

A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. Your diagnosis is confirmed by documented complement testing (a type of blood test)
C. You are 12 years of age or older
D. Orladeyo is being used for prevention of hereditary angioedema attacks
E. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy or immune system doctor) or hematologist (blood doctor)
F. You will NOT use Orladeyo concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, Cinryze, danazol)

**RENEWAL CRITERIA**

Our guideline named **BEROTRALSTAT (Orladeyo)** requires the following rule(s) be met for renewal:

A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
C. You will NOT use Orladeyo concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, Cinryze, danazol)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named BETAIN (Cystadane) requires the following rule(s) be met for approval:
A. You have homocystinuria (a type of genetic metabolic disorder), including cystathionine beta-synthase (CBS: a type of enzyme) deficiency, 5,10-methylenetetrahydrofolate reductase (MTHFR: a type of enzyme) deficiency, and cobalamin cofactor metabolism (cbl: vitamin B12 that is required for enzyme activity) defect

Commercial Effective: 04/01/23
## BEXAROTENE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BEXAROTENE SOFTGEL</td>
<td>TARGRETIN, BEXAROTENE</td>
</tr>
<tr>
<td>BEXAROTENE 1% TOPICAL GEL</td>
<td>TARGRETIN, BEXAROTENE</td>
</tr>
</tbody>
</table>

## GUIDELINES FOR USE

### TARGRETIN (BEXAROTENE) CAPSULE

Our guideline named **BEXAROTENE (Targretin capsule)** requires the following rule(s) be met for approval:

A. You have cutaneous T-cell lymphoma (CTCL: a type of blood cancer)
B. You are refractory (resistant) to at least one prior systemic therapy (therapy that spreads through the blood) such as gemcitabine, methotrexate, liposomal doxorubicin, or bortezomib

### TARGRETIN (BEXAROTENE) GEL

Our guideline named **BEXAROTENE (Targretin gel)** requires the following rule(s) to be met for approval:

A. You have cutaneous T-cell lymphoma (CTCL: a type of blood cancer) (stage IA or IB)
B. You meet ONE of the following:
   a. You have refractory (resistant) or persistent disease after other therapies
   b. You have not tolerated other therapies

Commercial Effective: 06/15/22
Our guideline named BINIMETINIB (Mektovi) requires the following rule(s) be met for approval:

A. You have a diagnosis of unresectable (cannot completely remove by surgery) or metastatic (disease that has spread) melanoma (skin cancer)
B. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by a Food and Drug Administration-approved test
C. The medication will be used in combination with Braftovi (encorafenib)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **BOSENTAN (Tracleer)** requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) (World Health Organization Group 1: a way to classify the severity of disease)

B. You are 3 years of age and older

C. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)

D. You do not have idiopathic pulmonary fibrosis (scarring of the lungs for an unknown reason)

E. Tracleer (bosentan) will NOT be used concurrently (at the same time) with cyclosporine A or glyburide

F. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named **BOSENTAN (Tracleer)** requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) (World Health Organization Group 1: a way to classify the severity of disease)

B. Tracleer (bosentan) will NOT be used concurrently (at the same time) with cyclosporine A or glyburide

C. **If you are 3 to 17 years of age, renewal also requires ONE of the following:**
   1. You have demonstrated an improvement in pulmonary vascular resistance (a type of measurement for pulmonary arterial hypertension)
   2. You have remained stable or shown improvement in exercise ability (such as the 6-minute walk test, World Health Organization [WHO] functional class symptoms) [way to classify how limited you are during physical activity])

*(Renewal denial text continued on next page)*
BOSENTAN

RENEWAL CRITERIA (CONTINUED)

D. If you are 18 years of age or older, renewal requires ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test AND World Health Organization (WHO) functional class has remained stable or improved

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named BOSUTINIB (Bosulif) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Newly diagnosed, chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML; a type of blood cancer)
   2. Chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia

B. You are 18 years of age or older

C. If you have chronic, accelerated, or blast phase Philadelphia chromosome-positive, approval also requires:
   1. You have previously tried or have a contraindication to (a medical reason why you cannot use) other tyrosine kinase inhibitors such as Gleevec (imatinib), Sprycel (dasatinib), Tasigna (nilotinib)
   2. You had a mutational analysis prior to initiation of therapy AND Bosulif is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile
Our guideline named **BOWEL PREP FOR CRC SCREENING ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. Your request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

*(Criteria continued on the next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

B. You are 45 to 75 years of age
C. The request is for colorectal cancer screening
D. **If the request is for a single-source brand or multi-source brand agent, approval also requires you meet ONE of the following:**
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include additional follow-up colonoscopy required after a positive/abnormal screening test)

Commercial Effective: 07/01/22
BREAST CANCER PREVENTION ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANASTROZOLE</td>
<td>ARIMIDEX, ANASTROZOLE</td>
</tr>
<tr>
<td>EXEMESTANE</td>
<td>AROMASIN, EXEMESTANE</td>
</tr>
<tr>
<td>RALOXIFENE HCL</td>
<td>EVISTA, RALOXIFENE HCL</td>
</tr>
<tr>
<td>TAMOXIFEN CITRATE</td>
<td>TAMOXIFEN CITRATE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named BREAST CANCER PREVENTION ZERO COST SHARE OVERRIDE requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. The requested medication is being used for prevention (risk reduction) of breast cancer

C. You are 35 years of age or older

D. If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Commercial Effective: 07/01/22
New drug guidelines for the treatment of hypoactive sexual desire disorder (HSDD). Our guideline named BREMELANOTIDE (Vyleesi) requires the following rule(s) be met for approval:

A. You have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD; also referred to as female sexual interest/arousal disorder where you do not desire sexual activity), as defined by ALL of the following:
   1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   2. HSDD is NOT a result of a co-existing medical or psychiatric (mental) condition, a problem within the relationship or the effects of a medication or drug substance
   3. HSDD symptom causes marked distress or interpersonal difficulty

B. You are a premenopausal female
C. You are 18 years of age or older
D. You had a previous trial of bupropion, unless there is a medical reason why you cannot (contraindication)
E. You are NOT currently using Addyi (flibanserin)

RENEWAL CRITERIA

Our guideline named BREMELANOTIDE (Vyleesi) requires the following rule(s) be met for approval:

A. You have a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD; also referred to as female sexual interest/arousal disorder [FSIAD] where you do not desire sexual activity), as defined by ALL of the following:
   1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   2. HSDD is NOT a result of a co-existing medical or psychiatric (mental) condition, a problem within the relationship or the effects of a medication or drug substance
   3. HSDD symptom causes marked distress or interpersonal difficulty

B. You are a premenopausal female
C. You are NOT currently using Addyi (flibanserin)
D. You have experienced continued improvement in symptoms of HSDD/FSIAD such as increased sexual desire, lessened distress

Commercial Effective: 07/01/20
Our guideline named **BRIGATINIB (Alunbrig)** requires the following rule(s) be met for approval:

A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)

B. You are 18 years of age or older

C. You are positive for anaplastic lymphoma kinase (ALK) fusion oncogene (a type of gene mutation that causes a change in your DNA) as detected by a Food and Drug Administration (FDA)-approved test

---

**Commercial Effective: 04/10/21**
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named BRODALUMAB (Siliq) requires the following rule(s) be met for approval:

A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
E. You had a trial of or contraindication (harmful for) to ONE or more forms of conventional therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
F. You have been counseled on and express an understanding of the risk of suicidal thoughts and behavior
G. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
BRODALUMAB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named BRODALUMAB (Siliq) requires the following rule(s) be met for renewal:
A. You have moderate to severe plaque psoriasis (PsO: a type of skin condition)
B. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more
C. You have NOT developed or reported worsening depressive symptoms or suicidal thoughts and behaviors while on treatment with Siliq (brodalumab)
D. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Commercial Effective: 07/01/23
BUDESONIDE - ORTIKOS

GUIDELINES FOR USE

Our guideline named BUDESONIDE - ORTIKOS requires the following rule(s) be met for approval:

A. You have mild to moderate Crohn's Disease (a type of bowel disorder)

B. If you have mild to moderate active Crohn's Disease, approval also requires:
   1. You are 8 years of age or older
   2. You have tried generic budesonide 3mg capsules OR you cannot tolerate the pill burden associated with the generic product

C. If you have mild to moderate Crohn's Disease, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication is being used for the maintenance of clinical remission (signs and symptoms of disease have either improved or disappeared)
   3. You have tried generic budesonide 3mg capsules OR you cannot tolerate the pill burden associated with the generic product

Commercial Effective: 01/17/22
Our guideline named **BUDESONIDE - TARPEYO** requires the following rule(s) be met for approval:

A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
D. Your diagnosis is confirmed by a renal biopsy (removal of cells or tissue from the kidney for examination)
E. You are currently on an angiotensin converting enzyme inhibitor (ACE-I: a type of drug used to protect kidneys such as benazepril, lisinopril, etc.) or an angiotensin receptor blocker (ARB: a type of drug used to protect kidneys such as losartan, valsartan, etc.) at maximum tolerated dose for at least three months OR have a contraindication (harmful for) to both
F. You have a progressively declining glomerular filtration rate (GFR: a tool for evaluating kidney function) and/or worsening proteinuria (such as greater than 1 gram protein in a 24-hour urine collection or greater than or equal to 1g/g urine protein to creatinine ratio [UPCR: test that measures the amount of protein in urine])
G. You had a trial of or contraindication to one generic systemic corticosteroid therapy (such as oral prednisone, oral prednisolone)

**RENEWAL CRITERIA**

Our guideline named **BUDESONIDE - TARPEYO** requires the following rule(s) be met for renewal:

A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
B. You have improved, or stable kidney function compared to baseline OR a reduction in proteinuria

Commercial Effective: 01/17/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named C1 ESTERASE INHIBITOR - BERINERT requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
C. Your diagnosis is confirmed by complement testing (a type of lab test)
D. Berinert is being used for acute (short term) attacks of hereditary angioedema
E. You will NOT be using Berinert concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Ruconest, Firazyr, Kalbitor)

RENEWAL CRITERIA

Our guideline named C1 ESTERASE INHIBITOR - BERINERT requires the following rule(s) be met for renewal:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You will NOT be using Berinert concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Ruconest, Firazyr, Kalbitor)
C1 ESTERASE INHIBITOR - CINRYZE

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named C1 ESTERASE INHIBITOR - CINRYZE requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You are 6 years of age or older
C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
D. Your diagnosis is confirmed by documented complement testing (a type of lab test)
E. Cinryze is being used for prevention of hereditary angioedema attacks
F. You will not be using Cinryze concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Haegarda, danazol)

RENEWAL CRITERIA

Our guideline named C1 ESTERASE INHIBITOR - CINRYZE requires the following rule(s) be met for renewal:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
C. You will NOT be using Cinryze concurrently (at the same time) with alternative prophylactic (preventive) agent for HAE (such as Takhzyro, Haegarda, danazol)

Commercial Effective: 11/01/22
C1 ESTERASE INHIBITOR - HAEGARDA

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1 ESTERASE INHIBITOR</td>
<td>HAEGARDA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named C1 ESTERASE INHIBITOR - HAEGARDA requires the following rule(s) be met for approval:

A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You are 6 years of age or older
C. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
D. Your diagnosis of HAE is confirmed by documented complement testing (a type of lab test)
E. Haegarda is being used for prevention of hereditary angioedema attacks
F. You will not be using Haegarda concurrently (at the same time) with an alternative preventive agent for HAE (such as Takhzyro, Cinryze, danazol)

RENEWAL CRITERIA

Our guideline named C1 ESTERASE INHIBITOR - HAEGARDA requires the following rule(s) be met for renewal:

A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in HAE attacks
C. You will NOT be using Haegarda concurrently (at the same time) with alternative prophylactic (preventive) agent for HAE (such as Takhzyro, Cinryze, danazol)

Commercial Effective: 11/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named C1 ESTERASE INHIBITOR - RUCONEST requires the following rule(s) be met for approval:

A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. Therapy is prescribed by or in consultation with an allergist (a type of allergy doctor), immunologist (a type of immune system doctor) or hematologist (a type of blood doctor)
C. Your diagnosis is confirmed by complement testing (a type of lab test)
D. Ruconest is being used for acute (short term) attacks of hereditary angioedema
E. You will NOT be using Ruconest concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Berinert, Firazyr, Kalbitor)

RENEWAL CRITERIA

Our guideline named C1 ESTERASE INHIBITOR - RUCONEST requires the following rule(s) be met for renewal:

A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You will NOT be using Ruconest concurrently (at the same time) with alternative acute treatment for HAE attacks (such as Berinert, Firazyr, Kalbitor)
CABOZANTINIB S-MALATE

** Please use the criteria for the specific drug requested **

GUIDELINES FOR USE

COMETRIQ

Our guideline named CABOZANTINIB S-MALATE (Cometriq) requires the following rule be met for approval:
A. You have progressive, metastatic medullary thyroid cancer (type of thyroid cancer that has spread)

CABOMETYX

Our guideline named CABOZANTINIB S-MALATE (Cabometyx) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
   2. Hepatocellular carcinoma (HCC: type of liver cancer)
   3. Locally advanced or metastatic differentiated thyroid cancer (DTC: type of thyroid cancer)
B. If you have advanced renal cell carcinoma, approval also requires ONE of the following:
   1. Cabometyx will be used as a single agent (used alone)
   2. Cabometyx will be used in combination with Opdivo (nivolumab) as first-line treatment (You have not received prior treatment for advanced renal cell carcinoma)
C. If you have hepatocellular carcinoma, approval also requires:
   1. You have previously been treated with Nexavar (sorafenib)
D. If you have locally advanced or metastatic differentiated thyroid cancer, approval also requires:
   1. You are 12 years of age or older
   2. You have disease progression (disease has gotten worse) following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy (a type of cancer therapy)
   3. You are radioactive iodine-refractory (resistant to) or ineligible

Commercial Effective: 10/04/21
CAPECITABINE

CAPECITABINE
XELODA

GUIDELINES FOR USE

Our guideline named CAPECITABINE (Xeloda) requires the following rule(s) to be met for approval:

A. You have ONE of the following diagnoses:
   1. Stage III colon cancer (colon cancer that has spread to lymph nodes)
   2. Locally advanced rectal cancer (cancer that has spread from where it started to nearby tissue or lymph nodes)
   3. Unresectable (unable to remove by surgery) or metastatic colorectal cancer (a type of digestive cancer that has spread to other parts of the body)
   4. Metastatic breast cancer (breast cancer that has spread to other parts of the body)
   5. Unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer (a type of digestive system cancer that has spread to other parts of the body)
   6. HER2 (a type of protein)-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)
   7. Pancreatic adenocarcinoma (a type of cancer of the pancreas)

B. If you have Stage III colon cancer, approval also requires:
   1. The requested medication will be used as adjuvant (add-on) treatment

C. If you have locally advanced rectal cancer, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used as perioperative (the time period before and after surgery) treatment
   3. The requested medication will be used as part of chemoradiotherapy (a type of cancer treatment)

D. If you have advanced or metastatic breast cancer, approval also requires ONE of the following:
   1. The requested medication will be used as a single agent (used alone), if an anthracycline (such as doxorubicin, daunorubicin)- or taxane (such as paclitaxel, docetaxel)-containing chemotherapy is not indicated
   2. The requested medication will be used in combination with docetaxel after disease progression (worsens) on prior anthracycline (such as doxorubicin, daunorubicin)-containing chemotherapy

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

E. If you have unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used as part of a combination chemotherapy (drugs used to treat cancer) regimen

F. If you have HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You have not received prior treatment for metastatic disease
   3. The requested medication will be used as part of a combination regimen (such as with cisplatin, trastuzumab)

G. If you have pancreatic adenocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used as adjuvant (add-on) treatment
   3. The requested medication will be used as part of a combination chemotherapy regimen (such as with gemcitabine)

Commercial Effective: 01/23/23
Our guideline named **CAPLACIZUMAB-YHDP (Cablivi)** requires the following rule(s) be met for approval:

A. You have a diagnosis of acquired thrombotic thrombocytopenia purpura (aTTP - a type of blood disorder)

B. You are 18 years of age or older

C. Therapy is prescribed by or given in consultation with a hematologist (blood specialist)

D. You have NOT experienced more than two recurrences of acquired thrombotic thrombocytopenia purpura, while on Cablivi therapy. For example there’s a new drop in platelet count requiring repeat plasma exchange during 30 days post-plasma exchange therapy (process of replacing a liquid part of the blood) and up to 28 days of extended therapy

E. You also meet ONE of the following:
   1. Your request is for continuation of Cablivi therapy from inpatient (hospital) setting and you previously received plasma exchange and immunosuppressive therapy (treatment that weakens your immune system) within the inpatient setting
   2. Your request is for continuation of Cablivi therapy from the initial 30 days treatment course (no break in therapy) AND:
      a. You are receiving immunosuppressive therapy, and
      b. You are experiencing signs of persistent underlying disease (such as suppressed ADAMTS13 [a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13: type of blood clot disorder] activity level remain present)

Commercial Effective: 11/21/22
GUIDELINES FOR USE

Our guideline named CAPMATINIB (Tabrecta) requires the following rule(s) be met for approval:

A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
B. You are 18 years of age or older
C. Your tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (an abnormal change in a gene that makes MET protein) as detected by an FDA-approved test

Commercial Effective: 04/10/21
## GUIDELINES FOR USE

Our guideline named **CAPSAICIN (Qutenza)** requires the following rule be met for approval:

A. You have a diagnosis of neuropathic pain associated with ONE of the following conditions:
   - Postherpetic neuralgia (PHN) (painful condition that affects the nerve fibers and skin after having shingles)
   - Diabetic peripheral neuropathy (DPN) of the feet (numbness of the feet that is caused by diabetes)

Commercial Effective: 08/24/20
GUIDELINES FOR USE

Our guideline named CARBIDOPA-LEVODOPA (Duopa) requires the following rule be met for approval:
A. You have a diagnosis of advanced Parkinson’s disease (nerve system disorder that affects movement)

Commercial Effective: 07/01/20
CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLENTY</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID (Plenity)** requires the following rule(s) be met for approval:

A. The request is for weight management
B. You are 18 years of age or older
C. You have a body mass index (BMI) of 25 to 40 kg/m(2)
D. The requested medication will be used in conjunction (together) with diet and exercise

Commercial Effective: 10/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named CARGLUMIC ACID (Carbaglu) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Acute or chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency (short-term or long-term high ammonia blood levels due to a genetic disorder)
   2. Acute hyperammonemia (HA) due to propionic acidemia (PA) or methylmalonic acidemia (MMA) (short-term high ammonia blood levels due to a genetic disorder)

B. If you have acute or chronic hyperammonemia due to N-acetylglutamate synthase deficiency, approval also requires:
   1. Your N-acetylglutamate synthase gene mutation is confirmed by biochemical or genetic testing (types of lab test)
   2. Requests for brand Carbaglu requires a trial of generic carglumic acid

C. If you have acute hyperammonemia due to propionic acidemia, approval also requires:
   1. Your diagnosis is confirmed by the presence of elevated methylcitric acid and normal methylmalonic acid (substances that indicate presence of a disease) OR genetic testing confirming mutation in the PCCA or PCCB gene (types of abnormal genes)

D. If you have acute hyperammonemia due to methylmalonic acidemia, approval also requires:
   1. Your diagnosis is confirmed by the presence of elevated methylmalonic acid, methylcitric acid OR genetic testing confirming mutation in the MMUT, MMA, MMAB or MMADHC genes (types of abnormal genes)

CONTINUED ON NEXT PAGE
CARGLUMIC ACID

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of acute hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) deficiency or acute hyperammonemia (HA) due to propionic acidemia (PA) or methylmalonic acidemia (MMA), please refer to the Initial Criteria section.

Our guideline named CARGLUMIC ACID (Carbaglu) requires the following rule(s) be met for renewal:

A. You have chronic hyperammonemia (HA) due to N-acetylglutamate synthase (NAGS) (long-term high ammonia blood levels due to a genetic disorder)
B. You have clinical improvement or improved plasma (blood) ammonia levels

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named **CELECOXIB (ELYXYB)** requires the following rule(s) be met for approval:

A. The request is for the acute (quick onset) treatment of migraines
B. You are 18 years of age or older
C. You had a trial of generic celecoxib AND over-the-counter (OTC) or generic aspirin, diclofenac, ibuprofen, or naproxen
D. You are unable to swallow pills (such as tablets or capsules)

Commercial Effective: 04/01/22
GUIDELINES FOR USE

Our guideline named CENEGERMIN-BKBJ (Oxervate) requires the following rule(s) be met for approval:
A. You have a diagnosis of neurotrophic keratitis (an eye disease due to a damaged eye nerve)
B. Therapy is prescribed by or given in consultation with an ophthalmologist (eye doctor)
C. You have a medical history that supports a cause for trigeminal nerve damage (damage to a nerve in the head) such as herpes zoster infection (shingles virus), multiple sclerosis (disorder where immune system attacks nerves), diabetes, ocular surgical (eye surgery) damage
D. You have loss of corneal sensitivity, corneal epithelium changes, and/or loss of tear production
E. You are refractory (not fully responsive) to conservative management that includes artificial tears, ocular lubricants, topical antibiotics, therapeutic contact lenses

Commercial Effective: 09/04/20
CEQUR SIMPLICITY INSULIN DEVICE

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CEQUR SIMPLICITY INSULIN DEVICE** requires the following rule(s) be met for approval:

A. You have diabetes mellitus (type 1 or type 2) (a disorder with high blood sugar)
B. You are 21 years of age or older
C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
D. You follow a maintenance program of at least 3 injections of insulin per day
E. You have worked with the physician to adjust the dose of insulin for the past 6 months and have not met glucose (blood sugar) goals
F. You require bolus insulin dosing in increments of 2 units per bolus
G. You had a trial of ONE of the following preferred devices: Omnipod, Omnipod Dash, V-Go
H. If requesting more than 10 patches per month, then you must be using more than 180 units of insulin per 72 hours
I. You are on a multiple daily insulin injection regimen and meet ONE of the following criteria:
   1. You have a glycosylated hemoglobin level (HbA1c: a type of lab test) greater than 7 percent
   2. You have a history of recurring hypoglycemia (low blood sugar)
   3. You have wide fluctuations (variations) in blood glucose before mealtime
   4. You experience the dawn phenomenon (abnormal early morning increase in blood sugar, usually between 2 a.m. and 8 a.m.) with fasting blood glucose levels frequently exceeding 200 mg/dL
   5. You have a history of severe glycemic excursions (sudden spikes in blood sugar levels)

**CONTINUED ON NEXT PAGE**
CEQUR SIMPLICITY INSULIN DEVICE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **CEQUR SIMPLICITY INSULIN DEVICE** requires the following rule(s) be met for renewal:

A. You have diabetes mellitus (type 1 or type 2) (a disorder with high blood sugar)
B. You have shown a positive response to therapy
C. You are adherent to your doctor follow-up visits
D. If requesting more than 10 patches per month, you are using more than 180 units of insulin per 72 hours

Commercial Effective: 04/01/23
GUIDELINES FOR USE

Our guideline named CERITINIB (Zykadia) requires the following rule(s) be met for approval:
A. You have metastatic non-small cell lung cancer (type of lung cancer that has spread)
B. You are 18 years of age or older
C. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme) positive as confirmed by a Food and Drug Administration-approved test

Commercial Effective: 10/25/21
CERTOLIZUMAB PEGOL

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named CERTOLIZUMAB PEGOL (Cimzia) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)
      c. You have tried a tumor necrosis factor (TNF) inhibitor (such as Enbrel [etanercept], Humira [adalimumab]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

(Initial criteria continued on next page)
CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzzaa), Taltz (ixekizumab)

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)
   4. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib), Taltz (ixekizumab)

E. If you have moderate to severe Crohn’s disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to the following preferred medication: Humira (adalimumab)

(Initial criteria continued on next page)
CERTOLIZUMAB PEGOL

INITIAL CRITERIA (CONTINUED)

F. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   5. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rrzaa), Enbrel (etanercept), Otezla (apremilast), Taltz (ixekizumab)

G. If you have non-radiographic axial spondyloarthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug such as (e.g., ibuprofen, naproxen, meloxicam)
   4. You have ONE of the following criteria:
      a. You were previously stable on another biologic (e.g., Cosentyx [secukinumab]) and you are switching to the requested drug
      b. You have C-reactive protein (CRP; a measure of how much inflammation you have) levels above the upper limit of normal
      c. You have sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
CERTOLIZUMAB PEGOL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named CERTOLIZUMAB PEGOL (Cimzia) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)
      c. You have tried a tumor necrosis factor (TNF) inhibitor (such as Enbrel [etanercept], Humira [adalimumab]) AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You meet ONE of the following:
      a. You are pregnant, breastfeeding, or trying to become pregnant
      b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rrza), Taltz (ixekizumab)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE
CERTOLIZUMAB PEGOL

RENEWAL CRITERIA (CONTINUED)

D. If you have ankylosing spondylitis, renewal also requires:
1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
2. You meet ONE of the following:
   a. You are pregnant, breastfeeding, or trying to become pregnant
   b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib), Taltz (ixekizumab)

E. If you have moderate to severe plaque psoriasis, renewal also requires:
1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more while on therapy
2. You meet ONE of the following:
   a. You are pregnant, breastfeeding, or trying to become pregnant
   b. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa), Taltz (ixekizumab)

F. If you have moderate to Crohn’s disease, renewal also requires:
1. You meet ONE of the following:
   a. You are pregnant, breastfeeding, or trying to become pregnant
   b. You had a trial of or contraindication (harmful for) to the following preferred medication: Humira (adalimumab)

G. If you have non-radiographic axial spondyloarthritis, renewal also requires:
1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.
CHENODIOL

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named CHENODIOL (Chenodal) requires the following rule(s) be met for approval:

A. You have radiolucent gallstones (hard deposits in your gall bladder that can barely be seen with x-rays) OR cerebrotendinous xanthomatosis (condition of missing an enzyme that changes cholesterol into a bile acid)

B. If you have radiolucent gallstones, approval also requires:
   1. You have tried ursodiol, unless there is a medical reason why you cannot (contraindication)
   2. You have not received previous chenodiol therapy for more than a total of 24 months

RENEWAL CRITERIA

Our guideline named CHENODIOL (Chenodal) requires the following rule(s) be met for renewal:

A. You have radiolucent gallstones (hard deposits in your gall bladder that can barely be seen with x-rays) OR cerebrotendinous xanthomatosis (condition of missing an enzyme that changes cholesterol into a bile acid)

B. If you have radiolucent gallstones, renewal also requires:
   1. You have NOT had chenodiol therapy for more than a total of 24 months
   2. You do NOT have complete or no gallstone dissolution (disappearance) seen on imaging (such as oral cholecystograms or ultrasonograms) after 12 months of therapy
   3. You have partial gallstone dissolution seen on imaging (such as oral cholecystograms or ultrasonograms) after 12 months of therapy

C. If you have cerebrotendinous xanthomatosis, renewal also requires you have experienced an improvement in ONE of the following:
   1. Normalization of elevated serum or urine bile alcohols
   2. Normalization of elevated serum cholestanol levels
   3. Improvement in neurologic and psychiatric symptoms (dementia, pyramidal tract and cerebellar signs)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **CHOLIC ACID (Cholbam)** requires the following rule(s) be met for approval:

A. You show signs of liver disease, steatorrhea (excess fat in feces), or complications from your body not being able to absorb fat-soluble vitamins that occur from ONE of the following conditions:
   1. Bile acid synthesis disorders (your body has a problem making bile acid)
   2. Peroxisomal disorders (Zellweger spectrum disorders) (problems with a part of a cell that contains enzymes)

RENEWAL CRITERIA

Our guideline named **CHOLIC ACID (Cholbam)** requires the following rule(s) be met for renewal:

A. You have experienced an improvement in your liver function as defined by at least ONE of the following criteria:
   1. ALT (alanine aminotransferase) or AST (aspartate transaminase) (types of liver enzymes) values have been lowered to less than 50 U/L or baseline levels reduced by 80%
   2. Total bilirubin values reduced to less than 1 mg/dL
   3. No evidence of cholestasis (condition where bile cannot flow from liver) on liver biopsy

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named CLADRIBINE (Mavenclad) requires the following rule(s) be met for approval:
A. You have a relapsing form of multiple sclerosis (MS: disease where body attacks its own nerves and returns after having no symptoms). This includes relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.
B. You are 18 years of age or older

RENEWAL CRITERIA

Our guideline named CLADRIBINE (Mavenclad) requires the following rule(s) be met for renewal:
A. You have a relapsing form of multiple sclerosis (MS: disease where body attacks its own nerves and returns after having no symptoms). This includes relapsing-remitting MS [RRMS], active secondary progressive MS [SPMS], etc.
B. You have demonstrated a clinical benefit compared to pre-treatment baseline (before you started therapy)
C. You do not have lymphopenia (low amount of a type of white blood cell called lymphocyte)
D. You have not received a total of two years of treatment with Mavenclad

Commercial Effective: 07/01/20
### CLASCOTERONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLASCOTERONE</td>
<td>WINLEVI</td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

Our guideline named **CLASCOTERONE (Winlevi)** requires the following rule(s) be met for approval:

E. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)

F. You are 12 years of age or older

G. Therapy is prescribed by or given in consultation with a dermatologist (skin doctor)

H. You have previously tried BOTH of the following unless there is a medical reason why you cannot (contraindication):
   1. ONE oral acne agent (such as oral antibiotics or oral isotretinoin)
   2. TWO topical acne agents (such as topical retinoids, topical antibiotics, benzoyl peroxide)

### RENEWAL CRITERIA

Our guideline named **CLASCOTERONE (Winlevi)** requires the following rule(s) be met for approval:

A. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)

B. You had improvement of acne lesions

Commercial Effective: 01/01/21
GUIDELINES FOR USE

Our guideline named **CLOBAZAM-SYMPAZAN** requires the following rule(s) be met for approval:
A. You have Lennox-Gastaut Syndrome (a type of seizure disorder in young children)
B. You are 2 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
D. Sympazan will be used for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome
E. You are unable to take tablets or suspension
F. You had a trial of or contraindication (harmful for) to generic/branded clobazam products (Onfi)

Commercial Effective: 07/01/22
COBIMETINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>COBIMETINIB</td>
<td>COTELLIC</td>
</tr>
<tr>
<td>FUMARATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named COBIMETINIB (Cotellic) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (skin cancer that has spread or cannot be completely removed with surgery)
   2. Histiocytic neoplasms (a type of white blood cell disorder)

B. If you have unresectable or metastatic melanoma, approval also requires:
   1. You are 18 years of age or older
   2. Your tumor has a BRAF V600E OR V600K mutation (a type of gene mutation)
   3. Cobimetinib will be used in combination with vemurafenib (Zelboraf)

C. If you have histiocytic neoplasms, approval also requires:
   1. You are 18 years of age or older
   2. Cobimetinib will be used as a single agent

Commercial Effective: 11/21/22
GUIDELINES FOR USE

Our guideline named COLLAGENASE TOPICAL (Santyl) requires the following rule(s) be met for approval:

A. You have chronic dermal (skin) ulcer(s) or severe burn(s) that require(s) debridement (removal of damaged tissue from a wound)

B. If the requested quantity is more than one tube (30 grams), approval also requires:
   1. The higher quantity is based on the size of your wound (width/length) and the anticipated duration of therapy, using the Santyl dosing calculator (https://santyl.com/hcp/dosing)

Commercial Effective: 04/01/22
GUIDELINES FOR USE

Our guideline named CGM STEP OVERRIDE requires ALL of the following rules be met for approval:
A. You meet ONE of the following:
   1. You are being treated with insulin (such as Humalog [insulin lispro], Lantus [insulin glargine])
   2. You have a clinical need that cannot be managed with self-monitoring of blood glucose (such as frequent hypoglycemia [low blood sugar], hypoglycemic unawareness, unable to achieve control of diabetes)
   3. You are currently stable on the requested agent

Commercial Effective: 07/01/23
CONTINUOUS GLUCOSE MONITORS - STAND-ALONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER</td>
<td>DEXCOM G4, DEXCOM G5</td>
</tr>
<tr>
<td>BLOOD-GLUCOSE TRANSMITTER</td>
<td>DEXCOM G4, DEXCOM G5, EVERSENSE SMART TRANSMITTER, GUARDIAN CONNECT TRANSMITTER, GUARDIAN 4 TRANSMITTER</td>
</tr>
<tr>
<td>BLOOD-GLUCOSE SENSOR</td>
<td>DEXCOM G5-G4 SENSOR, DEXCOM G4 SENSOR, GUARDIAN SENSOR 3, GUARDIAN 4 GLUCOSE SENSOR</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named CONTINUOUS GLUCOSE MONITORS - STAND-ALONE requires the following rule(s) be met for approval:
A. You have type 1, type 2, or gestational (during pregnancy) diabetes (too much sugar in your blood)
B. You had a trial of or contraindication (harmful for) to Dexcom G6 or Freestyle Libre, OR both products are not compatible with your current insulin pump
C. You meet ONE of the following:
   1. You are being treated with insulin (such as Humalog [insulin lispro], Lantus [insulin glargine])
   2. You have a clinical need that cannot be managed with self-monitoring of blood glucose (such as frequent hypoglycemia [low blood sugar], hypoglycemic unawareness, unable to achieve control of diabetes)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
CONTINUOUS GLUCOSE MONITORS – STAND-ALONE

INITIAL CRITERIA (CONTINUED)

D. If you are requesting Dexcom G4 or Dexcom G5 system (meter, sensor, transmitter), approval also requires:
   1. You are 2 years of age or older

E. If you are requesting Guardian Connect (sensor, transmitter), approval also requires:
   1. You are 14 to 75 years of age

F. If you are requesting Guardian 4 (sensor, transmitter), approval also requires:
   1. You are 7 years of age or older

G. If you are requesting Eversense Smart Transmitter, approval also requires:
   1. You are 18 years of age or older

RENEWAL CRITERIA

Our guideline named CONTINUOUS GLUCOSE MONITORS – STAND-ALONE requires the following rule be met for renewal:
A. You continue to require continuous glucose monitoring

Commercial Effective: 07/01/23
**CONTRACEPTIVE ZERO COST SHARE OVERRIDE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONTRACEPTIVES, ORAL</td>
<td></td>
</tr>
<tr>
<td>CONTRACEPTIVES, TRANSDERMAL</td>
<td></td>
</tr>
<tr>
<td>CONTRACEPTIVES, INTRAVAGINAL, SYSTEMIC</td>
<td></td>
</tr>
<tr>
<td>INTRA-UTERINE DEVICES (IUD'S)</td>
<td></td>
</tr>
<tr>
<td>CONTRACEPTIVES, INJECTABLE</td>
<td></td>
</tr>
<tr>
<td>CONTRACEPTIVES, IMPLANTABLE</td>
<td></td>
</tr>
<tr>
<td>CONTRACEPTIVE, INTRAVAGINAL</td>
<td></td>
</tr>
<tr>
<td>DIAPHRAGMS/CERVICAL CAP</td>
<td></td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **CONTRACEPTIVE ZERO COST SHARE OVERRIDE** requires that the following rules be met for approval:

A. The request is for ONE of the following:
   1. A generic contraceptive agent
   2. A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) contraceptive agent

B. Approval may also require that you have tried preferred agent(s), unless you have a contraindication (harmful for). (NOTE TO REVIEWER: Provide the list of the preferred medication(s))

*(Criteria continued on next page)*

**CONTINUED ON NEXT PAGE**
CONTRACEPTIVE ZERO COST SHARE OVERRIDE

GUIDELINE FOR USE (CONTINUED)

C. If the request is for a single-source brand or multi-source brand contraceptive medication, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
   3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects, differences in durability and reversibility of contraceptive and ability to adhere to the appropriate use)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named CORTICOTROPIN (Acthar, Cortrophin) requires the following rule(s) be met for approval:

A. You have infantile spasms (type of seizure disorder in young children)
B. You are less than 2 years of age

Acthar will not be approved for any other indications other than infantile spasms. Acthar has not demonstrated proven benefits or advantage over synthetic steroids in the treatment of other indications.

Commercial Effective: 01/01/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

**CRIZOTINIB**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRIZOTINIB</td>
<td>XALKORI</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **CRIZOTINIB (Xalkori)** requires the following rule(s) be met for approval:

**A.** You have ONE of the following diagnoses:
1. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
2. Relapsed (disease that has returned) or refractory (disease does not respond to treatment), systemic anaplastic large cell lymphoma (ALCL: type of blood cell cancer)
3. Unresectable (unable to remove by surgery), recurrent, or refractory (disease does not respond to treatment) inflammatory myofibroblastic tumor (IMT: a rare type of tumor)

**B. If you have metastatic non-small cell lung cancer, approval also requires:**
1. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive or ROS1 (a type of gene)-positive as detected by a Food and Drug Administration (FDA)-approved test

**C. If you have relapsed or refractory systemic anaplastic large cell lymphoma, approval also requires:**
1. You are 1 year of age or older
2. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive

**D. If you have unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, approval also requires:**
1. You are 1 year of age or older
2. Your tumors are anaplastic lymphoma kinase (ALK: a type of enzyme)-positive

Commercial Effective: 08/29/22
## GUIDELINES FOR USE

Our guideline named CYCLOSPORINE (Verkazia) requires the following rule(s) be met for approval:

A. You have vernal keratoconjunctivitis (allergic eye disease)
B. You had a trial of or contraindication (harmful for) to TWO ophthalmic dual-acting mast cell stabilizer/antihistamines (such as ketotifen) or mast cell stabilizers (such as cromolyn)

Commercial Effective: 10/01/22
GUIDELINES FOR USE

Our guideline named CYSTEAMINE BITARTRATE (Procysbi) requires the following rule(s) be met for approval:

A. You have nephropathic cystinosis (rare genetic, metabolic disease which results in an abnormal accumulation of a protein known as cysteine)
B. You are 1 year of age or older
C. You have previously tried an immediate-release formulation of cysteamine bitartrate such as Cystagon

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named CYSTEAMINE HYDROCHLORIDE (Cystaran/Cystadrops) requires the following rule(s) be met for approval:

A. You have cystinosis (a type of genetic disorder where a substance called cysteine builds up in body organs)
B. You require treatment for corneal cystine crystal accumulation or deposits (build up of cysteine in the eye)

Commercial Effective: 10/01/20
**GUIDELINES FOR USE**

Our guideline named **DABIGATRAN (Pradaxa)** requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. Treatment of a venous thromboembolic event (VTE: a type of blood clot disease in your veins)
   2. Reduce the risk of venous thromboembolic event recurrence (happening again)

B. You meet ONE of the following:
   1. You are 3 months to 7 years of age
   2. You are 8 to 11 years of age AND are unable to swallow dabigatran (Pradaxa) capsules

C. You have tried or have a contraindication (harmful for) to rivaroxaban (Xarelto) suspension

D. **If the request is for the treatment of a venous thromboembolic event, approval also requires:**
   1. You have been treated with parenteral anticoagulation agent (type of medication) for at least 5 days

E. **If the request is to reduce the risk of venous thromboembolic event recurrence, approval also requires:**
   1. You have been previously treated

---

**DABIGATRAN**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DABIGATRAN ETEXILATE</td>
<td>PRADAXA</td>
</tr>
<tr>
<td>MESELATE</td>
<td></td>
</tr>
</tbody>
</table>

---

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named **DABRAFENIB (Tafinlar)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (skin cancer that cannot be completely removed by surgery or has spread to other parts of the body)
   2. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
   3. Melanoma (a type of skin cancer)
   4. Locally advanced or metastatic anaplastic thyroid cancer (ATC: a type of thyroid cancer that has spread from where it started to nearby tissue or lymph nodes, or it has spread to other parts of the body)
   5. Unresectable or metastatic solid tumor (tumor that cannot be completely removed by surgery or has spread to other parts of the body)
   6. Low-grade glioma (LGG: a type of brain cancer)

B. **If you have unresectable or metastatic melanoma, approval also requires ONE of the following:**
   1. You have a BRAF V600E mutation (type of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test AND the requested medication will be used as a single agent (by itself)
   2. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test AND the requested medication will be used in combination with Mekinist (trametinib)

C. **If you have melanoma, approval also requires:**
   1. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
   2. The requested medication has not previously been used for more than one year
   3. The requested medication will be used in combination with Mekinist (trametinib) for adjuvant (add-on) treatment
   4. There is involvement of lymph node(s) following complete resection (removal by surgery)

D. **If you have metastatic non-small cell lung cancer, approval also requires:**
   1. You have a BRAF V600E mutation (type of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test
   2. The requested medication will be used in combination with Mekinist (trametinib)

*Criteria continued on next page*
GUIDELINES FOR USE (CONTINUED)

E. If you have locally advanced or metastatic anaplastic thyroid cancer, approval also requires:
   1. You have a BRAF V600E mutation (type of gene mutation)
   2. The requested medication will be used in combination with Mekinist (trametinib)
   3. You have no satisfactory locoregional (restricted to a localized region of the body) treatment options available

F. If you have an unresectable or metastatic solid tumor, approval also requires:
   1. You are 6 years of age or older
   2. You have a BRAF V600E mutation (type of gene mutation)
   3. The requested medication will be used in combination with Mekinist (trametinib)
   4. You have progressed following prior treatment and have no satisfactory alternative treatment options

G. If you have low-grade glioma, approval also requires:
   1. You are 1 to 17 years of age
   2. You have a BRAF V600E mutation (type of gene mutation)
   3. The requested medication will be used in combination with Mekinist (trametinib)
   4. You require systemic therapy (treatment that targets the entire body)

H. If the request is for the tablet for oral suspension, approval also requires:
   1. You cannot swallow Tafinlar (dabrafenib) capsules

Commercial Effective: 06/12/23
GUIDELINES FOR USE

Our guideline named DACLATASVIR (Daklinza) requires the following rule(s) be met for approval:

A. You have hepatitis C, with genotype 1 or genotype 3 infection

B. You are 18 years of age or older

C. You have documentation showing at least ONE detectable HCV (hepatitis C virus) RNA level (amount of virus in your blood) within the past 6 months as evidence of a current and chronic HCV infection.

D. You must be taking Daklinza in combination with Sovaldi, and must meet all required criteria for Sovaldi

E. For Genotype 1 infection approval also requires:

1. Patients without cirrhosis (liver scarring):
   a. You are treatment naïve (never previously treated) or treatment experienced with a peginterferon and ribavirin regimen
   b. You have previously tried Epclusa, Harvoni or Mavyret required and you had adverse effects, intolerance early in therapy or contraindication to (medical reason why you cannot use) Epclusa, Harvoni and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]

2. Patients with decompensated cirrhosis (you have symptoms related to liver scarring):
   a. You have previously tried Epclusa or Harvoni and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Epclusa and Harvoni; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
   b. Concurrent (used at the same time with) ribavirin use required

3. Patients status post liver transplant:
   a. You have previously tried Harvoni or Mavyret and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Harvoni and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]
   b. Concurrent (used at the same time with) ribavirin use required

(Criteria continued on next page)
DACLATASVIR

GUIDELINES FOR USE (CONTINUED)

F. For Genotype 3 infection approval also requires:
   1. Patients without cirrhosis:
      a. You are treatment naïve (never previously treated) or treatment experienced with a peginterferon and ribavirin regimen
      b. You have previously tried Epclusa or Mavyret and you had adverse effect, intolerance early in therapy, or contraindication to (medical reason why you cannot use) Epclusa and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virological response) will not be approved]

   2. Patients with decompensated cirrhosis (Child-Pugh B or C; you have symptoms related to liver scarring):
      a. You have previously tried Epclusa and you had adverse effect, intolerance early in therapy, or contraindication to (medical reason why you cannot use) therapy; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
      b. Concurrent (used at the same time with) ribavirin use required

   3. Post-liver transplant, without cirrhosis:
      a. Previous trial of Mavyret required and you had adverse effects, intolerance early in therapy, or contraindication to (medical reason why you cannot use) therapy; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
      b. Concurrent (used at the same time with) ribavirin use required

   4. Post-liver transplant, with compensated cirrhosis
      a. Previous trial of Epclusa or Mavyret required and you had adverse effects, intolerance early in therapy or contraindication to (medical reason why you cannot use) Epclusa and Mavyret; [an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response) will not be approved]
      b. Concurrent (used at the same time with) ribavirin use required

Daklinza will not be approved if you meet ANY of the following:
- You are using any of the following medications at the same time while on Daklinza: amiodarone, carbamazepine, phenytoin, or rifampin
- You are using any of the following medications at the same time while on Sovaldi: phenobarbital, oxcarbazepine, rifabutin, rifapentine, or tipranavir/ritonavir
- You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
- You have compensated cirrhosis (Child-Pugh A; you have no symptoms related to liver damage) and are not status post liver transplant (you have not had a liver transplant)

Commercial Effective: 01/01/23
GUIDELINES FOR USE

Our guideline named DACOMITINIB (Vizimpro) requires the following rule(s) be met for approval:
A. You have metastatic non-small cell lung cancer (type of cancer that has spread) to other parts of the body
B. You have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
C. Vizimpro will be used as first-line treatment
D. You will NOT be using Vizimpro concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [osimertinib], Iressa [gefitinib])

Commercial Effective: 07/01/22
**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

Our guideline named **DALFAMPRIDINE (Ampyra)** requires the following rule(s) be met for approval:

A. You have multiple sclerosis (MS: a type of nerve disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
D. You have symptoms of a walking disability such as mild to moderate bilateral (both sides) lower extremity weakness or unilateral (one side) weakness plus lower extremity or truncal ataxia (impaired balance or coordination)

**RENEWAL CRITERIA**

Our guideline named **DALFAMPRIDINE (Ampyra)** requires the following rule(s) be met for renewal:

A. You have multiple sclerosis (MS: a type of nerve disorder)
B. You have experienced or maintained at least a 15% improvement in walking ability

Commercial Effective: 08/29/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DARBEPOETIN ALFA (Aranesp) requires the following rule(s) be met for approval:

A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) associated with chronic kidney disease
   2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

B. If you have anemia associated with chronic kidney disease, approval also requires:
   1. You have tried the preferred medication: Retacrit
   2. You have a hemoglobin level (type of blood test) of less than 10g/dL

C. If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires:
   1. You have tried the preferred medication: Retacrit
   2. You have a hemoglobin level of less than 11g/dL OR your hemoglobin level has decreased at least 2g/dL below your baseline level

D. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:
   1. You have tried the preferred medication: Retacrit
   2. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
   3. You have a hemoglobin level of less than 10g/dL

CONTINUED ON NEXT PAGE
DARBEPOETIN ALFA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named DARBEPOETIN ALFA (Aranesp) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Anemia (low amount of healthy red blood cells) associated with chronic kidney disease
   2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

B. If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:
   1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
   2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
   3. Your hemoglobin has reached 10g/dL (if you are not on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
   4. Your hemoglobin has reached 11g/dL (if you are on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions.

C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:
   1. You have a hemoglobin level between 10g/Dl and 12g/Dl

D. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DARIDOREXANT (Quvviq) requires the following rule(s) be met for approval:
A. You have insomnia (a type of sleep condition)
B. You are 18 years of age or older
C. You have premature awakening (waking up too early) and/or abnormal sleep onset delay (cannot fall asleep) lasting 30 minutes or longer, occurring 3 or more times weekly for the last month for acute (short-term) insomnia or for at least 3 months for chronic (long-term) insomnia
D. You have daytime impairment despite adequate time attempting to sleep and treatment of any treatable causes
E. You are NOT using Quvviq at the same time with Z hypnotics (such as eszopiclone, zaleplon, zolpidem) or benzodiazepines (such as estazolam, temazepam, triazolam) for sleep
F. You do NOT have narcolepsy (a type of sleep condition)
G. You had a trial of or contraindication (harmful for) to TWO generic insomnia medications (such as eszopiclone, zaleplon, zolpidem) AND Belsomra

RENEWAL CRITERIA

Our guideline named DARIDOREXANT (Quvviq) requires the following rule(s) be met for renewal:
A. You have insomnia (a type of sleep condition)
B. You have demonstrated improvement of insomnia symptoms but are not currently a candidate for discontinuation
C. You are NOT using Quvviq at the same time with Z hypnotics (such as eszopiclone, zaleplon, zolpidem) or benzodiazepines (such as estazolam, temazepam, triazolam) for sleep
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DAROLUTAMIDE (Nubeqa) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Non-metastatic castration resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
   2. Metastatic hormone-sensitive prostate cancer (mHSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)

B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

C. If you have non-metastatic castration resistant prostate cancer, approval also requires:
   1. You are 18 years of age or older
   2. You have high risk prostate cancer (rapidly increasing prostate specific antigen [PSA: lab result that may indicate prostate cancer] levels)

D. If you have metastatic hormone-sensitive prostate cancer, approval also requires:
   1. The requested medication will be used in combination with docetaxel

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named DAROLUTAMIDE (Nubeqa) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Non-metastatic castration resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)
   2. Metastatic hormone-sensitive prostate cancer (mHSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)

B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

C. If you have metastatic hormone-sensitive prostate cancer, approval also requires:
   1. The requested medication will be used in combination with docetaxel

Commercial Effective: 01/01/23
GUIDELINES FOR USE

Our guideline named DASATINIB (Sprycel) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML: a type of blood cancer) in chronic, accelerated, or myeloid or lymphoid blast phase
   2. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL: a type of blood cancer)

B. If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, approval also requires ONE of the following:
   1. You are 18 years of age or older AND are newly diagnosed
   2. You are between 1 and 17 years of age

C. If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, accelerated phase, or myeloid or lymphoid blast phase, approval also requires:
   1. You are 18 years of age or older
   2. You have resistance or intolerance (side effect) to prior therapy including imatinib (Gleevec)
   3. You had a mutational analysis prior to initiation of therapy AND Sprycel is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile

D. If you have Philadelphia chromosome-positive acute lymphoblastic leukemia, approval also requires ONE of the following:
   1. You are 18 years of age or older AND you have a resistance or intolerance (side effect) to prior therapy such as imatinib (Gleevec) or nilotinib (Tasigna)
   2. You are newly diagnosed, between 1 and 17 years of age, AND using Sprycel in combination with chemotherapy

Commercial Effective: 04/01/22
DECITABINE/CEDAZURIDINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DECITABINE/CEDAZURIDINE</td>
<td>INQOVI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named DECITABINE/CEDAZURIDINE (Inqovi) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Myelodysplastic syndromes (MDS: type of blood cancer)
   2. Chronic myelomonocytic leukemia (CMML: rare form of blood cancer)

B. You are 18 years of age or older

C. If you have myelodysplastic syndromes (MDS), approval also requires:
   1. You meet ONE of the following International Prognostic Scoring System groups (scoring system used to predict the course of a patient's disease):
      a. Intermediate-1
      b. Intermediate-2
      c. High-risk

Commercial Effective: 01/01/21
Our guideline named DEFERASIROX (EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX) requires the following rule(s) be met for approval:

A. You have chronic iron overload due to blood transfusions (you have too much iron from blood transfers) or non-transfusion dependent thalassemia (a blood disorder involving less than normal amounts of an oxygen-carrying protein)

B. The medication is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist/oncologist (tumor/cancer doctor)

C. If you have chronic iron overload due to blood transfusions, approval also requires:
   1. You are 2 years of age or older
   2. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 1000mcg/L (we need at least 2 lab values taken within the previous 3 months)

D. If you have chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT), approval also requires:
   1. You are 10 years of age or older
   2. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 300mcg/L (we need at least 2 lab values taken within the previous 3 months)
   3. Your liver iron concentration (LIC) is at least 5mg Fe/g dry weight or greater

E. Requests for Jadenu sprinkle packets require a trial of equivalent generic Exjade or Jadenu tablets

CONTINUED ON NEXT PAGE
DEFERASIROX

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named DEFERASIROX (EXJADE, JADENU, JADENU SPRINKLE, DEFERASIROX) requires the following rule(s) be met for renewal:

A. You have chronic iron overload due to blood transfusions (you have too much iron from blood transfers) or non-transfusion dependent thalassemia (a blood disorder involving less than normal amounts of an oxygen-carrying protein)

B. If you have chronic iron overload due to blood transfusions, renewal also requires:
   1. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 500 mcg/L (we need at least 2 lab values taken within the previous 3 months)

C. If you have chronic iron overload resulting from non-transfusion dependent thalassemia (NTDT), renewal also requires ONE of the following:
   1. Your serum ferritin levels (amount of iron-containing blood cell proteins) are regularly greater than 300mcg/L (we need at least 2 lab values taken within the previous 3 months)
   2. Your liver iron concentration (LIC) is at least 3mg Fe/g dry weight or greater

Commercial Effective: 09/07/20
DEFEPRON

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEFERIPRONE</td>
<td>FERRIPROX</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DEFERIPRONE (Ferriprox) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Transfusional iron overload due to a thalassemia syndrome (you have too much iron in your body due to a type of blood disorder)
   2. Transfusional iron overload due to a sickle cell disease or other anemias (you have too much iron in your body due to a type of blood disorder)

B. Therapy is prescribed by or given in consultation with a hematologist (a type of blood doctor) or hematologist/oncologist (a type of cancer doctor)

C. You have tried or have a contraindication (harmful for) to at least ONE of the following: Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)

D. You meet ONE of the following:
   1. You are experiencing intolerable toxicities or clinically significant adverse effects or have a contraindication (harmful for) to current chelators (drugs that bind to iron): Exjade (deferasirox), Jadenu (deferasirox), or Desferal (deferoxamine)
   2. Current chelation therapy (therapy that lowers iron levels) with Exjade [deferasirox], Jadenu [deferasirox], or Desferal [deferoxamine]) is not working well enough

E. If the request is for Ferriprox (deferiprone) tablets, approval also requires:
   1. You are 8 years of age or older

F. If the request is for Ferriprox oral solution, approval also requires:
   1. You are 3 years of age or older

CONTINUED ON NEXT PAGE
DEFERIPRONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **DEFERIPRONE (Ferriprox)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Transfusional iron overload due to thalassemia syndrome (you have too much iron in your body due to a type of blood disorder)
   2. Transfusional iron overload due to a sickle cell disease or other anemias (you have too much iron in your body due to a type of blood disorder)

B. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay above 500mcg/L (at least 2 lab values in the previous 3 months)

C. **If the request is for Ferriprox (deferiprone) tablets, approval also requires:**
   1. You are 8 years of age or older

D. **If the request is for Ferriprox oral solution, approval also requires:**
   1. You are 3 years of age or older

Commercial Effective: 04/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DEFEROXAMINE (Desferal) requires the following rule(s) be met for approval:
A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
B. Therapy is prescribed by or given in consultation with a hematologist (blood specialty doctor) or hematologist-oncologist (tumor/cancer doctor)
C. You are 3 years of age or older
D. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 1000mcg/L (shown by at least 2 lab values in the previous 3 months)

RENEWAL CRITERIA

Our guideline named DEFEROXAMINE (Desferal) requires the following rules be met for renewal:
A. You have chronic iron overload due to transfusion-dependent anemias (blood doesn't have enough healthy red blood cells)
B. Your serum ferritin levels (amount of iron-containing blood cell proteins) stay greater than 500mcg/L (at least 2 lab values in the previous 3 months)

Commercial Effective: 04/17/23
DEFLAZACORT

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DEFLAZACORT (Emflaza) requires the following rules be met for approval:

A. You have Duchenne muscular dystrophy (inherited muscular weakness that gets worse)
B. You are 2 years of age or older
C. You doctor confirms your diagnosis with genetic testing
D. The drug is prescribed by or recommended by a neurologist (nerve system doctor) specializing in treatment of Duchenne muscular dystrophy (DMD) at a DMD treatment center
E. You have tried prednisone or prednisolone for at least 6 months and meet one of the following:
   1. Prednisone or prednisolone did not work and you meet ALL of the following criteria:
      a. You are not in Stage 1: pre-symptomatic phase
      b. There is no steroid myopathy (muscle disease due to steroid)
      c. You have documentation that your disease is advanced— you cannot walk, cannot function, cannot breathe using standard measures over time, consistent with advancing disease (stage 2 or higher). Acceptable standard measures include: 6-minute walk distance (6MWD), time to ascend/descend 4 stairs, rise from floor time (Gower’s maneuver), 10-meter run/walk time, or North Star Ambulatory Assessment (NSAA), Physician global assessments (PGA), pulmonary function (forced vital capacity, lung function tests), upper limb strength (propelling a wheelchair 30 feet)
   2. You had adverse side effects while on prednisone or prednisolone and there is documentation of literature-based evidence provided supporting Emflaza’s decreased effect for that side effect

Note: Requests due to side effects while on prednisone or prednisolone that are named or listed in the prescribing information of Emflaza will not be approved

CONTINUED ON NEXT PAGE
DEFLAZACORT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named DEFLAZACORT (Emflaza) requires the following rules be met for renewal:

A. You have Duchenne muscular dystrophy (inherited muscular weakness that worsens)

B. You meet ONE of the following criteria:

i. If you are currently ambulatory (can walk), renewal also requires:
   a. You have shown function, stabilization or improvement in a standard set of ambulatory or functional status measures since being on Emflaza. These measures must be monitored, tracked, and documented consistently. Acceptable standard measures include: 6-minute walk distance, time to ascend/descend 4 stairs, rise from floor time (Gower's maneuver), 10-meter run/walk time, North Star Ambulatory Assessment, Physician Global Assessments

ii. If you are currently non-ambulatory (cannot walk), renewal also requires:
   a. You have maintained or have a less than expected decrease in pulmonary (breathing) function and/or upper limb strength assessed by standard measures since being on Emflaza. These measures must be monitored, tracked, and documented consistently. Acceptable standard measures include: pulmonary function (force vital capacity, pulmonary function tests), upper limb strength measures (propelling a wheelchair 30 feet), Physician Global Assessments

Commercial Effective: 07/01/20
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

DELAFLOXACIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DELAFLOXACIN</td>
<td>BAXDELA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named DELAFLOXACIN (Baxdela) requires the following rule(s) be met for approval:

A. You meet ONE of the following:
   1. The requested medication is prescribed by or given in consultation with an infectious disease (ID) specialist or
   2. You have an acute (serious and short-term) bacterial skin or skin structure infection (ABSSSI); OR community-acquired bacterial pneumonia (CABP: type of lung infection)

B. If you have an acute bacterial skin or skin structure infection, approval also requires:
   1. You are at least 18 years of age
   2. The infection is caused by any of the following bacteria: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin susceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa
   3. You do not have a diagnosis of animal or human bite, necrotizing fasciitis (flesh eating disease), diabetic foot infection, decubitis ulcer formation (pressure/bed ulcer), myonecrosis (dead muscle tissue) or ecthyma gangrenosum
   4. You meet ONE of the following criteria:
      i. If antimicrobial susceptibility test is available (you have a test showing what drugs work on which bacteria of the infection site), we require the results of the test from the infection site show the bacteria is both a) resistant to ONE standard of care agent for acute bacterial skin or skin structure infection (such as sulfamethoxazole/trimethoprim, levofloxacin, clindamycin, cephalaxin, or vancomycin), AND b) delafloxacin will work against the bacteria
      ii. If antimicrobial susceptibility test is not available (you do not have a test showing what drugs work on which bacteria of the infection site), we require you had a trial of or contraindication to (a medical reason why you cannot use) ONE of the following agents: a penicillin (such as amoxicillin), a fluoroquinolone (such as levofloxacin, ciprofloxacin, moxifloxacin), a cephalosporin (such as ceftriaxone, cephalaxin, cefazolin), or a gram positive targeting antibiotic (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin)

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

C. If you have community-acquired bacterial pneumonia (CABP: type of lung infection), approval also requires:
   1. You are 18 years of age or older
   2. The infection is caused by any of the following bacteria: *Streptococcus pneumonia*, *Staphylococcus aureus* (methicillin-susceptible [MSSA] isolates only), *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Chlamydia pneumoniae*, *Legionella pneumophila* or *Mycoplasma pneumoniae*
   3. You meet **ONE** of the following criteria:
      i. If antimicrobial susceptibility test is available (you have a test showing what drugs work on which bacteria of the infection site), we require the results of the test from the infection site show the bacteria is both a) resistant to **TWO** standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid) AND b) delafloxacin will work against the bacteria
      ii. If antimicrobial susceptibility test is not available (you do not have a test showing what drugs work on which bacteria of the infection site), we require you had a trial or contraindication to (a medical reason why you cannot use) **TWO** standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid)

Commercial Effective: 04/01/20
GUIDELINES FOR USE

Our guideline named **DESIRUDIN (Iprivask)** requires that you are receiving Iprivask for the prevention of deep vein thrombosis (DVT; blood clot in a deep vein, usually in the legs) and you are undergoing elective hip replacement surgery.

Commercial Effective: 07/01/20
DEUCRAVACITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEUCRAVACITINIB</td>
<td>SOTYKTU</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEUCRAVACITINIB (Sotyktu)** requires the following rule(s) be met for approval:

A. You have moderate to severe plaque psoriasis (a type of skin condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, face, or genital area
E. You had a trial of or contraindication (harmful for) to ONE standard therapy (such as PUVA [Phototherapy Ultraviolet Light A], UVB [Ultraviolet Light B], topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, cyclosporine)
F. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Tremfya (guselkumab), Otezla (apremilast), Taltz (ixekizumab)

RENEWAL CRITERIA

Our guideline named **DEUCRAVACITINIB (Sotyktu)** requires the following rule(s) be met for renewal:

A. You have moderate to severe plaque psoriasis (a type of skin condition)
B. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: a tool for evaluating severity of psoriasis) of at least 50% or more while on therapy
C. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Skyrizi (risankizumab-rzza), Enbrel (etanercept), Tremfya (guselkumab), Otezla (apremilast), Taltz (ixekizumab)

Commercial Effective: 07/01/23
Guidelines for Use

Our guideline named **DEUTETRABENAZINE (Austedo)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Chorea (involuntary muscle movements) associated with Huntington’s disease
   2. Moderate to severe tardive dyskinesia (uncontrolled body movements)

B. You are 18 years of age or older

C. **If you have chorea associated with Huntington’s disease, approval also requires:**
   1. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor) or movement disorder specialist

D. **If you have moderate to severe tardive dyskinesia, approval also requires:**
   1. Moderate to severe tardive dyskinesia (uncontrolled body movements) has been present for at least 3 months
   2. Therapy is prescribed by or in consultation with a neurologist (type of brain doctor), movement disorder specialist, or psychiatrist (type of mental health doctor)
   3. You have a prior history of using antipsychotic medications (such as aripiprazole, haloperidol, ziprasidone) or metoclopramide for at least 3 months (or at least 1 month if you are 60 years of age or older) as documented in your prescription claims history

Commercial Effective: 05/08/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **DEXTROMETHORPHAN-BUPROPION (Auvelity)** requires the following rule(s) be met for approval:

A. You have major depressive disorder (MDD: a type of mental illness)
B. You are 18 years of age or older
C. You had a trial of or contraindication (harmful for) to Trintellix
D. You had a trial of or contraindication (harmful for) to any generic antidepressant indicated for the treatment of major depressive disorder (such as sertraline, duloxetine)

RENEWAL CRITERIA

Our guideline named **DEXTROMETHORPHAN-BUPROPION (Auvelity)** requires the following rule(s) be met for renewal:

A. You have major depressive disorder (MDD: a type of mental illness)
B. You have responded to therapy

Commercial Effective: 10/17/22
**GUIDELINES FOR USE**

Our guideline named **DEXTROMETHORPHAN with QUINIDINE (Nuedexta)** requires you have a pseudobulbar affect (sudden, uncontrollable laughter) for approval.

---

**Commercial Effective: 07/01/20**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEXTROMETHORPHAN/ QUINIDINE</td>
<td>NUEDEXTA</td>
</tr>
</tbody>
</table>

---
Our guideline named **DIABETIC TEST STRIPS** requires ONE of following rules be met for approval:

A. You have tried ONE preferred blood glucose (diabetic) meter and test strips. The preferred meters and test strips are FreeStyle and Precision by Abbott

B. You require a non-preferred blood glucose test strip due to significant visual and/or cognitive impairment (problems with sight and/or memory and thinking)

C. You require a non-preferred blood glucose test strip because you use another manufacturer’s companion insulin pump

Request for non-preferred test strips will not be approved if due to a need for data management software. Please note that data management software is available for the formulary test strip products. Please contact Abbott for data management software and a connection cable for the meter.

Commercial Effective: 02/08/21
DICHLORPHENAMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICHLORPHENAMIDE</td>
<td>KEVEYS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DICHLORPHENAMIDE (Keveyis) requires the following rule(s) be met for approval:

A. You have a primary hypokalemic periodic paralysis (extreme muscle weakness with low potassium levels in your blood), primary hyperkalemic periodic paralysis (extreme muscle weakness with high potassium levels in your blood), or related variants

B. You are 18 years of age or older

C. The medication is prescribed by or in consultation with a neurologist (a type of brain doctor)

D. You do not have hepatic insufficiency (liver failure), pulmonary obstruction (difficulty breathing due to blockage of airflow), or a health condition that requires you to use high-dose aspirin at the same time

E. If you have primary hypokalemic periodic paralysis, approval also requires:
   1. You have tried acetazolamide AND a potassium-sparing diuretic (spironolactone, triamterene)

F. If you have primary hyperkalemic periodic paralysis or related variants, approval also requires:
   1. You have tried acetazolamide AND a thiazide diuretic (hydrochlorothiazide)

RENEWAL CRITERIA

Our guideline named DICHLORPHENAMIDE (Keveyis) requires the following rules be met for renewal:

A. You have primary hyperkalemic periodic paralysis (extreme muscle weakness with high potassium levels in your blood), primary hypokalemic periodic paralysis (extreme muscle weakness with low potassium levels in your blood), or related variants

B. You have experienced at least two fewer attacks per week from baseline (measurement before you started treatment)

Commercial Effective: 02/06/23
DICLOFENAC TOPICAL GEL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICLOFENAC SODIUM</td>
<td>SOLARAZE, DICLOFENAC SODIUM</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named DICLOFENAC TOPICAL GEL (Solaraze) requires the following rule(s) be met for approval:

A. You have actinic keratosis (a type of skin condition)
B. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor) or oncologist (a type of cancer doctor)
C. You had a trial of or contraindication (harmful for) to topical fluorouracil (such as Efudex, Fluoroplex, Carac)

Commercial Effective: 11/01/22
DICLOFENAC TOPICAL SOLUTION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DICLOFENAC SODIUM</td>
<td>PENNSAID, DICLOFENAC SODIUM</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named DICLOFENAC TOPICAL SOLUTION (Pennsaid) requires the following rule(s) be met for approval:
A. You have osteoarthritis (a type of joint condition) of the knee(s)
B. You had a trial of diclofenac 1% gel AND diclofenac 1.5% drops

Commercial Effective: 11/01/22
Our guideline named **DIGOXIN** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Heart failure (a type of heart condition)
   2. Chronic atrial fibrillation (a type of heart condition)

B. **If you have chronic atrial fibrillation, approval also requires:**
   1. You are 18 years of age or older

**GUIDELINES FOR USE**

Commercial Effective: 07/01/22

---

**DIGOXIN**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIGOXIN</td>
<td>DIGOXIN</td>
</tr>
</tbody>
</table>

---

**DIGOXIN**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIGOXIN</td>
<td>DIGOXIN</td>
</tr>
</tbody>
</table>
DIMETHYL FUMARATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIMETHYL FUMARATE</td>
<td>TECFIDERA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **DIMETHYL FUMARATE (Tecfidera)** requires the following rules be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

C. If you are requesting brand Tecfidera, you must have previously tried generic dimethyl fumarate

Commercial Effective: 10/19/20
GUIDELINES FOR USE

Our guideline named **DIROXIMEL FUMARATE (Vumerity)** requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (immune system eats away at protective covering of nerves and you have new or increasing symptoms), to include clinically isolated syndrome, relapsing-remitting disease (symptoms return and go away) and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

Commercial Effective: 04/01/20
DONEPEZIL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>DONEPEZIL HCL</td>
<td>ADLARITY</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named DONEPEZIL (Adlarity) requires the following rule(s) be met for approval:

A. You have dementia (a type of memory disorder) associated with Alzheimer’s disease (a progressive brain disorder that slowly destroys memory and thinking skills)

B. You had a trial of or contraindication (harmful for) to TWO generic oral acetylcholinesterase inhibitors (such as donepezil, galantamine)

C. You had a trial of or contraindication (harmful for) to one generic acetylcholine inhibitor patch (such as rivastigmine)

Commercial Effective: 07/18/22
GUIDELINES FOR USE

Our guideline named DORNASE ALFA (Pulmozyme) requires the following rule(s) be met for approval:
A. You have cystic fibrosis (CF: an inherited disorder that damages lung and digestive system with fluid build up)
B. If you are requesting twice daily dosing, we require that you have tried and failed once daily dosing

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DROXIDOPA (Northera) requires the following rules be met for approval:
A. You have neurogenic orthostatic hypotension (a type of low blood pressure)
B. You are 18 years of age or older
C. You have a documented diagnosis of neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency (you are missing a type of enzyme), or non-diabetic autonomic neuropathy (nerve pain/damage)
D. You have previously tried midodrine OR fludrocortisone, unless there is a medical reason why you cannot (contraindication)
E. Therapy is prescribed or given in consultation with a neurologist (nerve doctor) or cardiologist (heart doctor)
F. Your doctor performed baseline blood pressure readings while you are sitting and also within 3 minutes of standing from a supine (lying face up) position
G. You have a documented decrease of at least 20 mmHg in systolic blood pressure or 10 mmHg diastolic blood pressure within 3 minutes after standing from a sitting position
H. You have persistent symptoms of neurogenic orthostatic hypotension which includes dizziness, lightheadedness, and the feeling of 'blacking out'

RENEWAL CRITERIA

Our guideline named DROXIDOPA (Northera) requires the following rule(s) be met for renewal:
A. You have neurogenic orthostatic hypotension (NOH)
B. You have demonstrated improvement in severity from baseline symptoms of dizziness, lightheadedness, feeling faint, or feeling like you may black out
C. You had an increase in systolic blood pressure from baseline of at least 10mmHg upon standing from a supine (lying face up) position

Commercial Effective: 03/15/21
DULOXETINE

GUIDELINES FOR USE

Our guideline named **DULOXETINE (Drizalma Sprinkle)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Major depressive disorder (a type of mental illness)
   2. Generalized anxiety disorder (a type of mental illness)
   3. Diabetic peripheral neuropathy (a type of nerve damage caused by high blood sugar)
   4. Fibromyalgia (a type of pain disorder)
   5. Chronic musculoskeletal pain (severe pain relating to muscles and bones)

B. **If you have major depressive disorder, diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain, approval also requires:**
   1. You are 18 years of age or older
   2. You had a trial of generic duloxetine
   3. You cannot swallow duloxetine capsules

C. **If you have generalized anxiety disorder, approval also requires:**
   1. You are 7 years of age or older
   2. You had a trial of generic duloxetine
   3. You cannot swallow duloxetine capsules

Commercial Effective: 04/01/23
DUPILUMAB

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named DUPILUMAB (Dupixent) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe atopic dermatitis (a type of skin condition)
   2. Moderate to severe asthma
   3. Chronic rhinosinusitis with nasal polyposis (a type of long-term nasal condition)
   4. Eosinophilic esophagitis (a type of immune system disorder)
   5. Prurigo nodularis (a type of skin condition)

B. If you have moderate to severe atopic dermatitis, approval also requires:
   1. You are 6 months of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
   3. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
   4. You had a trial of or contraindication (harmful for) to ONE of the following: topical corticosteroid (such as hydrocortisone, clobetasol, halobetasol propionate), topical calcineurin inhibitor [Elidel (pimecrolimus), Protopic (tacrolimus)], topical PDE-4 inhibitor [Eucrisa (crisaborole)], topical JAK inhibitor [Opzelura (ruxolitinib)], phototherapy (light therapy)
   5. You will NOT use Dupixent concurrently (at the same time) with other systemic biologics (such as Adbry [tralokinumab-Idrm]) or any JAK inhibitors (such as Rinvoq [upadacitinib], topical Opzelura [ruxolitinib], Cibinqo [abrocitinib]) for the treatment of atopic dermatitis
   6. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Adbry [tralokinumab-Idrm]) and switching to the requested drug
      b. You have atopic dermatitis involving at least 10 percent of body surface area (BSA)
      c. Your atopic dermatitis is affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds)

(Initial denial text continued on next page)
DUPILUMAB

INITIAL CRITERIA (CONTINUED)

C. If you have moderate to severe asthma, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a doctor specializing in pulmonary (lung/breathing) or allergy medicine
   3. You have an eosinophilic phenotype asthma (type of adult inflammatory asthma) with a documented blood eosinophil level of 150 to 1500 cells/mcL within the past 12 months OR you have oral corticosteroid-dependent asthma
   4. You are being treated at the same time with medium, high-dose, or maximally tolerated inhaled corticosteroid [such as triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication such as long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), or theophylline
   5. You will NOT use Dupixent concurrently (at the same time) with Xolair (omalizumab) or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when these are used for the treatment of asthma
   6. You meet ONE of the following:
      a. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid burst lasting at least 3 days within the past 12 months OR at least ONE serious exacerbation requiring hospitalization or emergency room (ER) visit within the past 12 months
      b. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
         i. Daytime asthma symptoms more than twice per week
         ii. Any night waking due to asthma
         iii. Use of short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
         iv. Any activity limitation due to asthma

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. If you have chronic rhinosinusitis with nasal polyposis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, throat doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
   3. There is documentation of evidence of nasal polyps (non-cancerous growths) by direct examination, endoscopy (using a small camera) or sinus CT scan
   4. You have inadequately controlled disease as determined by ONE of the following:
      a. Use of systemic steroids in the past 2 years
      b. Endoscopic sinus surgery (using a small camera to help in surgery)
   5. Dupixent will be used as add-on maintenance treatment (in conjunction with maintenance intranasal steroids)
   6. You had a previous 90-day trial of ONE intranasal corticosteroid

E. If you have eosinophilic esophagitis, approval also requires:
   1. You meet ONE of the following:
      a. You are 18 years of age or older
      b. You are 12 to 17 years of age AND weigh at least 40 kilograms
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
   3. Your diagnosis is confirmed by an esophagogastroduodenoscopy (EGD) with biopsy (a test that looks at the lining of your food pipe, stomach, and small intestine)
   4. You had a trial of or contraindication (harmful for) to dietary therapy
   5. You had a trial of or contraindication (harmful for) to a proton pump inhibitor (such as omeprazole, lansoprazole, pantoprazole)

F. If you have prurigo nodularis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (skin doctor), immunologist (type of immune system doctor), or allergist
   3. You have chronic pruritis (itch lasting longer than 6 weeks), presence of multiple pruriginous lesions (wounds), and a history or sign of a prolonged scratching behavior
   4. You had a trial of or contraindication (harmful for) to ONE of the following: topical capsaicin, topical ketamine/amitriptyline/lidocaine, gabapentinoids (e.g., gabapentin, pregabalin), antidepressants (serotonin-norepinephrine reuptake inhibitor [SNRI], selective serotonin reuptake inhibitor [SSRI], tricyclic antidepressant [TCA]), k-/mu-opioid receptor antagonists (e.g., naltrexone, butorphanol), thalidomide, topical corticosteroids, topical calcineurin inhibitors, topical calcipotriol, intralesional corticosteroids, phototherapy, methotrexate, cyclosporine, azathioprine
GUIDELINES FOR USE

Our guideline named **DUVELISIB (Copiktra)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Relapsed or refractory chronic lymphocytic leukemia (CLL: a type of blood cancer that has returned after treatment or does not fully respond to treatment)
   2. Small lymphocytic lymphoma (SLL: a type of blood cancer)

B. You are 18 years of age or older

C. You have received at least two prior therapies for chronic lymphocytic leukemia or small lymphocytic lymphoma

---

**Commercial Effective: 04/01/22**
EDARAVONE ORAL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDARAVONE</td>
<td>RADIJAVA ORS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **EDARAVONE ORAL (Radicava ORS)** requires the following rule(s) be met for approval:

A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
B. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist at an ALS Specialty Center or Care Clinic
C. You have had ALS (from onset of symptoms) for 3 years or less
D. You have a forced vital capacity (FVC: amount of air exhaled from lungs) of greater than 70 percent
E. You have tried riluzole OR are currently taking riluzole
F. You have mild to moderate ALS with a score of 2 or higher in all of the following 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R: a tool for evaluating functional status): speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, dyspnea (difficulty breathing), orthopnea (shortness of breath while lying down), respiratory insufficiency (a type of breathing condition)

RENEWAL CRITERIA

Our guideline named **EDARAVONE ORAL (Radicava ORS)** requires the following rule(s) be met for renewal:

A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
B. You do not require invasive ventilation (inserting a breathing tube into your throat)
C. You have improved baseline functional ability OR you have maintained a score of 2 or greater in all 12 items of the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)

Commercial Effective: 06/15/22
EFINACONAZOLE

GUIDELINES FOR USE

Our guideline named EFINACONAZOLE (Jublia) requires the following rule(s) be met for approval:

A. You have onychomycosis of the toenail(s) (toenail fungus)
B. You have previously tried the following unless contraindicated (a medical reason why you cannot use): ciclopirox topical solution AND either oral terbinafine OR oral itraconazole
C. You have at least ONE of the following conditions:
   1. Diabetes, peripheral vascular disease (narrowed blood vessels reduce blood flow to the limbs), or immunosuppression (weakened immune system)
   2. Pain surrounding the nail or soft tissue involvement

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named **ELACESTRANT (Orserdu)** requires the following rule(s) be met for approval:

A. You have advanced or metastatic breast cancer (breast cancer that has spread to other parts of the body)
B. Your breast cancer is estrogen receptor (ER: type of protein)-positive, human epidermal growth factor receptor 2 (HER2: type of protein)-negative with estrogen receptor 1 (ESR1: a gene) mutation(s)
C. You have disease progression following endocrine therapy (disease has worsened after using a type of hormone therapy)

Commercial Effective: 07/01/23
ELAGOLIX

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ELAGOLIX (Orilissa)** requires the following rule(s) be met for approval:

A. You have moderate to severe pain associated with endometriosis (condition affecting the uterus)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
D. Your diagnosis of endometriosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
E. Orilissa will NOT be used at the same time with another GnRH-modulating agent (such as Lupron Depot [leuprolide], Synarel [nafarelin], Zoladex [goserelin])
F. Requests for Orilissa 200mg twice daily will only be approved if you have normal liver function or mild hepatic (liver) impairment (Child-Pugh Class A)

RENEWAL CRITERIA

Our guideline named **ELAGOLIX (Orilissa)** requires the following rule(s) be met for renewal:

A. You have moderate to severe pain associated with endometriosis (condition affecting the uterus)
B. You have improvement of pain related to endometriosis while on therapy
C. You have normal liver function or mild hepatic (liver) impairment (Child-Pugh Class A)
D. Orilissa will NOT be used at the same time with another GnRH-modulating agent (such as Lupron Depot [leuprolide], Synarel [nafarelin], Zoladex [goserelin])

Requests will not be approved if you meet ONE of the following:

A. You have received a 6-month course of Orilissa 200mg twice daily
B. You have received a 6-month course of Orilissa 150mg once daily and you have moderate hepatic (liver) impairment (Child-Pugh Class B)
C. You have received a 24-month course of Orilissa 150mg once daily and you have normal liver function or mild (liver) hepatic impairment (Child-Pugh Class A)

Commercial Effective: 06/01/23
ELAGOLIX/ESTRADIOL/NORETHINDRONE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ELAGOLIX/ESTRADIOL/NORETHINDRONE (Oriahnn) requires the following rule(s) be met for approval:
A. The request is for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
B. You are 18 years of age or older
C. You are a premenopausal woman
D. Therapy is prescribed by or given in consultation with an obstetrician or gynecologist (OB/GYN: doctor who specializes in women’s reproductive system)
E. You have not received a total of 24 months cumulative treatment with Oriahnn

RENEWAL CRITERIA

Our guideline named ELAGOLIX/ESTRADIOL/NORETHISTERONE (Oriahnn) requires the following rule(s) be met for renewal:
A. The request is for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
B. You had improvement of heavy menstrual bleeding on therapy
C. You have not received a total of 24 months cumulative treatment with Oriahnn

Commercial Effective: 01/01/21
ELAPEGADEMASE-LVLR

Generic Brand
ELAPEGADEMASE-LVLR REVCOVİ

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ELAPEGADEMASE-LVLR (Revcovi) requires the following rule(s) be met for approval:

A. You have adenosine deaminase severe combined immune deficiency (type of inherited disorder that damages immune system) as shown by ONE of the following:
   1. Confirmatory generic test
   2. Suggestive laboratory findings such as elevated deoxyadenosine nucleotide levels or lymphopenia (not enough of a type of white blood cell) AND you have hallmark signs/symptoms such as recurrent infections, failure to thrive, persistent diarrhea

B. The requested medication is prescribed by or given in consultation with an immunologist (immune system doctor), hematologist/oncologist (blood/cancer doctor), or physician specializing in inherited metabolic disorders

C. You have failed or are not a candidate for hematopoietic cell transplant (blood cell transplant from bone marrow), OR the requested medication will be used as a bridging therapy prior to planned hematopoietic cell transplant or gene therapy

RENEWAL CRITERIA

Our guideline named ELAPEGADEMASE-LVLR (Revcovi) requires the following rule(s) be met for renewal:

A. You have adenosine deaminase severe combined immune deficiency (type of inherited disorder that damages immune system)

B. You have documentation of trough plasma adenosine deaminase activity greater than or equal to 30 mmol/hr/L AND trough deoxyadenosine nucleotide levels less than 0.02 mmol/L

C. You have improvement in/maintenance of immune function from baseline (such as decrease in number and severity of infections), AND you have not received successful hematopoietic cell transplantation (HCT) or gene therapy

Commercial Effective: 07/01/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
ELBASVIR/GRAZOPREVIR

GUIDELINES FOR USE

Our guideline for ELBASVIR/GRAZOPREVIR (Zepatier) requires the following rule(s) be met for approval:
A. You have chronic hepatitis C (type of liver infection)
B. You have genotype 1 or genotype 4 hepatitis C
C. You are 12 years of age or older OR weigh at least 30kg
D. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
E. You have previously tried Epclusa or Harvoni unless you have a contraindication (harmful for) to both. Patients with previous failure of a full treatment of Epclusa or Harvoni will not be approved
F. If you have genotype 1a infection, we require testing for baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)
G. Ribavirin use is required if you meet ANY of the following:
   1. You have genotype 1a or 1b infection and were previously treated with HCV protease inhibitor triple therapy (HCV protease inhibitor (such as Victrelis, Incivek, Olysio) plus peginterferon/ribavirin
   2. You have genotype 1a infection, are treatment naïve, and have baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)
   3. You have genotype 1a infection, were previously treated, and have baseline NS5A (nonstructural protein 5A) polymorphisms (variations of a type of protein)
   4. You have genotype 4 infection and were previously treated
H. Treatment experienced patients will be approved per product labeling (previous failure of peginterferon/ribavirin for genotype 1a, 1b or 4; previous failure of HCV protease inhibitor triple therapy regimen for genotype 1a or 1b infection)

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

Zepatier will not be approved if you meet any of the following:

A. You are using any of the following interacting medications at the same time while on elbasvir/grazoprevir (Zepatier): phenytoin, carbamazepine, rifampin, efavirenz (such as Atripla, Sustiva), atazanavir (such as Evotaz, Reyataz), darunavir (such as Prezobix, Prezista), lopinavir, saquinavir, tipranavir, cyclosporine, nafcillin, ketoconazole, modafinil, bosentan, etravirine, elvitegravir/cobicistat/emtricitabine/tenofovir (such as Stribild, Genvoya), atorvastatin at doses higher than 20mg daily, rosvastatin at doses greater than 10mg daily, sofosbuvir (Sovaldi), velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), pibrentasvir/glecaprevir (Mavyret), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)

B. You have moderate or severe liver impairment (Child-Pugh B or C: type of liver condition)

C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)

Commercial Effective: 01/01/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

ELEXACAFTOR/TEZACAFTOR/IVACAFTOR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELEXACAFTOR/TEZACAFTOR/IVACAFTOR</td>
<td>TRIKAFTA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (Trikafta)** requires the following rule(s) be met for approval:

A. You have cystic fibrosis (a type of lung disorder)
B. You are 2 years of age or older
C. Therapy is prescribed by or in consultation with a pulmonologist (doctor who specializes in lungs) or cystic fibrosis expert
D. You meet ONE of the following:
   1. There is documentation (such as chart notes, lab result, diagnostic test result) that you have at least one **F508del** mutation (an abnormal change in your gene) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
   2. There is documentation (such as chart notes, lab result, diagnostic test result) that you have at least one of the following mutations in the CFTR gene:

          3141del9 | E822K | G1069R | L967S | R117L | S912L
          546insCTA | F191V | G1244E | L997F | R117P | S945L
         A46D | F311del | G1249R | L1077P | R170H | S977F
         A120T | F311L | G1349D | L1324P | R258G | S1159F
         A234D | F508C | H139R | L1335P | R334L | S1159P
         A349V | F508C; S1251N | H199Y | L1480P | R334Q | S1251N
         A455E | F508del | H939R | M152V | R347H | S1255P
         A554E | F575Y | H1054D | M265R | R347L | T338I
         A1006E | F1016S | H1085P | M952I | R347P | T1036N
         A1067T | F1052V | H1085R | M952T | R352Q | T1053I
         D110E | F1074L | H1375P | M1101K | R352W | V201M
         D110H | F1099L | I148T | P5L | R553Q | V232D
         D192G | G27R | I175V | P67L | R668C | V456A
         D443Y; G576A; R668C | G85E | I336K | P205S | R751L | V456F
         D443Y; G576A; R668C | G126D | I502T | P574H | R792G | V562I
         D579G | G178E | I601F | Q98R | R933G | V754M
         D614G | G178R | I618T | Q237E | R1066H | V1153E
         D836Y | G194R | I807M | Q237H | R1070Q | V1240G

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/26/2023  Page 188 of 675
**RENEWAL CRITERIA**

Our guideline named ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (Trikafta) requires the following rule(s) be met for renewal:

A. You have cystic fibrosis (a type of lung disorder)

B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:

1. You have improved, maintained, or demonstrated less than expected decline in forced expiratory volume (FEV1: amount of air you can exhale in 1 second)

2. You have improved, maintained, or demonstrated less than expected decline in body mass index (BMI: a tool for evaluating body fat)

3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

Commercial Effective: 05/15/23
ELTROMBOPAG

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ELTROMBOPAG (Promacta) requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:
   1. Chronic immune (idiopathic) thrombocytopenia (low levels of the blood cells that prevent bleeding)
   2. Thrombocytopenia (low blood platelet count) due to chronic hepatitis C
   3. Severe aplastic anemia (type of blood disorder)

B. If you are greater than 12 years of age and the request is for Promacta packets, approval also requires:
   1. You previously had a trial of Promacta tablets
   2. You have a medical need for powder packets

C. If you have chronic immune (idiopathic) thrombocytopenia, approval also requires:
   1. You are 1 year of age or older
   2. You have tried corticosteroids or immunoglobulins, or did not have a good enough response to a splenectomy (removal of spleen) - unless there is a medical reason why you cannot (contraindication)
   3. The medication is prescribed by or given in consultation with a hematologist (blood specialist) or immunologist (allergy/immune system doctor)

D. If you have thrombocytopenia due to chronic hepatitis C, approval also requires:
   1. Your thrombocytopenia does not allow you to start interferon-based therapy (type of drug for hepatitis) or limits your ability to maintain interferon-based therapy

E. If you have severe aplastic anemia, approval also requires ONE of the following:
   1. You are 2 years of age or older and Promacta will be used in combination with standard immunosuppressive therapy (treatment that prevents activity from your immune system) as first-line treatment
   2. You did not have a good enough response to immunosuppressive therapy

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of thrombocytopenia due to chronic hepatitis C or severe aplastic anemia, please refer to the Initial Criteria section.

Our guideline named ELTROMBOPAG (Promacta) requires the following rules be met for renewal:

A. You have chronic immune (idiopathic) thrombocytopenia (low levels of the blood cells that prevent bleeding)
B. You have a clinical response, as defined by an increase in platelet count to at least 50X10⁹/L (at least 50,000 per microliter)

Commercial Effective: 04/20/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ELUXADOLINE (Viberzi) requires the following rule(s) be met for approval:

A. You have irritable bowel syndrome with diarrhea (an intestinal problem causing pain in the belly, gas, diarrhea, and constipation)
B. You are 18 years of age or older
C. The medication is prescribed by or given in consultation with a gastroenterologist (a doctor who specializes in conditions of the stomach, intestine and related organs)
D. You had a trial of Xifaxan (rifaximin) AND either tricyclic anti-depressants (such as amitriptyline, desipramine) OR dicyclomine, unless there is a medical reason why you cannot (contraindication)

RENEWAL CRITERIA

Our guideline named ELUXADOLINE (Viberzi) requires the following rule(s) be met for renewal:

1. You have irritable bowel syndrome with diarrhea (an intestinal problem causing pain in the belly, gas, diarrhea, and constipation)
2. You had at least 30% decrease in abdominal pain (stomach pain) on a 0-10 point pain scale
3. You had at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7).

Commercial Effective: 07/01/20
EMICIZUMAB-KXWH

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named EMICIZUMAB-KXWH (Hemlibra) requires the following rule(s) be met for approval:
A. You have hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
C. The requested medication will be used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
D. If you have hemophilia A with factor VIII inhibitors (a type of protein), approval also requires:
   1. You have a history of a high titer (concentration) of factor VIII inhibitor defined as at least 5 or more Bethesda units per milliliter
E. If you have hemophilia A without factor VIII inhibitors (a type of protein), approval also requires ONE of the following criteria:
   1. You have moderate to severe hemophilia A, defined as less than 5% factor VIII activity compared to normal
   2. You have mild hemophilia A, defined as 5%-40% factor VIII activity compared to normal, and meet ONE of the following:
      a. You have experienced severe, traumatic, or spontaneous (sudden) bleeding episode(s) (may occur in joint or muscle)
      b. You have experienced a life-threatening bleed (for example intracranial hemorrhage [ICH: a type of bleeding in your head])
      c. It is difficult to access your veins which prevents or delays you in receiving regular clotting factor infusions

RENEWAL CRITERIA

Our guideline named EMICIZUMAB-KXWH (Hemlibra) requires the following rule(s) be met for renewal:
A. You have hemophilia A (congenital factor VIII deficiency: a type of bleeding disorder)
B. You had a clinical benefit after using the medication compared to baseline

Commercial Effective: 04/01/23
GUIDELINES FOR USE

Our guideline named ENASIDENIB (Idhifa) requires the following rule(s) be met for approval:

A. You have relapsed or refractory acute myeloid leukemia (a type of blood and bone marrow cancer that has returned after or is resistant to treatment)
B. You are 18 years of age or older
C. You are isocitrate dehydrogenase-2 (a type of enzyme) mutation positive as detected by an FDA (Food and Drug Administration)-approved diagnostic test

Commercial Effective: 07/01/20
ENCORAFENIB

GUIDELINES FOR USE

Our guideline named ENCORAFENIB (Braftovi) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be completely removed with surgery or has spread to other parts of the body)
   2. Metastatic colorectal cancer (a type of digestive cancer that has spread to other parts of the body)

B. If you have unresectable or metastatic melanoma, approval also requires:
   1. You have a BRAF V600E or V600K mutation (types of gene mutations) as detected by an FDA (Food and Drug Administration)-approved test
   2. Braftovi will be used in combination with Mektovi (binimetinib)

C. If you have metastatic colorectal cancer, approval also requires:
   1. You are 18 years of age or older
   2. You have a BRAF V600E mutation (types of gene mutation) as detected by an FDA (Food and Drug Administration)-approved test
   3. Braftovi will be used in combination with Erbitux (cetuximab)
   4. You have previously received treatment

Commercial Effective: 04/01/22
Our guideline named **ENTRECTINIB (Rozlytrek)** requires the following rule(s) be met for approval:

A. You have metastatic non-small cell lung cancer (type of lung cancer that has spread to other parts of body) OR a solid tumor

B. **If you have metastatic non-small cell lung cancer (NSCLC), approval also requires:**
   1. You are 18 years of age or older
   2. You have *ROS1*-positive tumors (you have a type of gene mutation)

C. **If you have a solid tumor, approval also requires:**
   1. You are 12 years of age or older
   2. The tumor has a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation (you have a type of gene mutation that doesn’t have any known resistance)
   3. The tumor is metastatic (has spread to other parts of body) or surgical resection (removal) is likely to result in severe morbidity (disease)
   4. There are no satisfactory alternative treatments, or you have progressed (gotten worse) after treatment

Commercial Effective: 07/01/20
ENZALUTAMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENZALUTAMIDE</td>
<td>XTANDI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ENZALUTAMIDE (Xtandi) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
   2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
   3. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)

B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

C. If you have non-metastatic castration-resistant prostate cancer, approval also requires:
   1. You have a high-risk prostate cancer (rapidly increasing prostate specific antigen levels)

CONTINUED ON NEXT PAGE
ENZALUTAMIDE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named ENZALUTAMIDE (Xtandi) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)
   2. Metastatic castration-sensitive prostate cancer (mCSPC: prostate cancer that has spread to other parts of the body and responds to hormone therapy)
   3. Non-metastatic castration-resistant prostate cancer (nmCRPC: prostate cancer that has not spread to other parts of the body and does not respond to hormone therapy)

B. You meet ONE of the following:
   1. You previously received a bilateral orchiectomy (both testicles have been surgically removed)
   2. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
   3. The requested medication will be used together with a gonadotropin releasing hormone analog (such as leuprolide, goserelin, histrelin, degarelix)

Commercial Effective: 01/01/23
STANDARD COMMERICAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

EPOETIN ALFA

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOETIN ALFA</td>
<td>EPOGEN, PROCRIT</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named EPOETIN ALFA (Procrit, Epogen) requires the following rules be met for approval:

A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
   2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
   4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
   5. You are undergoing elective, noncardiac (not heart related), nonvascular surgery

B. If you have anemia associated with chronic kidney disease, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have a hemoglobin level (type of blood test) of less than 10g/Dl

C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have a hemoglobin level of less than 11g/Dl OR your hemoglobin level has decreased at least 2g/Dl below your baseline level

D. If you have anemia related to zidovudine therapy, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have a hemoglobin level of less than 10g/dL

E. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
   3. You have a hemoglobin level of less than 10g/Dl

F. If you are undergoing elective, noncardiac, nonvascular surgery, approval also requires:
   1. You had a trial of the preferred medication: Retacrit
   2. You have a hemoglobin level of less than 13g/dL

CONTINUED ON NEXT PAGE
EPOETIN ALFA

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: Requests for patients undergoing elective, noncardiac, nonvascular surgery, please refer to the Initial Criteria section.

Our guideline named EPOETIN ALFA (Procrit, Epogen) requires the following rule(s) be met for renewal:

A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
   2. Anemia due to the effects of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
   4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

B. If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:
   1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
   2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
   3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
   4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions

C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

D. If you have anemia related to zidovudine therapy, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

E. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

Commercial Effective: 04/17/23
EPOETIN ALFA-EPBX

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOETIN ALFA-EPBX</td>
<td>RETACRIT</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named EPOETIN ALFA-EPBX (Retacrit) requires the following rule(s) be met for approval:

A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
   2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
   4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa
   5. You are undergoing elective, noncardiac (not heart related), nonvascular surgery

B. If you have anemia associated with chronic kidney disease, approval also requires:
   1. You have a hemoglobin level (type of blood test) of less than 10g/dL

C. If you have anemia due to the effect of concomitantly administered cancer chemotherapy, approval also requires ONE of the following:
   1. You have a hemoglobin level of less than 11g/dL
   2. Your hemoglobin level has decreased at least 2g/dL below your baseline level

D. If you have anemia related to zidovudine therapy, approval also requires:
   1. You have a hemoglobin level of less than 10g/dL

E. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, approval also requires:
   1. You have tried or have a contraindication (harmful for) to a lower ribavirin dose
   2. You have a hemoglobin level of less than 10g/dL

F. If you are undergoing elective, noncardiac, nonvascular surgery, approval also requires:
   1. You have a hemoglobin level of less than 13g/dL

CONTINUED ON NEXT PAGE
EPOETIN ALFA-EPBX

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: Requests for patients undergoing elective, noncardiac, nonvascular surgery, please refer to the Initial Criteria section.

Our guideline named EPOETIN ALFA-EPBX (Retacrit) requires the following rule(s) be met for renewal:

A. You have ONE of the following:
   1. Anemia (low amount of healthy red blood cells) due to chronic kidney disease
   2. Anemia due to the effect of concomitantly administered (given at the same time) cancer chemotherapy
   3. Anemia related to zidovudine therapy (type of drug to treat human immunodeficiency virus)
   4. Anemia due to hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa

B. If you have anemia associated with chronic kidney disease, renewal also requires ONE of the following:
   1. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis (process of removing excess water, toxins from the blood)
   2. You have a hemoglobin level of less than 11g/dL if you are on dialysis
   3. Your hemoglobin level has reached 10g/dL (if you are not on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
   4. Your hemoglobin level has reached 11g/dL (if you are on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions

C. If you have anemia due to the effects of concomitantly administered cancer chemotherapy, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

D. If you have anemia related to zidovudine therapy, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

E. If you have anemia due to concurrent hepatitis C combination treatment with ribavirin plus an interferon alfa or peginterferon alfa, renewal also requires:
   1. You have a hemoglobin level between 10g/dL and 12g/dL

Commercial Effective: 04/17/23
GUIDELINES FOR USE

Our guideline named ERDAFITINIB (Balversa) requires the following rule(s) be met for approval:

A. You have locally advanced or metastatic urothelial carcinoma (type of bladder cancer that has spread)
B. You are 18 years of age or older
C. You have susceptible fibroblast growth factor receptor (FGFR3 or FGFR2) genetic alterations (abnormalities) as detected by a Food and Drug Administration (FDA)-approved companion diagnostic test
D. You meet ONE of the following:
   1. You have progressed (worsened disease) during or following at least one line of prior platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
   2. You have progressed within 12 months of neoadjuvant (treatment given before main therapy) or adjuvant (add-on) platinum-containing chemotherapy (such as cisplatin, carboplatin, oxaliplatin)
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ERENUMAB-AOOE (Aimovig) requires the following rule(s) be met for approval:

A. You have migraines

B. If you have episodic migraines (0-14 headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Aimovig is prescribed for the preventive treatment of migraines
   3. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

C. If you have chronic migraines (15 or more headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Aimovig is prescribed for the preventive treatment of migraines
   3. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs # 00023-1145-01 or 00023-3921-02 are allowable]

CONTINUED ON NEXT PAGE
ERENUMAB-AOOE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **ERENUMAB-AOOE (Aimovig)** requires the following rule(s) be met for renewal:

A. Aimovig is being prescribed for preventive treatment of migraines.
B. You will NOT use Aimovig concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
C. You meet ONE of the following criteria:
   1. You have experienced less migraines or headache attacks by at least 2 days per month with Aimovig therapy
   2. You have experienced a lessening in migraine severity with Aimovig therapy
   3. You have experienced a lessening in migraine duration with Aimovig therapy

Commercial Effective: 04/01/22
GUIDELINES FOR USE

Our guideline named **ERGOTAMINE-CAFFEINE (Migergot)** requires the following rule(s) be met for approval:

A. Migergot is being used to abort (stop) or prevent vascular headaches (such as migraines, migraine variants, so-called 'histaminic cephalalgia' [types of headaches])

B. You cannot swallow ergotamine/caffeine tablets

C. You had a trial of or contraindication (harmful for) to generic ergotamine/caffeine tablets AND two triptans (such as sumatriptan, rizatriptan)

Commercial Effective:04/01/23
ERLOTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERLOTINIB HCL</td>
<td>TARCEVA, ERLOTINIB HCL</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **ERLOTINIB (Tarceva)** requires the following rule(s) be met for approval:

A. **You have ONE of the following diagnoses:**
   1. Metastatic non-small cell lung cancer (type of lung cancer that has spread to other parts of the body)
   2. Locally advanced, unresectable, or metastatic pancreatic cancer (pancreas cancer that has spread or cannot be completely removed by surgery)

B. **If you have metastatic non-small cell lung cancer, approval also requires:**
   1. Your tumor has epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (types of gene mutations or permanent change in the DNA that makes up a gene) as detected by an FDA (Food and Drug Administration) approved test
   2. You will NOT be using Tarceva (erlotinib) concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (e.g., Gilotrif, Tagrisso, Iressa, Vizimpro)

C. **If you have locally advanced, unresectable, or metastatic pancreatic cancer, approval also requires:**
   1. The requested medication will be used in combination with gemcitabine
   2. The medication will be used as a first line treatment

Commercial Effective: 07/01/22
ETANERCEPT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETANERCEPT</td>
<td>ENBREL</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ETANERCEPT (Enbrel) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine

C. If you have moderate to severe polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
ETANERCEPT

INITIAL CRITERIA (CONTINUED)

E. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as naproxen, ibuprofen, meloxicam)

F. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 4 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested medication
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

RENEWAL CRITERIA

Our guideline named ETANERCEPT (Enbrel) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe polyarticular juvenile idiopathic arthritis (PJIA: a type of joint condition)
   4. Ankylosing spondylitis (AS: a type of joint condition)
   5. Moderate to severe plaque psoriasis (PsO: a type of skin condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.

(Renewal criteria continued on next page)
ETANCERCEPT

RENEWAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.

D. If you have moderate to severe polyarticular juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.

E. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) while on therapy.

F. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more while on therapy.

Commercial Effective: 07/01/23
ETHACRYNIC ACID

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETHACRYNIC ACID</td>
<td>EDECRIN, ETHACRYNIC ACID</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ETHACRYNIC ACID (Edecrin) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Edema (swelling caused by fluid build-up in the body) associated with congestive heart failure (a type of heart condition), cirrhosis (liver damage), or renal disease (including nephrotic syndrome [a type of kidney disorder])
   2. Ascites (accumulation of fluid in the abdominal cavity) due to malignancy (cancer), idiopathic (unknown cause) edema, or lymphedema (swelling in an arm or leg due to build-up of lymph fluid)
B. You had a trial of or contraindication (harmful for) to TWO generic loop diuretics (such as furosemide, bumetanide, torsemide)

Commercial Effective: 07/01/22
EVEROLIMUS-AFINITOR DISPERZ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVEROLIMUS</td>
<td>AFINITOR DISPERZ, EVEROLIMUS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named EVEROLIMUS (Afinitor Disperz) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated subependymal giant cell astrocytoma (SEGA: a type of brain tumor)
   2. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated partial-onset seizures

B. If you have tuberous sclerosis complex (TSC)-ependymal giant cell astrocytoma (SEGA), approval also requires:
   1. You are 1 year of age or older
   2. Your diagnosis requires therapeutic intervention but cannot be curatively resected (completely remove with surgery)

C. If you have tuberous sclerosis complex (TSC)-associated partial-onset seizures, approval also requires:
   1. You are 2 years of age or older
   2. Afinitor Disperz will be used as adjunctive (add-on) treatment

Commercial Effective: 04/10/23
EVEROLIMUS-AFINITOR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVEROLIMUS</td>
<td>AFINITOR, EVEROLIMUS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named EVEROLIMUS (Afinitor) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Advanced hormone receptor-positive (HR: a type of protein), human epidermal growth factor receptor 2 (HER2: a type of protein)-negative breast cancer
   2. Progressive, neuroendocrine tumors (NET: a rare type of tumor) with unresectable (unable to remove by surgery), locally advanced (cancer that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (cancer that has spread to other parts of the body)
   3. Advanced renal cell carcinoma (RCC: type of kidney cancer)
   4. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated renal angiomyolipoma (type of kidney tumor)
   5. Tuberous sclerosis complex (TSC: a rare type of tumor disorder)-associated subependymal giant cell astrocytoma (SEGA: a type of brain tumor)

B. If you have advanced hormone receptor-positive, HER2-negative breast cancer, approval also requires:
   1. You are a postmenopausal woman
   2. Afinitor will be used in combination with Aromasin (exemestane)
   3. You have failed or have a contraindication (harmful for) to treatment with Femara (letrozole) or Arimidex (anastrozole)

C. If you have progressive, neuroendocrine tumors (NET) with unresectable, locally advanced or metastatic disease, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You have neuroendocrine tumors of pancreatic origin (PNET: tumor in the pancreas)
      b. You have well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI: relates to the digestive system) or lung origin

D. If you have advanced renal cell carcinoma, approval also requires:
   1. You are 18 years of age or older

E. If you have tuberous sclerosis complex (TSC)-associated renal angiomyolipoma, approval also requires:
   1. You are 18 years of age or older
   2. You do not require immediate surgery

(Criteria continued on next page)
EVEROLIMUS-AFINITOR

GUIDELINES FOR USE (CONTINUED)

F. If you have tuberous sclerosis complex (TSC)-associated subependymal giant cell astrocytoma, approval also requires:
   1. You are 1 year of age or older
   2. Your diagnosis requires therapeutic intervention but cannot be curatively resected (completely remove with surgery)

Commercial Effective: 04/10/23
EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXCLUDED DRUGS</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA (reviewed for <insert drug name>) requires that ALL of the following rule(s) be met for approval:

A. The requested medication is being used for the treatment of ONE of the following:
   1. A Food and Drug Administration (FDA)-approved indication
   2. A medically accepted indication and it is considered safe and effective by approved compendia (medical references), peer-reviewed medical literature, or accepted standards of medical practice.

B. You meet one of the following criteria (1, 2, or 3):
   1. If the request is for a combination product and the individual components with the same route of administration are commercially available and are covered by your plan, you must meet the following (a, b, and c):
      a. You have previously tried <insert individual components> together
      b. Your doctor provided a medical rationale that the requested combination product would be safer and/or more efficacious than using the individual components together
      c. You have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents
   2. If the request is for a medication that has clinically appropriate covered alternative(s) with the same active ingredient and same route of administration, you must meet the following (a and b):
      a. You have previously tried at least three clinically appropriate covered alternatives with the same active ingredients and same route of administration (if available), including but not limited to <insert formulary agents>, OR there is a medical rationale why the covered alternatives cannot be tried.
      b. You have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents

(Criteria continued on next page)
EXCLUDED FORMULARY DRUG EXCEPTION CRITERIA

GUIDELINES FOR USE (CONTINUED)

3. If the requested medication does NOT have clinically appropriate covered alternatives with the same active ingredient and same route of administration, you must have previously tried at least three clinically appropriate covered agents with different active ingredients but the same route of administration for the specified indication (if available), one of which must be in the same class as the requested drug for the specific indication (if available) OR your physician has provided documentation that you have experienced a therapeutic failure, contraindication to (medical reason why you cannot use), or intolerance to those agents.

Effective: 12/17/20
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FECAL MICROBIOTA CAPSULE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FECAL MICROBIO SPORE, LIVE-BRPK</td>
<td>VOWST</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **FECAL MICROBIOTA CAPSULE (Vowst)** requires the following rule(s) be met for approval:

A. You are using the requested medication for the prevention of recurrent *Clostridioides difficile* (*C. difficile*) infection (CDI: a bacterial infection)

B. You are 18 years of age or older

C. **If you have NOT previously received Vowst, approval also requires:**
   1. You have completed antibiotic (such as vancomycin [Vancocin], fidaxomicin [Dificid]) treatment for recurrent CDI (defined as at least 3 CDI episodes)

D. **If you have been previously treated with Vowst, approval also requires:**
   1. You had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of the first dose of Vowst, AND a positive stool test for *C. difficile*
   2. You have not previously received more than 1 treatment course of Vowst AND the start of that treatment course was at least 12 days and not more than 8 weeks prior

Commercial Effective: 06/01/23
**GUIDELINES FOR USE**

Our guideline named **FECAL MICROBIOTA SUSPENSION (Rebyota)** requires the following rule(s) be met for approval:

A. You are using the requested medication for the prevention of recurrent *Clostridioides difficile* (*C. difficile*) infection (CDI: a bacterial infection)

B. You are 18 years of age or older

C. **If you have NOT previously received** Rebyota, approval also requires:
   
   1. You have completed antibiotic (such as vancomycin [Vancocin]) treatment for recurrent CDI (defined as at least 3 CDI episodes) at least 24 hours prior

D. **If you have been previously treated with** Rebyota, approval also requires:
   
   1. You had treatment failure, defined as the presence of CDI diarrhea within 8 weeks of the first dose of Rebyota AND a positive stool test for *C. difficile*
   2. You have not previously received more than 1 dose of Rebyota AND that dose was at least 7 days and not more than 8 weeks prior

---

**Commercial Effective:** 05/22/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FEDRATINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEDRATINIB DIHYDROCHLORIDE</td>
<td>INREBIC</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named FEDRATINIB (Inrebic) requires the following rule(s) be met for approval:
A. You have intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (type of bone marrow cancer)
B. You are 18 years of age or older
C. You previously had a trial of or contraindication (medical reason why you cannot use) to Jakafi (ruxolitinib)

RENEWAL CRITERIA

Our guideline named FEDRATINIB (Inrebic) requires the following rule(s) be met for renewal:
A. You have intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (type of bone marrow cancer)
B. You have shown symptom improvement by meeting ONE of the following:
   1. You have a spleen volume reduction of 35% or greater from baseline
   2. You have a 50% or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
   3. You have a 50% or greater reduction in palpable (can be felt by external examination) spleen length

Commercial Effective: 01/01/22
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named FENFLURAMINE (Fintepla) requires the following rule(s) be met for approval:

A. You have seizures associated with ONE of the following:
   1. Dravet syndrome (a rare type of seizure)
   2. Lennox-Gastaut syndrome (LGS: a type of seizure disorder in young children)

B. If you have Dravet syndrome, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. You had a trial of or contraindication (harmful for) to TWO of the following: valproic acid derivative, clobazam, topiramate

C. If you have Lennox-Gastaut syndrome, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or given in consultation with a neurologist (a type of brain doctor)
   3. You had a trial of or contraindication (harmful for) to valproic acid or derivatives
   4. You had a trial of or contraindication (harmful for) to TWO of the following: Epidiolex, rufinamide, felbamate, clobazam, topiramate, lamotrigine, clonazepam

RENEWAL CRITERIA

Our guideline named FENFLURAMINE (Fintepla) requires the following rule(s) be met for approval:

A. You have seizures associated with Dravet syndrome (a rare type of seizure)
B. You have shown continued clinical benefit (such as reduction of seizures, reduced length of seizures, seizure control maintained) while on therapy

Commercial Effective: 07/01/22
FENTANYL NASAL SPRAY

GUIDELINES FOR USE

Our guideline named FENTANYL NASAL SPRAY (Lazanda) requires the following rule(s) to be met for approval:

A. You have a diagnosis of cancer-related pain
B. You are currently taking a maintenance dose of a controlled-release pain medication (such as MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Kadian, Avinza or the generic forms of any of these drugs)
C. You had a trial of an oral immediate-release pain medication (such as morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)
E. You had a trial of Abstral or Fentora (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named **FENTANYL SUBLINGUAL SPRAY (Subsys)** requires the following rule(s) be met for approval:

A. You have cancer-related pain
B. You are currently using the requested medication with a controlled-release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Kadian, Avinza or the generic forms of any of these drugs)
C. You had a trial of an oral immediate-release pain medication (morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization), unless there is a medical reason why you cannot (contraindication)
E. You had a trial of Abstral or Fentora, all of which may also require a prior authorization, unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named FENTANYL TRANSDERMAL PATCH (Duragesic) requires the following rule(s) be met for approval:

A. You meet the definition of opioid tolerance. This is defined as those who are taking, for one week or longer, at least 60mg oral morphine per day, 25mcg transdermal fentanyl/hour, 30mg oral oxycodone/day, 25mg oral oxymorphone/day, 8mg oral hydromorphone/day, or an equianalgesic dose (equal pain-relieving dose) of another opioid

B. The requested medication is not prescribed on an 'as needed' basis

C. Requests for dosing every 48 hours requires a trial of transdermal (absorbed through the skin) fentanyl patch dosed every 72 hours

Commercial Effective: 07/01/20
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FENTANYL TRANSMUCOSAL AGENTS

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FENTANYL CITRATE</td>
<td>ACTIQ, ABSTRAL, FENTORA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **FENTANYL TRANSMUCOSAL AGENTS (Actiq, Fentora, Abstral)** requires the following rule(s) be met for approval:

A. You have cancer-related pain
B. You are currently using the requested medication with a controlled-release pain medication (MS Contin, Oxycontin, Oramorph SR, Duramorph, Roxanol SR, Duragesic, Avinza or the generic forms of any of these drugs)
C. You had a trial of an oral immediate-release pain medication (such as morphine sulfate immediate-release [MSIR], Percodan, Percocet, Vicodin, Tylenol with Codeine, Dilaudid, Demerol or the generic forms of any of these), unless you have difficulty swallowing tablets or capsules OR there is a medical reason why you cannot (contraindication)
D. You had a trial of generic fentanyl citrate lozenge (which also requires a prior authorization) unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named FERRIC MALTOL (Accrufer) requires the following rule(s) be met for approval:
A. You have iron deficiency (low iron levels)
B. You are 18 years of age or older
C. You had a trial of an over-the-counter (OTC) oral iron preparation (e.g., ferrous sulfate, ferrous gluconate, ferrous fumarate), unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 10/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named FEZOLINETANT (Veozah) requires the following rule(s) be met for approval:
A. You have moderate to severe menopausal vasomotor symptoms (VMS: a type of symptom related to menopause)
B. You experience 7 or more hot flashes per day
C. You had a trial of or contraindication (harmful for) to hormonal therapy (such as estradiol transdermal patch [Minivelle, Climara], oral conjugated estrogens [Premarin], micronized progesterone [Prometrium])

RENEWAL CRITERIA

Our guideline named FEZOLINETANT (Veozah) requires the following rule(s) be met for renewal:
A. You have moderate to severe menopausal vasomotor symptoms (VMS: a type of symptom related to menopause)
B. You have a continued need for VMS treatment (you still experience persistent hot flashes)
C. You had a reduction in VMS frequency OR severity due to Veozah (fezolinetant) treatment

Commercial Effective: 06/12/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FILGRASTIM

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FILGRASTIM</td>
<td>NEUPOGEN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named FILGRASTIM (Neupogen) requires the following rule(s) be met for approval:

A. You meet ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
   2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
   3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
   4. You will be using Neupogen for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
   5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown cause)
   6. You will be using Neupogen to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)

B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi)

Commercial Effective: 07/01/23
FILGRASTIM-AAFI

GUIDELINES FOR USE

Our guideline named FILGRASTIM-AAFI (Nivestym) requires the following rule(s) be met for approval:

A. You meet ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
   2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
   3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
   4. You will be using Nivestym for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
   5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low amount of a type of white blood cell at birth, in cycles or due to unknown cause)
   6. You will be using Nivestym to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)

B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named FILGRASTIM-AYOW (Releuko) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a nonmyeloid malignancy (a type of cancer) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
   2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
   3. You have a nonmyeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
   4. You will be using Releuko for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
   5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low amount of a type of white blood cell at birth, in cycles, or due to unknown cause)
   6. You will be using Releuko to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)

B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named FILGRASTIM-SNDZ (Zarxio) requires the following rule(s) be met for approval:

A. You meet ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow) and are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
   2. You have acute myeloid leukemia (AML: a type of blood cancer) and are undergoing induction or consolidation chemotherapy treatment (you are starting therapy so there is no sign of cancer cells or you have therapy to kill any remaining cancer cells in the body)
   3. You have a non-myeloid malignancy (cancer not affecting bone marrow), are undergoing myeloablative chemotherapy (high-dose drugs used to treat cancer) followed by bone marrow transplantation, and are experiencing neutropenia (a type of blood condition) and/or neutropenia-related clinical symptoms (such as febrile neutropenia [a type of blood condition with fever])
   4. You will be using Zarxio for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis (a type of blood cell is stimulated to be collected by a process where it is separated from the blood)
   5. You have congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia (low levels of a type of white blood cell at birth, in cycles, or due to unknown cause)
   6. You will be using Zarxio to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (doses that decrease bone marrow activity)

B. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

C. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym (filgrastim-aafi)

Commercial Effective: 07/01/23
FINASTERIDE-TADALAFIL

GUIDELINES FOR USE

Our guideline named FINASTERIDE-TADALAFIL (Entadfi) requires the following rule(s) be met for approval:
A. You are male and have benign prostatic hyperplasia (BPH: a type of prostate condition)
B. You are 18 years of age or older
C. You had a trial of or contraindication (harmful for) to TWO alpha blockers (such as terazosin, doxazosin, tamsulosin)
D. You had a trial of or contraindication (harmful for) to ONE 5-alpha-reductase inhibitor (such as finasteride, dutasteride)
E. You had a trial of or contraindication (harmful for) to tadalafil 2.5 mg or tadalafil 5 mg

Requests will not be approved if you have received a 26-week course of Entadfi.

Commercial Effective: 08/29/22
FINERENONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FINERENONE</td>
<td>KERENDIA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named FINERENONE (Kerendia) requires the following rule(s) be met for approval:
A. You have chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
B. You are 18 years of age or older
C. You had a trial of or contraindication to (medical reason why you cannot use) BOTH of the following:
   1. A sodium-glucose cotransport-2 (SGLT2) inhibitor (such as Farxiga, Invokana, Jardiance, Steglatro)
   2. Spironolactone OR eplerenone

Commercial Effective: 05/01/23
# GUIDELINES FOR USE

Our guideline named **FINGOLIMOD (Gilenya)** requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (immune system eats away at protective covering of nerves and you have new or increasing symptoms), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease

B. You are 10 years of age or older.

C. You do not have any of the following contraindications (medical reason why you cannot use) to Gilenya:

1. A recent (within past 6 months) occurrence of myocardial infarction (heart attack), unstable angina (chest pain), stroke, transient ischemic attack (short stroke-like attack), decompensated heart failure requiring hospitalization, or Class III/IV heart failure

2. A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome (types of irregular heartbeats), unless you have a functioning pacemaker

3. A baseline QTC interval 500 msec or above (a measure of the speed of electrical conduction in the heart)

4. Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)

---

**Commercial Effective: 07/01/20**
GUIDELINES FOR USE

Our guideline named FINGOLIMOD LAURYL SULFATE (Tascenso ODT) requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (a type of nerve disorder), to include clinically isolated syndrome (a type of nerve disorder that occurs once), relapsing-remitting disease (symptoms or disease returns and goes away) and active secondary progressive disease (advanced disease)
B. You are 10 years of age or older
C. You had a trial of fingolimod capsules
D. You are unable to swallow fingolimod capsules
E. You had a trial of or contraindication (harmful for) to one other agent indicated for the treatment of multiple sclerosis
F. You do not have any of the following contraindications (harmful for) to Tascenso ODT:
   1. A recent (within past 6 months) occurrence of myocardial infarction (heart attack), unstable angina (chest pain), stroke, transient ischemic attack (short stroke-like attack), decompensated heart failure requiring hospitalization, or Class III/IV heart failure
   2. A history or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome (types of irregular heartbeats), unless you have a functioning pacemaker
   3. A baseline QTc interval of 500 msec or greater (a measure of the speed of electrical conduction in the heart)
   4. Current treatment with Class Ia (quinidine, procainamide, or disopyramide) or Class III anti-arrhythmic drugs (amiodarone, dofetilide, dronedarone, ibutilide, or sotalol)
### FLIBANSERIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLIBANSERIN</td>
<td>ADDYI</td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)**

Our guideline named **FLIBANSERIN (Addyi)** requires the following rule(s) be met for approval:

A. You have acquired, generalized hypoactive sexual desire disorder (HSDD; lack or absence of sexual desire). This is also referred to as female sexual interest/arousal disorder per DSM-5 (a diagnostic tool for mental disorders), as defined by **ALL** of the following criteria:
   1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   2. Hypoactive sexual desire disorder is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
   3. Hypoactive sexual desire disorder symptom causes marked distress or interpersonal difficulty

B. You are a premenopausal female

C. You are 18 years of age or older

D. You previously had a trial of bupropion, unless there is a medical reason why you cannot (contraindication)

E. You are not currently using Vyleesi (bremelanotide)

CONTINUED ON NEXT PAGE
FLIBANSERIN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline for FLIBANSERIN (Addyi) requires the following rule(s) be met for renewal:
A. You have acquired, generalized hypoactive sexual desire disorder (HSDD; lack or absence of sexual desire). This is also referred to as female sexual interest/arousal disorder per DSM-5 (a diagnostic tool for mental disorders), as defined by ALL of the following criteria:
   1. Persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity that has persisted for at least 6 months
   2. Hypoactive sexual desire disorder is not a result of a co-existing medical or psychiatric condition, a problem within the relationship or the effects of a medication or drug substance
   3. Hypoactive sexual desire disorder symptom causes marked distress or interpersonal difficulty
B. You are a premenopausal female
C. You are 18 years of age or older
D. You are not currently using Vyleesi (bremelanotide)
E. You have demonstrated continued improvement in symptoms of hypoactive sexual desire disorder/female sexual interest and arousal disorder (such as increased sexual desire, lessened distress)

Commercial Effective: 07/01/20
FLUORIDE ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUORIDE</td>
<td>SODIUM</td>
</tr>
<tr>
<td>(SODIUM)</td>
<td>FLUORIDE,</td>
</tr>
<tr>
<td></td>
<td>LUDENT</td>
</tr>
<tr>
<td></td>
<td>FLUORIDE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **FLUORIDE ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. Your request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. You are 6 months to 6 years of age

C. **If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:**
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Commercial Effective: 07/01/22
** Please use the criteria for the specific drug requested **

**FLUOROURACIL CREAM**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLUOROURACIL 0.5%</td>
<td>CARAC</td>
</tr>
<tr>
<td>FLUOROURACIL 1%</td>
<td>FLUOROPLEX</td>
</tr>
</tbody>
</table>

**GUIDELINE FOR USE**

**CARAC**

Our guideline named **FLUOROURACIL CREAM (Carac)** requires the following rule(s) be met for approval:

A. You have actinic or solar keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure) of the face and anterior (front) scalp

B. You have previously tried TWO generic topical (applied to skin) agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

**FLUOROPLEX**

Our guideline named **FLUOROURACIL CREAM (Fluoroplex)** requires the following rule(s) be met for approval:

A. You have actinic or solar keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure)

B. You have previously tried TWO generic topical (applied to skin) agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

Commercial Effective: 10/01/21
FOLIC ACID ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOLIC ACID</td>
<td>FOLIC ACID, VARIOUS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named FOLIC ACID ZERO COST SHARE OVERRIDE requires the following rule(s) be met for approval:

A. Your request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named **FOSDENOPTERIN (Nulibry)** requires the following rule(s) be met for approval:

A. You have molybdenum cofactor deficiency (MoCD) Type A (rare condition characterized by brain dysfunction)

Commercial Effective: 07/01/21
FOSTAMATINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOSTAMATINIB</td>
<td>TAVALISSE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named FOSTAMATINIB (Tavalisse) requires the following rule(s) be met for approval:

A. You have chronic immune thrombocytopenia (cITP; Low levels of the blood cells that prevent bleeding)
B. You are 18 years of age or older
C. The requested medication is prescribed by or given in consultation with a hematologist (blood specialist) or immunologist (allergy/immune system doctor)
D. You had a splenectomy (surgical removal of spleen) OR a previous trial of or contraindication to (medical reason why you cannot use) at least TWO of the following treatments:
   1. Corticosteroids
   2. IVIG (intravenous immunoglobulin)
   3. Rhogam
   4. Rituxan (rituximab)
   5. Thrombopoietin receptor agonist such as Promacta (eltrombopag), Nplate (romiplostim)

RENEWAL CRITERIA

Our guideline named FOSTAMATINIB (Tavalisse) requires the following rule(s) be met for renewal:

A. You have chronic immune thrombocytopenia (cITP; Low levels of the blood cells that prevent bleeding)
B. You had clinically significant prevention of bleeds while on therapy
C. Your AST (aspartate transaminase) and ALT (alanine transaminase) levels (types of liver enzymes) have remained under 3 times the upper limits of normal per reference range
D. Your total bilirubin level has remained under 2 times the upper limits of normal per reference range
E. Your absolute neutrophil count (ANC; a measure of the number of neutrophils which are a type of white blood cell) has remained within normal limits per reference range
F. Your platelets have reached a level between 50 and 450 x 10(9)/L

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named **FOSTEMSAVIR (Rukobia)** requires the following rule(s) be met for approval:

A. You have human immunodeficiency virus type 1 (HIV-1) infection (a virus that attacks the body’s immune system and if untreated, can lead to AIDS [acquired immunodeficiency syndrome])

B. You are 18 years of age or older

C. The requested medication will be used in combination with other antiretroviral(s) (class of medication used to treat HIV)

D. You are treatment experienced (previously treated)

E. You have multidrug-resistant HIV-1 infection (your virus is resistant to more than one HIV medication)

F. You are failing your current antiretroviral regimen due to resistance, intolerance, or safety considerations

Commercial Effective: 08/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named FREMANEZUMAB-VFRM (Ajovy) requires the following rule(s) be met for approval:

A. You have migraines

B. If you have episodic migraines (0-14 headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Ajovy is prescribed for the preventive treatment of migraines
   3. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol
   5. You have tried TWO of the following: Aimovig, Emgality, Nurtec ODT, Qulipta

C. If you have chronic migraines (15 or more headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Ajovy is prescribed for the preventive treatment of migraines
   3. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Aimovig, Emgality, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]
   5. You have tried TWO of the following: Aimovig, Emgality, Nurtec ODT, Qulipta

CONTINUED ON NEXT PAGE
FREMANEZUMAB-VFRM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named FREMANEZUMAB-VFRM (Ajovy) requires the following rule(s) be met for renewal:

A. Ajovy is prescribed for the preventive treatment of migraines
B. You will NOT use Ajovy concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Amovig, Emgality, Vyepti, Nurtec ODT, Quilpta) for migraine prevention
C. You meet ONE of the following:
   1. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Ajovy therapy
   2. You have experienced a reduction in migraine severity with Ajovy therapy
   3. You have experienced a reduction in migraine duration with Ajovy therapy

Commercial Effective: 04/01/22
GUIDELINES FOR USE

Our guideline named **FUTIBATINIB (Lytgobi)** requires the following rule(s) be met for approval:

A. You have unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) (a type of bile duct cancer inside the liver that is unable to be removed by surgery, has spread from where it started to nearby tissue/lymph nodes or to other parts of the body)

B. You are 18 years of age or older

C. You have been previously treated for unresectable, locally advanced or metastatic iCCA

D. You have fibroblast growth factor receptor 2 (FGFR2: a type of protein) gene fusions or other rearrangements

E. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting Lytgobi and at the recommended scheduled times

Commercial Effective: 11/14/22
GALCANEZUMAB-GNLM

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named GALCANEZUMAB-GNLM (Emgality) requires the following rule(s) be met for approval:

A. You have migraines or episodic cluster headaches (very painful headaches that occur in patterns)

B. If you have episodic migraines (0-14 headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Emgality is prescribed for the preventive treatment of migraines
   3. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

C. If you have chronic migraines (15 or more headache days per month), approval also requires:
   1. You are 18 years of age or older
   2. Emgality is prescribed for the preventive treatment of migraines
   3. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   4. You have tried ONE of the following preventative migraine treatments: valproic acid/divalproex sodium, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol, or Botox [Note: For Botox, previous trial of only NDCs 00023-1145-01 or 00023-3921-02 are allowable]

D. If you have episodic cluster headaches, approval also requires:
   5. You are 18 years of age or older

CONTINUED ON NEXT PAGE
GALCANEZUMAB-GNLM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named GALCANEZUMAB-GNLM (Emgality) requires the following rule(s) be met for renewal:

A. Emgality is being prescribed for preventive treatment of migraines OR for the treatment of episodic cluster headache (very painful headaches that occur in patterns)

B. **If you have migraines, renewal also requires:**
   1. You will NOT use Emgality concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Vyepti, Nurtec ODT, Qulipta) for migraine prevention
   2. You meet ONE of the following:
      a. You have experienced a reduction in migraine or headache frequency of at least 2 days per month with Emgality therapy
      b. You have experienced a reduction in migraine severity with Emgality therapy
      c. You have experienced a reduction in migraine duration with Emgality therapy

C. **If you have episodic cluster headaches, renewal also requires:**
   1. You had improvement in episodic cluster headache frequency as compared to baseline

---

Commercial Effective: 04/01/22
GANAXOLONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>GANAXOLONE</td>
<td>ZTALMY</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named GANAXOLONE (Ztalmy) requires the following rule(s) be met for approval:
A. You have seizures
B. You are 2 years of age or older
C. Your seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD: a type of genetic disorder)

Commercial Effective: 10/01/22
GUIDELINES FOR USE

Our guideline named GEFITINIB (Iressa) requires the following rule(s) be met for approval:
A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
B. Your tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (abnormal changes in a gene) as detected by an FDA (Food and Drug Administration)-approved test
C. You will NOT be using Iressa (gefitinib) concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva [erlotinib], Tagrisso [osimertinib], Gilotrif [afatinib], Vizimpro [dacomitinib])

Commercial Effective: 05/22/23
GUIDELINES FOR USE

Our guideline named GILTERITINIB (Xospata) requires the following rule(s) be met for approval:

A. You have relapsed or refractory acute myeloid leukemia (AML: type of white blood cell cancer)
B. You are 18 years of age or older
C. You have FMS-like tyrosine kinase 3 (type of gene) mutation (change in the DNA gene) as detected by a Food and Drug Administration-approved test

Commercial Effective: 04/10/21
GLASDEGIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLASDEGIB MALEATE</td>
<td>DAURISMO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **GLASDEGIB (Daurismo)** requires the following rule(s) be met for approval:

A. You have newly-diagnosed acute myeloid leukemia (AML: type of white blood cell cancer)
B. The requested medication will be used in combination with low-dose cytarabine
C. You are 75 years of age or older, **OR** you have comorbidities (having more than one disease) that prevents the use of intensive induction chemotherapy

Commercial Effective: 07/01/20
GLATIRAMER ACETATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLATIRAMER ACETATE</td>
<td>COPAXONE, GLATOPA, GLATIRAMER ACETATE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **GLATIRAMER ACETATE** (Copaxone, Glatopa) requires the following rule(s) be met for approval:

1. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
2. You are 18 years of age or older

Commercial Effective: 01/01/21
GLECAPREVIR/PIBRENTASVIR

GUIDELINES FOR USE

Our guideline named GLECAPREVIR/PIBRENTASVIR (Mavyret) requires the following rule(s) be met for approval:

A. You have chronic hepatitis C (type of liver inflammation), genotype 1, 2, 3, 4, 5, or 6
B. You are 3 years of age or older
C. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
D. You have compensated cirrhosis (no symptoms related to liver damage) or no cirrhosis (no liver damage) and meet ONE of the following:
   1. You are treatment naive (never been treated) (genotype 1-6)
   2. You are treatment experienced with regimens containing interferon, peginterferon, ribavirin, and/or sofosbuvir (genotype 1-6)
   3. You are treatment experienced with NS5A (nonstructural protein 5A) inhibitor or NS3/4A protease inhibitor (genotype 1)
   4. You had a kidney transplant or liver transplant and are treatment naive or treatment experienced (genotype 1-6)
E. You had a short trial of a preferred formulary agent (you stopped because of intolerance or adverse effect early in therapy) or have a contraindication (medical reason why you cannot use) to therapy with the preferred formulary agent(s) as specified below unless you had prior NS5A (nonstructural protein 5A) inhibitor treatment:
   1. If you have genotype 1, 4, 5, or 6 infection, you had a short trial of Epclusa or Harvoni, or you have a contraindication to BOTH agents
   2. If you have genotype 2 or 3 infection, you had a short trial of Epclusa or you have a contraindication to this agent

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
GLECAPREVIR/PIBRENTASVIR

GUIDELINES FOR USE (CONTINUED)

Mavyret will not be approved if you meet any of the following:
A. You are concurrently taking (alone or in combination): rifampin, atazanavir, carbamazepine, efavirenz, darunavir, lopinavir, ritonavir, atorvastatin, lovastatin, simvastatin, rosuvastatin (at doses greater than 10mg), cyclosporine (for patients requiring stable cyclosporine doses greater than 100mg/day), medications containing ethinyl estradiol, velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), velpatasvir/sofosbuvir/voxilaprevir (Vosevi), or elbasvir/grazoprevir (Zepatier)
B. You have moderate or severe liver impairment (Child-Pugh B or C)
C. You have prior failure of a direct-acting antiviral (DAA) regimen that contains NS5A inhibitor AND NS3/4A protease inhibitor (for example, Technivie, Viekira, Vosevi, Zepatier) or you had previous concurrent (used at the same time) treatments containing a NS5A inhibitor AND NS3/4A protease inhibitor
D. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (having two or more diseases at the same time)
Our guideline named **GLP-1 AGONIST (Adlyxin)** requires the following rule(s) be met for approval:

A. You have type 2 diabetes (a disorder with high blood sugar)
B. You are 18 years of age or older
C. You had a trial of metformin (extended-release/immediate-release), a sulfonylurea (such as glipizide, glimepiride), pioglitazone, or a preferred combination product containing any of the above agents (such as glipizide-metformin, pioglitazone-metformin)
D. You had a trial of a preferred GLP-1 agonist (such as Byetta, Bydureon, Victoza)

---

**Commercial Effective: 02/01/23**
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

GLP-1 STEP OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXENATIDE MICROSPHERES</td>
<td>BYDUREON, BYDUREON BCISE, BYDUREON PEN</td>
</tr>
<tr>
<td>EXENATIDE</td>
<td>BYETTA</td>
</tr>
<tr>
<td>TIRZEPATIDE</td>
<td>MOUNJARO</td>
</tr>
<tr>
<td>SEMAGLUTIDE</td>
<td>OZEMPIC, RYBELSUS</td>
</tr>
<tr>
<td>DULAGLUTIDE</td>
<td>TRULICITY</td>
</tr>
<tr>
<td>LIRAGLUTIDE</td>
<td>VICTOZA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named GLP-1 STEP OVERRIDE requires ALL of the following rules be met for approval:

A. You have type 2 diabetes (a disorder with high blood sugar) AND
B. You meet ONE of the following rules:
   1. You had a trial of metformin (extended-release/immediate-release), a sulfonylurea (such as glipizide, glimepiride), pioglitazone, or any combination product containing any of the above agents (such as glipizide-metformin, pioglitazone-metformin)
   2. You are currently stable on the medication

Commercial Effective: 03/24/23
GLYCEROL PHENYLBUTYRATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLYCEROL PHENYLBUTYRATE</td>
<td>RAVICTI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named GLYCEROL PHENYLBUTYRATE (Ravicti) requires the following rule(s) be met for approval:

A. You have a urea cycle disorder (genetic disorder that causes buildup of ammonia in blood)
B. Documentation of confirmation of urea cycle disorder via enzymatic, biochemical or genetic testing (types of lab tests)
C. You are 2 months of age or older
D. Ravicti will be used as adjunctive (add-on) therapy along with dietary protein restriction
E. The disorder cannot be managed by dietary protein restriction and/or amino acid supplementation alone
F. The patient does NOT have a deficiency of N-acetylglutamate synthetase (type of enzyme) or acute hyperammonemia (short and sudden high ammonia levels)
G. You have previously tried Buphenyl (sodium phenylbutyrate), unless there is a medical reason why you cannot (contraindication)

RENEWAL CRITERIA

Our guideline named GLYCEROL PHENYLBUTYRATE (Ravicti) requires the following rule(s) be met for renewal:

A. You have a urea cycle disorder (genetic disorder that causes buildup of ammonia in blood)
B. You had clinical benefit from baseline (such as normal fasting glutamine, low-normal fasting ammonia levels, or mental status clarity).

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named GLYCOPYRRONIUM TOPICAL (Qbrexza) requires the following rule(s) be met for approval:

A. You have primary axillary hyperhidrosis (excessive underarm sweating)
B. You are 9 years of age or older
C. You had a trial of a prescription strength aluminum chloride product such as Drysol

Commercial Effective: 10/01/20
Our guideline named **GOLIMUMAB-SQ (Simponi)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. **If you have moderate to severe rheumatoid arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You are currently using or have a contraindication (harmful for) to methotrexate
   5. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept] AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

*(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinoq (upadacitinib), Skyrizi (risankizumab-riaa), Taltz (ixekizumab)

D. If you have moderate to severe ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug such as ibuprofen, naproxen, meloxicam)
   4. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib immediate release or extended release), Rinoq (upadacitinib), Taltz (ixekizumab)

E. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You had a trial of or contraindication (harmful for) to the following preferred medication: Humira (adalimumab)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
GOLIMUMAB - SQ

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **GOLIMUMAB-SQ (Simponi)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. **If you have moderate to severe rheumatoid arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You are currently using methotrexate at the same time, unless there is a contraindication (harmful for)
   3. You meet ONE of the following:
      a. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate release or extended release)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept] AND your physician has indicated you cannot use a JAK inhibitor (Janus kinase inhibitor such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. **If you have psoriatic arthritis, renewal also requires:**
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzzaa), Taltz (ixekizumab)

D. **If you have moderate to severe ankylosing spondylitis, renewal also requires:**
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (diagnostic test to determine the effectiveness of drug therapy) while on therapy
   2. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib), Taltz (ixekizumab)

*(Renewal criteria continued on next page)*

CONTINUED ON NEXT PAGE
GOLIMUMAB - SQ

RENEWAL CRITERIA (CONTINUED)

E. **If you have moderate to severe ulcerative colitis, approval also requires:**
   1. You had a trial of or contraindication (harmful for) to the following preferred medication:
      Humira (adalimumab)

   NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **GUSELKUMAB** (**Tremfya**) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (**PsO**: a type of skin condition)
   2. Psoriatic arthritis (**PsA**: a type of skin and joint condition)

B. **If you have moderate to severe plaque psoriasis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following criteria:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and switching to the requested drug
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

C. **If you have psoriatic arthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug) such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

CONTINUED ON NEXT PAGE
GUSELKUMAB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named GUSELKUMAB (Tremfya) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)

B. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Commercial Effective: 07/01/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

HIGH CONCENTRATION OPIOID ORAL SOLUTIONS

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MORPHINE SULFATE</td>
<td>MORPHINE SULFATE</td>
</tr>
<tr>
<td>OXYCODONE HCL</td>
<td>OXYCODONE HCL</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named HIGH CONCENTRATION OPIOID ORAL SOLUTIONS (morphine sulfate, oxycodone hydrochloride) requires the following rule(s) be met for approval:

A. You have pain severe enough to require opioid analgesic and for which alternative treatments are inadequate
B. You meet ONE of the following:
   1. You are enrolled in hospice OR you are receiving palliative care or end-of-life care
   2. You meet ALL of the following:
      a. You have previous use of at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid
      b. You have trouble swallowing opioid tablets, capsules, or large volumes of liquid

Commercial Effective: 10/01/21

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
HYDROCORTISONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROCORTISONE</td>
<td>ALKINDI SPRINKLE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named HYDROCORTISONE (Alkindi Sprinkle) requires the following rule(s) be met for approval:

A. You have adrenocortical insufficiency (your body does not produce enough of certain hormones)
B. You are less than 18 years of age
C. You are unable to take the tablet form of hydrocortisone (for example you need a lower strength, or you have difficulty swallowing)

Commercial Effective: 04/01/21
HYDROMORPHONE ER

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROMORPHONE HCL</td>
<td>EXALGO, HYDROMORPHONE ER</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named HYDROMORPHONE ER (Exalgo) requires the following rule(s) be met for approval:

A. You meet the definition of opioid tolerance. This is defined as those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 25 mg oral oxymorphone/day, 8 mg oral hydromorphone/day, or an equianalgesic dose (equal pain relieving dose) of another opioid

B. The requested medication is not prescribed on an as-needed basis

C. Dosages above 16mg require recommendation from a pain specialist

Commercial Effective: 03/04/22
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>IBREXAFUNGERP</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IBREXAFUNGERP CITRATE</td>
<td>BREXAFEMME</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named IBREXAFUNGERP (Brexafemme) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. Treatment of vulvovaginal candidiasis (VVC: vaginal yeast infection)
   2. Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC: repeated vaginal yeast infection)

B. If you are using Brexafemme for the treatment of vulvovaginal candidiasis, approval also requires:
   1. You are a post-menarchal (you have started having your period) female
   2. You have tried or have a contraindication to (harmful for) oral fluconazole AND an intravaginal azole (type of drug that is inserted into the vagina and used to treat yeast infections such as terconazole cream)

C. If you are using Brexafemme for the reduction in the incidence of recurrent vulvovaginal candidiasis, approval also requires:
   1. You are a post-menarchal (you have started having your period) female
   2. You have tried or have a contraindication to (harmful for) oral fluconazole (you had a breakthrough episode of VVC while taking fluconazole 150 mg weekly)
   3. You are NOT currently on oteseconazole for RVVC
   4. You meet ONE of the following:
      a. You have not previously received Brexafemme AND you had 3 or more episodes of RVVC in the past 12 months
      b. You have been previously treated with Brexafemme and meet ALL of the following:
         i. You have successfully completed a course of Brexafemme for prevention of RVVC
         ii. You are either being treated or have just completed treatment for a new recurrence of VVC

Commercial Effective: 04/01/23
GUIDELINES FOR USE

Our guideline named **IBRUTINIB (Imbruvica)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Mantle cell lymphoma (a type of blood cancer)
   2. Chronic lymphocytic leukemia (a type of blood cancer)
   3. Small lymphocytic lymphoma (a type of blood cancer)
   4. Waldenström's macroglobulinemia (a type of blood cancer)
   5. Marginal zone lymphoma (a type of blood cancer)
   6. Chronic graft versus host disease (a type of immune disorder)

B. Requests for ibrutinib 140mg or 280mg tablets requires you had a trial of or contraindication (harmful for) to ibrutinib 140mg capsules

C. Requests for ibrutinib 70mg/mL oral suspension requires you are unable to swallow the tablets or capsules

D. **If you have mantle cell lymphoma, approval also requires:**
   1. You are 18 years of age or older
   2. You have received at least one prior therapy for mantle cell lymphoma

E. **If you have chronic lymphocytic leukemia, small lymphocytic lymphoma, or Waldenström's macroglobulinemia, approval also requires:**
   1. You are 18 years of age or older

F. **If you have marginal zone lymphoma, approval also requires:**
   1. You are 18 years of age or older
   2. You need systemic (treatment spreads through the blood) therapy
   3. You have received at least one prior anti-CD20-based therapy (such as Rituxan)

G. **If you have chronic graft versus host disease, approval also requires:**
   1. You are 1 year of age or older
   2. You have failed one or more lines of systemic therapy (treatment spread through the blood, such as corticosteroids)

Commercial Effective: 09/17/22
ICATIBANT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICATIBANT ACETATE</td>
<td>FIRAZYR, SAJAIZIR, ICATIBANT ACETATE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ICATIBANT (Firazyr, Sajazir) requires the following rule(s) be met for approval:

A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy doctor or immune system doctor) or hematologist (blood doctor)
D. Your diagnosis is confirmed by complement testing (a type of lab test)
E. The requested medication is being used for treatment of acute (sudden and severe) attacks of hereditary angioedema
F. The requested medication will NOT be used concurrently (at the same time) with other acute treatments for HAE attacks (such as Berinert, Ruconest, Kalbitor)

Commercial Effective: 08/01/22
GUIDELINES FOR USE

Our guideline named IDELALISIB (Zydelig) requires the following rule(s) be met for approval:
A. You have relapsed chronic lymphocytic leukemia (CLL: a type of blood cancer)
B. Zydelig will be used in combination with rituximab

Commercial Effective: 04/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ILOPROST (Ventavis) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)
C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
D. You had a trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
   1. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
   2. Oral phosphodiesterase-5 inhibitor (such as Revatio [sildenafil], Adcirca [tadalafil])
   3. Oral cGMP stimulator (such as Adempas [riociguat])
   4. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [Treprostinil])

RENEWAL CRITERIA

Our guideline named ILOPROST (Ventavis) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable in the 6-minute walk distance test AND your World Health Organization functional class has remained stable or improved (WHO-FC: classification system for heart failure)
GUIDELINES FOR USE

Our guideline named IMATINIB (Gleevec) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Newly diagnosed Philadelphia positive chronic myeloid leukemia (type of blood cell cancer that begins in bone marrow with an abnormal gene) in chronic phase
   2. Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy
   3. Relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer that has returned or did not respond to treatment)
   4. Newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer)
   5. Myelodysplastic/myeloproliferative disease (a group of diseases where the bone marrow makes too many white blood cells) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements
   6. Aggressive systemic mastocytosis (a type of cell accumulates in internal tissues and organs) without D816V c-Kit mutation or with c-Kit mutational status unknown
   7. Hypereosinophilic syndrome and/or chronic eosinophilic leukemia (type of inflammatory cancer)
   8. Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (type of rare skin tumor that cannot be completely removed by surgery or returns/ spreads)
   9. Unresectable and/or metastatic malignant gastrointestinal stromal tumor (tumor in stomach/intestines that spreads or cannot be removed by surgery) with a Kit (CD117) positive
   10. Adjuvant (add-on) treatment after complete gross resection (surgical removal) of Kit (CD117) positive gastrointestinal stromal tumor

B. If you are newly diagnosed with Philadelphia positive chronic myeloid leukemia in chronic phase, approval also requires:
   1. You have NOT received previous treatment with another tyrosine kinase inhibitor such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

C. If you have Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy, approval also requires:
   1. You have NOT received previous treatment with another tyrosine kinase inhibitor such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Iclusig (ponatinib)

D. If you have relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), approval also requires:
   1. You are 18 years of age or older

E. If you have newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), approval also requires:
   1. The requested medication will be used in combination with chemotherapy

F. If you have myelodysplastic/myeloproliferative disease associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements, approval also requires:
   1. You are 18 years of age or older

G. If you have aggressive systemic mastocytosis without D816V c-Kit mutation or with c-Kit mutational status unknown, approval also requires:
   1. You are 18 years of age or older

H. If you have hypereosinophilic syndrome and/or chronic eosinophilic leukemia, approval also requires:
   1. You are 18 years of age or older

I. If you have unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans, approval also requires:
   1. You are 18 years of age or older

J. If the request is for adjuvant treatment following complete gross resection of Kit (CD117) positive gastrointestinal stromal tumor (GIST), approval also requires:
   1. You are 18 years of age or older

K. If you have gastrointestinal stromal tumor, approval also requires:
   1. For request of Gleevec 400mg twice daily, approval requires a trial of Gleevec 400mg once daily OR a GIST tumor expressing a KIT exon 9 (type of gene) mutation (a permanent change in your DNA that make up your gene)
GUIDELINES FOR USE

Our guideline named IMIQUIMOD (Zyclara) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Actinic keratosis (AK: rough, scaly patch on the skin caused by years of sun exposure) of the full face or balding scalp
   2. External genital or perianal (around the anus) warts

B. If you have actinic keratosis of the full face or balding scalp, approval also requires:
   1. You are 18 years of age or older
   2. You are immunocompetent (healthy immune system)
   3. You had a trial of TWO generic topical agents for AK (such as fluorouracil, imiquimod, diclofenac 3%)

C. If you have external genital or perianal warts, approval also requires:
   1. You are 12 years of age or older
   2. You have tried or have a contraindication (harmful for) to generic imiquimod 5% topical cream

Commercial Effective: 06/12/23
Our guideline named IMMUNE GLOBULIN requires the following rule(s) be met for approval:

A. For Gammagard Liquid, Gamunex-C, Gammaked, Bivigam, Carimune NF Nanofiltered, Flebogamma DIF, Gammagard S-D, Gammaplex, Privigen, Octagam, or Panzyga for intravenous (IV) injection, approval requires you to have ONE of the following diagnoses:

1. Primary Immunodeficiency Disease (genetic disease where your immune system is weak)
2. Idiopathic Thrombocytopenic Purpura (Low levels of the blood cells that prevent bleeding)
3. Chronic Inflammatory Demyelinating Polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)
4. Multifocal Motor Neuropathy (nerve disorder with increasing muscle weakness and wasting)

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

5. Kawasaki Syndrome (inflammation in the walls of blood vessels in the body)
6. B-cell Chronic Lymphocytic Leukemia (blood and bone marrow cancer of immune cells) with Autoimmune Hemolytic Anemia (body destroys red blood cells more rapidly than it produces them), Immune Thrombocytopenic Purpura (decreased number of blood cells that prevent bleeding with increased easy bruising) OR Pure Red Cell Blood Aplasia (bone marrow stops making red blood cells)
7. Guillain-Barre Syndrome (immune system attacks the nerves)
8. Myasthenia Gravis (weakness and rapid fatigue of muscles under voluntary control)
9. Autoimmune Graves’ Ophthalmopathy (type of eye disease from having little to no thyroid)
10. Cytomegalovirus-induced Pneumonitis related to a solid organ transplant (lung tissue inflammation) related to a solid organ transplant
11. Prevention of bacterial infection in an HIV-infected child (human immunodeficiency virus)-infected child
12. Reduction of secondary infections in pediatric HIV infections
13. Dermatomyositis (inflammatory disease with muscle weakness and skin rash) or polymyositis (type of inflammatory muscle disease)
14. Autoimmune uveitis (Birdshot retinochoroidopathy; inflammation of the middle layer of the eye)
15. Lambert-Eaton myasthenic syndrome (nerve disease in which the immune system attacks the body's own tissues)
16. IgM (Immunoglobulin M) anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathy (type of nerve damage)
17. Stiff-man syndrome (nerve disorder with increasing muscle stiffness (rigidity) and repeated episodes of painful muscle spasms)
18. Neonatal sepsis (blood infection in infants)
19. Rotaviral enterocolitis (severe diarrhea among infants and young children)
20. Toxic shock syndrome (life-threatening complication of certain bacterial infections)
21. Enteroviral meningoencephalitis (Inflammation of the brain and surrounding tissues caused by a virus)
22. Toxic Epidermal Necrolysis or Stevens-Johnson syndrome (both are types of serious skin bacterial infections)
23. Autoimmune Mucocutaneous Blistering Disease (group of serious skin conditions that start with blisters on the skin) such as pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, or epidermolysis bullosa acquisita

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

B. For Asceniv, approval requires:
   1. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)
   2. You are 12 years of age or older
   3. You have tried any other TWO immunoglobulin products

C. For Gamastan S-D, approval requires:
   1. You are using the requested drug for prophylaxis (prevention) or passive immunization (immune response where antibodies are obtained from outside the body) of hepatitis A, measles, varicella, or rubella

D. For Hizentra, approval requires:
   1. The medication is only for subcutaneous (under the skin) use
   2. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak) OR chronic Inflammatory Demyelinating Polyneuropathy (a nerve disorder with increasing weakness and loss of sensory function in the legs and arms)

E. For Cuvitru, Hyqvia, Cutaquig, or Xembify, approval requires:
   • The medication is only for subcutaneous (under the skin) use
   • You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)

F. For Gammagard Liquid, Gamunex-C, or Gammaked for subcutaneous use, approval requires:
   1. You have a diagnosis of primary immunodeficiency disease (genetic disease where your immune system is weak)

Commercial Effective: 04/01/20
INDOMETHACIN RECTAL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INDOMETHACIN</td>
<td>INDOCIN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **INDOMETHACIN RECTAL (Indocin)** requires that you meet ONE of the following rule(s) for approval:

A. You have dysphagia (difficulty swallowing), difficulty swallowing capsules, or have a feeding tube placed (such as a G-tube, J-tube)

B. You had a previous trial of at least two prescription strength oral NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, meloxicam, diclofenac, sulindac, indomethacin, celecoxib)

Commercial Effective: 07/01/20
INDOMETHACIN SUSPENSION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INDOMETHACIN</td>
<td>INDOCIN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **INDOMETHACIN SUSPENSION (Indocin)** requires the following rule(s) be met for approval:

A. You have ONE of following diagnoses:
   1. Moderate to severe rheumatoid arthritis (a type of joint condition)
   2. Moderate to severe ankylosing spondylitis (a type of joint condition)
   3. Moderate to severe osteoarthritis (a type of joint condition)
   4. Acute painful shoulder (such as bursitis, tendinitis)
   5. Acute gouty arthritis (a type of joint condition)

B. You had a trial of generic indomethacin capsules

C. You cannot swallow indomethacin capsules

Commercial Effective: 04/01/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

INFIGRATINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFIGRATINIB PHOSPHATE</td>
<td>TRUSELTIQ</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named INFIGRATINIB (Truseltiq) requires the following rule(s) be met for approval:

A. You have unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has grown outside the organ but has not yet spread to other parts of the body and cannot be removed by surgery, or bile duct cancer that has spread to other parts of the body)

B. You are 18 years of age or older

C. You have previously been treated for unresectable locally advanced or metastatic cholangiocarcinoma

D. You have a fibroblast growth factor receptor 2 (FGFR2: type of protein) fusion or other rearrangement, as detected by a Food and Drug Administration (FDA)-approved test

E. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

Commercial Effective: 01/01/23
INGENOL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INGENOL MEButate</td>
<td>PICATO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Do not approve requests for Picato gel.

(NOTE: Picato discontinued due to safety concerns and increased risk of cancer.)

Commercial Effective: 10/01/21
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **INHALED INSULIN (Afrezza)** requires the following rule(s) be met for approval:

A. You have type 1 or type 2 diabetes
B. You are 18 years of age or older
C. You have a baseline spirometry (test to measure how well your lungs work) to measure FEV1 (forced expiratory volume)
D. **If you have type 1 diabetes, approval also requires:**
   1. You are using a long-acting insulin with the requested medication and that you have tried a formulary rapid acting insulin: Humalog
E. **If you have type 2 diabetes, approval also requires:**
   1. You tried a formulary rapid acting insulin: Humalog
   2. Your prescriber has indicated that you are physically unable or unwilling to use injectable insulin

RENEWAL CRITERIA

Our guideline named **INHALED INSULIN (Afrezza)** requires the following rule(s) be met for renewal:

A. You have type 1 or type 2 diabetes
B. You have documentation of follow up spirometry (test to measure how well your lungs work) to measure FEV1 (forced expiratory volume in one second) after 6 months of treatment and annually thereafter
C. Your FEV1 has NOT declined 20% or more from baseline
D. **If you have type 1 diabetes, approval requires that you are using a long acting insulin at the same time with the requested medication**

Commercial Effective: 07/01/20
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named INOTERSEN (Tegsedi) requires the following rule(s) be met for approval:
A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve pain/damage)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), cardiologist (a type of heart doctor), hATTR specialist, or medical geneticist (doctor who treats gene disorders)
D. You have a documented diagnosis of hereditary TTR amyloidosis (hATTR) as confirmed by ONE of the following:
   1. Biopsy (surgical removal of a sample) of tissue/organ to confirm amyloid (abnormal protein that can build up in any tissue or organ) presence AND chemical typing to confirm presence of TTR (transthyretin) protein
   2. DNA genetic sequencing (lab test for genes) to confirm hATTR mutation
E. You have familial amyloidotic polyneuropathy (FAP) stage 1 or 2 OR up to polyneuropathy disability (PND) stage Illb polyneuropathy
F. You had a trial of or contraindication (harmful for) to the preferred medication: Amvuttra

RENEWAL CRITERIA

Our guideline named INOTERSEN (Tegsedi) requires the following rule(s) be met for renewal:
A. You have hereditary transthyretin-mediated amyloidosis (hATTR: a rare genetic disorder) with polyneuropathy (widespread nerve pain/damage)
B. You have not progressed to familial amyloidotic polyneuropathy (FAP) stage 3 OR polyneuropathy disability (PND) stage IV polyneuropathy as shown by functional decline such as being wheelchair-bound or bedridden

Commercial Effective: 10/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named INTERFERON ALFA-2B (Intron A) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Chronic hepatitis C (type of liver inflammation)
   2. Hairy cell leukemia (bone marrow cancer that makes too many white blood cells)
   3. Condylomata acuminate (genital warts)
   4. AIDS (acquired immunodeficiency syndrome)-related Kaposi's sarcoma (cancer in those with weak immune system that causes tumors of lymph nodes/skin)
   5. Chronic hepatitis B (type of liver inflammation)
   6. Non-Hodgkin's lymphoma (cancer that starts in your lymphatic system- the disease-fighting network in the body)
   7. Malignant melanoma (serious type of skin cancer)
   8. Chronic phase, Philadelphia chromosome (type of abnormal gene) positive chronic myelogenous leukemia (type of blood cell cancer that starts in bone marrow) who are minimally treated (within 1 year of diagnosis)
   9. Follicular lymphoma (type of lymphatic system cancer)
   10. Angioblastoma (certain blood-vessel tumors of the brain)
   11. Carcinoid (cancer) tumor
   12. Chronic myeloid leukemia (type of cancer that starts in immature white blood cells)
   13. Laryngeal papillomatosis (tumors form along the pathways for breathing/digestion)
   14. Multiple myeloma (plasma cell cancer)
   15. Neoplasm of conjunctiva-neoplasm of cornea (eye tumors)
   16. Ovarian cancer
   17. Polycythemia vera (cancer where bone marrow makes too many red blood cells)
   18. Renal cell carcinoma (type of kidney cancer)
   19. Skin cancer, thrombocytosis (your body makes too many platelets)
   20. Thrombocytosis (high level of platelets (cells that helps blood clot and stop bleeding) in your blood)
   21. Vulvar vestibulitis (type of pain around the female sex organ called the vulva)

(Initial criteria continued on next page)
INTERFERON ALFA-2B

INITIAL CRITERIA (CONTINUED)

B. **If you have chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6, approval also requires:**
   1. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), infectious disease specialist (a doctor who specializes in the treatment of infections), or a physician specializing in the treatment of hepatitis (such as a hepatologist: a type of liver doctor)
   2. You have a detectable pretreatment HCV (hepatitis C virus) RNA level/viral load (amount of virus in your blood) of 50 IU/mL or higher
   3. The requested medication will be used with ribavirin or you have a contraindication (harmful for)
   4. You had a trial of or contraindication (harmful for) to peginterferon alfa-2a or peginterferon alfa-2b

RENEWAL CRITERIA

Our guideline named **INTERFERON ALFA-2B (Intron A)** requires the following rule(s) be met for renewal:
A. The request is for continuation of current therapy or renewal with Intron A therapy
B. **If you have chronic hepatitis C (type of liver inflammation), renewal also requires:**
   1. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions), infectious disease specialist (a doctor who specializes in the treatment of infections), or a physician specializing in the treatment of hepatitis (such as a hepatologist: a type of liver doctor)
   2. If you already received 24 weeks or more of interferon treatment, your HCV (hepatitis C virus) RNA level (amount of virus in your blood) is undetectable (less than 50 IU/mL) at 24 weeks

Commercial Effective: 06/15/22
INTERFERON FOR MS - AVONEX

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERFERON BETA-1A</td>
<td>AVONEX, AVONEX PEN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named INTERFERON FOR MS - AVONEX requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

Commercial Effective: 11/01/22
GUIdELINES FOR USE

Our guideline named INTERFERON FOR MS - BETASERON requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

Commercial Effective: 11/01/22
GUIDELINES FOR USE

Our guideline named INTERFERON FOR MS - EXTAVIA requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

C. You had a trial of or contraindication (harmful for) to any TWO of the following preferred medications: Avonex, Copaxone/Glatiramer/Glatopa, Gilenya, Plegridy, Rebif, Betaseron, dimethyl fumarate, Mavenclad, Mayzent, Vumerity, Aubagio, Kesimpta

(Please note: other multiple sclerosis medications may also require prior authorization)
INTERFERON FOR MS - PLEGRIDY

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PEGINTERFERON BETA-1A</td>
<td>PLEGRIDY, PLEGRIDY PEN</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named INTERFERON FOR MS - PLEGRIDY requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

Commercial Effective: 11/01/22
INTERFERON FOR MS - REBIF

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERFERON BETA-1A/ALBUMIN</td>
<td>REBIF, REBIF, REBIDOSE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named INTERFERON FOR MS - REBIF requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

Commercial Effective: 11/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named INTERFERON GAMMA-1B, RECOMB (Actimmune) requires the following rules be met for approval:
A. You have ONE of the following diagnoses:
   1. Chronic granulomatous disease (CGD: inherited immune system disorder that occurs when a type of white blood cells that usually helps your body fight infections does not work properly)
   2. Severe malignant osteopetrosis (SMO: a bone disease that makes bone abnormally thick and prone to breakage/fracture)
B. If you have chronic granulomatous disease, approval also requires:
   1. The medication is prescribed by or given in consultation with a hematologist (blood doctor), infectious disease specialist (doctor that specializes in treating infections), or immunologist (doctor that specializes in treating and managing allergies, asthma and immunologic disorders)
C. If you have severe malignant osteopetrosis, approval also requires:
   1. The medication is prescribed by or given in consultation with an endocrinologist (doctor that specializes in all things relating to our hormones)

RENEWAL CRITERIA

Our guideline named INTERFERON GAMMA-1B, RECOMB (Actimmune) requires the following rules be met for renewal:
A. You have ONE of the following diagnoses:
   1. Chronic granulomatous disease (CGD: inherited immune system disorder that occurs when a type of white blood cells that usually helps your body fight infections does not work properly)
   2. Severe malignant osteopetrosis (SMO: a bone disease that makes bone abnormally thick and prone to breakage/fracture)
B. You have shown clinical (medical) benefit compared to baseline (such as reduction in frequency and severity of serious infections)
C. You have not received hematopoietic cell transplantation (transplant of stem cells from bone marrow, peripheral blood, or umbilical cord blood)
ISAVUCONAZONIUM

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ISAVUCONAZONIUM</td>
<td>CRESEMA</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **ISAVUCONAZONIUM (Cresemba)** requires the following rule(s) be met for approval:

A. You meet **ONE** of the following:
   1. This is a request for continuation of therapy after you were started on Cresemba in the hospital
   2. You have invasive aspergillosis OR invasive mucormycosis (types of fungal infections)

B. You are 18 years of age or older

C. Therapy is prescribed by or given in consultation with an infectious disease specialist

D. **If you have invasive aspergillosis, approval also requires:**
   1. You had a trial and failure of or contraindication to (medical reason why you cannot use) voriconazole

Commercial Effective: 10/01/21
GUIDELINES FOR USE

Our guideline named ISTRADEFYLLINE (Nourianz) requires the following rule(s) be met for approval:
A. You have Parkinson’s disease (a nerve system disorder that affects movement)
B. You are 18 years of age or older
C. You are experiencing ‘OFF’ episodes (times when medication wears off and you have movement problems)
D. Nourianz will be used along with levodopa/carbidopa
E. You had a previous trial of or contraindication to (medical reason why you cannot use) TWO Parkinson’s agents from TWO different drug classes:
   1. Dopamine agonists (such as ropinirole, pramipexole, rotigotine)
   2. Monoamine oxidase-inhibitors (such as selegiline, rasagiline)
   3. Catechol-O-methyl transferase inhibitors (such as entacapone, tolcapone)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named **ITRACONAZOLE (Tolsura)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following fungal infections:
   1. Blastomycosis, pulmonary and extrapulmonary (type of fungal infection affecting in and outside of the lungs)
   2. Histoplasmosis (type of fungal infection), including chronic cavitary pulmonary (affecting the lungs) disease and disseminated, nonmeningeal (not affecting spinal cord and brain membranes) histoplasmosis
   3. Aspergillosis, pulmonary and extrapulmonary (type of fungal infection in and outside of the lungs), **AND** you are intolerant to or refractory to (not responsive to) amphotericin B therapy

B. You are **18 years of age or older**

C. Therapy is prescribed by or given in consultation with an infectious disease specialist

D. You had a previous trial of a generic itraconazole formulation

E. Tolsura is prescribed because you had a poor clinical response to other formulations of itraconazole due to poor bioavailability (amount of drug in the body that has an effect)

---

Commercial Effective: 07/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named IVACAFTOR (Kalydeco) requires the following rule(s) be met for approval:
A. You have cystic fibrosis (CF: a type of lung disorder)
B. You are 1 month of age or older
C. Therapy is prescribed by or in consultation with a pulmonologist (lung doctor) or cystic fibrosis expert
D. You are NOT homozygous (have two copies of the same gene) for the F508del mutation (an abnormal change) in the CFTR (cystic fibrosis transmembrane conductance regulator) gene
E. You have documentation (such as chart notes, lab results, diagnostic test results) of ONE of the following mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene:

| 711+3A→G | F311del | I148T | R75Q | S589N |
| 2789+5G→A | F311L | I175V | R117C | S737F |
| 3272-26A→G | F508C | I807M | R117G | S945L |
| 3849+10kbC→T | F508C; S1251N | I1027T | R117H | S977F |

| A120T | F1052V | I1139V | R117L | S1159F |
| A234D | F1074L | K1060T | R117P | S1159P |
| A349V | G178E | L206W | R170H | S1251N |
| A455E | G178R | L320V | R347H | S1255P |
| A1067T | G194R | L967S | R347L | T338I |
| D110E | G314E | L997F | R352Q | T1053I |
| D110H | G551D | L1480P | R553Q | V232D |
| D192G | G551S | M152V | R668C | V562I |
| D579G | G576A | M952I | R792G | V754M |
| D924N | G970D | M952T | R933G | V1293G |
| D1152H | G1069R | P67L | R1070Q | W1282R |
| D1270N | G1244E | Q237E | R1070W | Y1014C |
| E56K | G1249R | Q237H | R1162L | Y1032C |
| E193K | G1349D | Q359R | R1283M |
| E822K | H939R | Q1291R | S549N |
| E831X | H1375P | R74W | S549R |

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **IVACAFTOR (Kalydeco)** requires the following rule(s) be met for renewal:

A. You have cystic fibrosis (CF: a type of lung disorder)

B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
   1. You have improved, maintained, or demonstrated a less than expected decline in forced expiratory volume (FEV1: amount of air you can exhale in 1 second)
   2. You have improved, maintained, or demonstrated a less than expected decline in body mass index (BMI: a tool for evaluating body fat)
   3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

Commercial Effective: 06/01/23
GUIDELINES FOR USE

Our guideline named IVOSIDENIB (Tibsovo) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Acute myeloid leukemia (AML: a type of blood cancer)
   2. Locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has spread from where it started to nearby tissue/lymph nodes or to other parts of the body)

B. If you have a new diagnosis of acute myeloid leukemia, approval also requires:
   1. The requested medication will be used in combination with azacitidine or as monotherapy (one drug)
   2. Your cancer has a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test
   3. You meet ONE of the following:
      a. You are 75 years of age or older
      b. You are 18 years of age or older AND have comorbidities (additional diseases) that prevent the use of intensive induction chemotherapy (start of a type of cancer treatment)

C. If you have relapsed or refractory acute myeloid leukemia, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test

D. If you have locally advanced or metastatic cholangiocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has an isocitrate dehydrogenase-1 (IDH1: type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test
   3. Your cancer has been previously treated

Commercial Effective: 07/18/22
GUIDELINES FOR USE

Our guideline named IXAZOMIB (Ninlaro) requires the following rule(s) be met for approval:

A. You have multiple myeloma (plasma cell cancer)
B. The requested medication will be used in combination with lenalidomide and dexamethasone
C. You have received at least one prior therapy such as bortezomib, carfilzomib, thalidomide, lenalidomide, melphalan or stem cell transplantation

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named IXEKIZUMAB (Taltz) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)

B. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

E. If you have non-radiographic axial spondyloarthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cosentyx [secukinumab], Cimzia [certolizumab]) and are switching to the requested drug
      b. You have C-reactive protein (CRP; a measure of how much inflammation you have) levels above the upper limit of normal
      c. You have sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)

RENEWAL CRITERIA

Our guideline named IXEKIZUMAB (Taltz) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)

B. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

D. If you have ankylosing spondylitis OR non-radiographic axial spondyloarthritis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

Commercial Effective: 07/01/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LACTIC ACID/CITRIC/POTASSIUM

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LACTIC ACID/CITRIC/POTASSIUM</td>
<td>PHEXXI</td>
</tr>
</tbody>
</table>

Please refer to CONTRACEPTIVE ZERO COST SHARE OVERRIDE section below if the request is also for zero copay override.

GUIDELINES FOR USE

Our guideline named LACTIC ACID/CITRIC/POTASSIUM (Phexxi) requires the following rule(s) be met for approval:
A. You are a female patient with reproductive potential using the requested medication for prevention of pregnancy
B. You are not using vaginal ring products (such as Annovera or Nuvaring) together with Phexxi
C. You had a previous trial of two contraceptive agents (such as an intrauterine device, hormonal implant, injection, patch, or oral products), unless there is a medical reason you cannot (contraindication)

CONTRACEPTIVE ZERO COST SHARE OVERRIDE CRITERIA

Our guideline named CONTRACEPTIVE ZERO COST SHARE OVERRIDE requires that the following rules be met for approval:
A. The request is for ONE of the following:
   1. A generic contraceptive agent
   2. A single-source brand (SSB) contraceptive agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) contraceptive agent
B. If the request is for a single-source brand or multi-source brand contraceptive medication, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
   3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects, differences in durability and reversibility of contraceptive and ability to adhere to the appropriate use)

Commercial Effective: 09/01/22
LANADELUMAB-FLYO

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LANADELUMAB-FLYO</td>
<td>TAKHZYRO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named LANADELUMAB-FLYO (Takhzyro) requires the following rule(s) be met for approval:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You are 2 years of age or older
C. Therapy is prescribed by or in consultation with an allergist, immunologist (allergy or immune system doctor) or hematologist (blood doctor)
D. Your diagnosis is confirmed by documentation (such as chart note, lab result, diagnostic test result) of complement testing (a type of blood test)
E. Takhzyro is being used for prevention of hereditary angioedema attacks
F. You will NOT be using Takhzyro concurrently (at the same time) with an alternative preventive agent for HAE (such as Cinryze, Haegarda, danazol, berotralstat)

RENEWAL CRITERIA

Our guideline named LANADELUMAB-FLYO (Takhzyro) requires the following rule(s) be met for renewal:
A. You have hereditary angioedema (HAE: a type of gene condition with severe body swelling)
B. You have experienced improvement (reductions in attack frequency or attack severity) compared to baseline in hereditary angioedema attacks
C. You will NOT be using Takhzyro concurrently (at the same time) with an alternative preventive agent for HAE (such as Cinryze, Haegarda, danazol, berotralstat)

Commercial Effective: 04/10/23
GUIDELINES FOR USE

Our guideline named LAPATINIB (Tykerb) requires the following rule(s) be met for approval:

A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of your body)

B. Your breast cancer is human epidermal growth factor receptor 2 (HER2: gene/protein in breast cancer) positive

C. **If you have advanced or metastatic breast cancer, approval also requires:**
   1. The requested medication will be used in combination with Xeloda (capecitabine)
   2. You have previously received treatment with Herceptin (trastuzumab), an anthracycline (such as daunorubicin, doxorubicin, epirubicin, idarubicin), AND a taxane (such as paclitaxel, docetaxel)

D. **If you have metastatic breast cancer, approval also requires:**
   1. Your tumor is hormone receptor-positive
   2. The requested medication will be used in combination with Femara (letrozole)
   3. You are a postmenopausal woman

Commercial Effective: 04/10/21
Our guideline named LAROTRECTINIB (Vitrakvi) requires the following rule(s) be met for approval:
A. You have a solid tumor (abnormal mass of tissue that usually does not contain cysts or liquid)
B. Your tumor has a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation (you have a type of enzyme that doesn’t have a mutation)
C. Your tumor is metastatic (spreads to other parts of body) or surgical resection (removal) is likely to result in severe morbidity (illness)
D. There are no satisfactory alternative treatments, or your tumor has gotten worse after treatment
E. Requests for Vitrakvi oral solution also require ONE of the following:
   1. You are a pediatric patient (less than 18 years of age)
   2. You are unable to take Vitrakvi capsules due to difficulty swallowing (or dysphagia)
   3. You have other medical need for the oral solution

Commercial Effective: 07/01/20
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

LASMIDITAN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LASMIDITAN</td>
<td>REYVOW</td>
</tr>
<tr>
<td>SUCCINATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named LASMIDITAN (Reyvow) requires the following rule(s) be met for approval:
A. You are being treated for acute (quick onset) migraine
B. You are 18 years of age or older
C. You have previously tried ONE triptan (such as sumatriptan, rizatriptan), unless there is a medical reason why you cannot (contraindication)

RENEWAL CRITERIA

Our guideline named LASMIDITAN (Reyvow) requires the following rule(s) be met for renewal:
A. You are being treated for acute (quick onset) migraine
B. You meet ONE of the following:
   1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as Migraine Assessment of Current Therapy [MIGRAINE-ACT])
   2. You have experienced clinical improvement as defined by ONE of the following:
      a. Ability to function normally within 2 hours of dose
      b. Headache pain disappears within 2 hours of dose
      c. Treatment works consistently in majority of migraine attacks

Commercial Effective: 12/12/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named L-GLUTAMINE (ENDARI) requires the following rule(s) be met for approval:

A. You have sickle cell disease (type of red blood cell disorder)
B. You are 5 years of age or older
C. The medication is prescribed by or given in consultation with a hematologist (blood doctor specialist)
D. The patient had a trial of or contraindication to hydroxyurea
E. If you are 18 years of age or older, approval also requires ONE of the following:
   1. You had at least 2 sickle cell crises in the past year (A sickle cell crises is defined as a visit to an emergency room/medical facility for sickle cell disease-related pain which was treated with a parenterally administered given into the vein, narcotic or parenterally administered ketorolac, the occurrence of chest syndrome, priapism (prolonged erection of penis), or splenic sequestration [suppressing of spleen])
   2. You are having sickle-cell associated symptoms such as pain or anemia (your blood doesn’t have enough healthy red blood cells and you’re tired) which are interfering with activities of daily living
   3. You have a history of or have recurrent acute chest syndrome (ACS: chest pain, cough, fever, low oxygen level)

RENEWAL CRITERIA

Our guideline named L-GLUTAMINE (Endari) requires the following rule(s) be met for renewal:

A. You have sickle cell disease (type of red blood cell disorder)
B. You have maintained or experienced a reduction in acute complications of sickle-cell disease such as number of sickle cell crises, hospitalizations, acute chest syndrome (ACS: chest pain, cough, fever, low oxygen level)

Commercial Effective: 04/01/20
LEDIPASVIR/SOFOSBUVIR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEDIPASVIR/SOFOSBUVIR</td>
<td>HARVONI, LEDIPASVIR/SOFOSBUVIR</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named LEDIPASVIR/SOFOSBUVIR (Harvoni) requires the following rule(s) be met for approval:
A. You have chronic hepatitis C (type of liver inflammation)
B. You have genotype 1, genotype 4, genotype 5, or genotype 6 hepatitis C
C. You are 3 years of age or older
D. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
E. If you are treatment-experienced (previously treated) with no cirrhosis (liver damage) and genotype 1, previous treatment should include one of the following: 1) peginterferon and ribavirin, 2) triple therapy with HCV protease inhibitor (type of drug to treat hepatitis C), peginterferon and ribavirin, or 3) a prior non-NS5A inhibitor (type of drug to treat hepatitis C), sofosbuvir-containing regimen
F. If you are treatment-experienced (previously treated) with compensated cirrhosis (no symptoms related to liver damage) and genotype 1, previous treatment should include either 1) peginterferon and ribavirin, or 2) triple therapy with HCV protease inhibitor (type of drug to treat hepatitis C), peginterferon and ribavirin
G. If you have decompensated cirrhosis (symptoms related to liver damage) or are post-liver transplant (without cirrhosis or with compensated cirrhosis), approval also requires:
   1. You will be using a ribavirin-containing regimen
H. If the request is for Harvoni 45mg/200 mg pellets, approval also requires:
   1. You are unable to swallow tablets

Harvoni will not be approved if you meet ANY of the following:
- You are using any of the following medications concurrently (at the same time) while on Harvoni: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, rosuvastatin, simprevir, sofosbuvir (Sovaldi), elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild), tipranavir/ritonavir, pibrentasvir/glecaprevir (Mavyret), velpatasvir/sofosbuvir (Epclusa), elbasvir/grazoprevir (Zepatier), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)
- You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions

Commercial Effective: 01/01/23
GUIDELINES FOR USE

Our guideline named LEFAMULIN (Xenleta) requires the following rule(s) be met for approval:
A. You have community-acquired bacterial pneumonia (type of lung infection)
B. You are 18 years of age or older
C. The infection is caused by any of the following susceptible microorganisms (bacteria that the drug can kill): Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydophila pneumoniae
D. You meet ONE of the following criteria:
   1. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
   2. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with a) resistance to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone), AND b) susceptibility to Xenleta
   3. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you had a trial of at least TWO standard of care agents (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone, linezolid) for community-acquired bacterial pneumonia, unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 07/01/20
LENACAPAVIR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LENACAPAVIR</td>
<td>SUNLENCA</td>
</tr>
<tr>
<td>SODIUM</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named LENACAPAVIR (Sunlenca) requires the following rule(s) be met for approval:

A. You have human immunodeficiency virus type 1 (HIV-1: a type of immune disorder)
B. You are 18 years of age or older
C. You are treatment-experienced
D. You have a multidrug resistant (not responding to treatment) HIV-1 infection and have failed your current antiretroviral regimen (HIV treatment) due to resistance, intolerance (side effects), or safety considerations

Commercial Effective: 06/01/23
LENALIDOMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LENALIDOMIDE</td>
<td>REVLIMID, LENALIDOMIDE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named LENALIDOMIDE (Revlimid) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Multiple myeloma (a type of blood cancer)
   2. Anemia due to a myelodysplastic syndrome (a type of blood cancer)
   3. Mantle cell lymphoma (a type of blood cell)
   4. Follicular lymphoma (a type of blood cancer)
   5. Marginal zone lymphoma (a type of blood cancer)
B. You are 18 years of age or older
C. If you have anemia due to a myelodysplastic syndrome, approval also requires:
   1. You have a deletion 5q (type of gene) abnormality
D. If you have mantle cell lymphoma, approval also requires:
   1. You have relapsed or progressed (disease has returned or worsened) after two prior therapies, one of which included Velcade (bortezomib) (Note: Velcade may be covered under the medical benefit and/or require prior authorization).
E. If you have follicular lymphoma, approval also requires:
   1. You have previously been treated for follicular lymphoma
   2. The requested medication is being taken in combination with a rituximab product (type of cancer drug)

Commercial Effective: 04/01/22
Our guideline named **LENIOLISIB (Joenja)** requires the following rule(s) be met for approval:

A. You have activated phosphoinositide 3-kinase delta (PI3Kdelta) syndrome (APDS: a type of mutation that impacts the immune system)

B. You are 12 years of age or older

---

**LENOLISIB**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LENOLISIB PHOSPHATE</td>
<td>JOENJA</td>
</tr>
</tbody>
</table>

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named **LENVATINIB (Lenvima)** requires the following rule(s) be met for approval:

A. You have **ONE** of the following diagnoses:
   1. Differentiated thyroid cancer (DTC: cancer cells look/act like normal thyroid cells)
   2. Advanced renal cell cancer (RCC: kidney cancer)
   3. Unresectable hepatocellular carcinoma (HCC: liver cancer that cannot be removed by surgery)
   4. Advanced endometrial carcinoma (EC: type of cancer that starts in the uterus)

B. **If you have differentiated thyroid cancer (DTC), approval also requires:**
   1. Your thyroid cancer is locally recurrent or metastatic (cancer that has spread to other parts of the body)
   2. Your thyroid cancer is progressive (getting worse)
   3. Your thyroid cancer is refractory (has not responded) to radioactive iodine therapy

C. **If you have advanced renal cell cancer (RCC), approval also requires:**
   1. You are 18 years of age or older
   2. You meet **ONE** of the following:
      a. Lenvima will be used as first-line treatment in combination with pembrolizumab (Keytruda)
      b. Lenvima is used in combination with everolimus AND you have tried one prior anti-angiogenic therapy (treatment that stop tumors from growing their own blood vessels, such as Sutent [sunitinib], Votrient [pazopanib], Inlyta [axitinib], Nexavar [sorafenib])

D. **If you have unresectable hepatocellular carcinoma (HCC), approval also requires:**
   1. Lenvima is being used as a first-line treatment

E. **If you have advanced endometrial carcinoma (EC), approval also requires:**
   1. Lenvima is used in combination with pembrolizumab (Keytruda)
   2. You do not have microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) biomarkers (characteristics that help determine what type of cancer you have and what treatment options there are for it)
   3. You have experienced disease progression following prior systemic therapy (disease has worsened after previous therapy)
   4. You are not a candidate for curative surgery or radiation

Commercial Effective: 04/01/22
LETTERMOVIR PO

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LETTERMOVIR</td>
<td>PREVYMIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **LETTERMOVIR PO (Prevymis)** requires the following rule(s) be met for approval:

A. Prevymis will be used for prophylaxis (prevention) of cytomegalovirus infection (a type of viral infection) and disease
B. You are 18 years of age or older
C. You are a CMV (cytomegalovirus)-seropositive recipient [R+] of an allogeneic hematopoietic stem cell transplant (you have cells transplanted from a matching donor)
D. Prevymis will be started between Day 0 and Day 28 post-transplantation (before or after engraftment)
E. You are not receiving the medication beyond 100 days post-transplantation

Commercial Effective: 09/12/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **LEUPROLIDE** requires the following rule(s) be met for approval:

**A.** You have ONE of the following diagnoses:
   1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
   2. Advanced prostate cancer (prostate cancer that has spread to nearby tissue or organs)
   3. Central precocious puberty (CPP: early sexual development in girls and boys)

**B. If you are female and have central precocious puberty, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
   3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   4. You are/were younger than 8 years of age when your condition started
   5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

**C. If you are male and have central precocious puberty, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
   3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   4. You are/were younger than 9 years of age when your condition started
   5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of gender dysphoria or advanced prostate cancer, please refer to the Initial Criteria section.

Our guideline named LEUPROLIDE requires the following rule(s) be met for renewal:

A. You have central precocious puberty (CPP: early sexual development in girls and boys)
B. Your Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
C. You have not reached the actual age which corresponds to your current pubertal age

Commercial Effective: 01/23/23
GUIDELINES FOR USE

Our guideline named **LEUPROLIDE-ELIGARD** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
   2. Advanced prostate cancer (prostate cancer that has spread to nearby tissue or organs)

Commercial Effective: 01/23/23
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

**GUIDELINES FOR USE**

Our guideline named **LEVAMLODIPINE (Conjupri)** requires the following rule(s) be met for approval:

A. You have hypertension (high blood pressure)
B. You are 6 years of age or older
C. You have tried or have a contraindication (harmful for) to TWO generic dihydropyridine calcium channel blockers (such as amlodipine, felodipine, nicardipine)
D. You have tried or have a contraindication (harmful for) to TWO other antihypertensive agents in another class (such as hydrochlorothiazide, lisinopril, losartan)

---

**Commercial Effective: 06/01/22**
GUIDELINES FOR USE

Our guideline named LEVETIRACETAM (Spritam) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Partial-onset seizures (type of seizure)
   2. Myoclonic seizures in juvenile myoclonic epilepsy (type of seizure in childhood)
   3. Primary generalized tonic-clonic seizures (type of seizure)

B. If you have partial-onset seizures, approval also requires:
   1. You are 4 years of age or older
   2. You are unable to swallow levetiracetam tablets
   3. You had a trial of levetiracetam oral solution

C. If you have myoclonic seizures in juvenile myoclonic epilepsy, approval also requires:
   1. You are 12 years of age or older
   2. Spritam will be used as adjunctive (add-on) therapy
   3. You are unable to swallow levetiracetam tablets
   4. You had a trial of levetiracetam oral solution

D. If you have primary generalized tonic-clonic seizures, approval also requires:
   1. You are 6 years of age or older
   2. Spritam will be used as adjunctive (add-on) therapy
   3. You are unable to swallow levetiracetam tablets
   4. You had a trial of levetiracetam oral solution
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named LEVODOPA INHALATION (Inbrija) requires the following rule(s) be met for approval:
A. You have Parkinson's disease (a nerve system disorder that affects movement)
B. Inbrija is being used for intermittent treatment of OFF episodes (times when you have symptoms return due to medication wearing off) associated with Parkinson's disease
C. You are currently being treated with carbidopa/levodopa
D. The requested medication is prescribed by or given in consultation with a neurologist (nerve doctor)
E. You are NOT currently taking more than 1600mg of levodopa per day
F. Your doctor has optimized drug therapy as evidenced by BOTH of the following:
   1. Change in levodopa/carbidopa dosing strategy or formulation
   2. Trial or contraindication to (medical reason why you cannot use) at least TWO Parkinson's agents from TWO different classes of the following: dopamine agonist (such as ropinirole, pramipexole, rotigotine), monoamine oxidase-inhibitors (MAO-I) (such as selegiline, rasagiline), catechol-O-methyl transferase (COMT) inhibitors (such as entacapone, tolcapone), adenosine receptor antagonist A2A (such as istradefylline)

RENEWAL CRITERIA

Our guideline named LEVODOPA INHALATION (Inbrija) requires the following rule(s) be met for renewal approval:
A. You have Parkinson's disease (a nerve system disorder that affects movement)
B. You had improvement with motor fluctuations during OFF episodes (times when you have symptoms return due to medication wearing off) with the use of Inbrija. Improvements can be in speech, facial expression, tremor at rest, action or postural tremor of hands, rigidity, finger taps, hand movements, rapid alternating movements of hands, posture, leg agility, arising from chair.
LEVKETOCONAZOLE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LEVKETOCONAZOLE</td>
<td>RECORLEV</td>
</tr>
</tbody>
</table>

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named LEVKETOCONAZOLE (Recorlev) requires the following rule(s) be met for approval:

A. You have Cushing’s syndrome (a type of hormone disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
D. You are not a candidate for surgery or surgery has not been curative
E. You have tried or have a contraindication (harmful for) to oral ketoconazole

RENEWAL CRITERIA

Our guideline named LEVKETOCONAZOLE (Recorlev) requires the following rule(s) be met for renewal:

A. You have Cushing's syndrome (a type of hormone disorder)
B. You continue to have improvement of Cushing's syndrome (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of your disease)
C. You continue to tolerate treatment with Recorlev

Commercial Effective: 02/01/22
GUIDELINES FOR USE

Our guideline named LEVOTHYROXINE-ERMEZA requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
   2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer
B. You had a trial and failure (drug did not work) of Thyquidity
C. You had a trial and failure (drug did not work) of generic levothyroxine tablets
D. You are unable to swallow levothyroxine tablets or capsules
E. If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:
   1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)

Commercial Effective: 04/01/23
GUIDELINES FOR USE

Our guideline named **LEVOTHYROXINE-TIROSINT** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
   2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer

B. You are 6 years of age or older

C. You had a trial and failure (drug did not work) of generic levothyroxine tablets

D. There is documentation of rationale (reason) for not using generic levothyroxine tablets

E. **If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:**
   1. The requested medication will be used as an adjunct (add-on) to surgery and radiiodine therapy (a type of radiation therapy)

Commercial Effective: 01/01/23
GUIDELINES FOR USE

Our guideline named LEVOTHYROXINE-TIROSINT-SOL requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Congenital (present from birth) or acquired hypothyroidism (low thyroid function)
   2. Thyrotropin (a type of thyroid hormone)-dependent well-differentiated thyroid cancer
B. You had a trial and failure (drug did not work) of Thyquidity
C. You had a trial and failure (drug did not work) of or contraindication (harmful for) to generic levothyroxine tablets
D. There is documentation of rationale (reason) for not using Thyquidity and generic levothyroxine tablets
E. If you have thyrotropin-dependent well-differentiated thyroid cancer, approval also requires:
   1. The requested medication will be used as an adjunct (add-on) to surgery and radioiodine therapy (a type of radiation therapy)

Commercial Effective: 01/01/23
LOFEXIDINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOFEXIDINE</td>
<td>LUCEMYRA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline name **LOFEXIDINE (Lucemyra)** requires the following rule(s) be met for approval:

A. Lucemyra is being used to lessen opioid withdrawal symptoms to help abrupt opioid discontinuation
B. You are 18 years of age or older
C. You are in a setting with close patient monitoring of Lucemyra (lofexidine) treatment for a maximum of 18 days
D. Treatment with Lucemyra is being administered as part of an opioid discontinuation plan that includes other withdrawal symptom management medications (such as stool softeners, sleep aids) and psychosocial support is in place to help prevent relapse

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named LOMITAPIDE (Juxtapid) requires the following rule(s) be met for approval:
A. You have homozygous familial hypercholesterolemia (type of inherited high cholesterol)
B. Your diagnosis of homozygous familial hypercholesterolemia (type of inherited high cholesterol) was determined by meeting ONE of the following criteria:
   1. Simon Broome diagnostic criteria
   2. Dutch Lipid Network criteria with a score of at least 8
   3. A clinical diagnosis based on a history of an untreated LDL (low density lipoprotein) - cholesterol level greater than 500 mg/dL, in combination with either (1) xanthoma (condition where fatty growth develops under the skin) before 10 years of age OR (2) evidence of heterozygous familial hypercholesterolemia (type of inherited high cholesterol) in both parents
C. The requested medication is prescribed by or given in consultation with a cardiologist (heart doctor), endocrinologist (hormone doctor), or lipidologist (cholesterol management doctor)
D. You have an LDL (low density lipoprotein) - cholesterol level greater than or equal to 70 mg/dL while on maximally tolerated statin (drug used for cholesterol) treatment
E. You previously had a trial of Repatha (evolocumab) unless you do not have functional LDL (low density lipoprotein) receptors
F. If you are statin tolerant, approval also requires:
   1. You meet ONE of the following criteria:
      a. You have been taking a high-intensity statin (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) for a duration of at least 8 weeks
      b. You have been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks given you cannot tolerate a high-intensity statin (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily)
   2. You will continue statin (drug used for cholesterol) treatment in combination with Juxtapid

(Criteria continued on next page)

CONTINUED ON NEXT PAGE
G. If you are statin intolerant, approval also requires ONE of the following:
   1. You have an absolute contraindication to (medical reason why you cannot use) statin therapy (drug used for cholesterol) such as active decompensated liver disease (you have symptoms related to liver damage), nursing female, pregnancy or plans to become pregnant, or hypersensitivity (allergic) reaction
   2. You have complete statin intolerance as defined by severe and intolerable adverse effects such as creatine kinase elevation (a measurement of how much muscle damage you have) greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (muscle breakdown), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group. These must have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin.

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named LOMUSTINE (Gleostine) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Hodgkin's lymphoma (type of immune system cancer)
   2. Primary and metastatic brain tumors (tumor that has spread to other parts of body)

B. If you have primary and metastatic brain tumors, approval also requires:
   1. You have previously received appropriate surgical and/or radiotherapeutic procedures
   2. The requested medication will be used as a part of the PCV regimen (procarbazine, lomustine, and vincristine)

Commercial Effective: 01/01/23
GUIDELINES FOR USE

Our guideline named LONAFARNIB (Zokinvy) requires the following rule(s) be met for approval:
A. You have Hutchinson-Gilford progeria syndrome (HGPS) OR processing-deficient progeroid laminopathies (rare genetic disorders that cause premature aging in children)
B. You are 1 year of age or older
C. You have a body surface area (BSA) of 0.39 meters squared or more
D. **If you have processing-deficient progeroid laminopathies, approval also requires you have ONE of the following:**
   1. Heterozygous LMNA (type of gene) mutation with progerin-like protein accumulation
   2. Homozygous or compound heterozygous ZMPSTE24 (type of gene) mutations

Commercial Effective: 04/01/21
LONAPEGSOMATROPIN-TCGD

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LONAPEGSOMATROPIN-TCGD</td>
<td>SKYTROFA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named LONAPEGSOMATROPIN-TCGD (Skytrofa) requires the following rule(s) be met for approval:

A. You have growth failure due to an inadequate secretion of endogenous (from your own body) growth hormone
B. Skytrofa is not being used for the treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (ISS: a type of growth condition)
C. You are 1 year of age or older and weigh at least 11.5 kg
D. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
E. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
F. You meet at least ONE of the following criteria for short stature:
   1. Your height is at least 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
   2. Your height velocity is less than the 25th percentile for your age
   3. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) at least 2 standard deviations below the mean for your age and gender

RENEWAL CRITERIA

Our guideline named LONAPEGSOMATROPIN-TCGD (Skytrofa) requires the following rule(s) be met for renewal:

A. You have growth failure due to an inadequate secretion of endogenous (from your own body) growth hormone
B. Skytrofa is not being used for the treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (ISS: a type of growth condition)

(Renewal criteria continued on next page)
LONAPEGSOMATROPIN-TCGD

RENEWAL CRITERIA (CONTINUED)

C. Therapy is prescribed by or given in consultation with an endocrinologist (a type of hormone doctor)
D. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
E. You meet ONE of the following:
   1. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
   2. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

Commercial Effective: 11/01/21
LORCASERIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>LORCASERIN HCL</td>
<td>BELVIQ,</td>
</tr>
<tr>
<td></td>
<td>BELVIQ XR</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Do not approve requests for Belviq or Belviq XR.

*(NOTE: Safety concerns [increased risk of cancer] have prompted market withdrawal of Belviq and Belviq XR.)*

Commercial Effective: 10/01/21
GUIDELINES FOR USE

Our guideline named LORLATINIB (Lorbrena) requires the following rule(s) be met for approval:
A. You have metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
B. You are 18 years of age or older
C. Your tumors are anaplastic lymphoma kinase (ALK: type of enzyme) - positive which is shown by an FDA (Federal and Drug Administration) approved test

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named LOTEPRDNL (Eysuvis) requires the following rule(s) be met for approval:
A. You have dry eye disease
B. You previously tried one generic loteprednol ophthalmic product AND one non-loteprednol ophthalmic (eye) corticosteroid (such as fluorometholone, dexamethasone, prednisolone) unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 04/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named LUMACAFTOR-IVACAFTOR (Orkambi) requires the following rule(s) be met for approval:
A. You have cystic fibrosis (a type of lung disorder)
B. You are 1 year of age or older
C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
D. There is documentation that you are homozygous (have 2 copies of the same gene) for the F508del-CFTR (type of gene: cystic fibrosis transmembrane conductance regulator) mutation

RENEWAL CRITERIA

Our guideline named LUMACAFTOR-IVACAFTOR (Orkambi) requires the following rule(s) be met for renewal:
A. You have cystic fibrosis (a type of lung disorder)
B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:
   1. You have improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume: amount of air you can exhale in 1 second)
   2. You have improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
   3. You have experienced a reduction in rate of pulmonary exacerbations (worsening in lung condition)

Commercial Effective: 10/01/22
LUSUTROMBOPAG

GUIDELINES FOR USE

Our guideline named LUSUTROMBOPAG (Mulpleta) requires the following rule(s) be met for approval:
A. You have thrombocytopenia (a type of blood disorder)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor), gastroenterologist (a doctor who treats digestive conditions), hepatologist (a type of liver doctor), immunologist (a type of immune system doctor), endocrinologist (a type of hormone doctor), or surgeon
D. You have chronic liver disease
E. You are scheduled to undergo a procedure 8 to 14 days after starting Mulpleta (lusutrombopag) therapy
F. You have a platelet count of less than 50x10^9 cells/L measured within the last 30 days
G. You are not receiving other thrombopoietin receptor agonist therapy, such as avatrombopag, romiplostim, eltrombopag

Commercial Effective: 04/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MACITENTAN (Opsumit) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named MACITENTAN (Opsumit) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)

Commercial Effective: 07/01/23
MARALIXIBAT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MARALIXIBAT CHLORIDE</td>
<td>LIVMARLI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named MARALIXIBAT (Livmarli) requires the following rule(s) be met for approval:

A. You have cholestatic pruritus (a type of skin condition) associated with Alagille syndrome (ALGS: a type of genetic disorder)
B. You are 3 months of age or older

Commercial Effective: 04/10/23
GUIDELINES FOR USE

Our guideline named MARIBAVIR (Livtencity) requires the following rule(s) be met for approval:
A. You have a post-transplant cytomegalovirus (CMV) infection (a type of viral infection)
B. You are 12 years of age or older
C. You are refractory to prior therapy with ganciclovir, valganciclovir, cidofovir or foscarnet

Commercial Effective: 01/01/22
**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

Our guideline named MAVACAMTEN (Camzyos) requires the following rule(s) be met for approval:

A. You have symptomatic obstructive hypertrophic cardiomyopathy (HCM: a type of heart condition)
B. You are 18 years of age or older
C. You have New York Heart Association (NYHA) class II-III (classification system for heart failure) symptoms
D. You have a left ventricular outflow track gradient (a predictor of heart failure and cardiovascular death) of 50 mmHg or higher
E. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor)
F. You had a trial of or contraindication (harmful for) to beta-blockers (such as metoprolol, carvedilol) AND non-dihydropyridine calcium channel blockers (such as verapamil, diltiazem)

**RENEWAL CRITERIA**

Our guideline named MAVACAMTEN (Camzyos) requires the following rule(s) be met for renewal:

A. You have symptomatic obstructive hypertrophic cardiomyopathy (HCM: a type of heart condition)
B. You have experienced continued clinical benefit (such as reduction of symptoms, NYHA classification improvement)

Commercial Effective: 06/01/22
MEBENDAZOLE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEBENDAZOLE</td>
<td>EMVERM</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **MEBENDAZOLE (Emverm)** requires the following rule(s) be met for approval:

A. Emverm is being used for the treatment of *Enterobius vermicularis* (pinworm), *trichuris trichiura* (whipworm), *ascaris lumbricoides* (common roundworm), *ancylostoma duodenale* (common hookworm), or *necator americanus* (American hookworm)

B. You are 2 years of age or older

C. **If you have *enterobius vermicularis* (pinworm), approval also requires:**
   1. You previously had a trial of over-the-counter (OTC) pyrantel pamoate, unless there is a medical reason why you cannot (contraindication)

D. **If you have *trichuris trichiura* (whipworm) or *ascaris lumbricoides* (common roundworm), approval also requires:**
   1. You have documentation confirming your diagnosis of *trichuris trichiura* (whipworm) or *ascaris lumbricoides* (common roundworm)
   2. You previously had a trial of albendazole (Albenza), unless there is a medical reason why you cannot (contraindication)

E. **If you have *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm), approval also requires:**
   1. You have documentation confirming your diagnosis of *ancylostoma duodenale* (common hookworm) or *necator americanus* (American hookworm)
   2. You previously had a trial of albendazole (Albenza), unless there is a medical reason why you cannot (contraindication) OR you had a trial of over-the-counter (OTC) pyrantel pamoate

Commercial Effective: 10/01/20
MECAMYLAMINE HYDROCHLORIDE

GUIDELINES FOR USE

Our guideline named MECAMYLMINE HYDROCHLORIDE (Vecamyl) requires the following rule(s) be met for approval:

A. The requested medication will be used for the management of moderately severe to severe essential (or primary) hypertension or in uncomplicated cases of malignant hypertension

B. You have had a trial of at least three of the following, unless there is a medical reason why you cannot (contraindication): angiotensin converting enzyme inhibitor (ACE-I) or ACE-I combination, angiotensin receptor blocker (ARB) or ARB combination, Beta Blocker, or Calcium Channel Blocker, such as benazepril, benazepril-HCTZ, captopril, captopril-HCTZ, enalapril, enalapril-HCTZ, fosinopril, fosinopril-HCTZ, lisinopril, lisinopril-HCTZ, quinapril, ramipril, moexipril, moexipril-HCTZ, perindopril erbumine, quinapril, quinapril-HCTZ, trandolapril, trandolapril/verapamil, losartan, losartan-HCTZ, irbesartan, irbesartan-HCTZ, olmesartan, olmesartan-HCTZ, olmesartan-amlodipine-HCTZ, valsartan, valsartan-HCTZ, diltiazem HCL, diltiazem sustained release (generics only), verapamil, verapamil sustained release (generics only), atenolol, atenolol-chlorthalidone, bisoprolol, bisoprolol-HCTZ, carvedilol, metoprolol tartrate, nadolol, acebutolol, betaxolol, labetalol, metoprolol succinate, metoprolol-HCTZ, pindolol, propranolol, propranolol-HCTZ, sotalol, timolol maleate, or nebivolol.

Commercial Effective: 07/01/20
MECASERMIN

Generic | Brand
---|---
MECASERMIN | INCRELEX

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MECASERMIN (Increlex) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Severe primary insulin growth-like factor 1 deficiency (IGF-1: hormone levels that promote normal bone and tissue growth and development are extremely low or undetectable in the blood)
   2. Growth hormone gene deletion (not growth hormone-deficient short stature) and developed neutralizing antibodies to growth hormone

B. You are 2 years to less than 18 years of age

C. The requested medication is prescribed by or given in consultation with a pediatric endocrinologist (hormone doctor) or pediatric nephrologist (kidney doctor)

D. You have a height standard deviation score less than or equal to -3.0, basal IGF-1 (insulin growth-like factor 1) standard deviation score less than or equal to -3.0, and normal or elevated growth hormone [serum growth hormone level of greater than or equal to 10ngm/mL to at least 2 stimuli (insulin, levodopa, arginine, clonidine or glucagon)]

E. Your bone growth plates (epiphyses) are open (as confirmed by radiograph of the wrist and hand)

RENEWAL CRITERIA

Our guideline named MECASERMIN (Increlex) requires the following rule(s) be met for renewal:

A. You have shown a response in the first 6 months of insulin growth-like factor-1 (IGF-1) therapy (increase in height, increase in height velocity)

Commercial Effective: 04/01/20
MECHLORETHAMINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MECHLORETHAMINE HCL</td>
<td>VALCHLOR</td>
</tr>
</tbody>
</table>
MEPOLIZUMAB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEPOLIZUMAB</td>
<td>NUCALA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MEPOLIZUMAB (Nucala) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Severe asthma with an eosinophilic phenotype (type of lung condition with inflammation)
   2. Chronic rhinosinusitis with nasal polyps (CRSwNP: inflammation of nasal and sinus passages with small growths in the nose)
   3. Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome (inflammation of blood vessels with high levels of a type of white blood cell)
   4. Hypereosinophilic syndrome (HES) (a rare blood disorder)

B. If you have severe asthma with an eosinophilic phenotype, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a doctor specializing in pulmonary (lung/breathing) medicine or allergy medicine
   3. You have a documented blood eosinophil (type of white blood cell) level of at least 150 cells/ml within the past 12 months
   4. You are being treated with a medium, high-dose, or maximally tolerated dose of an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or oral corticosteroid (such as prednisone)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
MEPOLIZUMAB

INITIAL CRITERIA (CONTINUED)

5. You meet ONE of the following:
   a. You experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months OR at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months
   b. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      i. Daytime asthma symptoms more than twice per week
      ii. Any night waking due to asthma
      iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      iv. Any activity limitation due to asthma

6. You will NOT use Nucala concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL-5 biologic (such as Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

C. If you have chronic rhinosinusitis with nasal polyps, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor) or allergist/immunologist (a type of allergy or immune system doctor)
   3. Nucala will be used as add-on maintenance treatment
   4. You had a 90-day trial of ONE intranasal corticosteroid (such as mometasone, fluticasone, beclomethasone)

D. If you have eosinophilic granulomatosis with polyangiitis, approval also requires:
   1. You are 18 years of age or older

E. If you have hypereosinophilic syndrome, approval also requires:
   1. You are 12 years of age or older
   2. You have had HES for 6 months or more without an identifiable non-hematologic (not present in the blood) secondary cause

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

NOTE: For the diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome) OR hypereosinophilic syndrome (HES), please refer to the Initial Criteria section.

Our guideline named MEPOLIZUMAB (Nucala) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Severe asthma with an eosinophilic phenotype (type of lung condition with inflammation)
   2. Chronic rhinosinusitis with nasal polyps (CRSwNP; inflammation of nasal and sinus ways with small growths in the nose)

B. If you have severe asthma with an eosinophilic phenotype, renewal also requires:
   1. You will continue to use an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, tiotropium, umeclidinium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or an oral corticosteroid (such as prednisone)
   2. You will NOT use Nucala concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or another anti-IL-5 biologic (such as Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma
   3. You have shown a clinical response as evidenced by ONE of the following:
      a. You have experienced a reduction in asthma exacerbation (worsening of symptoms) from baseline
      b. You have decreased use of rescue medications (such as albuterol)
      c. You have an increase in percent predicted FEV1 (amount of air you can forcefully exhale in one second) from pretreatment baseline (before starting Nucala)
      d. You have a reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

C. If you have chronic rhinosinusitis with nasal polyposis, renewal also requires:
   1. You have had a clinical benefit compared to baseline (before starting Nucala) (such as improvements in nasal congestion, sense of smell or size of polyps)

Commercial Effective: 06/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named METHOXY PEG-EPOETIN BETA (Mircera) requires the following rule(s) be met for approval:
A. You have anemia (low amount of healthy red blood cells) associated with chronic kidney disease
B. If you are 18 years of age or older, approval also requires:
   1. You have tried the preferred medication: Retacrit
   2. You have a hemoglobin level (type of blood test) of less than 10g/dL
C. If you are between 5 and 17 years of age, approval also requires:
   1. You are on hemodialysis (process of removing excess water, toxins from the blood)
   2. You are changing from another erythropoiesis-stimulating agent (ESA; epoetin alfa, darbepoetin alfa) after the hemoglobin level has been stabilized with the ESA

RENEWAL CRITERIA

Our guideline named METHOXY PEG-EPOETIN BETA (Mircera) requires the following rule(s) be met for renewal:
A. You have anemia (low amount of healthy red blood cells) associated with chronic kidney disease
B. If you are 18 years of age or older, renewal also requires ONE of the following:
   1. You have a hemoglobin level (type of blood test) of less than 11g/dL if you are on dialysis (process of removing excess water, toxins from the blood)
   2. The patient has a hemoglobin level that has reached 11g/dL (if you are on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions
   3. You have a hemoglobin level (type of blood test) of less than 10g/dL if you are not on dialysis
   4. You have a hemoglobin level that has reached 10g/dL (if you are not on dialysis) and your dose is being reduced/interrupted to decrease the need for blood transfusions

(Renewal criteria continued on next page)
C. If you are between 5 and 17 years of age, renewal also requires:
   1. You are currently receiving dialysis treatment (process of removing excess water, toxins from the blood)
   2. You have ONE of the following:
      a. A hemoglobin level (type of blood test) of less than 11g/dL
      b. A hemoglobin level that has reached 11g/dL and your dose is being reduced/interrupted to decrease the need for blood transfusions

Commercial Effective: 04/17/23
METHYLNALTREXONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>METHYLNALTREXONE</td>
<td>RELISTOR</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named METHYLNALTREXONE (Relistor) requires the following rule(s) be met for approval:

A. You have opioid (type of pain medication)-induced constipation with chronic non-cancer pain, OR you have an advanced illness or pain caused by active cancer and you require opioid dosage increase for palliative care (treatment of symptoms)

B. You are 18 years of age or older

C. If you have advanced (terminal) illness, or pain caused by active cancer and you require opioid dosage increase for palliative care (treatment of symptoms), only Relistor injection may be approved

D. If you have chronic non-cancer pain, approval also requires:
   1. You have been taking opioids for at least four weeks
   2. You had a previous trial of naloxegol (Movantik), unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named METHYLTESTOSTERONE (Testred, Android, Methitest) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
   3. Gender dysphoria (you identify yourself as a member of the opposite sex)
   4. Metastatic breast cancer (cancer spreading to other areas of body) in a female

B. If you are a male with primary or secondary hypogonadism, approval also requires:
   1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   2. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/Dl (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/Dl (0.17 nmol/L)
   3. You had a trial of or contraindication (harmful for) to TWO lower cost testosterone agents (such as intramuscular [injected into the muscle] testosterone cypionate, intramuscular testosterone enanthate)

C. If you are a male with delayed puberty not secondary to a pathological disorder, approval also requires:
   1. You had a trial of or contraindication (harmful for) to intramuscular (injected into the muscle) testosterone enanthate.

(Initial criteria continues on next page)
INITIAL CRITERIA (CONTINUED)

D. If you have gender dysphoria, approval also requires:
   1. Only agents supported by the compendia (accepted medical references such as
      DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender
      dysphoria may be approved
   2. You are 16 years of age or older

E. If you are a female with metastatic breast cancer, approval also requires:
   1. You had a trial of or contraindication (harmful for) intramuscular (injected into the muscle)
      testosterone enanthate.

RENEWAL CRITERIA

Our guideline named METHYLTESTOSTERONE (Testred, Android, Methitest) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
   3. Metastatic breast cancer (cancer spreading to other areas of body) in a female
   4. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as
      DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender
      dysphoria may be approved

C. If you are a male with primary or secondary hypogonadism, renewal also requires:
   1. You have shown improvement in your symptoms compared to baseline and tolerance to
      treatment
   2. There is documentation (such as chart notes, lab results) of normalized serum
      testosterone levels and hematocrit concentrations (type of blood test) compared to
      baseline
   3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that
      may indicate prostate cancer) has been evaluated for prostate cancer screening

Commercial Effective: 04/01/23
METOCLOPRAMIDE

**Guidelines for Use**

Our guideline named METOCLOPRAMIDE (Gimoti) requires the following rule(s) be met for approval:

A. You have acute (short duration) and recurrent (occurring repeatedly) diabetic gastroparesis (disorder that causes delayed emptying of food from the stomach)

B. You are 18 years of age or older

C. You have previously tried or have a contraindication (medical reason why you cannot take) to metoclopramide ODT (orally disintegrating tablet)

Commercial Effective: 01/01/21
GUIDELINES FOR USE

Our guideline named MIDOSTAURIN (Rydapt) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Newly diagnosed acute myeloid leukemia (AML: a type of blood cancer)
   2. Aggressive systemic mastocytosis (ASM: a type of blood disorder)
   3. Systemic mastocytosis with associated hematological neoplasm (SM-AHN: type of blood cancer)
   4. Mast cell leukemia (MCL: type of blood cell cancer)

B. If you have newly diagnosed acute myeloid leukemia, approval also requires:
   1. You are 18 years of age or older
   2. You are FLT3 (type of gene) mutation-positive as detected by a Food and Drug Administration (FDA)-approved diagnostic test
   3. The requested medication will be used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation (cancer drugs)
   4. The requested medication will not be used by itself to start treatment (single-agent induction therapy)

C. If you have aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia, approval also requires:
   1. You are 18 years of age or older

Commercial Effective: 04/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MIFEPRISTONE (Korlym) requires the following rule(s) be met for approval:

A. You have endogenous Cushing's syndrome (CS: condition that occurs after having high levels of cortisol hormone in the body for a long time)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
D. Your diagnosis has been confirmed by ONE of the following:
   1. 24-hour urine free cortisol test (at least 2 or more tests to confirm)
   2. Overnight 1mg dexamethasone test
   3. Late night salivary cortisol (at least 2 or more tests to confirm)
E. Your hypercortisolism (high levels of cortisol) is not a result of chronic glucocorticoids (class of drugs that consist of steroids)
F. You have type 2 diabetes mellitus (too much sugar in your blood) OR glucose intolerance (term for a group of conditions that result in elevated blood sugar)
G. You have failed surgical treatment for Cushing's syndrome OR you are not a candidate for surgery

RENEWAL CRITERIA

Our guideline named MIFEPRISTONE (Korlym) requires the following rule(s) be met for renewal:

A. You have endogenous Cushing's syndrome (condition that occurs after having high levels of cortisol hormone in the body for a long time)
B. You continue to have improvement of glucose tolerance and/or stable glucose tolerance (such as reduced hemoglobin A1C [average amount of sugar in your blood over the last 2 to 3 months], improved fasting glucose)
C. You continue to tolerate Korlym
D. You are not a candidate for surgery or have failed surgery for Cushing's syndrome

Commercial Effective: 10/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MIGALASTAT (Galafold) requires the following rule(s) be met for approval:
A. You have confirmed Fabry disease (rare genetic disease)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor), cardiologist (heart doctor), or specialist in genetics or inherited metabolic disorders
D. You have an amenable (responsive) galactosidase alpha gene (GLA) variant based on in vitro assay data (data collected from lab test tubes or cultures) that is interpreted by clinical genetics professional as the cause of disease (pathogenic/likely pathogenic)
E. You are NOT using Galafold together with an enzyme replacement therapy (Fabrazyme)
F. You are symptomatic OR have evidence of injury from globotriaosylceramide (GL-3: a type of fat) to the kidney, heart, or central nervous system recognized by laboratory, histological, or imaging findings. Evidence of injury includes decreased GFR (measurement of how well your kidneys are working) for age, persistent albuminuria (buildup of a type of protein), cerebral white matter lesions on brain MRI (magnetic resonance imaging: a type of imaging lab), cardiac fibrosis (scarring of the heart) on contrast cardiac MRI
G. You meet ONE of the following:
   1. Female patient: Confirmation of Fabry disease (rare genetic disease) via genetic test documenting galactosidase alpha gene (GLA) mutation
   2. Male patient: Confirmation of Fabry disease via enzyme assay (lab test) showing you have a low amount of alpha galactosidase A (a-Gal -A) OR genetic test documenting galactosidase alpha gene (GLA) mutation

CONTINUED ON NEXT PAGE
MIGALASTAT

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **MIGALASTAT (Galafold)** requires the following rule(s) be met for renewal:

A. You have Fabry disease (rare genetic disease)
B. You are NOT using Galafold together with an enzyme replacement therapy (Fabrazyme)
C. You have demonstrated improvement or maintenance/stabilization while on therapy to at least ONE of the following:
   1. Symptoms such as pain, hypohidrosis/anhidrosis (little to no sweat), exercise intolerance, gastrointestinal (GI) symptoms, angiokeratomas (dark red/purple raised spots), abnormal cornea, tinnitus (ringing in the ears), or hearing loss
   2. Imaging such as brain/cardiac MRI (magnetic resonance imaging: a type of imaging lab), DEXA (dual-energy X-ray absorptiometry: a type of bone scan), or renal (kidney) ultrasound
   3. Laboratory or histological (viewed by microscope) testing such as globotriaosylceramide (GL-3: a type of fat) in plasma/urine or renal biopsy

Commercial Effective: 07/01/22
Our guideline named **MIGLUSTAT (Zavesca)** requires the following rule(s) be met for approval:

A. You have mild to moderate type 1 Gaucher disease (rare genetic disorder that affects organs and tissues)
B. You are 18 years of age or older
C. The requested medication will be used as monotherapy (used alone)
D. Enzyme replacement therapy is not a therapeutic option for this patient (due to allergy, hypersensitivity, or poor venous access)

**Commercial Effective: 07/01/20**
GUIDELINES FOR USE

Our guideline for MILTEFOSINE (Impavido) requires the following rule(s) be met for approval:

A. You have Leishmaniasis (type of parasite disease) with ONE of the following types of infection:
   1. Visceral leishmaniasis (affects your organs) caused by *Leishmania donovani* (type of parasite)
   2. Cutaneous leishmaniasis (affects your skin layers) caused by any of the following types of parasites:
      a. *Leishmania braziliensis*
      b. *Leishmania guyanensis*
      c. *Leishmania panamensis*
   3. Mucosal leishmaniasis (affects inside mouth, throat and nose) caused by *Leishmania braziliensis*

B. Species identification must be confirmed via ONE of the following CDC (Center for Disease Control and Prevention) recommended tests:
   1. Stained slides (using tissue from biopsy specimens, impression smears or dermal scrapings)
   2. Culture medium
   3. Polymerase chain reaction (lab method to make copies of genes)
   4. Serologic testing (testing your blood and body fluids such as rK39 Rapid Test)

Commercial Effective: 11/01/21
MINOCYCLINE HCL MICROSPHERES (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MINOCYCLINE HCL MICROSPHERES</td>
<td>ARESTIN</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: SEE RENEWAL CRITERIA BELOW)

Our guideline named MINOCYCLINE HCL MICROSPHERES (Arestin) requires the following rule(s) be met for approval:
A. You have documentation of confirmed periodontitis (inflammation and infection of the gums)
B. You are age 18 years or older
C. The medication is prescribed by or given in consultation with an oral health care professional
D. You do not have a history of minocycline or tetracycline sensitivity or allergy
E. You do not have a history of candidiasis (a type of fungal infection) or active oral candidiasis
F. The requested medication will be administered by an oral health professional
G. The requested medication will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing
H. The requested medication is not being used for acutely abscessed periodontal pocket (not used for short-term and sudden infection with pus-filled pocket)
I. The medication is not being used in an immunocompromised individual (your immune system is weakened), such as those immunocompromised by any of the following conditions:
   1. Uncontrolled diabetes mellitus
   2. Chemotherapy
   3. Radiation therapy
   4. HIV (human immunodeficiency virus) infection
J. The medication is not being used in the regeneration of alveolar bone (bone that has tooth sockets), either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants

RENEWAL CRITERIA

Our guideline named MINOCYCLINE HCL MICROSPHERES (Arestin) requires the following rule(s) be met for renewal:
A. You have documentation of periodontitis (inflammation and infection of the gums)
B. The medication will be used as an adjunct (add-on therapy) to scaling and root planing procedures OR used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing

Commercial Effective: 07/01/20
MIPOMERSEN SODIUM

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIPOMERSEN SODIUM</td>
<td>KYNAMRO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named MIPOMERSEN SODIUM (Kynamro) requires the following rule(s) be met for approval:

A. You have homozygous familial hypercholesterolemia (type of inherited high cholesterol) which was determined by meeting ONE of the following criteria:
   1. Simon Broome diagnostic criteria (definite)
   2. Dutch Lipid Network criteria with a score of at least 8
   3. A clinical diagnosis based on a history of an untreated LDL (low density lipoprotein)-cholesterol level greater than 500 mg/dL, in combination with either (1) xanthoma (fatty growths underneath the skin) before 10 years of age OR (2) evidence of heterozygous familial hypercholesterolemia (type of inherited high cholesterol) in both parents

B. The medication is prescribed by or recommended by a cardiologist (heart doctor), endocrinologist (hormone doctor), or lipidologist (cholesterol management specialist)

C. You have an LDL (low density lipoprotein)-cholesterol level greater than or equal to 70 mg/dL while on maximally tolerated drug treatment

D. You previously had a trial of Repatha (evolocumab) unless you do not have functional LDL (low density lipoprotein) receptors

E. If you are statin tolerant, approval also requires:
   1. You meet ONE of the following:
      i. You have been taking a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) for a duration of at least 8 weeks, OR
      ii. You have been taking a maximally tolerated dose of any statin for a duration of at least 8 weeks and you cannot tolerate a high-intensity statin (i.e., atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily)
   2. You will continue statin treatment in combination with Kynamro

F. If you are statin intolerant, approval also requires ONE of the following:
   1. You have an absolute contraindication to (medical reason why you cannot use) statin therapy such as active decompensated liver disease (you have symptoms related to liver damage), nursing female, pregnancy or plans to become pregnant or hypersensitivity reaction
   2. You have complete statin intolerance as defined by severe and intolerable adverse effects such as creatine kinase elevation (a measure of how much muscle damage you have) greater than or equal to 10 times the upper limit of normal, liver function test elevation greater than or equal to 3 times the upper limit of normal, rhabdomyolysis (muscle breakdown), severe muscle weakness leading to temporary disability, fall, or inability to use a major muscle group. These must have occurred with trials of at least two separate statins and have improved with the discontinuation of each statin
GUIDELINES FOR USE

Our guideline named MIRABEGRON SUSPENSION (Myrbetriq) requires the following rule(s) be met for approval:
A. You have neurogenic detrusor overactivity (NDO: a type of bladder control condition)
B. You are 3 years of age or older
C. You had a trial of or contraindication (harmful for) to ONE anticholinergic (such as oxybutynin, solifenacin)
D. You are unable to swallow Myrbetriq tablets

Commercial Effective: 01/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **MITAPIVAT (Pyrukynd)** requires the following rule(s) be met for approval:
A. You have hemolytic anemia (a type of blood condition)
B. You are 18 years of age or older
C. You have pyruvate kinase (PK: a type of enzyme) deficiency

RENEWAL CRITERIA

Our guideline named **MITAPIVAT (Pyrukynd)** requires the following rule(s) be met for renewal:
A. You have hemolytic anemia (a type of blood condition)
B. You have pyruvate kinase (PK: a type of enzyme) deficiency
C. You have had clinical benefit while on Pyrukynd

Commercial Effective: 07/01/22
MOBOCERTINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOBOCERTINIB SUCCINATE</td>
<td>EXKIVITY</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **MOBOCERTINIB (Exkivity)** requires the following rule(s) be met for approval:

A. You have locally advanced or metastatic (cancer that has spread from where it started to nearby tissue or has spread to other parts of the body) non-small cell lung cancer (NSCLC: type of lung cancer)

B. You are 18 years of age or older

C. You have epidermal growth factor receptor (EGFR) exon 20 insertion mutations (type of gene mutation), as detected by a Food and Drug Administration (FDA)-approved test

D. Your disease progressed (disease has gotten worse) on or after platinum-based chemotherapy such as cisplatin, carboplatin, oxaliplatin

Commercial Effective: 01/01/22
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

MOMETASONE SINUS IMPLANT (NSA)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOMETASONE</td>
<td>SINUVA</td>
</tr>
<tr>
<td>FUROATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named MOMETASONE IMPLANT (Sinuva) requires the following rule(s) be met for approval:
A. You have nasal polyps (small growths inside the nose)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an otolaryngologist (ear, nose and throat doctor)
D. You previously had ethmoid sinus surgery (process to remove blockage in your sinuses)
E. You are a candidate for repeat ethmoid sinus surgery due to refractory moderate to severe symptoms (symptoms return and do not respond to surgery) of nasal obstruction, nasal congestion or nasal polyps in both ethmoid sinuses
F. You previously had a 90-day trial of ONE intranasal corticosteroid (such as fluticasone, beclomethasone, flunisolide, ciclesonide, mometasone)
G. You have not received 4 implants (2 per nostril) in your lifetime

RENEWAL CRITERIA

Our guideline named MOMETASONE IMPLANT (Sinuva) requires the following rule(s) be met for approval:
A. You have nasal polyps (small growths inside the nose)
B. You have ethmoid sinus polyps grade 1 or greater on any side
C. You do not have extensive ethmoid sinus polyp grade (grade 4 on at least one side) or extensive adhesions/synechiae (scar tissue) (grade 3 or 4)
D. You have not previously received 4 implants (2 per nostril) in your lifetime

Commercial Effective: 10/01/20
GUIDELINES FOR USE

Our guideline named MONOMETHYL FUMARATE (Bafiertam) requires the following rule(s) be met for approval:
A. You have a relapsing form of multiple sclerosis (MS: immune system eats away at the protective covering of the nerves), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)
B. You are 18 years of age or older
C. You have previously tried or have a contraindication to (medical reason why you cannot take) dimethyl fumarate AND ONE of the following: Avonex, Betaseron, Copaxone/Glatiramer/Glatopa, Plegridy, Rebif, Aubagio, Vumerity, Kesimpta
(Please note: Other multiple sclerosis medications may also require prior authorization)

Commercial Effective: 01/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named NAFARELIN (Synarel) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Gender dysphoria (your gender identity conflicts with your sex assigned at birth)
   2. Moderate to severe pain from endometriosis (condition affecting the uterus)
   3. Central precocious puberty (CPP: early sexual development in girls and boys)

B. If you have moderate to severe pain from endometriosis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an obstetrician/gynecologist (a type of women's health doctor)
   3. Your diagnosis is confirmed by surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
   4. You have tried or have a contraindication (harmful for) to a nonsteroidal anti-inflammatory drug (NSAID) AND a progestin-containing contraceptive preparation (such as combination hormonal contraceptive preparation, progestin-only contraceptive preparation)
   5. You are NOT using Synarel concurrently (at the same time) with another gonadotropin-releasing hormone (GnRH)-modulating agent (such as elagolix, relugolix, Lupron Depot)
   6. You have NOT received more than 6 months of treatment with Synarel per lifetime

C. If you are female and have central precocious puberty, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
   3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 4.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   4. You are/were younger than 8 years of age when your condition started
   5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for breast development (stage 2 or above) AND pubic hair growth (stage 2 or above)

(Initial criteria continued on next page)
NAFARELIN

INITIAL CRITERIA (CONTINUED)

D. If you are male and have central precocious puberty, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a pediatric endocrinologist (hormone doctor)
   3. You have high levels of follicle-stimulating hormone (FSH) (level greater than 5.0 mIU/mL) and luteinizing hormone (LH) (level greater than 0.2 to 0.3 mIU/mL) at diagnosis
   4. You are/were younger than 9 years of age when your condition started
   5. There is documentation of pubertal staging using the Tanner scale (scale of physical measurements of development based on external sex characteristics) for genital development (stage 2 or above) AND pubic hair growth (stage 2 or above)

RENEWAL CRITERIA

NOTE: For the diagnoses of gender dysphoria or pain from endometriosis, please refer to the Initial Criteria section.

Our guideline named NAFARELIN (Synarel) requires the following rule(s) be met for renewal:
A. You have central precocious puberty (CPP: early sexual development in girls and boys)
B. Your Tanner scale staging (scale of physical measurements of development based on external sex characteristics) at initial diagnosis of CPP has stabilized or regressed (lowered) during three separate medical visits in the previous year
C. You have not reached the actual age which corresponds to your current pubertal age

Commercial Effective: 01/23/23
GUIDELINES FOR USE

Our guideline named **NERATINIB (Nerlynx)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Early stage (stage I-III) breast cancer
   2. Advanced or metastatic breast cancer

B. **If you have early stage (stage I-III) breast cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You have a HER2-overexpressed/amplified (HER2-positive) tumor
   3. The requested medication will be used as a single agent for extended adjuvant therapy following Herceptin- (trastuzumab-) based therapy
   4. The medication is being requested within 2 years of completing the last trastuzumab dose

C. **If you have advanced or metastatic breast cancer, approval also requires:**
   1. You are 18 years of age or older
   2. You have a HER2-overexpressed/amplified (HER2-positive) tumor
   3. The requested medication will be used in combination with capecitabine
   4. You have received two or more prior anti-HER2 based regimens in the metastatic setting

Commercial Effective: 04/10/21
GUIDELINES FOR USE

Our guideline named **NILOTINIB (Tasigna)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML: a type of blood cell cancer) in chronic phase
   2. Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic or accelerated phase

B. **If you have newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, approval also requires:**
   1. You are 1 year of age or older

C. **If you have Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase or accelerated phase, approval also requires:**
   1. If you are 18 years of age or older, you are resistant or intolerant to prior therapy including Gleevec (imatinib)
   2. If you are 1 to 17 years of age, you are resistant or intolerant to prior therapy with other tyrosine kinase inhibitors (TKI) such as Gleevec (imatinib), Sprycel (dasatinib), Bosulif (bosutinib)
   3. You had a mutational analysis prior to initiation of therapy AND Tasigna is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile

Commercial Effective: 04/01/22
NIMODIPINE SOLUTION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIMODIPINE</td>
<td>NYMALIZE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **NIMODIPINE SOLUTION (Nymalize)** requires the following rule(s) be met for approval:

A. You have a history of subarachnoid hemorrhage (SAH: bleeding in the space surrounding your brain) from a ruptured intracranial berry aneurysm (an area of an artery wall in your brain ballooned and burst) within the past 21 days

B. You are 18 years of age or older

C. You are unable to swallow nimodipine oral capsules

Commercial Effective: 07/26/21
NINTEDANIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>NINTEDANIB</td>
<td>OFEV</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named NINTEDANIB (Ofev) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Idiopathic pulmonary fibrosis (IPF: scarring of the lungs with an unknown cause)
   2. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: disorder that causes hardening of lung tissue)
   3. Chronic fibrosing interstitial lung disease (ILDs) with a progressive phenotype (PF-ILD: scarring of the lungs caused by different underlying diseases or conditions that worsens over time)

B. If you have idiopathic pulmonary fibrosis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)
   3. You have a usual interstitial pneumonia pattern as evidenced by high-resolution computed tomography (HRCT: type of imaging test) alone or via a combination of surgical lung biopsy and HRCT
   4. You do NOT have other known causes of interstitial lung disease, such as connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis (lung inflammation from inhaled substances), systemic sclerosis (an immune system disorder), rheumatoid arthritis (joint pain and inflammation), radiation, sarcoidosis (growth of inflammatory cells in the body), bronchiolitis obliterans organizing pneumonia (type of lung infection), human immunodeficiency virus infection, viral hepatitis (type of liver inflammation), or cancer
   5. You have a predicted forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 50 percent at baseline
   6. You had a trial of or contraindication to (harmful for) the preferred medication: Esbriet (pirfenidone)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
NINTEDANIB

INITIAL CRITERIA (CONTINUED)

C. If you have systemic sclerosis-associated interstitial lung disease, approval also requires:
   1. You have systemic sclerosis (SSc) according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
   2. You are 18 years of age or older
   3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
   4. You have at least 10 percent fibrosis (tissue scarring) on a chest high resolution computed tomography (HRCT: type of imaging testing)
   5. You have a baseline forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 40 percent of predicted value
   6. Other causes of interstitial lung disease have been ruled out. Other causes may include heart failure/fluid overload, drug-induced lung toxicity [cyclophosphamide, methotrexate, ACE-inhibitors (class of blood pressure medications)], recurrent aspiration (inhaling) such as from GERD (acid reflux), pulmonary vascular disease (affecting blood vessels in lungs), pulmonary edema (excess fluid in the lungs), pneumonia (type of lung infection), chronic pulmonary thromboembolism (blood clot in lungs), alveolar hemorrhage (bleeding of a part of the lungs) or interstitial lung disease caused by another rheumatic (inflammatory) disease, such as mixed connective tissue disease (MCTD)
   7. You had a trial of or contraindication (harmful for) to the preferred medication: subcutaneous (under the skin) Actemra

D. If you have chronic fibrosing interstitial lung disease with progressive phenotype, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
   3. Your lung function and respiratory (breathing) symptoms OR chest imaging have worsened/progressed despite treatment with medications used in clinical practice for interstitial lung disease (not caused by comorbidities such as infection, heart failure)
   4. You have at least 10 percent fibrosis (tissue scarring) on a chest high resolution computed tomography (HRCT: type of imaging testing)
   5. You have a baseline forced vital capacity (FVC: amount of air that can be forcefully exhaled) of at least 45 percent of predicted value

CONTINUED ON NEXT PAGE
NINTEDANIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named NINTEDANIB (Ofev) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Idiopathic pulmonary fibrosis (IPF: scarring of the lungs with an unknown cause)
   2. Systemic sclerosis-associated interstitial lung disease (SSc-ILD: disorder that causes hardening of lung tissue)
   3. Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PF-ILD: scarring of the lungs caused by different underlying diseases or conditions that worsens over time)

B. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline

Commercial Effective: 05/23/22
GUIDELINES FOR USE

Our guideline named NIRAPARIB (Zejula) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Advanced epithelial ovarian (cancer that forms on the surface of the ovary), fallopian tube, or primary peritoneal cancer (type of abdominal cancer)
   2. Recurrent (returning) epithelial ovarian (cancer that forms on the surface of the ovary), fallopian tube, or primary peritoneal cancer (type of abdominal cancer)

B. If you have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:
   1. You are 18 years of age or older
   2. You are in complete or partial response to first-line platinum based-chemotherapy (such as cisplatin, carboplatin)
   3. The requested medication will be used for maintenance treatment

C. If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:
   1. You are 18 years of age or older
   2. You are in complete or partial response to platinum-based chemotherapy (such as cisplatin, carboplatin)
   3. The requested medication will be used for maintenance treatment (treatment to prevent cancer from coming back after it has disappeared after initial therapy)
   4. Your cancer has deleterious or suspected deleterious germline BRCA-mutation (gBRCAmut: a type of gene mutation) based on a Food and Drug Administration (FDA)-approved companion diagnostic for Zejula
   5. The requested medication will be used as monotherapy (used by itself for treatment)
   6. The requested medication is started no later than 8 weeks after your most recent platinum-containing regimen (such as cisplatin, carboplatin)
   7. You have completed at least 2 or more lines of platinum-based chemotherapy

Commercial Effective: 05/22/23
NITISINONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>NITISINONE</td>
<td>ORFADIN, NITYR, NITISINONE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named NITISINONE (Orfadin, Nityr) requires the following rule(s) be met for approval:
A. You have hereditary tyrosinemia type 1 (HT-1: a type of genetic disorder where you cannot breakdown an important component in proteins)
B. Your diagnosis is confirmed by elevated urinary or plasma succinylacetone levels (a chemical that is present in hereditary tyrosinemia) OR a mutation in the fumarylacetoacetate hydrolase gene
C. Therapy is prescribed by or in consultation with a prescriber specializing in inherited metabolic diseases
D. You have been counseled on maintaining dietary restriction of tyrosine and phenylalanine
E. If you are requesting Nityr tablets; brand Orfadin 2mg, 5mg, 10 mg, 20 mg capsules; or Orfadin oral suspension, approval also requires:
   1. You have tried or have a contraindication (harmful for) to generic nitisinone capsules

RENEWAL CRITERIA

Our guideline named NITISINONE (Orfadin, Nityr) requires the following rule(s) be met for renewal:
A. You have hereditary tyrosinemia type 1 (HT-1: a type of genetic disorder where you cannot breakdown an important component in proteins)
B. Your urinary or plasma succinylacetone levels (a chemical that is present in hereditary tyrosinemia) have decreased from baseline while on treatment with nitisinone

Commercial Effective: 04/17/23
OBETICHOLIC ACID

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named OBETICHOLIC ACID (Ocaliva) requires the following rule(s) be met for approval:

A. You have primary biliary cholangitis (type of liver disease), as confirmed by TWO of the following criteria:
   1. An alkaline phosphatase level (indicator of possible liver/gallbladder problems) of at least 1.5 times the upper limit of normal
   2. The presence of antimitochondrial antibodies (indicator of body attacking its own cells) at a titer (concentration) of 1:40 or higher
   3. Histologic evidence of non-suppurative destructive cholangitis and destruction of interlobular bile ducts (you have lab data that shows you have certain symptoms of liver disease)

B. You are 18 years of age and older

C. You do not have cirrhosis (liver damage) OR have compensated cirrhosis (a type of liver condition) with no evidence of portal hypertension (high blood pressure in the major vein that leads to the liver)

D. The medication is prescribed by or in consultation with a gastroenterologist (digestive system doctor) or hepatologist (liver doctor)

E. You meet ONE of the following:
   1. You have had an inadequate response to ursodeoxycholic acid (such as Ursodiol, Urso 250, Urso Forte) at a dosage of 13-15 mg/kg/day for at least 1 year and the requested medication will be used in combination with ursodeoxycholic acid
   2. You are unable to tolerate ursodeoxycholic acid and the requested medication will be used as monotherapy (only drug used for treatment)

F. You do not have complete biliary obstruction (blockage of bile ducts)

RENEWAL CRITERIA

Our guideline named OBETICHOLIC ACID (Ocaliva) requires the following rule(s) be met for renewal:

A. You have primary biliary cholangitis (type of liver disease)

B. Your alkaline phosphatase levels (indicator of possible liver/gallbladder problems) are less than 1.67-times the upper limit of normal or have decreased by at least 15% from baseline while on treatment with obeticholic acid

C. You have not developed complete biliary obstruction (blockage of bile ducts)
OCTREOTIDE - IM

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCTREOTIDE ACETATE, MI-SPHERES</td>
<td>SANDOSTATIN LAR DEPOT</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named OCTREOTIDE - IM (Sandostatin LAR Depot) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Acromegaly (a type of hormone disorder)
   2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
   3. Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (a type of cancer that starts from hormone producing cells)

B. You had a prior response to and tolerated subcutaneous octreotide injection for at least 2 weeks

C. If you have acromegaly, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
   2. You had an inadequate response (drug did not work) to surgery or radiotherapy (radiation to treat cancer), OR surgery or radiotherapy is not an option for you

CONTINUED ON NEXT PAGE
OCTREOTIDE - IM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named OCTREOTIDE - IM (Sandostatin LAR Depot) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Acromegaly (a type of hormone disorder)
   2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
   3. Profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumor (a type of cancer that starts from hormone producing cells)

B. If you have acromegaly, renewal also requires:
   1. You have a reduction, normalization or maintenance of insulin-like growth factor (IGF-1: a growth hormone) levels based on age and gender
   2. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

C. If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor OR profuse watery diarrhea associated with vasoactive intestinal peptide-secreting tumor, renewal also requires:
   1. You have an improvement or sustained remission (symptoms have gone away) of clinical symptoms

Commercial Effective: 04/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named OCTREOTIDE - ORAL (Mycapssa) requires the following rule(s) be met for approval:
A. You have acromegaly (a type of hormone disorder)
B. Therapy is prescribed by or in consultation with an endocrinologist (doctor who specializes in hormones)
C. You have responded to and tolerated treatment with octreotide or lanreotide

RENEWAL CRITERIA

Our guideline named OCTREOTIDE - ORAL (Mycapssa) requires the following rule(s) be met for renewal:
A. You have acromegaly (a type of hormone disorder)
B. You have had a reduction, normalization, or maintenance of insulin-like growth factor 1 (IGF-1: a type of hormone) levels based on your age and gender
C. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

Commercial Effective: 10/01/22
## GUIDELINES FOR USE

### INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **OCTREOTIDE - SQ (Bynfezia)** requires the following rule(s) be met for approval:

A. **You have ONE of the following diagnoses:**
   1. Acromegaly (a type of hormone disorder)
   2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
   3. Profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma: a type of cancer that starts from hormone producing cells)

B. **If you have acromegaly, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an endocrinologist (a type of hormone doctor)
   3. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)
   4. You had an inadequate response to or cannot be treated with **ALL** of the following:
      i. Surgical resection (removal by surgery)
      ii. Pituitary irradiation (radiation therapy directed at the pituitary)
      iii. Bromocriptine mesylate at maximally tolerated doses

C. **If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor, approval also requires:**
   1. You are 18 years of age or older
   2. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)

D. **If you have profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma), approval also requires:**
   1. You are 18 years of age or older
   2. You had a trial of or contraindication (harmful for) to ONE generic octreotide product (such as octreotide acetate)

**CONTINUED ON NEXT PAGE**
OCTREOTIDE - SQ

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named OCTREOTIDE - SQ (Bynefzia) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Acromegaly (a type of hormone disorder)
   2. Severe diarrhea and flushing episodes associated with metastatic carcinoid tumor (a type of slow growing cancer that has spread to different parts of the body)
   3. Profuse watery diarrhea associated with vasoactive intestinal peptide tumor (VIPoma: a type of cancer that starts from hormone producing cells)

B. If you have acromegaly, renewal also requires:
   1. You have a reduction, normalization or maintenance of insulin-like growth factor (IGF-1: a growth hormone) levels based on age and gender
   2. You have shown an improvement or sustained remission (symptoms have gone away) of clinical symptoms of acromegaly

C. If you have severe diarrhea and flushing episodes associated with metastatic carcinoid tumor OR profuse watery diarrhea associated with vasoactive intestinal peptide tumor, renewal also requires:
   1. You have an improvement or sustained remission (symptoms have gone away) of clinical symptoms

Commercial Effective: 10/01/22
Our guideline named ODEVIXIBAT (Bylvay) requires the following rule(s) be met for approval:

A. You have pruritus (itching) associated with progressive familial intrahepatic cholestasis (PFIC: an inherited liver condition)
B. You are 3 months of age or older

Commercial Effective: 01/01/22
OFATUMUMAB-SQ

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OFATUMUMAB</td>
<td>KESIMPTA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OFATUMUMAB-SQ (Kesimpta)** requires the following rules be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: an illness where the immune system eats away at the protective covering of the nerves), which includes clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return), and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

Commercial Effective: 01/01/21
OLANZAPINE/SAMIDORPHAN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OLANZAPINE/SAMIDORPHAN MALATE</td>
<td>LYBALVI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named OLANZAPINE/SAMIDORPHAN (Lybalvi) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Schizophrenia (type of mental health disorder)
   2. Bipolar I disorder (type of mood disorder)

B. You are 18 years of age or older

C. Therapy is prescribed by or in consultation with a psychiatrist (a type of mental health doctor)

D. You are at high risk for weight gain

E. You had a trial and failure of or contraindication (harmful for) to BOTH of the following:
   1. TWO generic antipsychotics (such as aripiprazole, quetiapine, risperidone)
   2. ONE of the following preferred brand agents: Vraylar, Latuda or Rexulti

F. If you have bipolar I disorder, approval also requires ONE of the following:
   1. Lybalvi is being used for acute treatment of manic or mixed episodes as monotherapy or as adjunct to lithium or valproate
   2. Lybalvi is being used as maintenance monotherapy treatment

Commercial Effective:10/11/21
### OLAPARIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OLAPARIB</td>
<td>LYNPARZA</td>
</tr>
</tbody>
</table>

## GUIDELINES FOR USE

Our guideline named **OLAPARIB (Lynparza)** requires the following rule(s) be met for approval:

**A.** You have ONE of the following diagnoses:
1. Recurrent (returning) or advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (types of reproductive system cancers)
2. HER2 (a type of protein)-negative high risk early breast cancer (a type of breast cancer)
3. HER2-negative metastatic breast cancer (a type of breast cancer that has spread to other parts of the body)
4. Metastatic pancreatic adenocarcinoma (a type of pancreas cancer that has spread to other parts of the body)
5. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and does not respond to hormone therapy)

**B.** If you have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:
1. You are 18 years of age or older
2. The requested medication will be used for maintenance treatment
3. You are in complete or partial response to first-line platinum-based chemotherapy (a type of therapy to treat cancer)
4. Your diagnosis is confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
5. You meet ONE of the following:
   a. Your cancer has a deleterious or suspected deleterious germline or somatic BRCA mutation (a type of gene mutation)
   b. Your cancer is associated with a homologous recombination deficiency (HRD: type of gene mutation) positive status as defined by either a deleterious or suspected deleterious BRCA mutation (type of gene mutation), and/or genomic instability (high rate of gene mutation), AND Lynparza will be used in combination with bevacizumab

**C.** If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:
1. You are 18 years of age or older
2. You are in complete or partial response to your most recent platinum-based chemotherapy (a type of therapy to treat cancer)
3. You have completed at least two or more lines of platinum-based chemotherapy
4. The requested medication will be used alone for maintenance treatment

*(Criteria continued on next page)*

---

*Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.*
GUIDELINES FOR USE (CONTINUED)

D. If you have HER2-negative high risk early breast cancer, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used as adjuvant (add-on) treatment
   3. Your cancer has a deleterious or suspected deleterious germline BRCA mutation
      (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration
      (FDA)-approved companion diagnostic for Lynparza
   4. You have been treated with neoadjuvant or adjuvant chemotherapy (cancer treatment
      given before main treatment or as add-on therapy)

E. If you have HER2-negative metastatic breast cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has a deleterious or suspected deleterious germline BRCA mutation
      (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration
      (FDA)-approved companion diagnostic for Lynparza
   3. You have been treated with chemotherapy in the neoadjuvant (given before main
      treatment), adjuvant (add-on to main treatment), or metastatic setting (to treat disease
      that has spread to other parts of the body)
   4. You meet ONE of the following:
      a. You do not have hormone receptor (HR)-positive breast cancer
      b. You have hormone receptor (HR)-positive breast cancer and you have been treated
         with a prior endocrine (hormone) therapy or endocrine therapy is considered
         inappropriate for you

F. If you have metastatic pancreatic adenocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication will be used for maintenance treatment
   3. Your cancer has a deleterious or suspected deleterious germline BRCA mutation
      (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration
      (FDA)-approved companion diagnostic for Lynparza
   4. Your disease has not progressed on at least 16 weeks of a first-line platinum-based
      chemotherapy regimen (a type of therapy to treat cancer)

(Criteria continued on next page)
G. If you have metastatic castration-resistant prostate cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has a deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation (type of mutation) as confirmed by a Food and Drug Administration (FDA)-approved companion diagnostic for Lynparza
   3. Your disease has worsened following prior treatment with enzalutamide or abiraterone
   4. You meet ONE of the following:
      a. You previously had a bilateral orchiectomy (both testicles have been surgically removed)
      b. You have a castrate level of testosterone (your blood testosterone levels are less than 50 ng/dL)
      c. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin, degarelix)

Commercial Effective: 09/12/22
GUIDELINES FOR USE

Our guideline named OLUTASIDENIB (Rezlidhia) requires the following rule(s) be met for approval:
A. You have relapsed or refractory acute myeloid leukemia (AML: a type of blood cancer that has returned or did not respond to treatment)
B. You are 18 years of age or older
C. You have a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: a type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test

Commercial Effective: 04/01/23
OMACETAXINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMACETAXINE</td>
<td>SYNRIBO</td>
</tr>
<tr>
<td>MEPESUCCINATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OMACETAXINE (Synribo)** requires the following rule(s) be met for approval:

A. You have chronic or accelerated phase chronic myeloid leukemia (CML: type of blood cell cancer)
B. You are 18 years of age or older
C. You had a resistance or intolerance to TWO or more tyrosine kinase inhibitors (such as Gleevec, Sprycel, Tasigna, Bosulif, Iclusig)

Commercial Effective: 04/11/22
OMADACYCLINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMADACYCLINE</td>
<td>NUZYRA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named OMADACYCLINE (Nuzyra) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Community-acquired bacterial pneumonia (CABP: type of lung infection)
   2. Acute (severe and sudden) bacterial skin or skin structure infection (ABSSSI)

B. If you have community-acquired bacterial pneumonia, approval also requires:
   1. You are 18 years of age or older
   2. The infection is caused by any of the following bacteria: *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Klebsiella pneumoniae*, *Legionella pneurnoniae*, *Mycoplasma pneumoniae*, or *Chlamydophila pneumoniae*

3. You meet ONE of the following criteria:
   a. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
   b. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with 1) resistance to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone), AND 2) Nuzyra will work against the bacteria
   c. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you have had a trial of or contraindication (medical reason why you cannot use) to at least TWO standard of care agents for community-acquired bacterial pneumonia (such as azithromycin, doxycycline, levofloxacin, moxifloxacin, amoxicillin, ceftriaxone)

*(Criteria continued on next page)*

CONTINUED ON NEXT PAGE
OMADACYCLINE

GUIDELINES FOR USE (CONTINUED)

C. If you have acute bacterial skin or skin structure infection (ABSSSI), approval also requires:
   1. You are 18 years of age or older
   2. The infection is caused by any of the following bacteria: *Staphylococcus aureus* (methicillin-susceptible and -resistant isolates), *Staphylococcus lugdunensis*, *Streptococcus pyogenes*, *Streptococcus anginosus grp.* (Includes *S. anginosus*, *S. intermedius*, and *S. constellatus*), *Enterococcus faecalis*, *Enterobacter cloacae*, or *Klebsiella pneumoniae*
   3. You meet ONE of the following criteria:
      a. The requested medication is prescribed by or given in consultation with an Infectious Disease (ID) specialist
      b. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is available, and the infection site culture results indicate pathogenic (disease-causing) organism(s) with 1) resistance to at least TWO standard of care agents for acute bacterial skin or skin structure infection (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalixin, cefazolin), AND 2) Nuzyra will work against the bacteria
      c. Antimicrobial susceptibility test (lab test that shows what drugs may kill the bacteria) is unavailable, and you had a trial of or contraindication to at least TWO standard of care agents for acute bacterial skin or skin structure infection (such as linezolid, clindamycin, doxycycline, sulfamethoxazole/trimethoprim, vancomycin, amoxicillin, nafcillin, ceftriaxone, cephalixin, cefazolin)

Commercial Effective: 07/01/20
OMALIZUMAB

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named OMALIZUMAB (Xolair) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe persistent asthma (a type of lung condition)
   2. Nasal polyps (small growths in the nose)
   3. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe persistent asthma, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary (relating to lungs/breathing) medicine
   3. You have a positive skin prick or blood test such as ELISA or FEIA (type of blood test to identify what you’re allergic to) to a perennial aeroallergen (airborne particles that cause allergies year-round)
   4. You have a documented baseline IgE (type of antibody that is produced by your immune system if you have an allergy) serum level greater than or equal to 30 IU/mL
   5. You are being treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or oral corticosteroid (such as prednisone)

(Initial criteria continued on next page)
OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

6. You meet ONE of the following:
   a. You have experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months OR at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months
   b. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      i. Daytime asthma symptoms more than twice per week
      ii. Any night waking due to asthma
      iii. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      iv. Any activity limitation due to asthma

7. You will NOT use Xolair concurrently (at the same time) with Dupixent (dupilumab) or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqua [reslizumab], Fasenra [benralizumab]) when used for treatment of asthma

C. If you have nasal polyps, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with an otolaryngologist (ear, nose, and throat doctor) or an allergist/immunologist (a type of allergy or immune system doctor)
   3. Xolair will be used as add-on maintenance treatment
   4. You had a previous 90-day trial of ONE intranasal corticosteroid (such as nasal mometasone)

D. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), approval also requires:
   1. You are 12 years of age or older
   2. Therapy is prescribed by or in consultation with a physician specializing in allergy or pulmonary (relating to lungs/breathing) medicine
   3. You still experience hives on most days of the week for at least 6 weeks
   4. You have tried a high dose H1 antihistamine (type of allergy medication such as four-fold dosing of Clarinex [desloratadine] or Xyzal [levocetirizine]) AND leukotriene antagonist (such as montelukast, zafirlukast, zileuton) for at least 2 weeks

CONTINUED ON NEXT PAGE
OMALIZUMAB

INITIAL CRITERIA (CONTINUED)

RENEWAL CRITERIA

Our guideline named OMALIZUMAB (Xolair) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe persistent asthma (a type of lung condition)
   2. Nasal polyps (small growths in the nose)
   3. Chronic spontaneous urticaria (also called chronic idiopathic urticaria) [severe itching with unknown cause]

B. If you have moderate to severe persistent asthma, renewal also requires:
   1. You will continue to use an inhaled corticosteroid (ICS) [such as triamcinolone acetonide, beclomethasone, mometasone, budesonide] AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), a long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, tiotropium, umeclidinium), a leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), theophylline, or oral corticosteroid (such as prednisone)
   2. You will NOT use Xolair concurrently (at the same time) with Dupixent (dupilumab) or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for treatment of asthma
   3. You have shown a clinical response as evidenced by ONE of the following:
      a. Reduction in asthma exacerbation (worsening of symptoms) from baseline
      b. Decreased use of rescue medications (such as albuterol)
      c. Increase in percent predicted FEV1 (amount of air you can forcefully exhale) from baseline before treatment
      d. Reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

C. If you have nasal polyps, renewal also requires:
   1. You have had a clinical benefit compared to baseline (before starting Xolair) (such as improvements in nasal congestion, sense of smell, size of polyps)

D. If you have chronic spontaneous urticaria (chronic idiopathic urticaria), renewal also requires:
   1. Therapy is prescribed by or in consultation with an allergist or immunologist (immune system doctor)

Commercial Effective: 06/01/23
OMAVELOXOLONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMAVELOXOLONE</td>
<td>SKYCLARYS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OMAVELOXOLONE (Skyclarys)** requires the following rule(s) be met for approval:

A. You have Friedreich's ataxia (a type of nervous system and movement disorder)
B. You are 16 years of age or older

Commercial Effective: 07/01/23
OMBITASVIR/PARITAPREVIR/RITONAVIR

GUIDELINES FOR USE

Our guideline named OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR (Viekira Pak or Viekira XR) requires the following rule(s) be met for approval:

A. You have chronic hepatitis C, genotype 1
B. You are treatment naïve (never previously treated) or treatment experienced (previous treatment with peginterferon/ribavirin)
C. You will be using ribavirin with the requested medication, unless you have genotype 1b
D. You are 18 years of age or older
E. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), infectious disease specialist (a doctor that specializes in the treatment of infections), physician specializing in the treatment of hepatitis (hepatologist: a type of liver doctor), or a specially trained group such as ECHO (Extension for Community Healthcare Outcomes) model
F. You have previously failed a short trial with Epclusa or Harvoni unless you have a medical reason why you cannot use (contraindication) BOTH drugs. Reasons for failure include adverse effect early in therapy, intolerance to therapy (NOTE: If you completed a full course of therapy with Epclusa or Harvoni and you did not achieve sustained virologic response [no virus can be detected in blood], the request will not be approved)
G. You have an HCV RNA level (amount of virus in the blood) within the past 6 months

The medication will not be approved for the following patients:

A. You are using any of the following medications at the same time while on Viekira: alfuzosin, carbamazepine, phenytoin, phenobarbital, gemfibrozil, rifampin, ergotamine dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, Nuvaring, Ortho Evra or Xulane transdermal patch system), St. John’s Wort, lovastatin, simvastatin, pimozide, efavirenz, Revatio, triazolam, oral midazolam, darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, or salmeterol
B. You have decompensated cirrhosis (symptoms related to liver damage)
C. You have moderate liver impairment (Child Pugh B) or severe liver impairment (Child Pugh C)
D. You are on hemodialysis (process of purifying the blood of a person whose kidneys are not working normally)

(Criteria continued on the next page)
GUIDELINES FOR USE (CONTINUED)

E. You have a limited life expectancy (less than 12 months) due to other conditions not related to the liver

F. You have previously used/failed a full course of therapy, or currently using any of the following regimens:
   1. A nucleotide NS5B polymerase inhibitor (type of hepatitis C drug) including Sovaldi (sofosbuvir)
   2. A combination NS5B polymerase inhibitor/NS5A inhibitor including Harvoni (ledipasvir/sofosbuvir)
   3. A hepatitis C virus protease inhibitor (type of hepatitis drug) including Olysio (simeprevir), Victrelis (boceprevir), and Incivek (telaprevir)

A total of 12 weeks of therapy will be approved except 24 weeks of therapy for 1) genotype 1a with cirrhosis if patient is treatment experienced, previous null responder or 2) a liver transplant recipient.

Commercial Effective: 01/01/23
OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

**GUIDELINES FOR USE**

Our guideline named **OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR (Viekira Pak, Viekira XR)** requires the following rule(s) be met for approval:

A. You have chronic hepatitis C, genotype 1 (a type of liver infection)
B. You are 18 years of age or older
C. You are treatment naïve (never previously treated) or treatment experienced (previous treatment with peginterferon/ribavirin)
D. You will be using ribavirin with the requested medication, unless you have genotype 1b
E. You have previously failed a short trial with Epclusa or Harvoni unless you have a medical reason why you cannot use (contraindication) BOTH drugs. Reasons for failure include adverse effect early in therapy, intolerance to therapy (NOTE: If you completed a full course of therapy with Epclusa or Harvoni and you did not achieve sustained virologic response [no virus can be detected in blood], the request will not be approved)
F. You have an HCV RNA level (amount of virus in the blood) within the past 6 months

**The medication will not be approved for the following patients:**

A. You are using any of the following medications at the same time while on Viekira: alfuzosin, carbamazepine, phenytoin, phenobarbital, gemfibrozil, rifampin, ergotamine dihydroergotamine, ergonovine, methylergonovine, ethinyl estradiol containing medications (such as combined oral contraceptives, Nuvaring, Ortho Evra or Xulane transdermal patch system), St. John’s Wort, lovastatin, simvastatin, pimozone, efavirenz, Revatio, triazolam, oral midazolam, darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, or salmeterol
B. You have decompensated cirrhosis (symptoms related to liver damage)
C. You have moderate liver impairment (Child Pugh B) or severe liver impairment (Child Pugh C)
D. You are on hemodialysis (process of purifying the blood of a person whose kidneys are not working normally)
E. You have a limited life expectancy (less than 12 months) due to other conditions not related to the liver

*(Criteria continued on the next page)*

**CONTINUED ON NEXT PAGE**
OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR

GUIDELINES FOR USE (CONTINUED)

F. You have previously used/failed a full course of therapy, or currently using any of the following regimens:
   1. A nucleotide NS5B polymerase inhibitor (type of hepatitis C drug) including Sovaldi (sofosbuvir)
   2. A combination NS5B polymerase inhibitor/NS5A inhibitor including Harvoni (ledipasvir/sofosbuvir)
   3. A hepatitis C virus protease inhibitor (type of hepatitis drug) including Olysio (simeprevir), Victrelis (boceprevir), and Incivek (telaprevir)

   A total of 12 weeks of therapy will be approved except 24 weeks of therapy for 1) genotype 1a with cirrhosis if patient is treatment experienced, previous null responder or 2) a liver transplant recipient.

Commercial Effective: 01/01/23
GUIDELINES FOR USE

Our guideline named **OPICAPONE (Ongentys)** requires the following rule(s) be met for approval:

A. You have Parkinson's disease (PD: a nerve system disorder that affects movement)
B. You are 18 years of age or older
C. You are experiencing 'OFF' episodes (times when you have symptoms return due to medication wearing off)
D. You are currently being treated with carbidopa/levodopa
E. You have tried or failed or have a contraindication (medical reason why you cannot use) to TWO Parkinson's disease medications from TWO different classes of medications:
   1. Dopamine agonist (such as ropinirole, pramipexole, rotigotine)
   2. Monoamine oxidase-inhibitors (MAO-I) (such as selegiline, rasagiline)
   3. Adenosine receptor antagonist A2A (such as istradefylline)
   4. Catechol-O-methyltransferase (COMT) inhibitors (such as entacapone, tolcapone)

Commercial Effective: 01/01/21
OPIOID-ANTIPSYCHOTIC CONCURRENT USE

GUIDELINES FOR USE

Our guideline named **OPIOID-ANTIPSYCHOTIC CONCURRENT USE** allows an approval for use of an opioid with an antipsychotic medication (type of mental health drug) together when one of the following criteria is met:

A. You have active cancer
B. You are receiving palliative care or end-of-life care (care focused on treating symptoms of illness)
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of red blood cell disorder)
F. Your doctor confirms that the use of an opioid and an antipsychotic medication together is intended and clinically appropriate for you

Commercial Effective: 03/01/21
OPIOID-BENZODIAZEPINE CONCURRENT USE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OPIOID-BENZODIAZEPINE CONCURRENT USE** allows for an approval of use of an opioid with a benzodiazepine together when ONE of the following criteria is met:

A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of red blood cell disorder)
F. Your doctor confirms (attests) to proceed with the concurrent use of an opioid and a benzodiazepine for a clinically appropriate indication

*Commercial Effective: 03/01/21*
OPIOID-BUPRENORPHINE CONCURRENT USE

Our guideline named **OPIOID-BUPRENORPHINE CONCURRENT USE** allows approval for use of an opioid with buprenorphine or a buprenorphine-containing agent together when ONE of the following rule(s) is met:

A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. Your doctor confirms (attests) that you have discontinued or will be discontinuing opioid dependency treatment with buprenorphine or buprenorphine-containing agents and you need to resume chronic opioid treatment. Consultation with an addiction medicine specialist is recommended.
F. Your doctor is aware that you are currently receiving buprenorphine or a buprenorphine-containing agent for treatment of opioid dependency and has confirmed to proceed with opioid treatment for an acute, clinically appropriate indication. Consultation with an addiction medicine specialist is recommended

Commercial Effective: 03/01/21
OPIOID CUMULATIVE DOSING OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

A claim for a pain medication will be denied when there are two or more providers prescribing opioid agents for a patient who is receiving a high quantity of these agents. Our guideline named OPIOID CUMULATIVE DOSING OVERRIDE will allow you to receive a higher quantity of an opioid medication if ONE of the following rules (A or B) is met:

A. You have ONE of the following conditions:
   1. You have active cancer
   2. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
   3. You are enrolled in a hospice
   4. You are a resident of a long-term care facility or intermediate care for intellectually disabled
   5. You have sickle cell disease (type of blood disorder)

B. Your prescriber is aware that there is more than one provider prescribing opiates for you, and you meet TWO of the following:
   1. You have documentation showing your current level of opioid use is necessary and required for your level of pain management needed
   2. You have been evaluated by a pain specialist, and/or the request is based on the recommendation of a pain specialist
   3. You have a pain contract in place
   4. You do not have a history of substance abuse or addiction
   5. Your provider has committed to monitoring the state’s Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record.

This safety edit allows for an override for an opioid product equal to or exceeding the [enter soft stop threshold]-mg morphine milligram equivalent (MME) or [enter hard stop threshold]-mg morphine milligram equivalent (MME). Please consult your physician if you have any questions about this safety edit on prescription opioid medications and the requirements needed for you to obtain an approval for higher quantities of these agents.

Commercial Effective: 11/01/22
GUIDELINES FOR USE

Our guideline named **OPIOID LONG ACTING DUPLICATIVE THERAPY** allows approval of the requested drug taken together with other long-acting opioid drug(s) from different prescribers when ONE of the following conditions are met:

A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of red blood cell disorder)
F. Your doctor confirms that they are aware that you are concurrently receiving more than one long-acting opioid medication

Commercial Effective: 03/01/21
OPIOID-NAIVE CUMULATIVE DOSING (ONCD)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OPIOID-NAIVE CUMULATIVE DOSING** allows approval of a higher quantity of an opioid medication if at least ONE of the following conditions is met:

- Diagnosis of active cancer
- Receiving palliative care or end-of-life care (care focused on treating symptoms of illness)
- Enrolled in hospice
- Resident of a long-term care facility or intermediate care for intellectually disabled
- Diagnosis of sickle cell disease (type of red blood cell disorder)
- You are not opioid naive

If none of these conditions apply, BOTH of the following criteria must be met:

- The provider has indicated that the patient's current level of opioid utilization is necessary and required for the level of pain management needed
- The provider has committed to monitoring the state’s Prescription Monitoring Program to ensure controlled substance history is consistent with prescribing record

Commercial Effective: 11/01/22
GUIDELINES FOR USE

Our guideline named **OPIOID-NAIVE DAY SUPPLY LIMITATION** allows approval of the requested drug for a longer day supply when you meet at least **ONE** of the following conditions:

A. You have active cancer
B. You are enrolled in hospice
C. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of blood disorder)
F. You are NOT opioid naïve (you have been consistently using opioid pain medications)
G. Your doctor confirms (attests) that the prescribed dose of opioids with the requested day supply is intended and medically necessary

Commercial Effective: 11/01/22
OPIOID NAIVE FILL LIMIT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OPIOID NAIVE FILL LIMIT** allows an approval of the requested drug when it exceeds the fill limit for an initially opioid-naïve patient (those who have not used opioid drugs within the past 60 days) when ONE of the following conditions is met:

A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. You have sickle cell disease (type of red blood cell disorder)
F. Your doctor confirms that the additional fill of the requested opioid analgesic (pain-relieving) medication is intended and clinically appropriate for you

Commercial Effective: 03/01/21
OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPIOIDS</td>
<td>OPIOIDS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OPIOID SINGLE CLAIM DOSING AT POS** allows for an override of an opioid product equal to or exceeding the soft-stop threshold of [enter soft stop threshold]-mg morphine milligram equivalent (MME) at the pharmacy or by a prior authorization. The hard-stop threshold of [enter hard stop threshold]-mg morphine milligram equivalent (MME) is not overridable and requires a prior authorization. An override will be provided if ONE (A or B) of the following rule(s) are met:

**A.** You meet ONE of the following conditions:
1. You have active cancer
2. You are receiving treatment for palliative care (treatment for comfort from symptoms)
3. You have sickle cell disease (type of blood disorder)
4. You are enrolled in a hospice
5. Your doctor is a pain management specialist

**B.** Your physician confirms that the requested high dose is considered medically necessary.
1. If the requested dose is lower than 300 MME, your prescriber must provide a maximum opioid threshold. If your prescriber does not provide a maximum threshold and the request is for an opioid with an MME equal to or exceeding [enter hard-stop threshold]-mg morphine milligram equivalent (MME), the claim will be approved up to 25 percent greater than the previously approved MME.
2. If the requested dose is equal to or greater than 300 MME, approval will be granted if you are stable on the dose.

Commercial Effective: 11/01/22
OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE** allows an approval for use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together when one of the following criteria is met:

A. You have active cancer
B. You are receiving palliative care (treatment for comfort from symptoms) or end-of-life care
C. You are enrolled in a hospice
D. You are a resident of a long-term care facility or intermediate care for intellectually disabled
E. Your doctor confirms that the use of an opioid with Soma (carisoprodol) and a benzodiazepine medication together is intended and clinically appropriate for you

Commercial Effective: 03/01/21
OSILODROSTAT

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSILODROSTAT</td>
<td>ISTURISA</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

Our guideline named OSILODROSTAT (Isturisa) requires the following rule(s) be met for approval:

A. You have Cushing’s disease (CD: a condition due to a tumor in the pituitary gland causing an excess release of the hormone cortisol in the blood)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
D. Pituitary (major hormone gland) surgery is not an option or has not cured your condition
E. You previously had a trial of oral ketoconazole, unless there is a medical reason you are cannot (contraindication)

**RENEWAL CRITERIA**

Our guideline named OSILODROSTAT (Isturisa) requires the following rule(s) be met for renewal:

A. You have Cushing’s disease (CD: a condition due to a tumor in the pituitary gland causing an excess release of the hormone cortisol in the blood)
B. You continue to have improvement of Cushing’s disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of disease)
C. You continue to tolerate treatment with Isturisa
OSIMERTINIB

GUIDELINES FOR USE

Our guideline named OSIMERTINIB (Tagrisso) requires the following rule(s) be met for approval:
A. You have non-small cell lung cancer (type of lung cancer)
B. You are 18 years of age or older
C. If you have non-small cell lung cancer, approval also requires:
   1. Tagrisso is being used as adjuvant therapy (add-on treatment) after tumor resection (surgical removal of a tumor)
   2. Your tumor is positive for an epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R (type of genes) mutations, as detected by an FDA-approved test
   3. You will NOT be using Tagrisso concurrently (at the same time) with an epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva, Iressa, Gilotrif, Vizimpro)
D. If you have metastatic non-small cell lung cancer (cancer that has spread throughout the body), approval also requires:
   1. You will NOT receiving another epidermal growth factor receptor (EGFR) tyrosine kinase-inhibitor (such as Tarceva, Iressa, Gilotrif, Vizimpro) together with Tagrisso
   2. You meet ONE of the following:
      a. Your tumor is positive for epidermal growth factor receptor (EGFR: type of protein) exon 19 deletions or exon 21 L858R (types of genes) mutations as confirmed by an FDA-approved test AND Tagrisso will be used as first-line treatment (initial treatment)
      b. Your tumor is positive for an epidermal growth factor receptor (EGFR) T790M (type of gene) mutation, as detected by an FDA (Food and Drug Administration)-approved test AND your disease has progressed (worsening of disease) while on or after EGFR tyrosine kinase-inhibitor therapy such as (Tarceva, Iressa, Gilotrif)

Commercial Effective: 07/01/22
Our guideline named **OTESECONAZOLE (Vivjoa)** requires the following rule(s) be met for approval:

A. You have recurrent vulvovaginal candidiasis (RVVC: a repeating vaginal fungal infection)
B. You are female
C. You are not able to reproduce, which means you are a biological female and are postmenopausal (after menopause) or you have another reason for permanent infertility (such as tubal ligation [having tubes tied], hysterectomy [removal of the uterus], salpingo-oophorectomy [removal of an ovary and its fallopian tube])
D. You are NOT currently on ibrexafungerp for RVVC
E. **If you have not previously received Vivjoa, approval also requires:**
   1. You had 3 or more episodes of RVVC in the past 12 months
F. **If you have previously received Vivjoa, approval also requires:**
   1. You have successfully completed a course of Vivjoa for prevention of RVVC
   2. You are either being treated or have just completed treatment for a new recurrence of VVC

Commercial Effective: 04/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named OXYMETAZOLINE (Upneeq) requires the following rule(s) be met for approval:
A. You have blepharoptosis (drooping of the upper eyelid)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
D. You have been evaluated for surgical intervention
E. You had a trial of TWO ophthalmic alpha-adrenergic agonists (such as apraclonidine, tetrahydrozoline, naphazoline)

RENEWAL CRITERIA

Our guideline named OXYMETAZOLINE (Upneeq) requires the following rule(s) be met for renewal:
D. You have blepharoptosis (drooping of the upper eyelid)
E. You continue to have benefit from Upneeq

Commercial Effective: 04/01/221
IZANIMOD

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named OZANIMOD (Zeposia) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. A relapsing form of multiple sclerosis (MS: type of nerve disorder) to include clinically isolated syndrome (occurs once), relapsing-remitting disease (periods of symptoms and no symptoms), and active secondary progressive disease (advanced disease)
   2. Moderate to severe ulcerative colitis (UC: a type of digestive condition)

B. If you have a relapsing form of multiple sclerosis, approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of ONE sphingosine-1-phosphate receptor modulator (such as Gilenya [fingolimod], Mayzent [Siponimod])
   3. You had a trial of ONE agent indicated for the treatment of multiple sclerosis (such as Aubagio [teriflunomide], Tecfidera [dimethyl fumarate], Mavenclad [cladribine])

C. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, mesalamine
   4. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
OZANIMOD

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnosis of multiple sclerosis, please refer to the Initial Criteria section.

Our guideline named **OZANIMIOD (Zeposia)** requires the following rule(s) be met for renewal:

A. You have moderate to severe ulcerative colitis (UC: a type of digestive condition)

B. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Humira (adalimumab), Stelara (ustekinumab), Xeljanz (tofacitinib immediate release or extended release), Rinvoq (upadacitinib)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PACRITINIB (Vonjo) requires the following rule(s) be met for approval:

A. You have intermediate- or high-risk primary or secondary (post-polycythemia vera [type of blood cell disorder] or post-essential thrombocythemia [type of blood cell disorder]) myelofibrosis (type of bone marrow cancer)
B. You are 18 years of age or older
C. You have a platelet count below 50,000/uL

RENEWAL CRITERIA

Our guideline named PACRITINIB (Vonjo) requires the following rule(s) be met for renewal:

A. You have intermediate- or high-risk primary or secondary (post-polycythemia vera [type of blood cell disorder] or post-essential thrombocythemia [type of blood cell disorder]) myelofibrosis (type of bone marrow cancer)
B. You have shown symptom improvement by meeting ONE of the following:
   1. You have a spleen volume reduction of 35% or greater from baseline
   2. You have a 50% or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
   3. You have a 50% or greater reduction in palpable (can be felt by external examination) spleen length

Commercial Effective: 04/01/22
GUIDELINES FOR USE

Our guideline named PALBOCICLIB (Ibrance) requires the following rule(s) be met for approval:
A. You have advanced or metastatic breast cancer (cancer that has worsened or has spread to other parts of the body)
B. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)
C. You meet ONE of the following:
   1. Ibrance will be used in combination with an aromatase inhibitor (such as anastrozole, letrozole, exemestane) AND you have not received prior endocrine (hormone)-based therapy (such as letrozole, anastrozole, tamoxifen)
   2. Ibrance will be used in combination with Faslodex (fulvestrant) AND your disease has worsened after endocrine (hormone) therapy (such as letrozole, anastrozole, tamoxifen)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PANOBINOSTAT (Farydak) requires the following rule(s) be met for approval:
A. You have multiple myeloma (cancer that forms in a type of white blood cell)
B. You have been treated with at least 2 prior regimens including:
   1. Velcade (bortezomb)
   2. Immunomodulatory medication such as Thalomid, Revlimid, or Pomalyst. (These drugs adjust immune responses)
C. The requested medication will be used in combination with Velcade (bortezomib) and dexamethasone

RENEWAL CRITERIA

Our guideline named PANOBINOSTAT (Farydak) requires the following rule(s) be met for renewal:
A. You have tolerated the first 8 weeks of therapy without experiencing any severe or medically significant toxicity

Commercial Effective: 07/01/20
PARATHYROID HORMONE

GUIDELINES FOR USE

Our guideline for PARATHYROID HORMONE requires the following rule(s) be met for approval:
A. You have hypocalcemia secondary to hypoparathyroidism (low blood calcium due to low levels of a type of hormone)
B. You have previously tried activated vitamin D (calcitriol) and calcium
C. Your hypoparathyroidism (low levels of a type of hormone) is not due to a calcium sensing receptor (CSR) mutation (changes in your DNA that make up your gene)
D. Your hypoparathyroidism is not considered acute post-surgical hypoparathyroidism (not sudden and severe due to surgery in past 30 days)
E. Therapy is prescribed by or given in consultation with an endocrinologist (hormone specialist)

Commercial Effective: 07/01/20
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

PASIREOTIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PASIREOTIDE</td>
<td>SIGNIFOR</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PASIREOTIDE (Signifor) requires the following rule(s) be met for approval:

A. You have Cushing's disease (CD: a condition in which the pituitary gland releases too much of a hormone called adrenocorticotropic hormone [ACTH])
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with an endocrinologist (doctor who specializes in hormones)
D. You have undergone pituitary (a major hormone gland) surgery OR pituitary surgery is not an option
E. You have previously tried oral ketoconazole, unless there is a medical reason you are cannot (contraindication)

RENEWAL CRITERIA

Our guideline named PASIREOTIDE (Signifor) requires the following rule(s) be met for renewal:

A. You have Cushing's disease (CD: a condition in which the pituitary gland releases too much of a hormone called adrenocorticotropic hormone [ACTH])
B. You continue to have improvement of Cushing’s disease (such as clinically meaningful reduction in 24-hour urinary free cortisol and/or improvements in signs and symptoms of your disease)
C. You continue to tolerate treatment with Signifor

Commercial Effective: 10/01/20
PATIROMER

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PATIROMER CALCIUM SORBITEX</td>
<td>VELTASSA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PATIROMER (Veltassa) requires the following rule(s) be met for approval:
A. You have hyperkalemia (high levels of potassium in blood)
B. Therapy is prescribed by or given in consultation with a nephrologist (kidney doctor) or cardiologist (heart doctor)
C. The requested medication is NOT being used as an emergency treatment for life-threatening hyperkalemia (high levels of potassium in blood)
D. You are NOT currently receiving dialysis
E. You have tried ONE of the following to lower the risks for hyperkalemia:
   1. Limit to taking no more than one of the following drugs at any given time:
      i. Angiotensin converting enzyme inhibitor (ACE-I such as lisinopril, benazepril)
      ii. Angiotensin receptor blocker (ARB such as valsartan, losartan)
   2. Lowering the dose of renin-angiotensin-aldosterone system (RAAS) inhibitors (such as ACE-I’s, ARB’s, aldosterone antagonists like spironolactone) has been considered
F. If your estimated glomerular filtration rate (eGFR) is below 30 mL/min/1.73 m(2), approval also requires:
   1. You have tried to treat hyperkalemia with loop diuretics such as bumetanide, ethacrynic acid, furosemide, torsemide
G. If your estimated glomerular filtration rate (eGFR) is 30 mL/min/1.73 m(2) or above approval also requires:
   1. You have tried to treat hyperkalemia with a loop diuretic such as bumetanide, ethacrynic acid, furosemide, torsemide, OR a thiazide diuretic such as chlorothalidone, hydrochlorothiazide, metolazone
H. You have previously tried Lokelma (sodium zirconium cyclosilicate)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named PAZOPANIB (Votrient) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Advanced renal cell carcinoma (RCC: a type of kidney cancer)
   2. Advanced soft tissue sarcoma (STS: cancer that starts in soft tissues like muscle, tendons, fat, lymph vessels, blood vessels, and nerves)

B. If you have advanced renal cell carcinoma, approval also requires:
   1. You are 18 years of age or older

C. If you have advanced soft tissue sarcoma, approval also requires:
   1. You are 18 years of age or older
   2. You have received prior chemotherapy (cancer treatment such as anthracycline treatment)
   3. You do NOT have adipocytic soft tissue sarcoma (type of cancer in fat cells) or gastrointestinal stromal tumors (GIST: type of cancer that starts in a type of cell in the digestive system)

Commercial Effective: 04/11/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **PEANUT ALLERGEN POWDER-DNFP (Palforzia)** requires the following rule(s) be met for approval:

A. You have a peanut allergy confirmed by ONE of the following:
   1. If you have undergone a purposeful food challenge: you have documentation of a positive skin prick test (wheal diameter of 3 mm or greater) (skin test to check for peanut allergy) OR peanut-specific immunoglobulin E (IgE level at 0.35 kUA/L or greater) (blood test that indicates an allergy to peanuts) within the past 24 months
   2. If you have NOT undergone a purposeful food challenge: you have documentation of a positive skin prick test (wheal diameter of 8 mm or greater) (skin test to check for peanut allergy) OR peanut-specific immunoglobulin E (IgE level at 14 kUA/L or greater) (blood test that indicates an allergy to peanuts) within the past 24 months

B. You are 4 to 17 years of age

C. Therapy is prescribed by given in consultation with an allergist/immunologist (allergy/immune system doctor)

D. You have a clinical history of allergic reaction to peanuts

E. The medication is to be used in conjunction with a peanut-avoidance diet

F. You are not currently on peanut-specific immunotherapy (such as Viaskin Peanut)

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named PEANUT ALLERGEN POWDER-DNFP (Palforzia) requires the following rule(s) be met for renewal:
A. You have an allergy to peanuts
B. Therapy is prescribed by or given in consultation with an allergist/immunologist (allergy/immune system doctor)
C. Palforzia will be used together with a peanut-avoidance diet
D. You are not currently on peanut-specific immunotherapy (such as Viaskin Peanut)
E. You meet ONE of the following:
   1. You have a persistent peanut allergy (your peanut allergy has not gone away)
   2. If you have undergone a purposeful food challenge: you have documentation of a persistent peanut allergy based on a positive skin prick test (wheal diameter of 3 mm or greater) (skin test to check for peanut allergy) OR peanut-specific immunoglobulin E (IgE level at 0.35 kUA/L or greater) (blood test that indicates an allergy to peanuts) within the past 24 months
   3. If you have NOT undergone a purposeful food challenge: you have documentation of a persistent peanut allergy based on a positive skin prick test (wheal diameter of 8 mm or greater) (skin test to check for peanut allergy) OR peanut-specific immunoglobulin E (IgE level at 14 kUA/L or greater) (blood test that indicates an allergy to peanuts) within the past 24 months

Commercial Effective: 10/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PEGCETACOPLAN (Empaveli) requires the following rule(s) be met for approval:
A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare disorder that causes red blood cells break)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a hematologist (blood specialist)
D. You have documented confirmation of PNH by flow cytometry (type of measurement of physical and chemical qualities of cells) demonstrating ALL of the following:
   1. At least 2 different GPI-protein deficiencies (missing a certain type of protein such as CD55, CD59) on at least 2 cell lineages (types of cells such as erythrocytes, granulocytes)
   2. PNH granulocyte clone size of 10% or greater
E. You have tried and failed Soliris or Ultomiris as evidenced by hemoglobin (type of protein in red blood cells) levels less than 10.5 g/dL, directly following at least 3 months of stable dosing
F. You are not concurrently (at the same time) using C5 complement inhibitor therapy (such as Soliris, Ultomiris)

RENEWAL CRITERIA

Our guideline named PEGCETACOPLAN (Empaveli) requires the following rule(s) be met for renewal:
A. You have paroxysmal nocturnal hemoglobinuria (PNH: a rare disorder that causes red blood cells break)
B. You are not concurrently (at the same time) using a C5 complement inhibitor therapy (such as Soliris, Ultomiris)
C. You had a clinical benefit while on Empaveli (such as reduction in number of blood transfusions [adding blood to your body], improvement/stabilization of lactate dehydrogenase [LDH: type of enzyme] or hemoglobin levels [type of protein in red blood cells]) compared to baseline (baseline defined as your condition post treatment with Soliris or Ultomiris)

Commercial Effective: 10/24/22
Our guideline named PEGFILGRASTIM (Neulasta, Neulasta Onpro) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You will be using Neulasta to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)
   2. You have a non-myeloid malignancy (cancer not affecting bone marrow)

B. **If you have a non-myeloid malignancy, approval also requires:**
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You meet ONE of the following:
      a. The request is for Neulasta AND you had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)
      b. The request is for Neulasta Onpro AND you have a barrier to access (such as travel barriers, or you are unable to return to the clinic for Neulasta injections)

C. **If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:**
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named PEGFILGRASTIM - APGF (NYVEPRIA) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Nyvepria to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named PEGFILGRASTIM - BMEZ (Ziextenzo) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Ziextenzo to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named PEGFILGRASTIM - CBQV (Udenyca) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Udenyca to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named PEGFILGRASTIM-FPGK (Stimufend) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)  
   2. You will be using Stimufend to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)  
   2. You are receiving myelosuppressive anti-cancer medications associated with a clinically significant incidence of neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever  
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)  
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Commercial Effective: 07/01/23
PEGFILGRASTIM-JMDB

GUIDELINES FOR USE

Our guideline named PEGFILGRASTIM - JMDB (Fulphila) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Fulphila to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer medications associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Nyvepria (pegfilgrastim-apgf)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named PEGFILGRASTIM-PBBK (Fylnetra) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. You have a non-myeloid malignancy (cancer not affecting bone marrow)
   2. You will be using Fylnetra to increase survival if you have been acutely exposed to myelosuppressive doses of radiation (radiation that affects your blood and bone marrow)

B. If you have a non-myeloid malignancy, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You are receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia (medications that affect the bone marrow and cause low levels of a type of white blood cell) with fever
   3. You had a trial of or contraindication (harmful for) to the preferred agent: Nyvepria (pegfilgrastim-apgf)

C. If the request is to increase survival if you have been acutely exposed to myelosuppressive doses of radiation, approval also requires:
   1. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor) or oncologist (a type of cancer doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred agent: Nyvepria (pegfilgrastim-apgf)

Commercial Effective: 07/01/23
PEG-INTERFERON ALFA-2B

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEG-INTERFERON ALFA-2B</td>
<td>SYLATRON, SYLATRON 4-PACK</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **PEG-INTERFERON ALFA-2B (Sylatron)** requires the following rule(s) be met for approval:

A. You meet ONE of the following:
   1. You are currently taking Sylatron and have NOT received 5 years of treatment with Sylatron
   2. You have melanoma (skin cancer) with the presence of cancer cells in your lymph nodes (microscopic or gross nodal involvement), within 84 days of surgical removal of the cancer

Commercial Effective: 10/01/20
GUIDELINES FOR USE

Our guideline named PEGINTERFERON ALFA-2A or 2B (Pegasys, PegIntron) requires the following rule(s) be met for approval:
A. You have chronic hepatitis B (a type of liver infection)
B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive condition), infectious disease specialist (a doctor who specializes in the treatment of infections), a doctor specializing in the treatment of hepatitis such as a hepatologist (liver doctor), or a specially trained group such as ECHO (Extension for Community Healthcare Outcomes) model
C. If you are between 3 to 17 years of age, approval also requires:
   1. You do NOT have cirrhosis (liver damage)
   2. Your blood test shows you have HBeAg (marker of active virus multiplying in the body)-positive chronic hepatitis B
   3. You have evidence of viral replication (virus is multiplying in the body) with elevated serum alanine aminotransferase (ALT: a type of liver enzyme test)
D. If you are 18 years of age or older, approval also requires:
   1. Your blood test shows you have HBeAg (marker of active virus multiplying in the body)-positive or HBeAg-negative chronic hepatitis B
   2. You have compensated liver disease (a type of liver condition) with evidence of viral replication and liver inflammation

Note: Pegasys and PegIntron will not be approved for the treatment of hepatitis C.

Commercial Effective: 05/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PEGVALIASE-PQPZ (Palynziq) requires the following rules be met for approval:
A. You have phenylketonuria (PKU: a type of birth defect that causes buildup of a chemical called phenylalanine)
B. You are 18 years of age or older
C. You have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management, as confirmed by a measurement in the last 30 days
D. You have tried Kuvan (sapropterin)
E. You are NOT receiving Kuvan (sapropterin) at the same time as Palynziq (pegvaliase)

RENEWAL CRITERIA

Our guideline named PEGVALIASE-PQPZ (Palynziq) requires the following rules be met for renewal:
A. You have phenylketonuria (PKU: a type of birth defect that causes buildup of a chemical called phenylalanine)
B. Your phenylalanine levels have dropped by at least 20% from baseline or to a level under 600 micromol/L

Commercial Effective: 04/10/23
GUIDELINES FOR USE

Our guideline named PEMIGATINIB (Pemazyre) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer that has spread to nearby tissue and lymph nodes and cannot be removed by surgery, or it has spread to other parts of the body)
   2. Relapsed or refractory myeloid/lymphoid neoplasms (a type of blood cancer that has returned or did not respond to treatment)

B. If you have unresectable locally advanced or metastatic cholangiocarcinoma, approval also requires:
   1. You are 18 years of age or older
   2. You have previously been treated for unresectable locally advanced or metastatic cholangiocarcinoma
   3. You have a fibroblast growth factor receptor 2 (FGFR2: a type of protein) fusion or other rearrangement as detected by a Food and Drug Administration (FDA)-approved test
   4. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

C. If you have relapsed or refractory myeloid/lymphoid neoplasms, approval also requires:
   1. You are 18 years of age or older
   2. You have a fibroblast growth factor receptor 1 (FGFR1: a type of protein) rearrangement
   3. You will complete a comprehensive ophthalmological examination (eye exam), including optical coherence tomography (OCT: a type of eye imaging test), before starting the medication and at the recommended scheduled times

Commercial Effective: 01/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PENICILLAMINE (Cuprimine, Depen, D-Penamine) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
   2. Cystinuria (a type of genetic metabolic disorder)
   3. Active rheumatoid arthritis (a type of joint condition)

B. If you have Wilson's disease, approval also requires:
   1. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
   2. You have a Leipzig score of 4 or greater (a type of diagnostic score)
   3. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
   4. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine)

(Initial criteria continued on next page)
C. **If you have cystinuria**, approval also requires:
   1. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor)
   2. You have a daily cystine output greater than 300mg per 24 hours after urine cystine excretion testing
   3. You have failed to respond to an adequate trial of or has a contraindication (harmful for) to conventional therapy which includes ALL of the following:
      a. Increased fluid intake
      b. Modest reductions in sodium and protein intake
      c. Urinary alkalinization (a process that makes urine basic)
   4. You have nephrolithiasis (kidney stones) and ONE of the following:
      a. Your kidney stone analysis shows that there is a presence of cystine (an amino acid)
      b. Your urine analysis shows that there are hexagonal cystine crystals in your urine that are pathognomonic (signs relating to the disease)
      c. You have a family history of cystinuria and positive test results in the cyanide-nitroprusside screen (a test to determine the amount of cysteine in your body)
   5. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine) AND Thiola (tiopronin)

D. **If you have active rheumatoid arthritis**, approval requires:
   1. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   2. You do not have a history or other evidence of renal insufficiency (kidney problems)
   3. You have failed to respond to an adequate trial of at least 3 months of conventional therapy including at least ONE of the following DMARD (disease-modifying antirheumatic drug) agents: methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. If you are requesting Cuprimine, you had a trial of or have a contraindication (harmful for) to Depen (penicillamine) or D-Penamine (penicillamine)

E. **If you have an active prior authorization approval for Depen, D-Penamine** will be approved without meeting additional criteria during the period of Depen shortage.

CONTINUED ON NEXT PAGE
PENICILLAMINE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named PENICILLAMINE (Cuprimine, Depen, D-Penamine) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
   2. Cystinuria (a type of genetic metabolic disorder)
   3. Active rheumatoid arthritis (a type of joint condition)

B. If you have Wilson's disease, approval also requires:
   1. You have achieved a free serum copper of less than 10 mcg/dL

C. If you have cystinuria, approval also requires:
   1. You have achieved a cystine excretion of less than 200 mg/day

D. If you have active rheumatoid arthritis, approval also requires:
   1. You do not have a history of or other evidence of renal insufficiency (kidney problems)
   2. You have experienced or maintained improvement in tender joint count or swollen joint count while on therapy compared to baseline

Commercial Effective: 05/08/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PENTOSAN POLYSULFATE (Elmiron) requires the following rule(s) be met for approval:
A. You have a diagnosis of interstitial cystitis/bladder (painful bladder condition) pain syndrome ongoing for at least six weeks

RENEWAL CRITERIA

Our guideline named PENTOSAN POLYSULFATE (Elmiron) requires the following rule(s) be met for renewal:
A. You have experienced clinical improvement from baseline secondary to treatment
Our guideline named **PEXDARTINIB (Turalio)** requires the following rules be met for approval:

A. You have symptomatic tenosynovial giant cell tumor (TGCT: type of non-cancerous growth in or around a joint causing tissue damage and reducing function)

B. TGCT is associated with severe morbidity (disease) or functional limitations

C. TGCT is NOT responsive to improvement with surgery

D. You are 18 years of age or older

---

**GUIDELINES FOR USE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEXDARTINIB</td>
<td>TURALIO</td>
</tr>
</tbody>
</table>

Commercial Effective: 04/10/21
PHENOXYBENZAMINE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHENOXYBENZAMINE</td>
<td>DIBENZYLINE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **PHENOXYBENZAMINE (Dibenzyline)** requires the following rules be met for approval:

A. You have pheochromocytoma (tumor in your adrenal gland)
B. The requested drug is used to treat pheochromocytoma before pheochromocytoma surgery to remove the tumor
C. The requested drug is prescribed by an endocrinologist (hormone doctor), an endocrine surgeon (surgeon specializing in removal of glands such as adrenal glands), or a hematologist/oncologist (cancer doctor)
D. You must have tried an alpha-1 selective adrenergic receptor blocker (such as doxazosin, terazosin, or prazosin), unless there is a medical reason why you cannot (contraindication)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PILOCARPINE (Vuity) requires the following rule(s) be met for approval:
A. You have presbyopia (not able to focus on nearby objects)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an ophthalmologist (a type of eye doctor) or optometrist (a type of eye doctor)
D. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
E. You had a trial of or contraindication (harmful for) to generic pilocarpine ophthalmic (eye) solution

RENEWAL CRITERIA

Our guideline named PILOCARPINE (Vuity) requires the following rule(s) be met for renewal:
A. You have presbyopia (not able to focus on nearby objects)
B. You are not using corrective lenses OR corrective lenses are insufficient to completely correct your vision
C. You continue to have benefit from Vuity

Commercial Effective: 04/24/23
INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named drug named PIMAVANSERIN (Nuplazid) requires you to meet the following rule(s) for approval:

A. You have a diagnosis of psychosis associated with Parkinson’s disease (a mental disorder that causes you to have false beliefs or to hear or see things that are not really there and is related to a movement disorder)
B. You are at least 18 years old; and
C. The drug is prescribed by a doctor specializing in one of the following areas: neurology (brain doctor), geriatric medicine (specialty that focuses on health care of elderly people), or behavioral health (such as a psychiatrist).

RENEWAL CRITERIA

Our guideline named PIMAVANSERIN (Nuplazid) requires that you have experienced an improvement in psychosis symptoms (mental issues such as false beliefs or hearing or seeing things that are not really there) from baseline during the past 12 months of therapy and you show a continued need for treatment.

Commercial Effective: 07/01/20
PIRFENIDONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIRFENIDONE</td>
<td>ESBRIET, PIRFENIDONE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PIRFENIDONE (Esbriet) requires the following rule(s) be met for approval:

A. You have idiopathic pulmonary fibrosis (IPF: a type of lung condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor)
D. You do NOT have other known causes of interstitial lung disease. Other causes may include connective tissue disease, drug toxicity, asbestos or beryllium exposure, hypersensitivity pneumonitis (type of lung infection), systemic sclerosis (chronic hardening and tightening of the skin and connective tissues), rheumatoid arthritis (a type of joint condition), radiation, sarcoidosis (a type of inflammatory disorder), bronchiolitis obliterans organizing pneumonia (infection affecting the small airways of the lung), human immunodeficiency virus infection (HIV: a type of immune disorder), viral hepatitis (a type of liver inflammation), or cancer
E. You have a usual interstitial pneumonia (type of lung infection) pattern as evidenced by high-resolution computed tomography (HRCT: type of imaging test) alone or via a combination of surgical lung biopsy (removal of cells or tissue from the body for examination) and HRCT
F. You have a predicted forced vital capacity (FVC: amount of air exhaled from lungs) of at least 50% at baseline
G. You do NOT currently smoke cigarettes

RENEWAL CRITERIA

Our guideline named PIRFENIDONE (Esbriet) requires the following rule(s) be met for renewal:

A. You have idiopathic pulmonary fibrosis (IPF: a type of lung condition)
B. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline.

Commercial Effective: 01/01/23
PIRTOBRUTINIB

Our guideline named **PIRTOBRUTINIB (Jaypirca)** requires the following rule(s) be met for approval:

A. You have relapsed or refractory mantle cell lymphoma (MCL: type of white blood cell cancer)
B. You are 18 years of age or older
C. You have previously received at least TWO lines of systemic therapy (treatment that targets the entire body) for mantle cell lymphoma, including a BTK inhibitor (Bruton’s tyrosine kinase inhibitors such as Imbruvica [ibrutinib], Calquence [acalabrutinib], Brukinsa [zanubrutinib])

Commercial Effective: 07/01/23
PITOLISANT

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PITOLISANT (Wakix) requires the following rule(s) be met for approval:

A. You have one of the following:
   1. Excessive daytime sleepiness (EDS) with narcolepsy (sleep disorder with extreme drowsiness)
   2. Narcolepsy as demonstrated by cataplexy (sleep disorder with extreme drowsiness with sudden and uncontrollable muscle weakness)

B. If you have excessive daytime sleepiness with narcolepsy, approval also requires:
   1. You have narcolepsy that is confirmed by ONE of the following:
      a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
      b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
      c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
   2. You have excessive daytime sleepiness (EDS) lasting for at least 3 months and Epworth Sleepiness Scale (type of sleepiness test) score of more than 10
   3. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   4. You had a trial of one generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.) AND solriamfetol, armodafinil, or modafinil, unless there is a medical reason why you cannot (contraindication)

C. If you have cataplexy with narcolepsy, approval also requires:
   1. Wakix is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   2. You have tried TWO of the following: venlafaxine, fluoxetine, or a TCA (tricyclic antidepressant such as clomipramine, imipramine)

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Our guideline named PITOLISANT (Wakix) requires the following rule(s) be met for renewal:
A. You have ONE of the following:
   1. Excessive daytime sleepiness (EDS) with narcolepsy (sleep disorder with extreme drowsiness)
   2. Narcolepsy as demonstrated by cataplexy (sleep disorder with extreme drowsiness with sudden and uncontrollable muscle weakness)
B. You meet ONE of the following:
   1. You have demonstrated 25% or more improvement in Epworth Sleepiness Scale (type of sleepiness test) scores compared to baseline
   2. You have shown improvement in cataplexy (sudden and uncontrollable muscle weakness) symptoms compared to baseline
   3. You have demonstrated improvement in sleep latency (the amount of time it takes to fall asleep) from baseline

Commercial Effective: 01/01/23
GUIDELINES FOR USE

Our guideline named **PLASMINOGEN (Ryplazim)** requires the following rule(s) be met for approval:

A. You have a diagnosis of plasminogen deficiency type 1 (hypoplasminogenemia: a type of genetic condition)

Commercial Effective: 04/01/22

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLASMINOGEN HUMAN-TVMH</td>
<td>RYPLAZIM</td>
</tr>
</tbody>
</table>
GUIDELINES FOR USE

Our guideline named POMALIDOMIDE (Pomalyst) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Multiple myeloma (MM: cancer that forms in your white blood cells)
   2. Kaposi sarcoma (KS: cancer that forms from the cells in your lymph or blood vessels)

B. If you have multiple myeloma, approval also requires:
   1. You are 18 years of age or older
   2. The requested medication is used in combination with dexamethasone
   3. You have tried at least two drugs including Revlimid (lenalidomide) and a proteasome inhibitor (type of cancer drug such as Velcade [bortezomib], Kyprolis [carfilzomib], or Ninlaro [ixazomib])

C. If you have Kaposi sarcoma, approval also requires:
   1. You are 18 years of age or older
   2. You meet ONE of the following:
      a. You have acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failing highly active antiretroviral therapy (HAART: medications used to treat human immunodeficiency virus [HIV])
      b. You are human immunodeficiency virus (HIV)-negative

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named PONATINIB (Iclusig) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Chronic myeloid leukemia (CML: type of blood-cell cancer that begins in the bone marrow)
   2. Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (type of white blood cell cancer)
B. You are 18 years of age or older
C. If you have chronic myeloid leukemia, approval also requires:
   1. You had a mutational analysis prior to initiation of therapy AND Iclusig is appropriate per the National Comprehensive Cancer Network (NCCN) guideline table for treatment recommendations based on BCR-ABL1 mutation (breakpoint cluster region-Abelson murine leukemia 1; a type of abnormal gene) profile
   2. You meet ONE of the following:
      a. You have T315I-positive (a genetic mutation) CML (chronic phase, accelerated phase, or blast phase)
      b. You have chronic phase CML AND have a resistance to or are not able to safely use at least TWO prior kinase inhibitor treatments such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)
      c. You have accelerated phase or blast phase CML AND there are no other kinase inhibitors, such as Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib), that can be used for your disease
D. If you have Philadelphia chromosome positive acute lymphoblastic leukemia, approval also requires you meet ONE of the following:
   1. Your cancer is positive for the T315I mutation (a type of abnormal gene)
   2. There are no other kinase inhibitors [e.g., Tasigna (nilotinib), Sprycel (dasatinib), Bosulif (bosutinib), Gleevec (imatinib)] indicated for the patient

Commercial Effective: 04/01/22
PONESIMOD

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PONESIMOD</td>
<td>PONVORY</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PONESIMOD (Ponvory) requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (type of disease where body attacks its own nerves and symptoms return after treatment) to include clinically isolated syndrome (occurs once), relapsing-remitting disease (periods of symptoms and no symptoms), and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

C. You had a trial of one sphingosine-1-phosphate receptor modulator (such as Gilenya or Mayzent) AND one other agent indicated for the treatment of multiple sclerosis (Please note: Other multiple sclerosis agents may also require prior authorization)

Commercial Effective:04/10/21
GUIDELINES FOR USE

Our guideline named **POSACONAZOLE (Noxafil)** requires the following rule(s) be met for approval:

A. The request is for **ONE** of the following:
   1. Continuation of therapy after hospital discharge
   2. Treatment of invasive aspergillosis (type of fungal infection)
   3. Prophylaxis (prevention) of invasive aspergillus or candida infections (types of fungal infection)
   4. Oropharyngeal candidiasis (fungal infection of the throat)
   5. Esophageal candidiasis (fungal infection in the tube connecting the throat and stomach)

B. **If the request is for treatment of invasive aspergillosis, approval also requires:**
   1. You are 13 years of age or older
   2. You are requesting Noxafil (posaconazole) tablets

C. **If the request is for prophylaxis of invasive aspergillus or candida infections, approval also requires:**
   1. You are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplantation (HSCT: bone marrow transplant) recipient with graft versus host disease (GVHD: a type of immune disorder) or you have hematologic malignancies (cancer affecting the blood) with prolonged neutropenia (low levels of a type of white blood cell) from chemotherapy (cancer treatment)
   2. If the request is for posaconazole (Noxafil) tablets, you meet **ONE** of the following:
      You are 18 years of age or older
      You are 2 years of age or older AND weigh greater than 40 kg
   3. If the request is for posaconazole (Noxafil) suspension, you meet **ALL** of the following:
      You are 13 years of age or older
      You are unable to swallow tablets
   4. If the request is for posaconazole (Noxafil) PowderMix, you meet the following:
      You are 2 to 18 years of age AND weigh less than 40 kg
      You are unable to swallow tablets

D. **If the request is for oropharyngeal candidiasis, approval also requires:**
   1. You are 13 years of age or older
   2. You had a trial of or contraindication (harmful for) to fluconazole OR itraconazole
   3. You are requesting Noxafil (posaconazole) oral suspension

(Continued on next page)
POSACONAZOLE

GUIDELINES FOR USE (CONTINUED)

E. **If the request is for esophageal candidiasis, approval also requires:**
   1. You are 13 years of age or older
   2. You had a trial and failure of or contraindication (harmful for) to TWO of the following:
      fluconazole, itraconazole solution, or voriconazole

Commercial Effective: 01/01/23
PRALSETINIB

Generic                  Brand
PRALSETINIB              GAVRETO

GUIDELINES FOR USE

Our guideline named PRALSETINIB (Gavreto) requires the following rule(s) be met for approval:

A. You have ONE of the following:
   1. Metastatic non-small cell lung cancer (NSCLC: type of lung cancer that has spread to other parts of the body)
   2. Advanced or metastatic medullary thyroid cancer (MTC: thyroid cancer that started in the center of the thyroid and has spread to other parts of the body)
   3. Advanced or metastatic thyroid cancer (thyroid cancer that has spread to other parts of the body)

B. If you have metastatic non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. You have a rearranged during transfection (RET: type of gene) fusion-positive tumor that has been detected by an Food and Drug Administration (FDA)-approved test

C. If you have advanced or metastatic medullary thyroid cancer, approval also requires:
   1. You are 12 years of age or older
   2. You have a rearranged during transfection (RET: type of gene) mutant tumor
   3. You need systemic therapy (medicine that goes into the entire body)

D. If you have advanced or metastatic thyroid cancer, approval also requires:
   1. You are 12 years of age or older
   2. You have a rearranged during transfection (RET: type of gene) fusion-positive tumor
   3. You need systemic therapy (medicine that goes into the entire body)
   4. You have received treatment with radioactive iodine, and it did not work or is no longer working (if radioactive iodine is appropriate)

Commercial Effective: 04/10/21
PREDNISONE DELAYED-RELEASE TABS

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREDNISONE</td>
<td>RAYOS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named PREDNISONE DELAYED-RELEASE TABS (Rayos) requires the following rule(s) be met for approval:
A. The request is for a Food and Drug Administration-approved indication
B. You had a previous trial of ONE of the following, unless there is a medical reason why you cannot (contraindication): generic prednisone, prednisolone, or methylprednisolone
C. You have had a subclinical response (not a full response) or treatment failure of generic prednisone, prednisolone, or methylprednisolone

RENEWAL CRITERIA

Our guideline named PREDNISONE DELAYED-RELEASE TABS (Rayos) requires the following rule(s) be met for renewal approval:
A. The request is for a Food and Drug Administration-approved indication
B. You have had a clinical benefit from using Rayos (such as improvement in inflammatory condition from baseline)
C. You cannot be tapered off (slowly lowering the dose to stop use) corticosteroid (Rayos)

Commercial Effective: 07/01/20
PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE</td>
<td>TRUVADA, EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE</td>
</tr>
<tr>
<td>EMTRICITABINE/TENOFOVIR ALAFENAMIDE FUMARATE</td>
<td>DESCOVY</td>
</tr>
<tr>
<td>TENOFOVIR DISOPROXIL FUMARATE</td>
<td>VIREAD, TENOFOVIR DISOPROXIL FUMARATE</td>
</tr>
<tr>
<td>EMTRICITABINE</td>
<td>EMTRIVA, EMTRICITABINE</td>
</tr>
<tr>
<td>CABOTEGRAVIR</td>
<td>APRETUDE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named PRE-EXPOSURE PROPHYLAXIS ZERO COST SHARE OVERRIDE requires the following rule(s) be met for approval:

A. Your request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. The requested medication is FDA (Food and Drug Administration)-approved for pre-exposure prophylaxis (PrEP) or recommended by the CDC (Centers for Disease Control and Prevention) PrEP Guidelines

C. You are using the medication for PrEP regardless of your human immunodeficiency virus (HIV) medication use history (such as you have a history of post-exposure prophylaxis (PEP) medication use)

D. If the request is for a single-source brand or multi-source brand medication, approval also requires you meet ONE of the following:
   1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to two preferred medications (or one if only one agent is available)
   3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to appropriate use)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline for PYRIMETHAMINE (Daraprim) requires the following rule(s) be met for approval:

A. The request is ONE of the following:
   5. Acute treatment of toxoplasmosis (sudden and severe type of parasite infection)
   6. Chronic maintenance therapy for toxoplasmosis
   7. Primary prophylaxis of toxoplasmosis (prevention of a type of parasite infection)
   8. Congenital toxoplasmosis (the infection was passed on to you as a baby from your mother)

B. If you are being treated for acute toxoplasmosis, approval also requires:
   1. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)

C. If you are being treated for chronic maintenance for toxoplasmosis, approval also requires:
   1. You are also infected with human immunodeficiency virus (HIV: a virus that weakens your immune system with a parasite infection)
   2. You have successfully completed treatment for acute toxoplasmosis for at least 6 weeks treatment duration
   3. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)

D. If you are being treated for primary prophylaxis of toxoplasmosis, approval also requires:
   1. You are also infected with human immunodeficiency virus (HIV)
   2. The medication is prescribed by or given in consultation with an infectious disease specialist (doctor that specializes in treating infections)
   3. You had a previous trial of Bactrim (sulfamethoxazole and trimethoprim), unless there is a medication reason why cannot (contraindication)
   4. You tested positive for Toxoplasma gondii (a type of parasite) Immunoglobulins (IgG) (i.e., you had a current or past infection with Toxoplasma gondii)
   5. Your CD4 count (an indicator of how weak your immune system is) is less than 100 cells/mm(3)

E. If you have congenital toxoplasmosis, approval also requires:
   1. The medication is prescribed by or given in consultation with a neonatologist (doctor that specializes in sick and premature newborn infants) or pediatric (children and adolescents) infectious disease specialist

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnosis of congenital toxoplasmosis, please refer to Initial Criteria section.

Our guideline for **PYRIMETHAMINE (Daraprim)** requires the following rule(s) be met for renewal:

A. The request is ONE of the following:
   1. Acute treatment of toxoplasmosis (sudden and severe type of parasite infection)
   2. Chronic maintenance therapy for toxoplasmosis
   3. Primary prophylaxis of toxoplasmosis (prevention of a type of parasite infection)

B. **If you are being treated for acute toxoplasmosis, renewal also requires:**
   1. You have persistent clinical disease (headache, neurological symptoms, or fever) and persistent radiographic disease (one or more mass lesions on brain imaging)

C. **If you are being treated for chronic maintenance of toxoplasmosis OR primary prophylaxis for toxoplasmosis, renewal also requires:**
   1. You are also infected with human immunodeficiency virus (HIV: a virus that weakens your immune system with a parasite infection)
   2. Your CD4 count (an indicator of how weak your immune system is) is less than 200 cells/mm(3)
   3. You are currently taking ART (anti-retroviral therapy)

Commercial Effective: 04/01/20
GUIDELINES FOR USE

Our guideline named RANOLAZINE (Aspruzyo Sprinkle) requires the following rule(s) be met for approval:

A. You have chronic angina (a type of heart condition)
B. You had a trial of or contraindication (harmful for) to ranolazine ER (extended release) tablets
C. You are unable to swallow ranolazine ER tablets
D. You had a trial of or contraindication (harmful for) to a nitrate (such as nitroglycerin, isosorbide mononitrate, isosorbide dinitrate)

Commercial Effective: 10/01/22
REGORAFENIB

GUIDELINES FOR USE

Our guideline named REGORAFENIB (Stivarga) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic colorectal cancer (CRC: a type of digestive cancer that has spread to other parts of the body)
   2. Locally advanced, unresectable, or metastatic gastrointestinal stromal tumor (GIST: a type of digestive tumor that has spread from where it started to nearby tissue or lymph nodes, unable to remove by surgery, or has spread to other parts of the body)
   3. Hepatocellular carcinoma (HCC: a type of liver cancer)

B. If you have metastatic colorectal cancer, approval also requires:
   1. You had previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy such as FOLFOX, FOLFIRI, FOLFOXIRI, CapeOx, infusional 5-FU/LV, capecitabine
   2. You had previous treatment with an anti-VEGF therapy such as Avastin (bevacizumab), Zaltrap (ziv-aflibercept)
   3. If you have RAS wild-type (a type of unmutated gene) metastatic colorectal cancer, approval also requires you had previous treatment with an anti-EGFR therapy such as Erbitux (cetuximab), Vectibix (panitumumab)

C. If you have locally advanced, unresectable, or metastatic gastrointestinal stromal tumor, approval also requires:
   1. You had previous treatment with Gleevec (imatinib) and Sutent (sunitinib)

D. If you have hepatocellular carcinoma, approval also requires:
   1. You had previous treatment with Nexavar (sorafenib)

Commercial Effective: 04/01/22
GUIDELINES FOR USE

Our guideline named RELUGOLIX (Orgovyx) requires the following rule(s) be met for approval:
A. You have advanced prostate cancer
B. You are 18 years of age or older

Commercial Effective: 04/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RELUGOLIX-ESTRADIOL-NORETHINDRONE (Myfembree) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
   2. Management of moderate to severe pain associated with endometriosis (condition affecting the uterus)

B. If the request is for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), approval also requires:
   1. You are 18 years of age or older
   2. You are a premenopausal (before menopause) woman
   3. Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN: a type of women's health doctor)
   4. You have not received a total of 24 months cumulative (total) treatment with Myfembree

C. If the request is for management of moderate to severe pain associated with endometriosis, approval also requires:
   1. You are 18 years of age or older
   2. You are a premenopausal (before menopause) woman
   3. Therapy is prescribed by or in consultation with an obstetrician or gynecologist (OB/GYN: a type of women's health doctor)
   4. Your diagnosis of endometriosis is confirmed via surgical or direct visualization (such as pelvic ultrasound [type of imaging]) or histopathological (tissue) confirmation (such as laparoscopy [type of surgery] or laparotomy [type of surgery]) in the last 10 years
   5. Myfembree will NOT be used concurrently (at the same time) with another GnRH-modulating agent (such as Orilissa, Lupron Depot, Synarel)
   6. You have not received a total of 24 months cumulative (total) treatment with Myfembree

CONTINUED ON NEXT PAGE
RELUGOLIX-ESTRADIOL-NORETHINDRONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named RELUGOLIX-ESTRADIOL-NORETHINDRONE (Myfembree) requires the following rule(s) be met for renewal:

A. The request is for ONE of the following:
   1. Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids: non-cancerous growths in the uterus)
   2. Management of moderate to severe pain associated with endometriosis (condition affecting the uterus)

B. If the request is for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), renewal also requires:
   1. You had improvement of heavy menstrual bleeding on therapy
   2. You have not received a total of 24 months cumulative (total) treatment with Myfembree

C. If the request is for management of moderate to severe pain associated with endometriosis, renewal also requires:
   1. You have had improvement in pain related to endometriosis while on therapy
   2. Myfembree will NOT be used concurrently (at the same time) with another GnRH-modulating agent (such as Orilissa, Lupron Depot, Synarel)
   3. You have not received a total of 24 months cumulative (total) treatment with Myfembree

Commercial Effective: 09/12/22
RIBOCICLIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIBOCICLIB</td>
<td>KISQALI</td>
</tr>
<tr>
<td>SUCCINATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named **RIBOCICLIB (Kisqali)** requires the following rule(s) be met for approval:

A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of the body)

B. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)

C. **If you are requesting Kisqali in combination with an aromatase inhibitor (such as anastrozole, exemestane, letrozole)**, approval also requires:
   1. You have NOT received prior endocrine (hormone)-based therapy (such as letrozole, anastrozole, tamoxifen) for advanced or metastatic breast cancer
   2. You had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

D. **If you are requesting Kisqali in combination with (Faslodex) fulvestrant**, approval also requires:
   1. You are a male or a postmenopausal (after menopause) female
   2. You meet ONE of the following:
      a. You have NOT received prior endocrine (hormone)-based therapy (such as letrozole, anastrozole, tamoxifen) for advanced or metastatic breast cancer
      b. You have experienced disease progression (your condition worsened) on endocrine (hormone) therapy AND you had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named RIBOCICLIB-LETROZOLE (Kisqali/Femara Co-Pack) requires the following rule(s) be met for approval:

A. You have advanced or metastatic breast cancer (breast cancer that has progressed or has spread to other parts of the body)

B. Your cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (a type of protein)

C. You have NOT received prior endocrine (hormone)-based therapy for advanced or metastatic breast cancer (such as letrozole, anastrozole, tamoxifen)

D. You had a trial of Ibrance (palbociclib) or Verzenio (abemaciclib)

Commercial Effective: 07/01/23
RIFAXIMIN

** Please use the criteria for the specific drug requested **

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

XIFAXAN 550MG TABLETS

Our guideline named RIFAXIMIN (Xifaxan 550 mg tablets) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Reduction of risk of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage) recurrence
   2. Irritable bowel syndrome with diarrhea (IBS-D: a type of bowel disease)

B. For reduction in risk of overt hepatic encephalopathy recurrence, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor)
   3. You have previously tried lactulose or you are currently taking lactulose monotherapy (drug used alone for treatment)

C. If you have irritable bowel syndrome with diarrhea, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to tricyclic anti-depressants (such as amitriptyline, nortriptyline, etc.) or dicyclomine

CONTINUED ON NEXT PAGE
RIFAXIMIN

INITIAL CRITERIA (CONTINUED)

XIFAXAN 200MG TABLETS

Our guideline named RIFAXIMIN (Xifaxan 200 mg tablets) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Travelers’ diarrhea
   2. Clostridium difficile infection (a type of bacterial infection)
   3. Treatment of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage)
B. If you have traveler’s diarrhea, approval also requires:
   1. You are 12 years of age or older
   2. You had a trial of or contraindication (harmful for) to oral azithromycin, ciprofloxacin, ofloxacin, or levofloxacin
C. For the treatment of overt hepatic encephalopathy, approval also requires:
   1. The requested medication will be used in combination with lactulose
D. If you have Clostridium difficile infection, approval also requires:
   1. You had at least one previous occurrence of Clostridium difficile infection
   2. The requested medication will be used in combination with vancomycin
   3. Therapy is prescribed by or in consultation with an infectious disease specialist (a doctor who specializes in the treatment of infections)

RENEWAL CRITERIA

Our guideline named RIFAXIMIN (Xifaxan 550 mg tablets) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Reduction of risk of overt hepatic encephalopathy (HE: a type of brain condition caused by liver damage) recurrence
   2. Irritable bowel syndrome with diarrhea (IBS-D: a type of bowel disease)
B. If you have irritable bowel syndrome with diarrhea, renewal also requires:
   1. At least 6 weeks have passed since your last treatment course of rifaximin
   2. You have experienced at least 30% decrease in abdominal pain (on a 0-10 point pain scale)
   3. You have experienced at least 50% reduction in the number of days per week with a stool consistency of mushy stool (Bristol Stool scale type 6) or entirely liquid stool (Bristol Stool scale type 7)

Commercial Effective: 04/01/22
RILUZOLE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>RILUZOLE</td>
<td>EXSERVAN, TIGLUTIK</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named RILUZOLE (Exservan, Tiglutik) requires the following rule(s) be met for approval:
A. You have amyotrophic lateral sclerosis (ALS: nervous system disease that weakens muscles and affects physical function)
B. You are 18 years of age or older
C. You have tried riluzole tablets
D. You are unable to take riluzole tablet formulation

Commercial Effective: 06/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RIMEGEPANT (Nurtec ODT) requires the following rule(s) be met for approval:

A. The request is for ONE of the following:
   1. Treatment of acute (quick onset) migraine
   2. Preventive treatment of episodic migraines

B. You are 18 years of age or older

C. If the request is for the treatment of acute migraine, approval also requires:
   1. You had a trial of or contraindication (harmful for) to ONE triptan (such as sumatriptan, rizatriptan)

D. If the request is for the preventive treatment of episodic migraines, approval also requires:
   1. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Vyepti, Qulipta) for migraine prevention
   2. You had a trial of or contraindication (harmful for) to ONE of the following preventive migraine treatments: divalproex sodium/sodium valproate, topiramate, propranolol, timolol, metoprolol, amitriptyline, venlafaxine, atenolol, nadolol

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named RIMEGEPANT (Nurtec ODT) requires the following rule(s) be met for renewal:

A. The request is for ONE of the following:
   1. Treatment of acute (quick onset) migraine
   2. Preventive treatment of episodic migraines

B. If the request is for treatment of acute migraine, renewal also requires ONE of the following:
   1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
   2. You have experienced clinical improvement as defined by ONE of the following:
      a. Ability to function normally within 2 hours of dose
      b. Headache pain disappears within 2 hours of dose
      c. Treatment works consistently in majority of migraine attacks

C. If the request is for the preventive treatment of episodic migraines, renewal also requires:
   1. You will NOT use Nurtec ODT concurrently (at the same time) with other calcitonin gene-related peptide (CGRP) inhibitors (such as Ajovy, Aimovig, Emgality, Vyepti, Quilpta) for migraine prevention
   2. You meet ONE of the following:
      a. You have experienced a reduction in migraine or headache frequency of at least 2 days per month
      b. You experienced a reduction in migraine severity
      c. You experienced a reduction in migraine duration

Commercial Effective: 04/01/22
RIOCIGUAT

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RIOCIGUAT (Adempas) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH: form of high blood pressure affecting the lungs caused by blood clots) World Health Organization (WHO: Group 4: a way to classify the severity of disease)
   2. Pulmonary arterial hypertension (PAH: type of high blood pressure that affects the arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. If you have pulmonary arterial hypertension, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   3. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
   4. You are not concurrently taking nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

C. If you have chronic thromboembolic pulmonary hypertension, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   3. You have persistent or recurrent disease after surgical treatment (it continues to exist or returns after surgery) OR you are not a candidate for surgery or have inoperable chronic thromboembolic pulmonary hypertension
   4. You have NYHA-WHO Functional Class II to IV symptoms (a way to classify how limited you are during physical activity)
   5. You are not concurrently taking nitrates or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named RIOCIUGAT (Adempas) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH: form of high blood pressure affecting the lungs caused by blood clots) World Health Organization (WHO Group 4: a way to classify the severity of disease)
   2. Pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. You are not concurrently (at the same time) taking nitrate or nitric oxide donors (such as amyl nitrate), phosphodiesterase inhibitors (such as Viagra [sildenafil], Cialis [tadalafil], Levitra [vardenafil]), or non-specific phosphodiesterase inhibitors (such as dipyridamole, theophylline)

C. You show improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: classification system for heart failure)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named RIPRETINIB (Qinlock) requires ALL of the following rule(s) be met for approval:
A. You have advanced gastrointestinal stromal tumor (GIST: a type of cancer in your digestive tract)
B. You are 18 years of age or older
C. You have received prior treatment with 3 or more kinase inhibitors (class of drugs), including imatinib

Commercial Effective: 04/10/21
RISANKIZUMAB-RZAA

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RISANKIZUMAB-RZAA (SKYRIZI) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe Crohn's disease (CD: a type of bowel disorder)

B. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to one or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

D. If you have moderate to severe Crohn's disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named RISANKIZUMAB-RZAA (Skyrizi) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)

B. **If you have moderate to severe plaque psoriasis, renewal also requires:**
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

C. **If you have psoriatic arthritis, renewal also requires:**
   1. You experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RISDIPLAM (Evrysdi) requires the following rule(s) be met for approval:
A. You have spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
B. Your diagnosis of spinal muscular atrophy (SMA) is confirmed by documentation of a gene mutation analysis indicating mutations or deletions of both alleles of the survival motor neuron 1 (SMN1: type of protein in spinal cord) gene (such as homozygous deletions of SMN1, homozygous mutations of SMN1, compound heterozygous mutations in SMN1 [deletion of SMN1 on one allele and point mutation of SMN1 on the other allele])
C. The requested medication is prescribed by or given in consultation with a neuromuscular (nerve and muscle) specialist or spinal muscular atrophy (SMA) specialist at a SMA Specialty Center
D. **If you are presymptomatic (symptoms have not yet appeared), approval also requires:**
   1. There is documentation showing you have up to three copies of survival motor neuron 2 (SMN2: type of protein in spinal cord) based on screening done when you were a newborn
E. **If you are symptomatic (symptoms have appeared), approval also requires:**
   1. The onset of spinal muscular atrophy (SMA) symptoms occurred before 20 years of age
   2. There is documentation showing you had a baseline motor function assessment by a neuromuscular (nerve and muscle) specialist or SMA specialist
   3. If you previously had gene therapy, you had less than expected clinical benefit

RENEWAL CRITERIA

Our guideline named RISDIPLAM (Evrysdi) requires the following rule(s) be met for renewal:
A. You have spinal muscular atrophy (SMA: genetic disorder where your muscles become weak and break down)
B. You meet ONE of the following:
   1. You have improved, maintained, or demonstrated less than expected decline in motor function assessments compared to baseline. Some types of motor assessment tests include Hammersmith Infant Neurological Examination (HINE), Hammersmith Functional Motor Scale - Expanded (HFMSE) and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
   2. You have improved, maintained, or demonstrated less than expected decline in other muscle function such as pulmonary (lung/breathing) function

Commercial Effective: 09/07/20

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named ROFLUMILAST (Zoryve) requires the following rule(s) be met for approval:
A. You have plaque psoriasis (a type of skin condition)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have psoriasis covering 2% to 20% of body surface area (BSA) (excluding scalp, palms, and soles)
E. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
F. You had a trial of or contraindication (harmful for) to TWO of the following (from different categories):
   1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
   2. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)
   3. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
   4. Topical retinoid (such as tazarotene cream/gel)
   5. Anthralin

RENEWAL CRITERIA

Our guideline named ROFLUMILAST (Zoryve) requires the following rule(s) be met for renewal:
A. You have plaque psoriasis (a type of skin condition)
B. You have achieved or maintained clear or minimal disease
C. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)

Commercial Effective: 08/29/22
GUIDELINES FOR USE

Our guideline named ROPEGINTERFERON ALFA-2B-NJFT (Besremi) requires the following rule(s) be met for approval:
A. You have polycythemia vera (a type of blood cancer)
B. You are 18 years of age or older
GUIDELINES FOR USE

Our guideline named **RUCAPARIB (Rubraca)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (types of reproductive system cancers that has returned)
   2. Metastatic castration-resistant prostate cancer (mCRPC: prostate cancer that has spread to other parts of the body and no longer responds to testosterone lowering treatment)

B. **If you have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, approval also requires:**
   1. You are 18 years of age or older
   2. Your cancer has a deleterious BRCA mutation (germline and/or somatic) (a type of gene mutation that is passed on from parent to child and/or acquired during life)
   3. You are in complete or partial response to platinum-based chemotherapy (a type of therapy to treat cancer)
   4. The requested medication will be used for maintenance treatment

C. **If you have metastatic castration-resistant prostate cancer, approval also requires:**
   1. You are 18 years of age or older
   2. Your cancer has a deleterious BRCA mutation (germline and/or somatic) (a type of gene mutation that is passed on from parent to child and/or acquired during life) based on a Food and Drug Administration (FDA)-approved companion diagnostic for Rubraca
   3. You have been treated with an androgen receptor-directed therapy and a taxane-based chemotherapy (types of therapy to treat cancer)
   4. You meet ONE of the following:
      a. You previously received a bilateral orchiectomy (removal of testicles)
      b. You have a castrate level of testosterone (blood testosterone levels are less than 50 ng/dL)
      c. The requested medication will be used together with a gonadotropin-releasing hormone (GnRH) analog (such as leuprolide, goserelin, histrelin)

Commercial Effective: 01/23/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named RUXOLITINIB (Jakafi) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Intermediate or high-risk myelofibrosis, (type of bone marrow cancer such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis)
   2. Polycythemia vera (a type of blood cancer)
   3. Steroid-refractory acute graft-versus-host disease (a type of short-term immune disorder that did not respond to a type of treatment)
   4. Chronic graft-versus-host disease (a type of long-term immune disorder)

B. If you have intermediate or high-risk myelofibrosis, such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis, approval also requires:
   1. You are 18 years of age or older

C. If you have polycythemia vera, approval also requires:
   1. You are 18 years of age or older
   2. You had a trial of hydroxyurea, unless you have a contraindication (harmful for)

D. If you have steroid-refractory acute graft-versus-host disease, approval also requires:
   1. You are 12 years of age or older

E. If you have chronic graft-versus-host disease, approval also requires:
   1. You are 12 years of age or older
   2. You had a failure of one or two lines of systemic therapy (treatment that targets the entire body)

CONTINUED ON NEXT PAGE
RUXOLITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnoses of polycythemia vera, acute graft-versus-host disease, or chronic graft-versus-host disease, please refer to the Initial Criteria section.

Our guideline named RUXOLITINIB (Jakafi) requires the following rule(s) be met for renewal:

A. You have intermediate or high-risk myelofibrosis, (type of bone marrow cancer such as primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis)

B. You have shown symptom improvement by meeting ONE of the following:
   1. You have a 50 percent or greater reduction in total symptom score (such as Myeloproliferative Neoplasm Symptom Assessment Form [MPN-SAF TSS], modified Myelofibrosis Symptom Assessment Form [MFSAF] v2.0)
   2. You have a 50 percent or greater reduction in palpable (can be felt by external examination) spleen length
   3. You have a spleen volume reduction of 35 percent or greater from baseline

Commercial Effective: 01/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **RUXOLITINIB TOPICAL** (Opzelura) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Mild to moderate atopic dermatitis (a type of skin condition)
   2. Nonsegmental vitiligo (a type of skin condition)

B. **If you have mild to moderate atopic dermatitis, approval also requires:**
   1. You are 12 years of age or older
   2. You are NOT immunocompromised (low immune system)
   3. You had a trial of or contraindication (harmful for) to a topical corticosteroid (such as halobetasol, triamcinolone, fluocinonide) OR a topical non-steroidal immunomodulating agent (such as pimecrolimus, tacrolimus)
   4. You are NOT using Opzelura together with ANY of the following:
      a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
      b. Systemic therapeutic biologics (such as Dupixent, Adbry)
      c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
      d. Potent immunosuppressants (such as azathioprine, cyclosporine)

C. **If you have nonsegmental vitiligo, approval also requires:**
   1. You are 12 years of age or older
   2. You have depigmented (lightening of the skin) areas covering 10 percent or less of total body surface area
   3. You had a trial of or contraindication (harmful for) to a topical corticosteroid (such as halobetasol, triamcinolone, fluocinonide) OR a topical calcineurin inhibitor (such as pimecrolimus, tacrolimus)
   4. You are NOT using Opzelura together with ANY of the following:
      a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
      b. Systemic therapeutic biologics (such as Dupixent, Adbry)
      c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
      d. Potent immunosuppressants (such as azathioprine, cyclosporine)

CONTINUED ON NEXT PAGE
RUXOLITINIB TOPICAL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named RUXOLITINIB TOPICAL (Opzelura) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Mild to moderate atopic dermatitis (a type of skin condition)
   2. Nonsegmental vitiligo (a type of skin condition)

B. If you have mild to moderate atopic dermatitis, renewal also requires:
   1. You have experienced or maintained improvement in pruritus (itchiness), relapsing-remitting (disease returns and goes away) dermatitis, or facial/interdigital (between the fingers or toes) involvement
   2. You are NOT using Opzelura together with ANY of the following:
      a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
      b. Systemic therapeutic biologics (such as Dupixent, Adbry)
      c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
      d. Potent immunosuppressants (such as azathioprine, cyclosporine)

C. If you have nonsegmental vitiligo, renewal also requires:
   1. You have experienced or maintained clinically meaningful regimentation (recoloration of the skin after loss in color)
   2. You are NOT using Opzelura together with ANY of the following:
      a. Other non-steroidal topicals (such as tacrolimus, pimecrolimus, Eucrisa)
      b. Systemic therapeutic biologics (such as Dupixent, Adbry)
      c. Other JAK inhibitors (such as Rinvoq, Cibinqo)
      d. Potent immunosuppressants (such as azathioprine, cyclosporine)

Commercial Effective: 01/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SACROSIDASE (Sucraid) requires the following rule be met for approval:
A. You have a genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (a type of genetic digestive condition)
B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions) or medical geneticist (doctor who treats gene disorders)
C. Your diagnosis is confirmed by ONE of the following:
   1. Small bowel biopsy (removal of cells or tissue from the body for examination)
   2. Sucrose breath test
   3. Genetic test

RENEWAL CRITERIA

Our guideline named SACROSIDASE (Sucraid) requires the following rule(s) be met for renewal:
A. You have a genetically determined sucrase deficiency which is part of congenital sucrase-isomaltase deficiency (a type of genetic digestive condition)
B. You have experienced or maintained improvement on treatment

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named **SARGRAMOSTIM (Leukine)** requires the following rule(s) be met for approval:

A. The requested medication is prescribed by or given in consultation with a hematologist (blood specialist) or oncologist (cancer/tumor doctor), **OR** you meet **ONE** of the following:

1. You have acute myeloid leukemia (AML: type of blood and bone marrow cancer) and are using the requested medication to shorten time to neutrophil (a type of white blood cell) recovery and to reduce the incidence of severe, life-threatening, or fatal infections following induction chemotherapy **AND** you are 55 years of age or older

2. You are undergoing autologous transplantation (your own blood-forming stem cells are collected) and using the requested medication for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis (to collect blood sample and separate white blood cells in a lab test) **AND** you are 18 years of age or older

3. You have non-Hodgkin's lymphoma (NHL: type of cancer), acute lymphoblastic leukemia (ALL: type of white blood cell cancer) or Hodgkin's lymphoma (type of cancer) and are using the requested medication for the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation (to help your blood and bone marrow recover) **AND** you are 2 years of age or older

4. The requested medication is being used for the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation from HLA-matched related donors (to help your blood and bone marrow recover after using a lab test to match you to the correct donors) **AND** you are 2 years of age or older

5. The requested medication is being used for the treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation **AND** you are 2 years of age or older

6. You are acutely exposed to myelosuppressive doses (doses that suppress bone marrow activity) of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]) and using the requested medication to increase your survival

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SARILUMAB (Kevzara) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Polymyalgia rheumatica (PMR: an inflammatory disorder causing muscle pain and stiffness)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You have tried or have a contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You meet ONE of the following:
      a. You have tried or have a contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
      b. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinoq [upadacitinib], Xeljanz [tofacitinib] due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

C. If you have polymyalgia rheumatica, approval also requires:
   1. You are 18 years of age or older
   2. You had an inadequate response (drug did not work) to corticosteroids or cannot tolerate a corticosteroid taper

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
SARILUMAB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

NOTE: For the diagnosis of polymyalgia rheumatica, please refer to the initial criteria section.

Our guideline named **SARILUMAB (Kevzara)** requires the following rule(s) be met for renewal:

A. You have moderate to severe rheumatoid arthritis (RA: a type of joint condition)
B. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy.
C. You meet ONE of the following:
   1. You have tried or have a contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib immediate-release or extended-release)
   2. You have tried a tumor necrosis factor (TNF) inhibitor (such as Humira [adalimumab], Enbrel [etanercept]) AND your physician has indicated you cannot use a JAK inhibitor (such as Rinvoq [upadacitinib], Xeljanz [tofacitinib]) due to the black box warning for increased risk of mortality (death), malignancies (cancerous), and serious cardiovascular (heart-related) events

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SATRALIZUMAB-MWGE (ENSPRYNG)** requires the following rule(s) be met for approval:

A. You have neuromyelitis optica spectrum disorder (NMOSD: a rare immune system disease that affects the central nervous system and causes inflammation in the optic nerve and spinal cord)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a neurologist (doctor who specializes in the brain, spinal cord, and nerves)
D. Your diagnosis is confirmed by a positive serologic (blood) test for anti-aquaporin-4 (AQP4: type of protein) antibodies
E. You are not concurrently (at the same time) using rituximab, inebilizumab, or eculizumab
F. You have at least ONE of the following core clinical characteristics:
   1. Optic neuritis (inflammation that damages an eye nerve)
   2. Acute myelitis (sudden and severe inflammation of the spinal cord)
   3. Area postrema syndrome (attacks of uncontrollable nausea, vomiting, or hiccups)
   4. Acute brainstem syndrome (problems with vision, hearing, swallowing and muscle weakness in the head)
   5. Symptomatic narcolepsy (sudden attacks of sleep) or acute diencephalic clinical syndrome (rare disorder caused by a tumor above the brainstem) with NMOSD-typical diencephalic MRI lesions
   6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

RENEWAL CRITERIA

Our guideline named **SATRALIZUMAB-MWGE (ENSPRYNG)** requires the following rule(s) be met for renewal:

A. You have neuromyelitis optica spectrum disorder (NMOSD: a rare disorder that affects the central nervous system and causes inflammation in the optic nerve and spinal cord)
B. You had a reduction in relapse frequency from baseline
C. You are not concurrently (at the same time) using rituximab, inebilizumab, or eculizumab

Commercial Effective: 07/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SECUKINUMAB (Cosentyx) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
   5. Enthesitis-related arthritis (ERA: a type of joint condition)

B. If you have moderate to severe plaque psoriasis, approval also requires:
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
   3. You have psoriasis covering 3% or more of body surface area (BSA) OR psoriatic lesions (rashes) affecting the hands, feet, genital area, or face
   4. You had a trial of or contraindication (harmful) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   5. You meet ONE of the following:
      a. You are 6 to 17 years of age AND had a trial of or contraindication (harmful for) to THREE of the preferred medications: Enbrel (etanercept), Taltz (ixekizumab), Stelara (ustekinumab)
      b. You are 18 years of age or older AND had a trial of or contraindication (harmful for) to FOUR of the following preferred medications: Taltz (ixekizumab), Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast)

(Initial criteria continued on next page)
SEUKINUMAB

INITIAL CRITERIA (CONTINUED)

C. **If you have psoriatic arthritis, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful) to ONE DMARD (disease-modifying anti-rheumatic drug) such as methotrexate, leflunomide, hydroxychloroquine, sulfasalazine
   4. Request for 300mg dosage in psoriatic arthritis without coexisting plaque psoriasis requires you have tried the 150mg maintenance dosing schedule AND continue to have active psoriatic arthritis
   5. You had a trial of or contraindication (harmful for) to THREE of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz IR/XR (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rrzaa)

D. **If you have ankylosing spondylitis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (such as ibuprofen, naproxen, meloxicam)
   4. Request for 300mg dosage requires you have tried the 150mg maintenance dosage schedule AND continue to have active ankylosing spondylitis
   5. You had a trial or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Taltz (ixekizumab), Xeljanz IR/XR (tofacitinib immediate release or extended release), Rinvoq (upadacitinib)

*(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

E. **If you have non-radiographic axial spondyloarthritis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (such as ibuprofen, naproxen, meloxicam)
   4. You have ONE of the following signs of inflammation:
      a. C-reactive protein (CRP: a measure of how much inflammation you have) levels above the upper limit of normal
      b. Sacroilitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI)
   5. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Taltz (ixekizumab), Cimzia (certolizumab), Rinvoq (upadacitinib)

F. **If you have enthesitis-related arthritis, approval also requires:**
   1. You are 4 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (such as ibuprofen, naproxen, meloxicam), sulfasalazine, OR methotrexate

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

RENEWAL CRITERIA

Our guideline named **SECUKINUMAB (Cosentyx)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Non-radiographic axial spondyloarthritis (nr-axSpA: a type of joint condition)
   5. Enthesitis-related arthritis (ERA: a type of joint condition)

*(Renewal criteria continued on next page)*

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA (CONTINUED)

B. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease or a decrease in PASI (Psoriasis Area and Severity Index: used to measure the severity and extent of psoriasis) of at least 50% or more while on therapy
   2. You meet ONE of the following:
      a. You are 6 to 17 years of age AND had a trial of or contraindication (harmful for) to THREE of the preferred medications: Enbrel (etanercept), Taltz (ixekizumab), Stelara (ustekinumab)
      b. You are 18 years of age or older AND had a trial of or contraindication (harmful for) to FOUR of the following preferred medications: Taltz (ixekizumab), Humira (adalimumab), Stelara (ustekinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa), Enbrel (etanercept), Otezla (apremilast)

C. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful for) to THREE of the following preferred medications: Taltz (ixekizumab), Enbrel (etanercept), Humira (adalimumab), Stelara (ustekinumab), Xeljanz IR/XR (tofacitinib immediate release or extended release), Otezla (apremilast), Tremfya (guselkumab), Rinvoq (upadacitinib), Skyrizi (risankizumab-rzaa)

D. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
   2. You had a trial or contraindication (harmful for) to TWO of the following preferred medications: Enbrel (etanercept), Humira (adalimumab), Taltz (ixekizumab), Xeljanz IR/XR (tofacitinib immediate release or extended release), Rinvoq (upadacitinib)

E. If you have non-radiographic axial spondyloarthritis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1 - 10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) while on therapy
   2. You had a trial of or contraindication (harmful for) to TWO of the following preferred medications: Taltz (ixekizumab), Cimzia (certolizumab), Rinvoq (upadacitinib)

(Renewal criteria continued on next page)
RENEWAL CRITERIA (CONTINUED)

F. If you have enthesitis-related arthritis, renewal also requires:
   1. You have experienced or maintained an improvement in global assessment of disease activity, functional ability, number of joints with active arthritis, OR number of joints with limited range of motion

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Commercial Effective: 07/01/23
## SELEXIPAG

### INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SELEXIPAG (Uptravi)** requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung doctor)

C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

D. You had a trial of or contraindication (harmful for) to TWO of the following agents from different drug classes:
   1. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
   2. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
   3. Oral cGMP stimulator (such as Adempas [riociguat])
   4. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [treprostinil])

### RENEWAL CRITERIA

Our guideline named **SELEXIPAG (Uptravi)** requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization (WHO) functional class (classification system for heart failure)
GUIDELINES FOR USE

Our guideline named SELINEXOR (Xpovio) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Multiple myeloma (MM: cancer of a type of white blood cells called plasma cells)
   2. Relapsed or refractory multiple myeloma (RRMM: cancer of a type of white blood cells called plasma cells, that has return or did not respond to treatment)
   3. Relapsed or refractory diffuse large B-cell lymphoma (DLBCL: type of cancer that starts in the immune system), including DLBCL arising from follicular lymphoma

B. You are 18 years of age or older

C. If you have multiple myeloma, approval also requires:
   1. The requested medication will be used in combination with Velcade (bortezomib) and dexamethasone
   2. You have received at least one therapy before Xpovio

D. If you have relapsed or refractory multiple myeloma, approval also requires:
   1. The requested medication will be used in combination with dexamethasone
   2. You have received at least four prior therapies for the treatment of RRMM
   3. Your RRMM is refractory (non-responsive) to ALL of the following:
      a. Two proteasome inhibitors (such as bortezomib, carfilzomib)
      b. Two immunomodulatory agents (such as lenalidomide, pomalidomide)
      c. One anti-CD38 monoclonal antibody (such as daratumumab)

E. If you have relapsed or refractory diffuse large B-cell lymphoma (DLBCL), approval also requires:
   1. You have received at least two lines of systemic therapy (treatment that spreads throughout the body)

Commercial Effective: 05/10/21
SELPERCATINIB

GUIDELINES FOR USE

Our guideline named SELPERCATINIB (Retevmo) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Locally advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)
   2. Advanced or metastatic medullary thyroid cancer (a type of thyroid cancer that has progressed or has spread to other parts of the body)
   3. Advanced or metastatic thyroid cancer (thyroid cancer that has progressed or has spread to other parts of the body)
   4. Locally advanced or metastatic solid tumors (abnormal mass that has spread to nearby tissue or lymph nodes, or has spread to other parts of the body)

B. If you have locally advanced or metastatic non-small cell lung cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has a rearranged during transfection (RET: type of gene) gene fusion, as detected by a Food and Drug Administration (FDA) approved test

C. If you have advanced or metastatic medullary thyroid cancer, approval also requires:
   1. You are 12 years of age or older
   2. Your cancer has a rearranged during transfection (RET: type of gene) mutation, as detected by a Food and Drug Administration (FDA) approved test
   3. You require systemic therapy (treatment that travels through the entire body)

D. If you have advanced or metastatic thyroid cancer, approval also requires:
   1. You are 12 years of age or older
   2. You require systemic therapy (treatment that travels through the entire body)
   3. Your cancer has a rearranged during transfection (RET: type of gene) gene fusion, as detected by a Food and Drug Administration (FDA) approved test
   4. Your thyroid cancer is refractory (has not responded) to radioactive iodine therapy, if radioactive iodine is appropriate

E. If you have locally advanced or metastatic solid tumors, approval also requires:
   1. You are 18 years of age or older
   2. Your tumor has a rearranged during transfection (RET: type of gene) gene fusion
   3. Your tumor has progressed on or following prior systemic treatment OR you have no satisfactory alternative treatment options

Commercial Effective: 10/17/22
SELUMETINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SELUMETINIB</td>
<td>KOSELUGO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named SELUMETINIB (Koselugo) requires the following rule(s) be met for approval:

A. You have neurofibromatosis type 1 (NF1: a genetic disorder that causes light brown skin spots and non-cancerous tumors to form on nerve tissue)
B. You are 2 to 17 years of age
C. You have symptomatic, inoperable (not treatable by surgery) plexiform neurofibromas (PN: tumors that grow from nerves anywhere in the body)

Commercial Effective: 10/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SETMELANOTIDE (Imcivree) requires the following rule(s) be met for approval:

A. The request is for chronic weight loss management
B. You are 6 years of age or older
C. Your obesity is confirmed by ONE of the following deficiencies:
   1. Proopiomelanocortin (POMC: type of gene)
   2. Proprotein convertase subtilisin/kexin type 1 (PCSK1: type of gene)
   3. Leptin receptor (LEPR: type of gene)
D. Confirmed genetic testing shows variants (changes) in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic (causing disease), likely pathogenic, or of uncertain significance (VUS)

RENEWAL CRITERIA

Our guideline named SETMELANOTIDE (Imcivree) requires the following rule(s) be met for approval:

A. You have lost at least 5% of your baseline body weight or 5% of your baseline body mass index (BMI: a measure of body fat based on your height and weight)

Commercial Effective: 04/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SILDENAFIL IV (Revatio)** requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. You are 18 years of age or older

C. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)

D. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

E. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form

F. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

CONTINUED ON NEXT PAGE
SILDENAFIL IV

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named SILDENAFIL IV (Revatio) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
D. You have shown improvement from baseline in the 6-minute walk distance test, OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (a way to classify how limited you are during physical activity)

Commercial Effective: 07/01/23
SILDENAFIL SUSPENSION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>SILDENAFIL CITRATE</td>
<td>REVATIO, LIQREV, SILDENAFIL CITRATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SILDENAFIL SUSPENSION (Revatio, Liqrev) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. If you are 1 to 17 years of age, approval also requires:
   1. You are requesting Revatio (sildenafil) suspension
   2. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)
   3. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
   4. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
   5. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   6. You are unable to swallow pills AND you have tried crushed sildenafil tablets

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
C. **If you are 18 years of age or older, approval also requires:**

1. Therapy is prescribed by or in consultation with a cardiologist (a type of heart doctor) or pulmonologist (lung/breathing doctor)

2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   c. Pulmonary vascular resistance (PVR) greater than 2 Wood units

3. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)

4. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

5. If you are requesting Revatio (sildenafil) suspension, you are unable to swallow pills AND you have tried crushed sildenafil tablets

6. If you are requesting Liqrev suspension, you are unable to swallow Revatio (sildenafil) tablet AND you have tried generic sildenafil powder for suspension

**CONTINUED ON NEXT PAGE**
SILDENAFIL SUSPENSION

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named SILDENAFIL SUSPENSION (Revatio, Liqrev) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)

B. If you are 1 to 17 years of age, approval also requires:
   1. You are requesting Revatio (sildenafil) suspension
   2. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
   3. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   4. You meet ONE of the following criteria:
      a. You have shown improvement from baseline in the 6-minute walk distance test
      b. You remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)
      c. You cannot perform exercise testing and are stable or improving on treatment

C. If you are 18 years of age or older, approval also requires:
   1. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form (such as nitroglycerin, isosorbide mononitrate)
   2. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   3. You have shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)

Commercial Effective: 06/12/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SILDENAFIL TABLET

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SILDENAFIL CITRATE</td>
<td>REVATIO, SILDENAFIL CITRATE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SILDENAFIL TABLET (Revatio) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. You are 1 year of age or older

C. If you are 18 years of age or older, approval also requires:
   1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
   3. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   4. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
SILDENAFIL TABLET

INITIAL CRITERIA (CONTINUED)

D. If you are 1 to 17 years of age or older, approval also requires:
   1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units
   3. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   4. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

RENEWAL CRITERIA

Our guideline named SILDENAFIL TABLET (Revatio) requires the following rule(s) be met for renewal:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)
B. You are 1 year of age or older
C. If you are 18 years of age or older, approval also requires:
   1. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   2. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   3. You have shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE
SILDENAFIL TABLET

RENEWAL CRITERIA (CONTINUED)

D. If you are 1 to 17 years of age, approval also requires:
   1. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
   2. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
   3. You meet ONE of the following criteria:
      a. You have shown improvement from baseline in the 6-minute walk distance test
      b. You remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)
      c. You cannot perform exercise testing and are stable or improving on treatment

Commercial Effective: 07/01/23
### Guidelines for Use

Our guideline named **SIMEPREVIR (Olysio)** requires the following rule(s) be met for approval:

A. You have chronic hepatitis C, genotype 1 (type of liver inflammation)
B. You are 18 years of age or older
C. You must have documentation of a recent hepatitis C virus infection by at least one detectable HCV RNA level (amount of virus in your blood) within the past 6 months
D. You will be using Olysio with Sovaldi taken at the same time
E. You have previously failed a short trial of Harvoni, Mavyret or Epclusa and stopped due to reasons such as adverse effect or intolerance early in therapy, unless there is a medical reason why you cannot (contraindication) take all 3 agents. The medication will not be approved for an individual who has completed a full course of therapy that did not achieve SVR (sustained virologic response)
F. You are treatment naïve (never previously treated) or treatment-experienced with prior treatment with peginterferon/ribavirin

**Olysio will not be approved for the following patients:**

A. You have failed a full course of treatment with 1) any HCV protease inhibitor (for example, simeprevir [Olysio], telaprevir [Incivek] or boceprevir [Victrelis]) OR 2) a regimen containing an NS5A inhibitor (e.g., Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, or Daklinza-containing regimen)
B. You have compensated cirrhosis (no symptoms related to liver damage) or decompensated cirrhosis (you have symptoms related to liver damage)
C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions
D. You are using Olysio with ribavirin and peginterferon alfa
E. You are taking any of the following medications that are not recommended for concurrent use with Olysio:
   - Amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, erythromycin, clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)
   - Any cobicistat-containing medication (such as Stivarga or Genvoya [elvitegravir/cobicistat/emtricitabine/tenofovir], Evotaz, Prezco, BBrTe, Tybost)
   - Delavirdine, etravirine, nevirapine, or efavirenz
   - Any HIV protease inhibitor (such as atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, tipranavir, ritonavir, darunavir/ritonavir)

**Commercial Effective: 01/01/23**
**GUIDELINES FOR USE**

Our guideline named **SIMVASTATIN 80 (VYTORIN, ZOCOR)** requires the following rule(s) be met for approval:

A. You have been taking the medication for at least 12 months

Commercial Effective: 05/14/21
SIMVASTATIN ORAL SUSPENSION

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIMVASTATIN</td>
<td>FLOLIPID</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named SIMVASTATIN ORAL SUSPENSION (Flolipid) requires the following rule(s) be met for approval:

A. You had a previous trial of simvastatin tablets, unless there is a medical reason why you cannot (contraindication)
B. Your prescriber provides documentation showing that you have dysphagia (general swallowing difficulties), difficulty swallowing tablets, or a feeding tube such as a G-tube or J-tube
C. Requests for zero dollar cost share also requires that you are between 40-75 years of age without a history of cardiovascular disease (relating to heart and blood vessels) and you have not used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on your prescription claims profile or medical records:
   1. Aspirin/dipyridamole (Aggrenox)
   2. Clopidogrel (Plavix)
   3. Dipyridamole
   4. Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
   5. Prasugrel (Effient)
   6. Praluent Pen
   7. Repatha
   8. Ticagrelor (Brilinta)
   9. Ticlopidine
   10. Vorapaxar sulfate (Zontivity)

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SIPONIMOD (Mayzent) requires the following rule(s) be met for approval:
A. You have relapsing forms of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (symptoms occur once), relapsing-remitting disease (symptoms return and go away), or active secondary progressive disease (advanced disease)
B. You are 18 years of age or older
C. You have CYP2C9 (type of enzyme) *1/*1, *1/*2, *2/*2, *1/*3, or *2/*3 genotype

RENEWAL CRITERIA

Our guideline named SIPONIMOD (Mayzent) requires the following rule(s) be met for renewal:
A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (symptoms occur once), relapsing-remitting disease (symptoms return and go away), or active secondary progressive disease (advanced disease)
B. You have demonstrated a clinical benefit compared to pre-treatment baseline
C. You do not have lymphopenia (low levels of a type of white blood cell)
D. You have CYP2C9 (type of enzyme) *1/*1, *1/*2, *2/*2, *1/*3, or *2/*3 genotype
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

   Our guideline named SIROLIMUS TOPICAL (Hyftor) requires the following rule(s) be met for approval:
   A. You have facial angiofibroma (a skin condition) associated with tuberous sclerosis (a rare type of tumor disorder)
   B. You are 6 years of age or older

RENEWAL CRITERIA

   Our guideline named SIROLIMUS TOPICAL (Hyftor) requires the following rule(s) be met for renewal:
   A. You have facial angiofibroma (a skin condition) associated with tuberous sclerosis (a rare type of tumor disorder)
**SMOKING CESSATION ZERO COST SHARE OVERRIDE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUPROPION HCL</td>
<td>ZYBAN, BUROPION HCL SR</td>
</tr>
<tr>
<td>VARENICLINE TARTRATE</td>
<td>CHANTIX, VARENICLINE TARTRATE</td>
</tr>
<tr>
<td>NICOTINE</td>
<td>NICOTROL, NICOTROL NS, NICOTINE PATCH, NICODERM CQ, NTS, NICOTINE</td>
</tr>
<tr>
<td>NICOTINE POLACRILEX</td>
<td>NICOTINE GUM, NICOTINE LOZENGE, NICORETTE, VARIOUS</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **SMOKING CESSATION ZERO COST SHARE OVERRIDE** requires the following rule(s) be met for approval:

A. Your request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. You are 18 years of age or older

C. Approval may also require that you have tried preferred agent(s), unless you have a contraindication (harmful for). (NOTE TO REVIEWER: Provide the list of the preferred medication(s))

*(Criteria continued on next page)*

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

D. If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (one if only one agent is available)
   3. Your doctor has provided documentation confirming that your requested drug is considered medically necessary for you (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Commercial Effective: 07/01/22
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM/CALCIUM/MAG/POT OXYBATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM, CALCIUM, MAG, POT OXYBATE</td>
<td>XYWAV</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Idiopathic hypersomnia (IH: a type of sleep disorder)
   2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
   3. Excessive daytime sleepiness (EDS) in narcolepsy (a type of sleep disorder)

B. You are not concurrently on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]

C. **If you have idiopathic hypersomnia, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. Your diagnosis is confirmed by ALL of the following:
      a. You do not have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
      b. You have a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
      c. You have 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
      d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months

4. You tried and failed or have a contraindication (harmful for) to armodafinil OR modafinil

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
D. If you have cataplexy in narcolepsy, approval also requires:
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You have tried TWO of the following: venlafaxine, fluoxetine, or tricyclic anti-depressants (such as amitriptyline, clomipramine, imipramine)

E. If you have excessive daytime sleepiness in narcolepsy, approval also requires:
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You have EDS persisting for 3 or more months and an Epworth Sleepiness Scale (tool to measure your sleepiness) score of more than 10
   4. Your diagnosis of narcolepsy is confirmed by ONE of the following:
      a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
      b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
      c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
   5. If you are 7 to 17 years old, you tried and failed or have a contraindication (harmful for) to one generic stimulant indicated for EDS in narcolepsy (such as amphetamine, dextroamphetamine, or methylphenidate)
   6. If you are 18 years or older, you tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
      a. Generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.)
      b. Armodafinil OR modafinil

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Narcolepsy (uncontrollable daytime sleepiness)
   2. Idiopathic hypersomnia (IH: a type of sleep disorder)

B. You are not concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]

C. If you have narcolepsy, renewal also requires you meet ONE of the following:
   1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
   2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
   3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep)

D. If you have idiopathic hypersomnia, renewal also requires you meet ONE of the following:
   1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
   2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SODIUM OXYBATE (LUMRYZ)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
   2. Excessive daytime sleepiness (EDS) in narcolepsy (sleep disorder)

B. You are NOT concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]

C. **If you have cataplexy in narcolepsy, approval also requires:**
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You have tried generic sodium oxybate (Xyrem)
   4. You have tried TWO of the following: venlafaxine (Effexor), fluoxetine (Prozac), TCA (tricyclic antidepressant, such as amitriptyline [Elavil], clomipramine [Anafranil], imipramine [Tofranil])

D. **If you have excessive daytime sleepiness (EDS) in narcolepsy, approval also requires:**
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. Your diagnosis of narcolepsy is confirmed by ONE of the following:
      a. A Multiple Sleep Latency Test (MLST) showing both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
      b. A Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREM (within approximately 15 minutes) on a polysomnography (type of sleep test) the night before the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
      c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)

*(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE
SODIUM OXYBATE-LUMRYZ

INITIAL CRITERIA (CONTINUED)

4. You have excessive daytime sleepiness (EDS) persisting for 3 or more months
5. You have an Epworth Sleepiness Scale (ESS: questionnaire used to assess daytime sleepiness) score of more than 10
6. You have tried, failed (drug did not work), or have a contraindication (harmful for) to generic sodium oxybate (Xyrem)
7. If you are 7 to 17 years old, you have tried, failed (drug did not work) or have a contraindication (harmful for) to a generic typical stimulant (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
8. If you are 18 years or older, you have tried, failed (drug did not work) or have a contraindication (harmful for) to one agent from EACH of the following categories:
   a. Generic typical stimulant (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], or methylphenidate [Ritalin])
   b. Armodafinil (Nuvigil) or modafinil (Provigil)

RENEWAL CRITERIA

Our guideline named SODIUM OXYBATE (LUMRYZ) requires the following rule(s) be met for renewal:
A. You have narcolepsy (uncontrollable daytime sleepiness)
B. You are NOT concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]
C. You meet ONE of the following:
   1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
   2. You have maintained improvement in Epworth Sleepiness Scale (ESS: questionnaire used to assess daytime sleepiness) scores by at least 25% compared to baseline
   3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep)
### GUIDELINES FOR USE

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

Our guideline named **SODIUM OXYBATE (Xyrem)** requires the following rule(s) be met for approval:

A. **You have ONE of the following diagnoses:**
   1. Idiopathic hypersomnia (IH: a type of sleep disorder)
   2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
   3. Excessive daytime sleepiness (EDS) in narcolepsy (sleep disorder)

B. Xyrem (sodium oxybate) will NOT be used concurrently (at the same time) with a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta (eszopiclone), Ambien (zolpidem), or Restoril (temazepam)

C. **If you have idiopathic hypersomnia, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. Your diagnosis is confirmed by ALL of the following:
      a. You do NOT have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
      b. You have a Multiple Sleep Latency Test (MSLT) showing less than two sleep-onset REM (rapid eye movement) sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
      c. You have one or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
      d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of an irrepressible need to sleep or daytime lapses into sleep for at least 3 months
   4. You have tried and failed or have a contraindication (harmful for) to armodafinil (Nuvigil) OR modafinil (Provigil)
   5. If you are requesting brand Xyrem, you have tried and failed or have a contraindication (harmful for) to generic sodium oxybate

*(Initial criteria continued on next page)*
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SODIUM OXYBATE-XYREM

INITIAL CRITERIA (CONTINUED)

D. If you have cataplexy in narcolepsy, approval also requires:
   5. You are 7 years of age or older
   6. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   7. You have tried TWO of the following: venlafaxine (Effexor), fluoxetine (Prozac), a tricyclic anti-depressant (such as amitriptyline [Elavil], clomipramine [Anafranil], imipramine [Tofranil])

E. If you have excessive daytime sleepiness in narcolepsy, approval also requires:
   1. You are 7 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
   3. You have EDS persisting for 3 or more months
   4. You have an Epworth Sleepiness Scale (tool to measure sleepiness) score of more than 10
   5. Your diagnosis of narcolepsy is confirmed by ONE of the following:
      a. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND two or more early-onset rapid eye movement (REM) sleep test periods
      b. A Multiple Sleep Latency Test showing an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
      c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing low levels of a chemical that help with staying awake)
   6. If you are 7 to 17 years old, you have tried and failed or have a contraindication (harmful for) to one generic stimulant indicated for EDS in narcolepsy (such as amphetamine [Evekeo], dextroamphetamine [Dexedrine], or methylphenidate [Ritalin])
   7. If you are 18 years or older, you have tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
      a. Generic typical stimulant (such as amphetamine sulfate [Evekeo], dextroamphetamine [Dexedrine], methylphenidate [Ritalin])
      b. Armodafinil (Nuvigil) OR modafinil (Provigil)
      c. If you are requesting brand Xyrem, you have tried and failed or have a contraindication (harmful for) to generic sodium oxybate

CONTINUED ON NEXT PAGE
SODIUM OXYBATE-XYREM

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named SODIUM OXYBATE (Xyrem) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Narcolepsy (uncontrollable daytime sleepiness)
   2. Idiopathic hypersomnia (IH: a type of sleep disorder)

B. Xyrem (sodium oxybate) will NOT be used concurrently (at the same time) with a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], or Restoril [temazepam]

C. If you have narcolepsy, renewal also requires ONE of the following:
   1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
   2. You have maintained improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
   3. You have demonstrated improvement in sleep latency (the amount of time it takes to fall asleep)

D. If you have idiopathic hypersomnia, renewal also requires ONE of the following:
   1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
   2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline

Commercial Effective: 06/12/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SODIUM PHENYL BUTYRATE (Buphenyl, Pheburane) requires the following rule(s) be met for approval:
A. You have urea cycle disorder (a genetic disorder that causes high ammonia levels in the blood)
B. There is documentation confirming you have urea cycle disorder via enzymatic, biochemical or genetic testing (types of lab tests)
C. The requested medication will be used as adjunctive (add-on) therapy along with dietary protein restriction
D. Your condition cannot be managed by dietary protein restriction or amino acid supplementation alone
E. **If your request is for Pheburane, approval also requires ALL of the following:**
   1. You have tried or have a contraindication to (harmful for) generic sodium phenylbutyrate powder
   2. You are unable to swallow Buphenyl (sodium phenylbutyrate) tablets

RENEWAL CRITERIA

Our guideline named SODIUM PHENYL BUTYRATE (Buphenyl, Pheburane) requires the following rule(s) be met for renewal:
A. You have a urea cycle disorder (a genetic disorder that causes high ammonia levels in the blood)
B. You have experienced clinical benefit from baseline (such as you are having normal fasting glutamine, low-normal fasting ammonia levels, mental status clarity).

Commercial Effective: 01/01/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOD PHENYLBUTYRATE-TAURURSODIOL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOD PHENYLBUTYRATE-TAURURSODIOL</td>
<td>RELYVRIO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOD PHENYLBUTYRATE-TAURURSODIOL (Relyvrio) requires the following rule(s) be met for approval:
A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor) or ALS specialist or being seen at an ALS Specialty Center or Care Clinic

RENEWAL CRITERIA

Our guideline named SOD PHENYLBUTYRATE-TAURURSODIOL (Relyvrio) requires the following rule(s) be met for renewal:
A. You have amyotrophic lateral sclerosis (ALS: a type of brain and nerve condition)
B. You do not require invasive ventilation (inserting a breathing tube into your throat)
C. You have improved or maintained baseline functional ability measured by functional assessments (e.g., Amyotrophic Lateral Sclerosis Functional Rating Scale [ALSFRS: a tool for evaluating functional status])

Commercial Effective: 10/24/22
GUIDELINES FOR USE

Our guideline named SOFOSBUVIR (Sovaldi) requires the following rule(s) be met for approval:
A. You have chronic hepatitis C (type of liver inflammation)
B. You are 18 years of age or older with genotype 1 or 3, OR you are 3 to 17 years old with genotype 2 or 3
C. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
D. If you are an adult patient (18 years of age or older), approval also requires:
   1. You are treatment naive (never previously treated) or treatment experienced (prior treatment with peginterferon/ribavirin)
   2. You will be using Sovaldi with Olysio (genotype 1 only) or Daklinza (genotype 1 or 3 only)
   3. You had a short trial of a preferred formulary agent (you stopped because of intolerance or adverse effect early in therapy) or have a contraindication (medical reason why you cannot use) to therapy with the preferred formulary agent(s) as specified below. An individual who has completed a full course of therapy that did not achieve a sustained virologic response (SVR) will not be approved
      a. If you have genotype 1 infection, you had a short trial of Epclusa or Harvoni or you have a contraindication to BOTH agents
      b. If you have genotype 3 infection, you had a short trial of Epclusa or you have a contraindication to this agent
E. If you are a pediatric patient (under 18 years of age), approval also requires:
   1. The request must meet the Food and Drug Administration (FDA)-approved indication [treatment naive (never previously treated) or treatment experienced patient with compensated cirrhosis (no symptoms related to liver damage) (Child-Pugh A) or without cirrhosis (liver scarring)]
   2. You will be using Sovaldi together with ribavirin (genotypes 2 and 3)

(Criteria continued on next page)
SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

Sovaldi will not be approved if you meet any of the following:
A. You have severe renal (kidney) impairment (glomerular filtration rate less than 30 mL/min/1.73m2), end stage renal disease and/or those requiring dialysis
B. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (additional diseases)
C. You are an adult with compensated cirrhosis (no symptoms related to liver damage)
D. You are using any of the following medications at the same time while on Sovaldi: carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, tipranavir/ritonavir, velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), velpatasvir/sofosbuvir/voxilaprevir (Vosevi), or elbasvir/grazoprevir (Zepatier)
E. You are using Sovaldi with another direct acting antiviral (e.g., Olysio or Daklinza) AND are on concurrent amiodarone
F. You are an adult who is taking Sovaldi with ribavirin OR peginterferon alfa and ribavirin

For requests for Sovaldi/Olysio regimen for genotype 1, the following must also be met:
A. You are 18 years of age or older
B. You do not have cirrhosis (liver scarring)
C. You have not previously failed a full course of therapy with 1) any hepatitis c virus protease inhibitor (type of Hep C drug such as Incivek [telaprevir], Olysio [simeprevir], or Victrelis [boceprevir] OR 2) a regimen containing NS5A inhibitor (type of hepatitis medication such as Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, or Daklinza-containing regimen)

(Criteria continued on next page)
SOFOSBUVIR

GUIDELINES FOR USE (CONTINUED)

D. You will not be using the requested medication together with any of the following medications as they are contraindicated (there is a medical reason why you cannot use the drug) or not recommended by the manufacturer:

1. Carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, erythromycin (does not include topical formulations), clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole (does not include topical formulations), voriconazole, dexamethasone, cisapride, cyclosporine, rosuvastatin (dose above 10mg), or atorvastatin (dose above 40mg)

2. Any of the following human immunodeficiency virus (HIV) medications: delavirdine, etravirine, nevirapine, or efavirenz

3. A cobicistat-containing medication such as Striibild or Genvoya [elvitegravir/cobicistat/emtricitabine/tenofovir], Evotaz, PrezCISION, or Tybost

4. A human immunodeficiency virus (HIV) protease inhibitor such as atazanavir, fosamprenavir, lopinavir, indinavir, nelfinavir, saquinavir, tipranavir, ritonavir, or darunavir/ritonavir

For patients using Sovaldi with Daklinza, the following must also be met:

A. You are 18 years of age or older
B. You have genotype 1 or 3 hepatitis C (type of liver inflammation)
C. You will not be using the requested medication together with any of the following medications because they are contraindicated (medical reason why you cannot use a drug) or not recommended by the manufacturer): amiodarone, carbamazepine, phenytoin, rifampin, or rifapentine
D. You will be taking ribavirin together with Sovaldi and Daklinza if you have decompensated cirrhosis (you have symptoms related to liver damage) or you are post-liver transplant
GUIDELINES FOR USE

Our guideline named SOFOSBUVIR/VELPATASVIR (Epclusa) requires the following rule(s) be met for approval:

A. You have chronic hepatitis C (type of liver inflammation) with genotype 1, 2, 3, 4, 5, or 6
B. You are 3 years of age or older
C. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
D. If you have decompensated cirrhosis (symptoms related to liver damage), approval also requires:
   1. The requested medication will be used with ribavirin
E. If you do not have cirrhosis (liver damage) OR you have compensated cirrhosis (a condition where liver is extensively scarred, but you do not have symptoms of liver damage), approval also requires ONE of the following:
   1. You are treatment naive (never previously treated)
   2. You are treatment experienced (have previously been treated) with peginterferon/ribavirin or NS3 protease inhibitor triple therapy (type of hepatitis drug such as Olysio, Incivek or Victrelis with peginterferon/ribavirin)
   3. You have genotype 1b or genotype 2 infection AND you are treatment experienced with a Sovaldi (sofosbuvir)-containing regimen that does not include an NS5A inhibitor (type of hepatitis drug) such as Sovaldi/ribavirin with or without peginterferon or Sovaldi/Olysio

Epclusa will not be approved if you meet any of the following:

A. You are using any of the following medications with the requested agent: amiodarone, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, efavirenz-containing HIV (human immunodeficiency virus) regimens, rosuvastatin at doses above 10mg, tipranavir/ritonavir, topotecan, sofosbuvir (Sovaldi) (as a single agent), ledipasvir/sofosbuvir (Harvoni), elbasvir/grazoprevir (Zepatier), pibrentasvir/glecaprevir (Mavyret), or velpatasvir/sofosbuvir/voxilaprevir (Vosevi)
B. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions

Commercial Effective: 01/01/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR</td>
<td>Vosevi</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR (Vosevi) requires the following rule(s) be met for approval:

A. You have chronic hepatitis C (type of liver inflammation)
B. You are 18 years of age or older
C. You have an HCV RNA level (amount of virus in your blood) within the past 6 months
D. You meet ONE of the following:
   1. You have genotype 1, 2, 3, 4, 5, or 6 and previously failed a full course of therapy with a direct-acting antiviral (DAA) regimen that includes NS5A inhibitor (class of hepatitis C drug such as Harvoni, Epclusa, Technivie, Viekira Pak or Viekira XR, Zepatier, Daklinza/Sovaldi combination)
   2. You have genotype 1a or genotype 3 and previously failed a full course of therapy with DAA regimen that includes sofosbuvir without NS5A inhibitor (class of hepatitis C drug such as Sovaldi/ribavirin, Sovaldi/peginterferon/ribavirin, Olysio/Sovaldi (or other hepatitis c virus protease inhibitor in combination with Sovaldi))

Vosevi will not be approved if you meet any of the following:

A. You are using the requested agent concurrently (at the same time) with any of the following medications: amiodarone, rifampin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifabutin, rifapentine, HIV (human immunodeficiency virus) regimen containing atazanavir, lopinavir, tipranavir/ritonavir, or efavirenz, rosvastatin, pitavastatin, pravastatin (at doses above 40mg), cyclosporine, methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, sulfasalazine, topotecan, sofosbuvir (Sovaldi) (as a single agent), velpatasvir/sofosbuvir (Epclusa), ledipasvir/sofosbuvir (Harvoni), elbasvir/grazoprevir (Zepatier), or pibrentasvir/glecaprevir (Mavyret)
B. You have moderate or severe hepatic (liver) impairment (Child-Pugh B or C)
C. You have a limited life expectancy (less than 12 months) due to non-liver related comorbid conditions (other diseases)

Commercial Effective: 01/01/23
GUIDELINES FOR USE

Our guideline named SOLIFENACIN SUSPENSION (Vesicare LS) requires the following rule(s) be met for approval:

A. You have neurogenic detrusor overactivity (type of bladder dysfunction)
B. You are 2 years of age or older
C. You had a trial of or contraindication (harmful for) to TWO of the following:
   1. Anticholinergics (such as oxybutynin)
   2. Beta-3 agonists (such as mirabegron)
D. You are unable to swallow oral solifenacin tablets

Commercial Effective: 01/01/22
SOLRIAMFETOL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOLRIAMFETOL</td>
<td>SUNOSI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOLRIAMFETOL (Sunosi) requires the following rule(s) be met for approval:

A. You have excessive daytime sleepiness (EDS) with narcolepsy (a sleep disorder); or obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep).

B. If you have excessive daytime sleepiness (EDS) with narcolepsy, approval also requires:

1. Your diagnosis of narcolepsy is confirmed by ONE of the following:
   i. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less AND two (2) or more early-onset rapid eye movement (REM) sleep test periods (SOREMPs)
   ii. You have a Multiple Sleep Latency Test (MSLT) showing an average sleep latency of 8 minutes or less AND one (1) early-onset rapid eye movement (REM) sleep test period (SOREMP) AND one (1) SOREMP (within about 15 minutes) on a sleep study (polysomnography) the night before the MSLT, with the sleep study ruling out non-narcolepsy causes of excessive daytime sleepiness (EDS)
   iii. You have low orexin levels on a cerebrospinal fluid (CSF) assay (a test to determine the amount of a type of chemical for wakefulness in your brain)

2. You have had Excessive Daytime Sleepiness (EDS) persisting for at least 3 months and Epworth Sleepiness Scale (ESS) score of more than 10

3. Therapy is prescribed by or given in consultation with a neurologist (brain doctor), psychiatrist (mental health doctor), or specialist in sleep medicine

4. You have tried one amphetamine derivative (e.g., amphetamine sulfate, methylphenidate, etc.) AND modafinil or armodafinil, unless there is a medical reason why you cannot (contraindication)

(Initial criteria continued on the next page)
SOLRIAMFETOL

INITIAL CRITERIA (CONTINUED)

C. If you have excessive daytime sleepiness (EDS) with obstructive sleep apnea (OSA), approval also require:
   1. Your diagnosis of OSA is confirmed by a sleep study (polysomnography), home sleep apnea testing devices, or hospital-based bedside monitoring
   2. You have had Excessive Daytime Sleepiness (EDS) for at least 3 months and your Epworth Sleepiness Scale (ESS) score is more than 10
   3. You have tried modafinil or armodafinil, unless there is a medical reason why you cannot (contraindication)
   4. You have been on a treatment for the obstructive causes of OSA, for at least one month since initiation, and you have been counseled on weight-loss intervention [if your BMI (Body Mass Index: a measure of body fat based on height and weight) is greater than 30]

RENEWAL CRITERIA

Our guideline named SOLRIAMFETOL (Sunosi) requires the following rule(s) be met for renewal:
   A. You have excessive daytime sleepiness (EDS) with narcolepsy (a sleep disorder); or obstructive sleep apnea (OSA: a disorder where airflow is blocked during sleep).
   B. You have sustained improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline

Commercial Effective: 07/01/20
SOMATROPIN - GENOTROPIN

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOMATROPIN (Genotropin) requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure associated with Turner syndrome (TS: a type of gene condition)
   3. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
   4. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause of short height)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
SOMATROPIN - GENOTROPIN

INITIAL CRITERIA (CONTINUED)

C. If you have growth failure associated with Turner syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

D. If you have growth failure due to Prader-Willi syndrome (PWS), approval also requires:
   1. You have a confirmed genetic diagnosis of Prader-Willi syndrome
   2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin

E. If you have growth failure and are a child born small for gestational age (SGA), approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph of the wrist and hand
   4. You had no catch-up growth by age 2 years
   5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

F. If you have adult growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named **SOMATROPIN (Genotropin)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD)
   2. Growth failure associated with Turner syndrome (type of genetic disorder where you are missing a X chromosome)
   3. Growth failure due to Prader-Willi syndrome (PWS: genetic disorder that causes obesity, intellectual disability, and short height)
   4. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause of short height)

B. If you have **pediatric growth hormone deficiency**, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have **short stature associated with Turner syndrome**, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

D. If you have **growth failure due to Prader-Willi syndrome**, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You have experienced improvement in body composition

*(Renewal criteria continued on next page)*

CONTINUED ON NEXT PAGE
SOMATROPIN - GENOTROPIN

RENEWAL CRITERIA (CONTINUED)

E. If you have growth failure and are a child born small for gestational age, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Commercial Effective: 11/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOMATROPIN (Humatrope) requires the following rule(s) be met for approval:

A. You have one of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you’re missing a certain gene, causing short height)
   4. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause for short height)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
SOMATROPIN - HUMATROPE

INITIAL CRITERIA (CONTINUED)

C. If you have short stature associated with Turner syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

D. If you have short stature or growth failure in short stature homeobox-containing gene deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. If you have growth failure and are a child born small for gestational age, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
   5. You had no catch-up growth by age 2 to 4 years

F. If you have adult growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

CONTINUED ON NEXT PAGE
SOMATROPIN - HUMATROPE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named SOMATROPIN (Humatrope) requires the following rule(s) be met for renewal:

A. You have one of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you’re missing a certain gene, causing short height)
   4. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause for short height)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have short stature associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

(Renewal criteria continued on next page)
SOMATROPIN - HUMATROPE

RENEWAL CRITERIA (CONTINUED)

D. If you have short stature or growth failure in children with SHOX deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you have growth failure and are a child born small for gestational age, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

SOMATROPIN - NORDITROPIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOMATROPIN</td>
<td>NORDITROPIN FLEXPRO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOMATROPIN (Norditropin Flexpro) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature associated with Noonan syndrome (a type of gene condition)
   4. Short stature born small for gestational age (SGA) in a pediatric patient
   5. Adult growth hormone deficiency
   6. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two GH (growth hormone) stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. If you have short stature associated with Turner syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/26/2023
Page 546 of 675
SOMATROPIN - NORDITROPIN

INITIAL CRITERIA (CONTINUED)

D. If you have short stature associated with Noonan syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. If you are a child with short stature born small for gestational age, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. You had no catch-up growth by age 2 to 4 years
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

F. If you have adult growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

G. If you have growth failure due to Prader-Willi syndrome, approval also requires:
   1. You have confirmed genetic diagnosis of Prader-Willi syndrome
   2. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

CONTINUED ON NEXT PAGE
SOMATROPIN - NORDITROPIN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named SOMATROPIN (Norditropin Flexpro) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD)
   2. Short stature associated with Turner syndrome (type of genetic disorder where you are missing a X chromosome)
   3. Short stature associated with Noonan syndrome (a type of genetic disorder causing abnormal body development)
   4. Short stature born small for gestational age (SGA) in a pediatric patient
   5. Adult growth hormone deficiency
   6. Growth failure due to Prader-Willi syndrome (PWS: genetic disorder that causes obesity, intellectual disability, and short height)

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause for short height)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have short stature associated with Noonan syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE
D. If you have short stature associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you are a child with short stature born small for gestational age, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

G. If you have growth failure due to Prader-Willi syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had improvement in body composition
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOMATROPIN (Nutropin AQ Nuspin) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure secondary to chronic kidney disease (CKD)
   3. Short stature associated with Turner syndrome (TS: a type of gene condition)
   4. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. If you have growth failure secondary to chronic kidney disease, approval also requires:
   1. You have NOT undergone a renal (kidney) transplantation
   2. Therapy is prescribed by or in consultation with a nephrologist (kidney doctor)
   3. Your height or growth velocity is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

(Initial criteria continued on next page)
SOMATROPIN - NUTROPIN

INITIAL CRITERIA (CONTINUED)

D. If you have short stature associated with Turner syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. If you have adult growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

RENEWAL CRITERIA

Our guideline named SOMATROPIN (Nutropin AQ Nuspin) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure secondary to chronic kidney disease (CKD)
   3. Short stature associated with Turner syndrome (TS: a type of gene condition)
   4. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

(Renewal criteria continued on next page)
SOMATROPIN - NUTROPIN

INITIAL CRITERIA (CONTINUED)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have growth failure secondary to chronic kidney disease, renewal also requires:
   1. You have not had a renal (kidney) transplantation
   2. Your growth velocity is 2 cm or more compared with what was observed from the previous year or you have not reached 50th percentile for your predicted adult height

D. If you have short stature associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Commercial Effective: 11/01/22
SOMATROPIN - OMNITROPE

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOMATROPIN (Omnitrope) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
   3. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (unknown cause of short height)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. If you have growth failure due to Prader-Willi syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You have confirmed genetic diagnosis of Prader-Willi Syndrome
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
INITIAL CRITERIA (CONTINUED)

D. **If you have growth failure and are a child born small for gestational age, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had no catch-up growth by age 2 years
   3. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   4. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. **If you have growth failure associated with Turner syndrome, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

F. **If you have adult growth hormone deficiency, approval also requires:**
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

RENEWAL CRITERIA

Our guideline named **SOMATROPIN (Omnitrope)** requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Growth failure due to Prader-Willi syndrome (PWS: a type of gene condition)
   3. Growth failure in children born small for gestational age (SGA)
   5. Adult growth hormone deficiency

*(Renewal criteria continued on next page)*
SOMATROPIN - OMNITROPE

RENEWAL CRITERIA (CONTINUED)

This medication will not be approved for treatment of ANY of the following conditions:
1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have growth failure due to Prader-Willi syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You have experienced improvement in body composition

D. If you have growth failure and are a child born small for gestational age, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you have growth failure associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Commercial Effective: 11/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOMATROPIN (Saizen) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      Your height velocity is less than the 25th percentile for your age
      You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below the mean for your age and gender

C. If you have adult growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypotalamic disease (disease of a small area of the brain important for hormone production and body processes), surgery, radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

CONTINUED ON NEXT PAGE
SOMATROPIN - SAIZEN

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named SOMATROPIN (Saizen) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)

Commercial Effective: 11/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SOMATROPIN (Serostim)** requires the following rule(s) be met for approval:

A. You have HIV (human immunodeficiency virus) wasting/cachexia (extreme weight loss and muscle loss)
B. The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
C. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions), nutritional support specialist OR infectious disease specialist (doctor who specializes in the treatment of infections)
D. You are on HIV (human immunodeficiency virus) anti-retroviral therapy
E. You have had an inadequate response to previous therapy such as exercise training, nutritional supplements, appetite stimulants or anabolic steroids
F. You have had an inadequate response to previous pharmacological (drug) therapy including one of the following: cyproheptadine, Marinol (dronabinol), or Megace (megestrol acetate)
G. Alternative causes of wasting have been ruled out. Alternative causes may include:
   1. Altered metabolism (from metabolic and hormonal abnormalities) including testosterone deficiency or peripheral growth hormone resistance
   2. Diarrhea
   3. Inadequate energy (caloric) intake
   4. Malignancies (tumors)
   5. Opportunistic infections (an infection that can occur because of a weakened immune system)
H. You meet ONE of the following criteria for weight loss:
   1. 10% unintentional weight loss over 12 months
   2. 7.5% unintentional weight loss over 6 months
   3. 5% body cell mass (BCM) loss within 6 months
   4. BCM less than 35% (men) and a body mass index (BMI) less than 27 kg per meter squared
   5. BCM less than 23% (women) of total body weight and a body mass index (BMI) less than 27 kg per meter squared
   6. BMI less than 18.5 kg per meter squared

*(Initial criteria continued on next page)*

**CONTINUED ON NEXT PAGE**
SOMATROPIN - SEROSTIM

INITIAL CRITERIA (CONTINUED)

I. If you are hypogonadal (you have low testosterone levels), approval also requires:
   1. You meet one of the following criteria for low testosterone:
      a. Total serum testosterone level of less than 300ng/dL (10.4nmol/L)
      b. A low total serum testosterone level as indicated by a lab result, with a reference range, obtained within 90 days
      c. A free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
   2. You have tried testosterone therapy (examples include testosterone cypionate, AndroGel, Androderm, Axiron, Delatestryl, Fortesta, Striant, Testim, Testopel, Vogelxo, Natesto)

RENEWAL CRITERIA

Our guideline named SOMATROPIN (Serostim) requires the following rule(s) be met for renewal:
A. You have HIV (human immunodeficiency virus) wasting/cachexia (severe muscle and weight loss)
B. You have NOT received more than 24 weeks of therapy within the plan year
C. The requested agent is NOT prescribed for athletic enhancement or anti-aging purposes
D. You have shown clinical benefit in muscle mass and weight as indicated by at least a 10 percent increase in weight or BCM (body cell mass) from baseline (Note: current and baseline weight must be documented including dates of measurement)
E. You are on HIV anti-retroviral therapy

Commercial Effective: 01/01/23
SOMATROPIN - ZOMACTON

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOMATROPIN (Zomacton) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature in children born small for gestational age (SGA)
   4. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you're missing a certain gene, causing short height)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:

1. Athletic enhancement
2. Anti-aging purposes
3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You meet at least ONE of the following criteria for short stature:
      a. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender
      b. Your height velocity is less than the 25th percentile for your age
      c. You have documented low peak growth hormone (less than 10ng/mL) on two growth hormone stimulation tests or insulin-like growth factor 1 (IGF-1) greater than or equal to 2 standard deviations below mean for your age and gender

(Initial criteria continued on next page)
SOMATROPIN - ZOMACTON

INITIAL CRITERIA (CONTINUED)

C. If you have short stature associated with Turner syndrome, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

D. If you are a child with short stature born small for gestational age, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   4. You had no catch-up growth by age 2 to 4 years
   5. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

E. If you have short stature or growth failure in children with SHOX deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your height is greater than or equal to 2 standard deviations (SD) below the mean (average) height for normal children of the same age and gender

F. If you have adult growth hormone deficiency, approval also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Norditropin
   3. You have growth hormone deficiency alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary diseases (disease of a major hormone producing gland), hypothalamic disease, surgery (disease of a small area of the brain important for hormone production and body processes), radiation therapy, trauma, or continuation of therapy from childhood onset growth hormone deficiency

CONTINUED ON NEXT PAGE
SOMATROPIN - ZOMACTON

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named SOMATROPIN (Zomacton) requires the following rule(s) be met for renewal:

A. You have one of the following diagnoses:
   1. Pediatric growth hormone deficiency (GHD: a type of hormone disorder with low growth hormone)
   2. Short stature associated with Turner syndrome (TS: a type of gene condition)
   3. Short stature in children born small for gestational age (SGA)
   4. Short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency (you’re missing a certain gene, causing short height)
   5. Adult growth hormone deficiency

This medication will not be approved for treatment of ANY of the following conditions:
   1. Athletic enhancement
   2. Anti-aging purposes
   3. Idiopathic short stature (short height due to unknown cause)

B. If you have pediatric growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed (confirmed by radiograph [type of imaging test] of the wrist and hand or you have not completed prepubertal growth)
   3. You meet ONE of the following:
      a. Your annual growth velocity is 2 cm or more compared with what was observed from the previous year
      b. Your annual growth velocity is 1 cm or more compared with what was observed from the previous year if you are near the terminal (end) phase of puberty

C. If you have short stature associated with Turner syndrome, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

(Renewal criteria continued on next page)

CONTINUED ON NEXT PAGE
SOMATROPIN - ZOMACTON

RENEWAL CRITERIA (CONTINUED)

D. If you have growth failure and are a child born small for gestational age, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

E. If you have short stature or growth failure in children with SHOX deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
   2. Your epiphyses (end part of long bone) are NOT closed as confirmed by radiograph (type of imaging test) of the wrist and hand
   3. Your growth velocity is 2 cm or more compared with what was observed from the previous year and/or you have not reached 50th percentile for your predicted adult height

F. If you have adult growth hormone deficiency, renewal also requires:
   1. Therapy is prescribed by or in consultation with an endocrinologist (hormone doctor)
SOMATROPIN - ZORBTIVE

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named SOMATROPIN (Zorbtive) requires the following rule(s) be met for approval:
A. You have short bowel syndrome (the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
B. Therapy is prescribed by or in consultation with a gastroenterologist (digestive system doctor)
C. The requested medication is NOT prescribed for athletic enhancement or anti-aging purposes
D. You are currently on specialized nutritional support such as high carbohydrate, low-fat diet, adjusted for individual requirements and preferences

RENEWAL CRITERIA

Our guideline named SOMATROPIN (Zorbtive) requires the following rule(s) be met for renewal:
A. You have short bowel syndrome (the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
B. You have not been on the requested medication for 4 weeks

Commercial Effective: 11/01/22
SONIDEGIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SONIDEGIB</td>
<td>ODOMZO</td>
</tr>
<tr>
<td>PHOSPHATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named SONIDEGIB (Odomzo) requires the following rule(s) be met for approval:
A. You have locally advanced basal cell carcinoma (BCC: type of skin cancer).
B. You are 18 years of age or older
C. This is a recurrence (disease returns) of basal cell carcinoma after surgery or radiation therapy OR you are not a candidate for surgery or radiation therapy
D. Baseline serum creatine kinase (CK: type of lab test) and serum creatinine levels have been obtained before starting therapy
E. If you are a female of reproductive potential, you must verify your pregnancy status before starting therapy

Commercial Effective: 01/01/22
GUIDELINES FOR USE

Our guideline named SORAFENIB (Nexavar) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
   2. Unresectable hepatocellular carcinoma (liver cancer that cannot be removed with surgery)
   3. Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment (thyroid cancer that has returned or spread, is getting worse and is not responding to a type of treatment)

Commercial Effective: 07/18/22
GUIDELINES FOR USE

Our guideline named **SOTORASIB (Lumakras)** requires the following rule(s) be met for approval:

A. You have locally advanced or metastatic non-small cell lung cancer (NSCLC) (type of lung cancer that has grown outside the organ it started in but has not spread to other parts of the body or lung cancer that has spread to other parts of the body)

B. You are 18 years of age or older

C. You have a KRAS G12C-mutation (type of gene mutation), as determined by a Food and Drug Administration (FDA)-approved test

D. You have received at least one prior systemic therapy (treatment that spreads throughout the body through the bloodstream)

Commercial Effective: 04/17/23
SPARSENTAN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPARSENTAN</td>
<td>FILSPARI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **SPARSENTAN (Filspari)** requires the following rule(s) be met for approval:
A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (a type of kidney doctor)
D. Your diagnosis is confirmed by a biopsy (removal of cells or tissue for examination)
E. You are at risk of rapid disease progression (such as urine protein-to-creatinine-ratio [UPCR: test that measures the amount of protein in urine] of 1.5 g/g or greater)
F. You have proteinuria (increased levels of protein in the urine) of at least 1 g/day
G. You have an eGFR (a tool for evaluating kidney function) of at least 30 mL/min/1.73 m(2)
H. You had a trial of or contraindication (harmful for) to an angiotensin converting enzyme inhibitor (ACE-I: such as lisinopril, enalapril) or an angiotensin receptor blocker (ARB: such as losartan, valsartan) for at least 12 weeks
I. Filspari will NOT be used concurrently (at the same time) with ACE-I (such as lisinopril, enalapril), an ARB (such as losartan, valsartan), an endothelin receptor antagonist (such as ambrisentan, bosentan), or aliskiren

RENEWAL CRITERIA

Our guideline named **SPARSENTAN (Filspari)** requires the following rule(s) be met for renewal:
A. You have primary immunoglobulin A nephropathy (IgAN: a type of kidney disease)
B. You meet ONE of the following:
   1. You had a reduction in proteinuria (increased levels of protein in the urine)
   2. You have improvement or stable kidney function compared to baseline
C. Filspari will NOT be used concurrently (at the same time) with angiotensin converting enzyme inhibitor (ACE-I: such as lisinopril, enalapril), an angiotensin receptor blocker (ARB: such as losartan, valsartan), an endothelin receptor antagonist (such as ambrisentan, bosentan), or aliskiren

Commercial Effective: 07/01/23
**STANDARD COMMERCIAL DRUG FORMULARY**

**PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

---

**STATIN ZERO COST SHARE OVERRIDE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROSUVASTATIN CALCIUM</td>
<td>CRESTOR, EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM</td>
</tr>
<tr>
<td>PRAVASTATIN SODIUM</td>
<td>PRAVACHOL, PRAVASTATIN SODIUM</td>
</tr>
<tr>
<td>SIMVASTATIN</td>
<td>ZOCOR, SIMVASTATIN</td>
</tr>
<tr>
<td>ATORVASTATIN CALCIUM</td>
<td>LIPITOR, ATORVASTATIN CALCIUM</td>
</tr>
<tr>
<td>LOVASTATIN, LOVASTATIN EXTENDED-RELEASE</td>
<td>ALTOPREV, LOVASTATIN</td>
</tr>
<tr>
<td>FLUVASTATIN SODIUM, FLUVASTATIN EXTENDED-RELEASE</td>
<td>LECOL, FLUVASTATIN SODIUM, LECOL XL, FLUVASTATIN EXTENDED-RELEASE</td>
</tr>
<tr>
<td>PITAVASTATIN CALCIUM</td>
<td>LIVALO, PITAVASTATIN CALCIUM</td>
</tr>
<tr>
<td>PITAVASTATIN MAGNESIUM</td>
<td>ZYPITAMAG, PITAVASTATIN MAGNESIUM</td>
</tr>
</tbody>
</table>

CONTINUED ON NEXT PAGE
STATIN ZERO COST SHARE OVERRIDE

GUIDELINES FOR USE

Our guideline named STATIN ZERO COST SHARE OVERRIDE requires that the following rules be met for approval:

A. The request is for ONE of the following:
   1. A generic agent
   2. A single-source brand (SSB) agent that has no preferred generic agents or therapeutically equivalent products available
   3. A multi-source brand (MSB) agent

B. You are between 40 to 75 years of age without a history of cardiovascular disease (heart disease)

C. You have not used any of the following secondary prevention medications for cardiovascular disease within the past 120 days based on your prescription claims profile or medical records:
   1. Aspirin/dipyridamole (Aggrenox)
   2. Clopidogrel (Plavix)
   3. Dipyridamole
   4. Nitroglycerin (i.e., oral, sublingual, transdermal patch or ointment, translingual dosage forms)
   5. Prasugrel (Effient)
   6. Praluent Pen
   7. Repatha
   8. Ticagrelor (Brilinta)
   9. Ticlopidine
   10. Vorapaxar sulfate (Zontivity)

D. If the request is for a single-source brand or multi-source brand agent, approval also requires ONE of the following:
   1. Two preferred medications are medically inappropriate for you (or one if only one agent is available)
   2. You have tried or have a documented medical contraindication (harmful for) to TWO preferred medications (or a trial of one if only one agent is available)
   3. Your doctor has provided documentation confirming that the requested drug is considered medically necessary for you, (considerations may include severity of side effects and ability to adhere to the appropriate use of the item or service)

Commercial Effective: 07/01/22
STIRIPENTOL

Guidelines for Use

**Initial Criteria**

(Note: For renewal criteria see below)

- You have seizures associated with Dravet syndrome (a rare type of seizure)
- You are 6 months of age or older AND weighs 7kg or more
- Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
- You are currently being treated with clobazam (a type of seizure drug)
- You had a trial of or contraindication (harmful for) to TWO of the following: valproic acid derivatives, clobazam, topiramate

**Renewal Criteria**

- You have seizures associated with Dravet syndrome (a rare type of seizure)
- You are currently being treated with clobazam (type of seizure drug)

Commercial Effective: 08/29/22
Our guideline named **SUNITINIB (Sutent)** requires the following rule(s) be met for approval:

A. The requested medication is being used for ONE of the following:
   1. Advanced renal cell carcinoma (RCC: type of kidney cancer)
   2. Gastrointestinal stromal tumor (GIST: type of growth in the digestive system)
   3. Unresectable locally advanced or metastatic pancreatic neuroendocrine carcinoma (pNET: type of pancreas cancer)

B. **If you have advanced renal cell carcinoma (RCC), approval also requires:**
   1. You are 18 years of age or older

C. **If you have gastrointestinal stromal tumor (GIST), approval also requires:**
   1. You are 18 years of age or older
   2. You had a trial of imatinib mesylate (Gleevec), unless there is a medical reason why you cannot (contraindication)

D. **If you have unresectable locally advanced or metastatic pancreatic neuroendocrine carcinoma (pNET), approval also requires:**
   1. You are 18 years of age or older
   2. Your tumor is progressive (getting worse) and well-differentiated

E. **If the request is for adjuvant treatment of renal cell carcinoma, approval also requires:**
   1. You are 18 years of age or older
   2. You are at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of kidney)

Commercial Effective: 09/06/21
TADALAFIL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TADALAFIL</td>
<td>CIALIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named TADALAFIL (Cialis) requires the following rule(s) be met for approval:

A. You have benign prostatic hyperplasia (BPH: your prostate is too big causing difficulty urinating) OR erectile dysfunction (difficulty getting/keeping an erection)

B. If you have benign prostatic hyperplasia (BPH), approval also requires:
   1. You previously tried at least two preferred formulary alternatives, including one medication from each of the following classes:
      a. 5-alpha-reductase inhibitors: (such as finasteride or dutasteride)
      b. Alpha blockers: (such as doxazosin, terazosin, tamsulosin, or alfuzosin)

C. If you have erectile dysfunction, approval also requires:
   1. You have previously tried generic sildenafil (Viagra)

Commercial Effective: 09/07/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TADALAFIL-ADCIRCA, ALYQ (Adcirca/Alyq) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
D. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form
E. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])
Guidelines for Use (Continued)

Renewal Criteria

Our guideline named TADALAFIL-ADCIRCA, ALYQ (Adcirca/Alyq) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)

B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form

C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

D. You have shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TADALAFIL-TADLIQ (Tadliq)** requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)

C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units

D. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form

E. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

F. You are unable to swallow tadalafil tablets

CONTINUED ON NEXT PAGE
TADALAFIL-TADLIQ

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TADALAFIL-TADLIQ (Tadliq) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO) Group 1 (a way to classify the severity of disease)

B. You are NOT concurrently (at the same time) or intermittently (off and on) taking oral erectile dysfunction agents (such as Cialis [tadalafil], Viagra [sildenafil]) or any organic nitrates in any form

C. You are NOT concurrently (at the same time) taking guanylate cyclase stimulators (drugs that also treat pulmonary hypertension such as Adempas [riociguat])

D. You have shown improvement from baseline in the 6-minute walk distance test OR remain stable from baseline in the 6-minute walk distance test with a stable or improved World Health Organization functional class (WHO-FC: a way to classify how limited you are during physical activity)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TAFAMIDIS (Vyndaqel, Vyndamax) requires the following rule(s) be met for approval:
A. You have cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein) which is confirmed by ONE of the following:
   1. Bone scan (scintigraphy) strongly positive for myocardial uptake of 99mtcpyp/DPD (a type of test that shows your heart absorbs a chemical for imaging)( Note: Strongly positive defined as heart to contralateral lung [H/Cl] ratio of at least 1.5 or grade 2 or greater localization to the heart using the Perugini grade 1-3 scoring system
   2. Biopsy of tissue of affected organ(s) (can be heart or non-heart related organs) to confirm amyloid (type of protein) presence AND chemical typing to confirm presence of transthyretin (TTR) protein
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a cardiologist (heart doctor), transthyretin amyloidosis (ATTR) specialist, or medical geneticist
D. You have New York Heart Association (NYHA) class I, II or III heart failure (classification of heart failure symptoms)

RENEWAL CRITERIA

Our guideline named TAFAMIDIS (Vyndaqel, Vyndamax) requires the following rule(s) be met for renewal:
A. You have cardiomyopathy associated with wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM: heart disease caused by a build-up of a type of protein)
B. You have not progressed to (gotten worse to) New York Heart Association (NYHA) Class IV heart failure (classification of heart failure symptoms)
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

**TALAZOPARIB TOSYLATE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TALAZOPARIB TOSYLATE</td>
<td>TALZENNA</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **TALAZOPARIB (Talzenna)** requires the following rule(s) be met for approval:

A. You have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer (cancer that does not have a type of protein and has spread from where it started to nearby tissue or lymph nodes or has spread to other parts of the body)

B. You are 18 years of age or older

C. You have a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutation (gBRCAm: a type of gene mutation) as confirmed by a Food and Drug Administration-approved test

D. You have been treated with chemotherapy in the neoadjuvant (drugs used to treat cancer given before main treatment), adjuvant (add-on to main treatment), or metastatic setting (treating disease that has spread)

E. **If you have hormone receptor (HR)-positive breast cancer, approval also requires:**
   1. You have had additional treatment with endocrine (hormone) therapy or are considered inappropriate for endocrine therapy

Commercial Effective: 07/01/22
## TAPINAROF

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAPINAROF</td>
<td>VTAMA</td>
</tr>
</tbody>
</table>

### GUIDELINES FOR USE

#### INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TAPINAROF (Vtama) requires the following rule(s) be met for approval:

A. You have plaque psoriasis (a type of skin condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor)
D. You have psoriasis covering 3% to 20% of body surface area (BSA) (excluding scalp, palms, fingernails, toenails, and soles)
E. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)
F. You had a trial of or contraindication (harmful for) to TWO of the following (from different categories):
   1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate, halobetasol propionate)
   2. Topical vitamin D analog (such as calcipotriene cream, calcitriol ointment)
   3. Topical calcineurin inhibitor (such as tacrolimus, pimecrolimus)
   4. Topical retinoid (such as tazarotene cream/gel)
   5. Anthralin

#### RENEWAL CRITERIA

Our guideline named TAPINAROF (Vtama) requires the following rule(s) be met for renewal:

A. You have plaque psoriasis (a type of skin condition)
B. You have achieved or maintained clear or minimal disease
C. You are NOT concurrently (at the same time) using other systemic immunomodulating agents (such as Stelara, Otezla), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), or topical non-steroidals (such as calcitriol, tazarotene)

Commercial Effective: 06/15/22
GUIDELINES FOR USE

Our guideline named **TASIMELTEON (Hetlioz, Hetlioz LQ)** requires the following rules(s) be met for approval:

A. You have one of the following:
   1. Non-24 hour sleep-wake disorder (N24HSWD) (type of sleep disorder where your sleep time increasingly gets delayed)
   2. Nighttime sleep disturbances in Smith-Magenis syndrome (SMS) (type of genetic disorder that causes sleeping problems)

B. **If you have non-24 hour sleep-wake disorder, approval also requires:**
   1. You are 18 years of age or older
   2. You are light-insensitive or have total blindness
   3. You have previously tried and failed maximally-tolerated melatonin therapy
   4. You are requesting the capsule

C. **If you have nighttime sleep disturbances in Smith-Magenis syndrome, approval also requires:**
   1. You are requesting brand Hetlioz capsules if you are 16 years of age or older
   2. You are requesting Hetlioz LQ oral suspension if you are 3 to 15 years old
   3. You have previously tried and failed maximally-tolerated melatonin therapy

Commercial Effective: 02/01/23
TAVABOROLE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAVABOROLE</td>
<td>KERYDIN, TAVABOROLE</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **TAVABOROLE (Kerydin)** requires the following rule(s) be met for approval:

A. You have onychomycosis of the toenails (toenail fungus infection)
B. You have complicating factors such as diabetes, peripheral vascular disease (narrowed blood vessels cause low blood flow), a suppressed immune system, or pain surrounding the nail or soft tissue
C. You have previously tried the following agents, unless there is a medical reason why you cannot (contraindication):
   1. Oral terbinafine OR oral itraconazole
   2. Ciclopirox topical solution

Commercial Effective: 11/09/20
Our guideline named TAZEMETOSTAT (Tazverik) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic or locally advanced (cancer that has spread to other parts of the body or has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma (rare type of soft tissue cancer)
   2. Relapsed or refractory follicular lymphoma (cancer of the white blood cells that has returned or is resistant to previous treatment)

B. **If you have metastatic or locally advanced epithelioid sarcoma,** approval also requires:
   1. You are 16 years of age or older
   2. You are not eligible for complete resection (surgically removing all of a tissue/organ)

C. **If you have relapsed or refractory follicular lymphoma,** approval also requires:
   1. You are 18 years or older
   2. You meet ONE of the following:
      a. Your tumors are positive for an EZH2 (type of gene) mutation as detected by a Food and Drug Administration (FDA)-approved test AND you have received at least 2 prior systemic therapies (medication/treatment that spreads throughout your body)
      b. You have no satisfactory alternative treatment options
GUIDELINES FOR USE

Our guideline named TBO-FILGRASTIM (Granix) requires the following rule(s) be met for approval:
A. You have a non-myeloid malignancy (cancer not affecting bone marrow)
B. You are 1 month of age or older
C. Therapy is prescribed by or in consultation with a hematologist (blood specialist) or oncologist (cancer/tumor doctor)
D. You are receiving myelosuppressive anti-cancer drugs (drugs that decrease bone marrow activity) associated with a significant incidence of severe neutropenia (a type of blood condition) with fever
E. You had a trial of or contraindication (harmful for) to the preferred medication: Nivestym

Commercial Effective: 11/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TEDUGLUTIDE (Gattex) requires the following rule(s) be met for approval:
A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
B. You are 1 year of age or older
C. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
D. You are dependent on parenteral nutrition (administration of nutrition through a vein), defined as requiring parenteral nutrition at least three times per week

RENEWAL CRITERIA

Our guideline named TEDUGLUTIDE (Gattex) requires the following rule(s) be met for renewal:
A. You have short bowel syndrome (SBS: the body cannot absorb fluids and nutrients due to a lack of a functional small intestine)
B. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
C. You have achieved or maintained a decreased need for parenteral support (administration of nutrition through a vein) compared to baseline

Commercial Effective: 04/01/22
TELOTRISTAT

Generic

Brand

TELOTRISTAT

XERMELO

GUIDELINES FOR USE

Our guideline named TELOTRISTAT (Xermelo) requires the following rule(s) be met for approval:
A. You have carcinoid syndrome diarrhea (diarrhea caused by a type of tumor affecting nerves/hormones)
B. The medication will be used in combination with a somatostatin analog such as octreotide
C. You are 18 years of age or older
D. The medication is being prescribed by or given in consultation with an oncologist (cancer/tumor doctor) or gastroenterologist (digestive system doctor)
E. There is documentation showing that you have been receiving a stable dose of long-acting somatostatin analog therapy such as Sandostatin LAR (octreotide) or Somatuline Depot (lanreotide) for a minimum of 3 months – unless there is a medical reason why you cannot (contraindication)
F. You have diarrhea that is inadequately controlled as defined by the presence of at least four bowel movements per day

Commercial Effective: 07/01/20
TEMOZOLOMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEMOZOLOMIDE</td>
<td>TEMODAR , TEMOZOLOMIDE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TEMOZOLOMIDE (Temodar) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Anaplastic astrocytoma (type of brain tumor)
   2. Glioblastoma multiforme (type of tumor affecting brain or spine)
   4. Metastatic melanoma (type of skin cancer)

B. If you have metastatic melanoma, approval also requires:
   1. You are not concurrently (at the same time) using an immunosuppressive therapy (treatment that lowers the activity of the body’s immune system) or a medical therapy for the treatment of melanoma

RENEWAL CRITERIA

NOTE: For the diagnoses of Anaplastic astrocytoma, Glioblastoma multiforme, or Small cell lung cancer (SCLC), please refer to the Initial Criteria section.

Our guideline named TEMOZOLOMIDE (Temodar) requires the following rule(s) be met for renewal:

A. You have metastatic melanoma (type of skin cancer)

B. You are not concurrently (at the same time) using an immunosuppressive therapy (treatment that lowers the activity of the body’s immune system) or a medical therapy for the treatment of melanoma

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named TENAPANOR (Ibsrela) requires the following rule(s) be met for approval:

A. You have irritable bowel syndrome with constipation (IBS-C: a type of bowel disease)
B. You are 18 years of age or older
C. You had a trial of the preferred agents: lubiprostone AND Linzess

Commercial Effective: 07/01/22
GUIDELINES FOR USE

Our guideline named **TEPOTINIB (Tepmetko)** requires the following rule(s) be met for approval:
A. You have metastatic non-small cell lung cancer (NSCLC) (type of lung cancer that has spread to other parts of the body)
B. You are 18 years of age or older
C. Mesenchymal-epithelial transition (MET) exon 14 skipping alterations (abnormal change in a gene that makes MET protein) are present

---

Commercial Effective: 10/09/21
**TERIFLUNOMIDE**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TERIFLUNOMIDE</td>
<td>AUBAGIO, TERIFLUNOMIDE</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **TERIFLUNOMIDE (Aubagio)** requires the following rule(s) be met for approval:

A. You have a relapsing form of multiple sclerosis (MS: a type of nerve disorder), to include clinically isolated syndrome (disease occurs once), relapsing-remitting disease (symptoms go away and return) and active secondary progressive disease (advanced disease)

B. You are 18 years of age or older

Commercial Effective: 04/17/23
TERIPARATIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TERIPARATIDE</td>
<td>FORTEO, TERIPARATIDE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named TERIPARATIDE (Forteo) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Postmenopausal osteoporosis (a type of joint condition)
   2. Primary or hypogonadal (sex organs don’t function properly) osteoporosis in a male patient
   3. Glucocorticoid (steroid)-induced osteoporosis

B. You meet ONE of the following:
   1. You are at high risk for fractures defined as ONE of the following:
      a. History of osteoporotic (i.e., fragility, low trauma) fracture(s)
      b. Two or more risk factors for fracture (such as history of multiple recent low trauma fractures, bone marrow density (BMD) T-score less than or equal to -2.5, corticosteroid use, or use of GnRH analogs such as Synarel [nafarelin])
      c. No prior treatment for osteoporosis AND FRAX (test for your risk of fractures) score of at least 20 percent for any major fracture OR at least 3 percent for hip fracture
   2. You are unable to use oral therapy due to reasons such as upper gastrointestinal [GI] problems - unable to tolerate oral medication, lower GI problems - unable to absorb oral medications, trouble remembering to take oral medications or coordinating an oral bisphosphonate with other oral medications or their daily routine
   3. You had a trial of, intolerance (side effect), or contraindication (harmful for) to a bisphosphonate (such as Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate])

C. You meet ONE of the following:
   1. You have received a total of 24 months of cumulative treatment with Forteo (teriparatide) AND remain at or have returned to having a high risk for fracture
   2. You have received less than 24 months of cumulative treatment

Commercial Effective: 04/17/23
GUIDELINES FOR USE

Our guideline named TESAMORELIN (Egrifta, Egrifta SV) requires the following rule(s) be met for approval:

A. You have human immunodeficiency virus (HIV: a type of immune disorder) with lipodystrophy (abnormal distribution of fat in the body)
B. You are 18 years of age or older
C. The requested medication is being used for the reduction of excess abdominal fat
D. You are currently receiving treatment with a protease inhibitor (PI: a type of drug), PI combination (saquinavir, ritonavir, indinavir, nelfinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, or tipranavir), a nucleoside reverse transcriptase inhibitor (NRTI: a type of drug), OR an NRTI combination (zidovudine, didanosine, stavudine, lamivudine, abacavir, tenofovir, emtricitabine, lamivudine/zidovudine, or abacavir/lamivudine/zidovudine, efavirenz/emtricitabine/tenofovir, emtricitabine/tenofovir)

Commercial Effective: 04/01/22
TESTOSTERONE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TESTOSTERONE</td>
<td>ANDRODERM, ANDROGEL, AXIRON, FORTESTA, NATESTO, STRIANT, TESTIM, VOGELXO, TESTOSTERONE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TESTOSTERONE requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you are a male with primary or secondary hypogonadism, approval also requires:
   1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   2. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

C. If the request is for Androderm, Fortesta, Natesto or Striant, you had a trial of or contraindication (harmful for) to TWO lower cost testosterone agents (such as testosterone cypionate, intramuscular [injected into the muscle] testosterone enanthate)

D. If you have gender dysphoria, approval also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved
   2. You are 16 years of age or older

CONTINUED ON NEXT PAGE
TESTOSTERONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TESTOSTERONE requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you are a male with primary or secondary hypogonadism, renewal also requires:
   1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
   2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
   3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

C. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

Commercial Effective: 05/08/23
TESTOSTERONE CYPIONATE

<table>
<thead>
<tr>
<th>Testosterone Cypionate</th>
<th>Brand</th>
</tr>
</thead>
</table>
| TESTOSTERONE CYPIONATE | DEPO-
|                        | TESTOSTERONE, |
|                        | TESTOSTERONE |
|                        | CYPIONATE    |

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TESTOSTERONE CYPIONATE (Depo-Testosterone) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, approval also requires:
   1. You are 16 years of age or older
   2. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

C. If you are a male with primary or secondary hypogonadism, approval also requires:
   1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   2. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)

CONTINUED ON NEXT PAGE
TESTOSTERONE CYPIONATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TESTOSTERONE CYPIONATE (Depo-Testosterone) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

C. If you are a male patient with primary or secondary hypogonadism, renewal also requires:
   1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
   2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
   3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Commercial Effective: 04/01/23
Our guideline named **TESTOSTERONE ENANTHATE** *(Xyosted)* requires the following rule(s) to be met for approval:

**A. You have ONE of the following diagnoses:**
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
   3. Gender dysphoria (you identify yourself as a member of the opposite sex)
   4. Metastatic breast cancer (cancer spreading to other areas of body) in a female

**B. If you are a male with primary or secondary hypogonadism, approval also requires:**
   1. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   2. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
   3. If the request is for Xyosted, approval also requires:
      a. You are 18 years of age or older
      b. The requested medication is being used for testosterone replacement therapy

**C. If you are a female with metastatic breast cancer OR you are a male with delayed puberty not secondary to a pathological disorder**, only intramuscular (injected into muscle) testosterone enanthate may be approved

**D. If you have gender dysphoria, approval also requires:**
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved
   2. You are 16 years of age or older

---

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TESTOSTERONE ENANTHATE</td>
<td>TESTOSTERONE ENANTHATE, XYOSTED</td>
</tr>
</tbody>
</table>

	

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
TESTOSTERONE ENANTHATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TESTOSTERONE ENANTHATE (Xyosted) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Delayed puberty not due to a pathological disorder (not due to disease) in a male
   3. Metastatic breast cancer (cancer spreading to other areas of body) in a female
   4. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you are a male with primary or secondary hypogonadism, renewal also requires:
   1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
   2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
   3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

C. If you are a female with metastatic breast cancer OR you are a male with delayed puberty not secondary to a pathological disorder, only intramuscular (injected into muscle) testosterone enanthate may be approved.

D. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved.

Commercial Effective: 04/01/23
TESTOSTERONE-KYZATREX

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TESTOSTERONE-KYZATREX requires the following rule(s) be met for approval:

A. You have primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
B. You are 18 years of age or older
C. You meet ONE of the following:
   1. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
   2. You have ONE of the following lab values showing you have low testosterone levels:
      1. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
      2. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
D. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

RENEWAL CRITERIA

Our guideline named TESTOSTERONE-KYZATREX requires the following rule(s) be met for renewal:

A. You have primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
B. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
C. There is documentation of normalized serum (blood) testosterone and hematocrit concentrations (type of blood test) compared to baseline
D. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Commercial Effective: 12/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TESTOSTERONE-TLANDO requires the following rule(s) be met for approval:
A. You have primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
B. You are 18 years of age or older
C. You have tried or have a contraindication (harmful for) to TWO lower cost testosterone agents (such as AndroGel 1% or 1.62%, Axiron, Testim, Vogelxo, Depo-Testosterone, intramuscular testosterone enanthate, Androderm, Fortesta, Natesto, Striant, Jatenzo)
D. You meet ONE of the following:
   1. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
   2. You have ONE of the following lab values showing you have low testosterone levels:
      a. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
      b. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
E. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

RENEWAL CRITERIA

Our guideline named TESTOSTERONE-TLANDO requires the following rule(s) be met for renewal:
A. You have primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
B. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
C. There is documentation of normalized serum testosterone and hematocrit concentrations (type of blood test) compared to baseline
D. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Commercial Effective: 12/01/22
TESTOSTERONE UNDECANOATE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TESTOSTERONE UNDECANOATE</td>
<td>JATENZO, KYZATREX, TLANDO</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TESTOSTERONE UNDECANOATE (Jatenzo, Kyzatrex, Tlando) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, approval also requires:
   1. You are 16 years of age or older
   2. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, Iia, or Iib) for treatment of gender dysphoria may be approved

C. If you are a male with primary or secondary hypogonadism, approval also requires:
   1. You are 18 years of age or older
   2. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening
   3. You meet ONE of the following:
      a. You have a previously approved prior authorization for testosterone, or you have been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history
      b. You have ONE of the following lab values showing you have low testosterone levels:
         i. At least two total serum (blood) testosterone levels of less than 300 ng/dL (10.4 nmol/L) taken on separate occasions
         ii. Free serum testosterone level of less than 5 ng/dL (0.17 nmol/L)
   4. If the request is for Jatenzo or Tlando, you had a trial of or contraindication to (harmful for) TWO lower cost testosterone agents (such as intramuscular testosterone cypionate, intramuscular testosterone enanthate)

CONTINUED ON NEXT PAGE
TESTOSTERONE UNDECANOATE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TESTOSTERONE UNDECANOATE (Jatenzo, Kyzatrex, Tlando) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Primary or secondary male hypogonadism (hypotestosteronism or low testosterone)
   2. Gender dysphoria (you identify yourself as a member of the opposite sex)

B. If you have gender dysphoria, renewal also requires:
   1. Only agents supported by the compendia (accepted medical references such as DrugDex strength of recommendation Class I, IIa, or IIb) for treatment of gender dysphoria may be approved

C. If you are a male with primary or secondary hypogonadism, renewal also requires:
   1. You have shown improvement in your symptoms compared to baseline and tolerance to treatment
   2. There is documentation (such as chart notes, lab results) of normalized serum testosterone levels and hematocrit concentrations (type of blood test) compared to baseline
   3. If you are 40 years of age or older, your prostate specific antigen (PSA: lab result that may indicate prostate cancer) has been evaluated for prostate cancer screening

Commercial Effective: 04/01/23
TETRABENAZINE

GUIDELINES FOR USE

Our guideline named TETRABENAZINE (Xenazine) requires the following rule(s) be met for approval:
A. You have chorea (involuntary movements) associated with Huntington’s disease (type of inherited disease that causes nerve cells in brain to break down over time)
B. The medication has been prescribed or given in consultation with a neurologist (nerve doctor)
C. If your request is for a tetrabenazine dosage that exceeds 50mg, approval also requires:
1. You have been genotyped for CYP2D6 (type of enzyme) and you are identified as an extensive (EM) or intermediate metabolizer (IM) of CYP2D6.

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA, SEE BELOW)

Our guideline named TEZACAFTOR/IVACAFTOR (Symdeko) requires the following rule(s) be met for approval:
A. You have cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)
B. You are 6 years of age or older
C. Therapy is prescribed by or given in consultation with a pulmonologist (lung/breathing doctor) or cystic fibrosis expert
D. You have documentation that you are either homozygous (you have 2 copies of the same gene) for the F508del-CFTR (Cystic fibrosis transmembrane conductance regulator) gene mutation;  
   OR you have documentation that you have at least one of the following mutations in the CFTR gene:

<table>
<thead>
<tr>
<th>Mutation</th>
<th>546insCTA</th>
<th>E92K</th>
<th>G576A</th>
<th>L346P</th>
<th>R117G</th>
<th>S589N</th>
</tr>
</thead>
<tbody>
<tr>
<td>711+3A→G</td>
<td>E116K</td>
<td>G576A; R668C</td>
<td>L967S</td>
<td>R117H</td>
<td>S737F</td>
<td></td>
</tr>
<tr>
<td>2789+5G→A</td>
<td>E193K</td>
<td>G622D</td>
<td>L997F</td>
<td>R117L</td>
<td>S912L</td>
<td></td>
</tr>
<tr>
<td>3272-26A→G</td>
<td>E403D</td>
<td>G970D</td>
<td>L1324P</td>
<td>R117P</td>
<td>S945L</td>
<td></td>
</tr>
<tr>
<td>3849+10kbC→T</td>
<td>E588V</td>
<td>G1069R</td>
<td>L1335P</td>
<td>R170H</td>
<td>S977F</td>
<td></td>
</tr>
<tr>
<td>A120T</td>
<td>E822K</td>
<td>G1244E</td>
<td>L1480P</td>
<td>R258G</td>
<td>S1159F</td>
<td></td>
</tr>
<tr>
<td>A234D</td>
<td>E831X</td>
<td>G1249R</td>
<td>M152V</td>
<td>R334L</td>
<td>S1159P</td>
<td></td>
</tr>
<tr>
<td>A349V</td>
<td>F191V</td>
<td>G1349D</td>
<td>M265R</td>
<td>R334Q</td>
<td>S1251N</td>
<td></td>
</tr>
<tr>
<td>A455E</td>
<td>F311del</td>
<td>H939R</td>
<td>M952I</td>
<td>R347H</td>
<td>S1255P</td>
<td></td>
</tr>
<tr>
<td>A554E</td>
<td>F311L</td>
<td>H1054D</td>
<td>M952T</td>
<td>R347L</td>
<td>T338I</td>
<td></td>
</tr>
<tr>
<td>A1006E</td>
<td>F508C</td>
<td>H1375P</td>
<td>P5L</td>
<td>R347P</td>
<td>T1036N</td>
<td></td>
</tr>
<tr>
<td>A1067T</td>
<td>F508C; S1251N</td>
<td>I148T</td>
<td>P67L</td>
<td>R352Q</td>
<td>T1053I</td>
<td></td>
</tr>
<tr>
<td>D110E</td>
<td>F508del</td>
<td>I175V</td>
<td>P205S</td>
<td>R352W</td>
<td>V201M</td>
<td></td>
</tr>
<tr>
<td>D110H</td>
<td>F575Y</td>
<td>I336K</td>
<td>Q98R</td>
<td>R553Q</td>
<td>V232D</td>
<td></td>
</tr>
<tr>
<td>D192G</td>
<td>F1016S</td>
<td>I601F</td>
<td>Q237E</td>
<td>R668C</td>
<td>V562I</td>
<td></td>
</tr>
</tbody>
</table>
Drugs listed in this document do not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

### RENEWAL CRITERIA

Our guideline named **TEZACAFTOR/IVACAFTOR (Symdeko)** requires the following rule(s) be met for renewal:

A. You have cystic fibrosis (CF: inherited life-threatening disorder that damages the lungs and digestive system)

B. You have shown improvement in clinical (medical) status compared to baseline as shown by ONE of the following:

1. You have improved, maintained, or demonstrated less than expected decline in FEV1 (forced expiratory volume: amount of air you can exhale in 1 second)
2. You have improved, maintained, or demonstrated less than expected decline in BMI (body mass index)
3. You have experienced a reduction in rate of pulmonary exacerbations (you have less attacks of breathing problems)

---

**Commercial Effective: 02/01/21**

---

<table>
<thead>
<tr>
<th>D443Y</th>
<th>F1052V</th>
<th>I618T</th>
<th>Q237H</th>
<th>R751L</th>
<th>V754M</th>
</tr>
</thead>
<tbody>
<tr>
<td>D443Y; G576A; R668C</td>
<td>F1074L</td>
<td>I807M</td>
<td>Q359R</td>
<td>R792G</td>
<td>V1153E</td>
</tr>
<tr>
<td>D579G</td>
<td>F1099L</td>
<td>I980M</td>
<td>Q1291R</td>
<td>R933G</td>
<td>V1240G</td>
</tr>
<tr>
<td>D614G</td>
<td>G126D</td>
<td>I1027T</td>
<td>R31L</td>
<td>R1066H</td>
<td>V1293G</td>
</tr>
<tr>
<td>D836Y</td>
<td>G178E</td>
<td>I1139V</td>
<td>R74Q</td>
<td>R1070Q</td>
<td>W1282R</td>
</tr>
<tr>
<td>D924N</td>
<td>G178R</td>
<td>I1269N</td>
<td>R74W</td>
<td>R1070W</td>
<td>Y109N</td>
</tr>
<tr>
<td>D979V</td>
<td>G194R</td>
<td>I1366N</td>
<td>R74W; D1270N</td>
<td>R1162L</td>
<td>Y161S</td>
</tr>
<tr>
<td>D1152H</td>
<td>G194V</td>
<td>K1060T</td>
<td>R74W; V201M</td>
<td>R1283M</td>
<td>Y1014C</td>
</tr>
<tr>
<td>D1270N</td>
<td>G314E</td>
<td>L15P</td>
<td>R74W; V201M; D1270N</td>
<td>R1283S</td>
<td>Y1032C</td>
</tr>
<tr>
<td>E56K</td>
<td>G551D</td>
<td>L206W</td>
<td>R75Q</td>
<td>S549N</td>
<td></td>
</tr>
<tr>
<td>E60K</td>
<td>G551S</td>
<td>L320V</td>
<td>R117C</td>
<td>S549R</td>
<td></td>
</tr>
</tbody>
</table>
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TEZEPELUMAB-EKKO (Tezspire)** requires the following rule(s) be met for approval:

A. You have severe asthma (a type of lung condition)
B. You are 12 years of age or older
C. Therapy is prescribed by or in consultation with a doctor specializing in allergy or pulmonary (lung/breathing) medicine
D. You are being treated with a medium, high-dose, or maximally tolerated inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone, mometasone, budesonide) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as salmeterol, formoterol), long-acting muscarinic antagonist (such as aclidinium bromide, ipratropium, umeclidinium, tiotropium), leukotriene receptor antagonist (such as montelukast, zafirlukast, zileuton), or theophylline
E. You meet ONE of the following:
   1. You experienced at least ONE asthma exacerbation (worsening of symptoms) requiring systemic corticosteroid (such as prednisone) burst lasting at least 3 days within the past 12 months OR at least ONE serious asthma exacerbation requiring hospitalization or emergency room visit within the past 12 months
   2. You have poor symptom control despite current therapy as evidenced by at least THREE of the following within the past 4 weeks:
      a. Daytime asthma symptoms more than twice per week
      b. Any night waking due to asthma
      c. Use of a short-acting inhaled beta2-agonist reliever (such as albuterol) for symptoms more than twice per week
      d. Any activity limitation due to asthma
F. You will NOT use Tezspire concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma
G. **If you have severe asthma with an eosinophilic phenotype (type of inflammatory asthma), approval also requires:**
   1. You have a documented blood eosinophil (a type of white blood cell) level of at least 150 cells/mcL within the last 12 months
   2. You had a trial of or contraindication (harmful for) to TWO of the following: Fasenra (benralizumab), Nucala (mepolizumab), Dupixent (dupilumab)

(Initial criteria continued on next page)
TEZEPELUMAB-EKKO

INITIAL CRITERIA (CONTINUED)

H. If you have severe oral corticosteroid-dependent asthma, approval also requires:
   1. You had a trial of or contraindication (harmful for) to Dupixent (dupilumab)

I. If you have severe allergic asthma, approval also requires:
   1. You had a trial of or contraindication (harmful for) to Xolair (omalizumab)

RENEWAL CRITERIA

Our guideline named TEZEPELUMAB-EKKO (Tezspire) requires the following rule(s) be met for renewal:

A. You have shown a clinical response as evidenced by ONE of the following:
   1. Reduction in asthma exacerbation (worsening of symptoms) from baseline
   2. Decreased use of rescue medications (such as albuterol)
   3. Increase in percent predicted FEV1 (amount of air exhaled in one second) from pretreatment baseline
   4. Reduction in severity or frequency of asthma-related symptoms (such as wheezing, shortness of breath, coughing)

B. You will continue to use an inhaled corticosteroid (such as triamcinolone acetonide, beclomethasone) AND at least one other maintenance medication such as a long-acting inhaled beta2-agonist (such as formoterol, salmeterol), long-acting muscarinic antagonist (such as ipratropium, tiotropium), leukotriene receptor antagonist (such as montelukast, zafirlukast), or theophylline

C. You will NOT use Tezspire concurrently (at the same time) with Xolair (omalizumab), Dupixent (dupilumab), or an anti-IL5 biologic (such as Nucala [mepolizumab], Cinqair [reslizumab], Fasenra [benralizumab]) when used for the treatment of asthma

Commercial Effective: 06/01/23
THALIDOMIDE

Our guideline named THALIDOMIDE (Thalomid) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Multiple myeloma (a type of blood cancer)
   2. Erythema nodosum leprosum (ENL: a type of immune condition)
   3. Anemia due to myelodysplastic syndrome (a type of blood condition due to blood cancer)
   4. Waldenström's macroglobulinemia (a type of blood cancer)

B. **If you have multiple myeloma, approval also requires:**
   1. Thalomid will be used in combination with dexamethasone

C. **If you have anemia due to myelodysplastic syndrome, approval also requires:**
   1. You have been previously treated for anemia due to myelodysplastic syndrome

Commercial Effective: 04/01/22
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIVOZANIB HCL</td>
<td>FOTIVDA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named TIVOZANIB (Fotivda) requires the following rule(s) be met for approval:
A. You have relapsed or refractory advanced renal cell carcinoma (type of kidney cancer that returned or no longer responds to treatment)
B. You are 18 years of age or older
C. You previously received two or more systemic therapies (such as Cabometyx, Keytruda, Opdivo)

Commercial Effective: 07/01/21
Our guideline named **TOBRAMYCIN INHALED (Bethkis, Tobi, Tobi Podhaler, Kitabis Pak)** requires the following rule(s) be met for approval:

A. You have cystic fibrosis (inherited life-threatening disorder that damages the lungs and digestive system)

B. You are 6 years of age or older

C. You have a lung infection with a gram-negative species (type of bacteria that does not stain a purple color)

D. **If the request is for Tobi Podhaler, approval also requires ONE of the following:**
   1. You had a trial and failure of or contraindication (harmful for) to ONE generic inhaled tobramycin product
   2. You are not able to tolerate the prolonged administration of nebulizers

---

Commercial Effective: 01/01/22
TOCILIZUMAB - SQ

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TOCILIZUMAB - SQ (Actemra - SQ) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (a type of joint condition)
   2. Giant cell arteritis (inflammation of blood vessels typically in and around the head)
   3. Systemic sclerosis-associated interstitial lung disease (disorder that causes hardening of lung tissue)
   4. Polyarticular juvenile idiopathic arthritis (a type of joint condition)
   5. Systemic juvenile idiopathic arthritis (a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to the preferred medication: Humira (adalimumab)

C. If you have giant cell arteritis, approval also requires:
   1. You are 18 years of age or older

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
TOCILIZUMAB - SQ

INITIAL CRITERIA (CONTINUED)

D. If you have systemic sclerosis-associated interstitial lung disease, approval also requires:
   1. You are 18 years of age or older
   2. Your diagnosis of systemic sclerosis (SSc) is according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)
   3. Therapy is prescribed by or in consultation with a pulmonologist (lung/breathing doctor) or rheumatologist (a type of immune system doctor)
   4. Other causes of interstitial lung disease have been ruled out. Other causes may include heart failure or fluid overload, drug-induced lung toxicity [cyclophosphamide, methotrexate, ACE-inhibitors (class of blood pressure medications)], recurrent aspiration (inhaling) such as from GERD (acid reflux), pulmonary vascular disease (affecting blood vessels in lungs), pulmonary edema (excess fluid in the lungs), pneumonia (type of lung infection), chronic pulmonary thromboembolism (blood clot in lungs), alveolar hemorrhage (bleeding of a part of the lungs) or interstitial lung disease caused by another rheumatic (inflammatory) disease, such as mixed connective tissue disease

E. If you have polyarticular juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had a trial of or contraindication (harmful for) to the preferred medication: Humira (adalimumab)

F. If you have systemic juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor), dermatologist (a type of skin doctor), or immunologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
TOCILIZUMAB - SQ

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TOCILIZUMAB - SQ (Actemra - SQ) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (a type of joint condition)
   2. Giant cell arteritis (inflammation of blood vessels typically in and around the head)
   3. Systemic sclerosis-associated interstitial lung disease (disorder that causes hardening of lung tissue)
   4. Polyarticular juvenile idiopathic arthritis (a type of joint condition)
   5. Systemic juvenile idiopathic arthritis (a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, renewal also requires:
   1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
   2. You had a trial of or contraindication (harmful for) to the preferred medication: Humira (adalimumab)

C. If you have polyarticular juvenile idiopathic arthritis, renewal also requires:
   3. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy
   4. You had a trial of or contraindication (harmful for) to the preferred medication: Humira (adalimumab)

D. If you have systemic sclerosis-associated interstitial lung disease, renewal also requires:
   1. You have experienced a clinically meaningful improvement or maintenance in annual rate of decline

E. If you have Systemic Juvenile Idiopathic Arthritis, renewal also requires ONE of the following:
   1. You have experienced or maintained a 20 percent or greater improvement in tender joint count or swollen joint count while on therapy
   2. You have shown maintained or improved systemic inflammatory disease (such as fevers, pain, rash, arthritis)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

Commercial Effective: 07/01/23
TOFACITINIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOFACITINIB</td>
<td>XELJANZ,</td>
</tr>
<tr>
<td>CITRATE</td>
<td>XELJANZ XR</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TOFACITINIB (Xeljanz, Xeljanz XR) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   5. Polyarticular course juvenile idiopathic arthritis (pcJIA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to at least 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (a type of skin doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
TOFACITINIB

INITIAL CRITERIA (CONTINUED)

D. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (nonsteroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam, diclofenac)
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

E. If you have moderate to severe ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira)

F. If you have polyarticular course juvenile idiopathic arthritis, approval also requires:
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira, Enbrel)

NOTE: The use of pharmaceutical samples (from the prescriber or manufacturer assistance program) will not be considered when evaluating the medical condition or prior prescription history for drugs that require prior authorization.

CONTINUED ON NEXT PAGE
TOFACITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TOFACITINIB (Xeljanz, Xeljanz XR) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: a type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Ankylosing spondylitis (AS: a type of joint condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   5. Polyarticular course juvenile idiopathic arthritis (pcJIA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, psoriatic arthritis, or polyarticular course juvenile idiopathic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

C. If you have ankylosing spondylitis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

Commercial Effective: 06/15/22
TOLVAPTAN

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TOLVAPTAN (Jynarque) requires the following rule(s) be met for approval:
A. You have autosomal dominant polycystic kidney disease (ADPKD: inherited disorder in which clusters of cysts develop in the kidneys)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a nephrologist (kidney specialist)
D. You do not have end-stage renal disease (ESRD: advanced kidney disease) including no renal transplantation (kidney transplant) or dialysis

RENEWAL CRITERIA

Our guideline named TOLVAPTAN (Jynarque) requires the following rule(s) be met for renewal:
A. You have autosomal dominant polycystic kidney disease (ADPKD: inherited disorder in which clusters of cysts develop in the kidneys)
B. You have NOT progressed to end stage renal (kidney) disease (ESRD)
TOPIRAMATE

GUIDELINES FOR USE

Our guideline named TOPIRAMATE (Eprontia) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Partial-onset seizures (a type of seizure)
   2. Primary generalized tonic-clonic seizures (a type of seizure)
   3. Seizures associated with Lennox-Gastaut syndrome (a type of seizure disorder in young children)
   4. Migraine

B. You are unable to take oral tablets or capsules

C. If you have partial-onset seizures or primary generalized tonic-clonic seizures, approval also requires:
   1. Eprontia will be used as initial monotherapy OR adjunctive therapy (drugs taken together with)
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. You meet ONE of the following:
      a. You are 2 to 5 years of age AND had a trial of or contraindication (harmful for) to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
      b. You are 6 years of age or older AND had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

D. If you have seizures associated with Lennox-Gastaut syndrome, approval also requires:
   1. Eprontia will be used as adjunctive therapy (drugs taken together with)
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. You meet ONE of the following:
      a. You are 2 to 5 years of age AND had a trial of or contraindication (harmful for) to ONE preferred agent: generic topiramate tablet/sprinkle, topiramate ER sprinkle
      b. You are 6 years of age or older AND had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

E. If you have migraines, approval also requires:
   1. You are 12 years of age or older
   2. Eprontia will be used as preventative treatment of migraines
   3. You had a trial of or contraindication (harmful for) to ONE preferred agent: Trokendi XR, generic topiramate tablet/sprinkle, topiramate ER sprinkle

Commercial Effective: 07/01/22
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOREMIFENE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOREMIFENE</td>
<td>FARESTON</td>
</tr>
<tr>
<td>CITRATE</td>
<td></td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named TOREMIFENE (Fareston) requires the following rule(s) be met for approval:

A. You have metastatic breast cancer (cancer has spread to other parts of body)
B. You are a postmenopausal female (already gone through menopause)
C. You have an estrogen-receptor positive or unknown tumor

Commercial Effective: 07/01/20
GUIDELINES FOR USE

Our guideline named **TORSEMIDE (Soaanz)** requires the following rule(s) be met for approval:

A. You have edema (swelling caused by fluid build-up in the body) associated with heart failure (a type of heart condition) or renal (kidney) disease
B. You are 18 years of age or older
C. You had a trial of or contraindication (harmful for) to **TWO** generic loop diuretics (such as furosemide, bumetanide)

Commercial Effective: 07/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TRALOKINUMAB-LDRM (Adbry) requires the following rule(s) be met for approval:
A. You have moderate to severe atopic dermatitis (a type of skin condition)
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
D. You have atopic dermatitis involving at least 10% of body surface area (BSA) OR atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)
E. You have TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
F. You had a trial of or contraindication (harmful for) to TWO of the following:
   1. High or super-high potency topical corticosteroid (such as triamcinolone acetonide, fluocinonide, clobetasol propionate)
   2. Topical calcineurin inhibitor (such as tacrolimus, Elidel [pimecrolimus])
   3. Topical PDE-4 inhibitor (Phosphodiesterase-4 Inhibitors such as Eucrisa [crisaborole])
   4. Topical JAK inhibitor (Janus kinase inhibitor such as Opzelura [ruxolitinib])
   5. Phototherapy (light therapy)
G. You had a trial of or contraindication (harmful for) to ONE preferred medication: Dupixent (dupilumab), Rinvoq (upadacitinib)
H. You will NOT use Adbry (tralokinumab-ldram) concurrently (at the same time) with other systemic biologics (such as Dupixent [dupilumab]) or any JAK inhibitors (Janus kinase inhibitor such as Cibinqo [abrocitinib], topical Opzelura [ruxolitinib], Rinvoq [upadacitinib]) for the treatment of atopic dermatitis

CONTINUED ON NEXT PAGE
GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TRALOKINUMAB-LDRM (Adbry) requires the following rule(s) be met for renewal:
A. You have moderate to severe atopic dermatitis (a type of skin condition)
B. You have shown improvement while on therapy
C. You had a trial of or contraindication (harmful for) to ONE preferred medication: Dupixent (dupilumab), Rinvoq (upadacitinib)
D. You will NOT use Adbry (tralokinumab-ldrm) concurrently (at the same time) with other systemic biologics (such as Dupixent [dupilumab]) or any JAK inhibitors (Janus kinase inhibitor such as Cibinqo [abrocitinib], topical Opzelura [ruxolitinib], Rinvoq [upadacitinib]) for the treatment of atopic dermatitis

Commercial Effective: 07/01/23
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRAMADOL HCL</td>
<td>QDolo, TRAMADOL HCL</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named TRAMADOL (Qdolo) requires the following rule(s) be met for approval:

A. The request is for the management of pain
B. You are 18 years of age or older
C. Your pain is severe enough to require an opioid analgesic (type of pain medication) and alternative treatments are inadequate
D. You had a trial of or contraindication (harmful for) to generic tramadol immediate-release (IR) tablet or a generic tramadol with acetaminophen product
E. You are unable to take oral solid formulations of tramadol or tramadol with acetaminophen (such as with difficulty swallowing)

Commercial Effective: 03/14/22
GUIDELINES FOR USE

Our guideline named TRAMETINIB (Mekinist) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed by surgery or has spread to other parts of the body)
   2. Metastatic non-small cell lung cancer (NSCLC: a type of lung cancer that has spread to other parts of the body)
   3. Melanoma (a type of skin cancer)
   4. Locally advanced or metastatic anaplastic thyroid cancer (ATC: a type of thyroid cancer that has spread from where it started to nearby tissue or lymph nodes or has spread to other parts of the body)
   5. Unresectable or metastatic solid tumor (tumor that cannot be removed by surgery or has spread to other parts of the body)
   6. Low-grade glioma (LGG: a type of brain cancer)

B. **If you have unresectable or metastatic melanoma, approval also requires:**
   1. You have a BRAF V600E or V600K mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
   2. The requested medication will be used as a single agent in a BRAF-inhibitor treatment-naïve patient (you have not been previously treated for this cancer) OR in combination with Tafinlar (dabrafenib)

C. **If you have metastatic non-small cell lung cancer, approval also requires:**
   1. You have a BRAF V600E mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
   2. The requested medication will be used in combination with Tafinlar (dabrafenib)

D. **If you have melanoma, approval also requires:**
   1. You have a BRAF V600E or V600K mutation (abnormal change in gene) as detected by a Food and Drug Administration (FDA)-approved test
   2. The requested medication will be used in combination with Tafinlar (dabrafenib)
   3. There is involvement of lymph node(s), following complete resection (surgical removal)

*Criteria continued on next page*

CONTINUED ON NEXT PAGE
TRAMETINIB

GUIDELINES FOR USE (CONTINUED)

E. If you have locally advanced or metastatic anaplastic thyroid cancer, approval also requires:
   1. You have a BRAF V600E mutation (abnormal change in gene)
   2. The requested medication will be used in combination with Tafinlar (dabrafenib)
   3. You do not have any satisfactory locoregional treatment options available (treatments that are focused on the affected area)

F. If you have an unresectable or metastatic solid tumor, approval also requires:
   1. You are 6 years of age or older
   2. You have a BRAF V600E mutation (abnormal change in gene)
   3. The requested medication will be used in combination with Tafinlar (dabrafenib)
   4. You have progressed following prior treatment and have no satisfactory alternative treatment options

G. If you have low-grade glioma, approval also requires:
   1. You are 1 to 17 years of age
   2. You have a BRAF V600E mutation (abnormal change in gene)
   3. The requested medication will be used in combination with Tafinlar (dabrafenib)
   4. You require systemic therapy (treatment that targets the entire body)

H. If the request is for the oral solution, approval also requires:
   1. You are unable to swallow Mekinist (trametinib) tablets

Commercial Effective: 06/12/23
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TREPROSTINIL INHALED

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TREPROSTINIL</td>
<td>TYVASO</td>
</tr>
<tr>
<td>TREPROSTINIL DPI</td>
<td>TYVASO DPI</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TREPROSTINIL INHALED (Tyvaso, Tyvaso DPI) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO: Group 1: a way to classify the severity of disease)

B. If you have PAH (WHO Group 1), approval also requires:
   1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units
   3. You had a trial of or contraindication (harmful for) to TWO of the following medications from different drug classes:
      a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
      b. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
      c. Oral cGMP stimulator (such as Adempas [riociguat])
      d. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [treprostinil])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/26/2023

Page 626 of 675
INITIAL CRITERIA (CONTINUED)

C. If you have PH-ILD (WHO Group 3), approval also requires:
   1. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
   2. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart
      a. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
      b. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
      c. Pulmonary vascular resistance (PVR) greater than 2 Wood units

RENEWAL CRITERIA

Our guideline named TREPROSTINIL INHALED (Tyvaso, Tyvaso DPI) requires the following rule(s) be met for renewal:
A. You have ONE of the following diagnoses:
   1. Pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO: Group 1: a way to classify the severity of disease)
B. If you have PAH (WHO Group 1), renewal also requires ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)
C. If you have PH-ILD (WHO Group 3), renewal also requires ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remained stable in the 6-minute walk distance test

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TREPROSTINIL INJECTABLE (Remodulin) requires the following rule(s) be met for approval:
A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
D. For new start requests of Remodulin (treprostinil), approval also requires ONE of the following:
   1. You are intermediate or high risk
   2. You had a trial of or contraindication (harmful for) to TWO of the following medications from different drug classes:
      a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
      b. Oral phosphodiesterase-5 inhibitor (such as Revatio [sildenafil], Adcirca [tadalafil])
      c. Oral cGMP stimulator (such as Adempas [riociguat])
E. If you are continuing current therapy from a hospital discharge, there is no additional requirement for approval.

CONTINUED ON NEXT PAGE
RENEWAL CRITERIA

Our guideline named TREPROSTINIL INJECTABLE (Remodulin) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)

Commercial Effective: 07/01/23
TREPROSTINIL ORAL

Generic | Brand
---|---
TREPROSTINIL DIOLAMINE | ORENITRAM ER

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TREPROSTINIL ORAL (Orenitram) requires the following rule(s) be met for approval:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)

C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
   1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
   2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
   3. Pulmonary vascular resistance (PVR) greater than 2 Wood units (WU)

D. You do NOT have severe hepatic (liver) impairment

E. For new start requests of Orenitram (treprostinil), approval also requires:
   1. You had a trial of or contraindication (harmful for) to the preferred oral prostanooid: Uptravi
   2. You had a trial of or contraindication (harmful for) to TWO of the following medications from different drug classes:
      a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
      b. Oral phosphodiesterase-5 inhibitor for PAH (such as Revatio [sildenafil], Adcirca [tadalafil])
      c. Oral cGMP stimulator (such as Adempas [riociguat])
      d. Intravenous or subcutaneous prostacyclin (such as Flolan [epoprostenol], Remodulin [Treprostinil])

F. If you are continuing current therapy from a hospital discharge, there is no additional requirement for approval.

CONTINUED ON NEXT PAGE
TREPROSTINIL ORAL

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named TREPROSTINIL ORAL (Orenitram) requires the following rule(s) be met for renewal:

A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)

B. You meet ONE of the following:
   1. You have shown improvement from baseline in the 6-minute walk distance test
   2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TRIENTINE (Syprine, Clovique)** requires the following rule(s) be met for approval:

A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
B. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
C. You have a Leipzig score (a type of diagnostic score) of 4 or higher
D. You are willing to follow a diet avoiding high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
E. You had a trial of or contraindication (harmful for) to penicillamine (Depen, Cuprimine)

RENEWAL CRITERIA

Our guideline named **TRIENTINE (Syprine, Clovique)** requires the following rules be met for renewal:

A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
B. You have achieved a free serum copper (amount of copper in your blood) level of less than 10 mcg/dL

Commercial Effective: 05/08/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **TRIENTINE - CUVRIOR** requires the following rule(s) be met for approval:

A. You have Wilson's disease (a genetic disorder that leads to copper accumulation in the organs)
B. You are 18 years of age or older
C. You have a prior or current Leipzig score (a type of diagnostic score) of 4 or higher
D. You have a non-ceruloplasmin copper (NCC: a type of test to check copper levels) level between 50 to 150 mcg/L or a 24-hour urinary copper excretion (UCE: a type of test to check copper levels) between 100 to 500 mcg per 24 hours
E. Therapy is prescribed by or in consultation with a hepatologist (a type of liver doctor) or gastroenterologist (a type of digestive system doctor)
F. You are willing to maintain a diet that avoids high copper foods (such as shellfish, nuts, chocolate, mushrooms, organ meat)
G. You had a trial of penicillamine (Depen, Cuprimine) for at least one year prior to starting Cuvrior
H. You had a trial of trientine hydrochloride (Syprine)

RENEWAL CRITERIA

Our guideline named **TRIENTINE - CUVRIOR** requires the following rules be met for renewal:

A. You have Wilson’s disease (a genetic disorder that leads to copper accumulation in the organs)
B. Your body’s copper levels are monitored by a non-ceruloplasmin copper (NCC: a type of test to check copper levels) test or 24-hour urinary copper excretion (UCE: a type of test to check copper levels) test
TRIFLURIDINE/TIPIRACIL

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRIFLURIDINE/TIPIRACIL</td>
<td>LONSURF</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named TRIFLURIDINE/TIPIRACIL (Lonsurf) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Metastatic colorectal cancer (a type of digestive system cancer that has spread to other parts of the body)
   2. Metastatic gastric or gastroesophageal junction adenocarcinoma (a type of digestive system cancer that has spread to other parts of the body)

B. If you have metastatic colorectal cancer, approval also requires:
   1. You are 18 years of age or older
   2. You had previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy (drugs used to treat cancer) in combination with an anti-VEGF biological therapy such as Avastin (bevacizumab), Zaltrap (ziv-aflibercept), or Cyramza (ramucirumab)
   3. If your metastatic colorectal cancer is RAS wild-type (a type of gene), you also had a previous treatment with an anti-EGFR agent such as Erbitux (cetuximab), Vectibix (panitumumab)

C. If you have metastatic gastric or gastroesophageal junction adenocarcinoma, approval also requires:
   A. You are 18 years of age or older
   B. You had previous treatment with at least two prior lines of chemotherapy (drugs used to treat cancer) that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2 (type of gene)/neu-targeted therapy

Commercial Effective: 04/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named TRIHEPTANOIN (Dojolvi) requires the following rule(s) be met for approval:

A. You have a long-chain fatty acid oxidation disorder (LC-FAOD: rare, genetic disorder that affects how the body breaks down fat)
B. Your diagnosis is confirmed by documentation of at least TWO of the following:
   1. Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma
   2. Low enzyme activity in cultured fibroblasts
   3. One or more known pathogenic mutations in CPT2, ACADVL, HADHA, or HADHB
C. You are symptomatic for LC-FAOD (for example you have rhabdomyolysis [break down of muscle tissue] or cardiomyopathy [disease of the heart muscle])
D. Therapy is prescribed by or given in consultation with a gastroenterologist (digestive tract doctor) or physician specialist in medical genetics/inherited metabolic disorders
E. You have previously tried commercial MCT oil (a medical food product) unless there is a medical reason you are unable to (contraindication)

RENEWAL CRITERIA

Our guideline named TRIHEPTANOIN (Dojolvi) requires the following rule(s) be met for renewal:

A. You have a long-chain fatty acid oxidation disorder (LC-FAOD: rare, genetic disorder that affects how the body breaks down fat)
B. You had a positive clinical response (such as improved exercise tolerance) or stabilization of clinical status compared to baseline

Commercial Effective: 01/01/21
GUIDELINES FOR USE

Our guideline named TROFINETIDE (Daybue) requires the following rule(s) be met for approval:
A. You have Rett syndrome (a type of nervous system disorder)
B. You are 2 years of age or older

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named T: SLIM/MINIMED INSULIN PUMPS requires the following rule(s) be met for approval:

A. The requested insulin pump is prescribed by or given in consultation with an endocrinologist (hormone doctor)
B. You have completed a comprehensive diabetes education program within the previous 24 months
C. You follow a maintenance program of at least 3 injections of insulin per day and require frequent self-adjustments of your insulin dose for the past 6 months
D. You require glucose self-testing of at least 4 times per day on average in the previous 2 months
E. You have not received an insulin pump within the last 4 years (Exception: your pump is malfunctioning, not repairable, and not under warranty)
F. You are on a multiple daily insulin injection regimen and meet ONE of the following:
   1. You have a glycosylated hemoglobin level (HbA1c: measure of how well controlled your blood sugar has been over a period of about 3 months) greater than 7 percent
   2. You have a history of recurring hypoglycemia (low blood sugar)
   3. You have wide fluctuations in blood sugar before mealtime
   4. You experience the dawn phenomenon (abnormal early morning increase in blood sugar, usually between 2 a.m. and 8 a.m.) with fasting blood glucose levels frequently exceeding 200 mg/dL
   5. You have a history of severe glycemic excursions (sudden spikes in blood sugar levels)
G. If you are requesting the T: Slim X2 OR T: Slim X2 with Basal-IQ, approval also requires:
   1. You are 6 years of age or older
H. If you are requesting the T: Slim X2 with Control-IQ, approval also requires:
   1. You are 6 years of age or older

(Criteria continued on next page)
GUIDELINES FOR USE (CONTINUED)

I. If you are requesting the MiniMed 670G, approval also requires:
   1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
   2. You are 7 years of age or older

J. If you are requesting the MiniMed 770G, approval also requires:
   1. You have type 1 diabetes mellitus (a disorder with high blood sugar)
   2. You are 2 years of age or older

Commercial Effective: 10/01/22
GUIDELINES FOR USE

Our guideline named TUCATINIB (Tukysa) requires the following rule(s) be met for approval:
A. You have ONE of the following diagnoses:
   1. Advanced unresectable (cannot be removed with surgery) or metastatic (disease that has spread to other parts of the body) human epidermal growth factor receptor 2 (HER2: type of protein)-positive breast cancer
   2. RAS wild-type (a type of gene), HER2-positive unresectable or metastatic colorectal cancer (a type of digestive cancer)
B. If you have advanced unresectable or metastatic HER2-positive breast cancer, approval also requires:
   1. You are 18 years of age or older
   2. You have received one or more prior anti-HER2-based treatment (specifically either trastuzumab or trastuzumab with pertuzumab) for metastatic disease
   3. The requested medication will be used in combination with trastuzumab and capecitabine
C. If you have RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer, approval also requires:
   1. You are 18 years of age or older
   2. Your cancer has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy (drugs used to treat cancer)
   3. The requested medication will be used in combination with trastuzumab

Commercial Effective: 02/06/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named UBROGEPANT (Ubrelvy) requires the following rule(s) be met for approval:
A. You are being treated for acute (quick onset) migraine
B. You are 18 years of age or older
C. You have previously tried ONE triptan (such as sumatriptan, rizatriptan), unless there is a medical reason why you cannot (contraindication)

RENEWAL CRITERIA

Our guideline named UBROGEPANT (Ubrelvy) requires the following rule(s) be met for approval:
A. You are being treated for acute (quick onset) migraine
B. You meet ONE of the following:
   1. You have experienced an improvement from baseline in a validated acute treatment patient-reported outcome questionnaire (assessment tool used to help guide treatment such as migraine assessment of current therapy [MIGRAINE-ACT])
   2. You have experienced clinical improvement as defined by ONE of the following:
      a. Ability to function normally within 2 hours of dose
      b. Headache pain disappears within 2 hours of dose
      c. Treatment works consistently in majority of migraine attacks

Commercial Effective: 01/01/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named UPADACITINIB (Rinvoq) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: type of joint condition)
   2. Psoriatic arthritis (PsA: type of skin and joint condition)
   3. Moderate to severe atopic dermatitis (a type of skin condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Ankylosing spondylitis (AS: a type of joint condition)
   7. Non-radiographic axial spondyloarthritis (NR-axSpA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor)
   3. You have tried or have a contraindication (harmful for) to 3 months of treatment with ONE DMARD (disease-modifying antirheumatic drugs), such as methotrexate dose greater than or equal to 20mg per week or maximally tolerated dose, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Enbrel [etanercept])

C. If you have psoriatic arthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor) or dermatologist (skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Enbrel [etanercept])

(Initial criteria continued on next page)

CONTINUED ON NEXT PAGE
UPADACITINIB

INITIAL CRITERIA (CONTINUED)

D. **If you have moderate to severe atopic dermatitis, approval also requires:**
   1. You are 12 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (a type of skin doctor), allergist (a type of allergy doctor), or immunologist (a type of immune system doctor)
   3. You have at least TWO of the following: intractable pruritus (severe itching), cracking and oozing/bleeding of affected skin, impaired activities of daily living
   4. You had a trial of or contraindication (harmful for) to ONE of the following: topical corticosteroid (such as hydrocortisone, clobetasol, halobetasol propionate), topical calcineurin inhibitor (such as Elidel [pimecrolimus], Protopic [tacrolimus]), topical PDE-4 inhibitor (such as Eucrisa [crisaborole]), topical JAK inhibitor (such as Opzelura [ruxolitinib]), phototherapy (light therapy)
   5. You will NOT use Rinvoq (upadacitinib) concurrently (at the same time) with other systemic biologics (such as Adbry [tralokinumab-Idrm], Dupixent [dupilumab]) and any JAK inhibitors (such as topical Opzelura [ruxolitinib], Cibinqo [abrocitinib]) for the treatment of atopic dermatitis
   6. You meet ONE of the following:
      a. You were previously on another biologic (such as Adbry [tralokinumab-Idrm], Dupixent [dupilumab]) and switching to the requested drug
      b. You have atopic dermatitis involving at least 10% of body surface area (BSA)
      c. You have atopic dermatitis affecting the face, head, neck, hands, feet, groin, or intertriginous areas (between skin folds, the hands, feet, etc.)

E. **If you have moderate to severe ulcerative colitis, approval also requires:**
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (a doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab])

*(Initial criteria continued on next page)*

CONTINUED ON NEXT PAGE
UPADACITINIB

INITIAL CRITERIA (CONTINUED)

F. If you have moderate to severe Crohn's disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You had a trial of or contraindication (harmful for) to ONE standard therapy, such as corticosteroids (such as budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Stelara [ustekinumab])

G. If you have ankylosing spondylitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor)
   3. You had a trial of or contraindication (harmful for) to an NSAID (nonsteroidal anti-inflammatory drug, such as ibuprofen, naproxen, meloxicam)
   4. You had an inadequate response (drug did not work) or intolerance (side effect) to one or more tumor necrosis factor (TNF) blockers (such as Humira [adalimumab], Enbrel [etanercept])

H. If you have non-radiographic axial spondyloarthritis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (a type of immune system doctor)
   3. You had an inadequate response (drug did not work) or intolerance (side effect) to at least ONE tumor necrosis factor (TNF) blockers (such as Cimzia [certolizumab])
   4. You had a trial of or contraindication (harmful for) to an NSAID (non-steroidal anti-inflammatory drug: such as ibuprofen, naproxen, meloxicam)
   5. You meet ONE of the following:
      a. You have previously on another biologic (such as Cimzia [certolizumab]) and switching to the requested drug
      b. You have C-reactive protein (CRP: a measure of how much inflammation you have) levels above the upper limit of normal
      c. You have sacroiliitis (type of inflammation where lower spine and pelvis connect) on magnetic resonance imaging (MRI: type of imaging lab)

CONTINUED ON NEXT PAGE
UPADACITINIB

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

Our guideline named UPADACITINIB (Rinvoq) requires the following rule(s) be met for renewal:

A. You have ONE of the following diagnoses:
   1. Moderate to severe rheumatoid arthritis (RA: type of joint condition)
   2. Psoriatic arthritis (PsA: a type of skin and joint condition)
   3. Moderate to severe atopic dermatitis (a type of skin condition)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)
   5. Moderate to severe Crohn's disease (CD: a type of bowel disorder)
   6. Ankylosing spondylitis (AS: a type of joint condition)
   7. Non-radiographic axial spondyloarthritis (NR-axSpA: a type of joint condition)

B. If you have moderate to severe rheumatoid arthritis or psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

C. If you have moderate to severe atopic dermatitis, renewal also requires:
   1. You have shown improvement while on therapy
   2. You will NOT use Rinvoq (upadacitinib) concurrently (at the same time) with other systemic biologics (such as Adbyr [tralokinumab-ldrm], Dupixent [dupilumab]) or any JAK inhibitors (such as topical Opzelura [ruxolitinib], Cibinqo [abrocitinib]) for the treatment of atopic dermatitis

D. If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis, renewal also requires:
   1. You have experienced or maintained an improvement of at least 50% or 2 units (scale of 1-10) in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI: diagnostic test which allows a physician to determine the effectiveness of a current medication) score while on therapy

Commercial Effective: 07/01/23
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **URIDINE TRIACETATE (Xuriden)** requires the following rule(s) be met for approval:

A. You have hereditary orotic aciduria (HOA: genetic disease where you do not have a type of protein to make a chemical)

B. Your diagnosis is confirmed by ALL of the following:
   1. Presence of a mutation in the uridine monophosphate synthase (UMPS) gene
   2. Elevated urinary orotic acid levels according to your age-specific reference range

C. Therapy is prescribed by or given in consultation with a doctor specializing in inherited metabolic diseases (genetic diseases that result in metabolism problems)

RENEWAL CRITERIA

Our guideline named **URIDINE TRIACETATE (Xuriden)** requires the following rule(s) to be met for renewal:

A. Your age dependent hematologic parameters (blood lab tests) have stabilized or improved from baseline while on treatment with Xuriden (uridine triacetate).
GUIDELINES FOR USE

Our guideline named URSODIOL (Reltone) requires the following rule(s) be met for approval:

E. You have radiolucent, noncalcified gallbladder stones (hardened deposits of bile, that is barely visible on x-ray, in your gallbladder that do not contain calcium)
F. Your gallbladder stones are less than 20 mm in diameter
G. You plan to have elective cholecystectomy (surgery to remove gallbladder) unless you are at increased surgical risk due to systemic (entire body) disease, advanced age, or idiosyncratic reaction (an unexpected adverse reaction) to general anesthesia, OR you refuse surgery
H. You have tried generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet)
I. You are unable to take generic ursodiol (300mg capsule, 250mg tablet, or 500mg tablet) formulations

Commercial Effective: 04/01/22
USTEKINUMAB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>USTEKINUMAB</td>
<td>STELARA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named **USTEKINUMAB (Stelara)** requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (PsA: a type of skin and joint condition)
   2. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   3. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)
   4. Moderate to severe active ulcerative colitis (UC: a type of digestive disorder)

B. **If you have moderate to severe plaque psoriasis, approval also requires:**
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a dermatologist (type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE or more forms of standard therapies, such as PUVA (Phototherapy Ultraviolet Light A), UVB (Ultraviolet Light B), topical corticosteroids (such as betamethasone dipropionate, clobetasol propionate), calcipotriene, acitretin, methotrexate, or cyclosporine
   4. You meet ONE of the following:
      a. You were previously stable on another biologic (such as Cimzia [certolizumab], Cosentyx [secukinumab]) and are switching to the requested drug
      b. You have psoriasis covering 3% or more of body surface area (BSA)
      c. You have psoriatic lesions (rashes) affecting the hands, feet, genital area, or face

C. **If you have psoriatic arthritis, approval also requires:**
   1. You are 6 years of age or older
   2. Therapy is prescribed by or in consultation with a rheumatologist (type of immune system doctor) OR dermatologist (type of skin doctor)
   3. You have tried or have a contraindication (harmful for) to ONE DMARD (disease-modifying antirheumatic drug), such as methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine

*Initial criteria continued on next page*
USTEKINUMAB

INITIAL CRITERIA (CONTINUED)

D. If you have moderate to severe Crohn’s disease, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

E. If you have moderate to severe active ulcerative colitis, approval also requires:
   1. You are 18 years of age or older
   2. Therapy is prescribed by or in consultation with a gastroenterologist (doctor who treats digestive conditions)
   3. You have tried or have a contraindication (harmful for) to ONE standard therapy, such as corticosteroids (budesonide, methylprednisolone), azathioprine, mercaptopurine, methotrexate, or mesalamine

RENEWAL CRITERIA

Our guideline named USTEKINUMAB (Stelara) requires the following rules be met for renewal:

A. You have ONE of the following diagnoses:
   1. Psoriatic arthritis (PsA: a type of skin and joint condition)
   2. Moderate to severe plaque psoriasis (PsO: a type of skin condition)
   3. Moderate to severe Crohn’s disease (CD: a type of bowel disorder)
   4. Moderate to severe ulcerative colitis (UC: a type of digestive disorder)

B. If you have psoriatic arthritis, renewal also requires:
   1. You have experienced or maintained a 20% or greater improvement in tender joint count or swollen joint count while on therapy

C. If you have moderate to severe plaque psoriasis, renewal also requires:
   1. You have achieved or maintained clear or minimal disease OR a decrease in PASI (Psoriasis Area and Severity Index) of at least 50% or more

Commercial Effective: 07/01/23
GUIDELINES FOR USE

Our guideline named VALBENAZINE (Ingrezza) requires the following rule(s) be met for approval:
A. You have moderate to severe tardive dyskinesia (uncontrolled body movements) AND it has been present for at least 3 months
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor), movement disorder specialist, or psychiatrist (a type of mental health doctor)
D. You have a history of using antipsychotic medications or metoclopramide for at least 3 months (or at least 1 month if you are 60 years of age or older) as documented in your prescription claims history
E. You had a trial of or contraindication (harmful for) to Austedo

Commercial Effective: 04/01/22
VANDETANIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>VANDETANIB</td>
<td>CAPRELSA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline for VANDETANIB (Caprelsa) requires ONE of the following rule(s) be met for approval:
A. You are currently stable on the requested medication
B. You have symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease (advanced thyroid cancer that cannot be removed with surgery or has spread in body)

Commercial Effective: 04/10/21
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named VARENICLINE (Tyrvaya) requires the following rule(s) be met for approval:
A. You have dry eye disease
B. You are 18 years of age or older
C. Therapy is prescribed by or in consultation with an ophthalmologist or optometrist (types of eye doctor)
D. You have at least one positive diagnostic test (such as tear breakup time, tear film osmolarity, ocular surfacing staining, Schirmer test)
E. You had a trial of or contraindication to (harmful for) to ONE ocular lubricant (such as carboxymethylcellulose [Refresh, Celluvisc, Thera Tears, Genteal, etc.], polyvinyl alcohol [Liquitears, Refresh Classic], or wetting agents [Systane, Lacrilube])
F. You had a trial of or contraindication to (harmful for) BOTH of the following preferred agents: Restasis (cyclosporine) AND Xiidra (lifitegrast)

RENEWAL CRITERIA

Our guideline named VARENICLINE (Tyrvaya) requires the following rule(s) be met for renewal:
A. You have dry eye disease
B. You have demonstrated improvement of dry eye disease
Our guideline named VEMURAFENIB (Zelboraf) requires the following rules be met for approval:

A. You have ONE of the following diagnoses:
   1. Unresectable or metastatic melanoma (a type of skin cancer that cannot be removed with surgery or has spread to other parts of the body)
   2. Erdheim-Chester Disease (a type of multisystem mutation)

B. If you have unresectable or metastatic melanoma, approval also requires:
   1. You have a BRAF V600E mutation (a type of gene mutation) as detected by a Food and Drug Administration (FDA)-approved test
   2. Zelboraf will be used alone or in combination with Cotellic (cobimetinib)

C. If you have Erdheim-Chester Disease, approval also requires:
   1. You have a BRAF V600 mutation (a type of gene mutation)

VEMURAFENIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEMURAFENIB</td>
<td>ZELBORAF</td>
</tr>
</tbody>
</table>

Commercial Effective: 07/01/22
VENETOCLAX

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>VENETOCLAX</td>
<td>VENCLEXTA</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named VENETOCLAX (Venclexta) requires that the following rules are met for approval:

A. You have ONE of the following diagnoses:
   1. Chronic lymphocytic leukemia (CLL: type of blood and bone marrow cancer), small lymphocytic lymphoma (SLL: type of immune system cancer)
   2. Newly-diagnosed acute myeloid leukemia (AML: type of blood and bone marrow cancer with too many undeveloped white blood cells)

B. If you have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), approval also requires:
   1. You are 18 years of age or older

C. If you have newly-diagnosed acute myeloid leukemia (AML), approval also requires:
   1. You are 75 years of age or older, OR you are 18 years of age or older with comorbidities (additional diseases) that preclude (prevent) the use of intensive induction chemotherapy
   2. The requested medication will be used in combination with azacitidine or decitabine or low-dose cytarabine

Commercial Effective: 07/01/20
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named VERICIGUAT (Verquvo) requires the following rule(s) be met for approval:
A. You have chronic heart failure
B. You have an ejection fraction (measurement of how well your heart pumps out blood with each heartbeat) of less than 45%
C. You are 18 years of age or older
D. You will not be taking Verquvo together with long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (such as vardenafil, tadalafil)
E. You have previously tried ONE of the following sodium-glucose transporter-2 inhibitors (SGLT-2 inhibitors: class of drugs) unless there is a medical reason why you cannot (contraindication): Farxiga, Xigduo XR, Jardiance, Synjardy
F. You have previously tried ONE agent from EACH of the following classes unless there is a medical reason why you cannot (contraindication):
1. Angiotensin converting enzyme (ACE) inhibitors (such as enalapril, lisinopril), angiotensin II receptor blockers (ARB: such as valsartan, candesartan), or angiotensin receptor-neprilysin inhibitor (ARNI: such as sacubitril/valsartan)
2. Beta-blocker (bisoprolol, carvedilol, metoprolol succinate)
3. Aldosterone antagonists (spironolactone or eplerenone)

RENEWAL CRITERIA

Our guideline named VERICIGUAT (Verquvo) requires the following rule(s) be met for renewal:
A. You have chronic heart failure
B. You have an ejection fraction (measurement of how well your heart pumps out blood with each heartbeat) of less than 45%
C. You will not be taking Verquvo together with long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (such as vardenafil, tadalafil)

Commercial Effective: 02/15/21
GUIDELINES FOR USE

Our guideline named **VIGABATRIN (Sabril, Vigadrone)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Refractory complex partial seizures (a type of seizure)
   2. Infantile spasms (a type of seizure disorder in infancy and childhood)

B. **If you have refractory complex partial seizures, approval also requires:**
   1. You are 2 years of age or older
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. The requested medication will be used as adjunctive (add-on) therapy
   4. The potential benefits outweigh the risk of vision loss
   5. You had a trial of or contraindication (harmful for) to THREE antiepileptic medications, at least two of which must be generic (seizure drugs such as carbamazepine, divalproex/valproic acid, oxcarbazepine, levetiracetam immediate-release/extended-release, gabapentin, zonisamide, topiramate, lamotrigine)

C. **If you have infantile spasms, approval also requires:**
   1. You are 1 month to 2 years of age
   2. Therapy is prescribed by or in consultation with a neurologist (a type of brain doctor)
   3. The requested medication will be used as monotherapy (one drug for treatment)
   4. The potential benefits outweigh the risk of vision loss

Commercial Effective: 05/22/23
### VISMODEGIB

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>VISMODEGIB</td>
<td>ERIVEDGE</td>
</tr>
</tbody>
</table>

**GUIDELINES FOR USE**

Our guideline named **VISMODEGIB (Erivedge)** requires the following rule(s) be met for approval:

A. You have metastatic basal cell carcinoma or locally advanced basal cell carcinoma (type of skin cancer that has spread in the body or is advanced but has not spread)

B. You are 18 years of age or older

C. **If you have locally advanced basal cell carcinoma, approval also requires:**
   1. Your cancer has returned after surgery OR you are not a candidate for surgery or radiation

---

Commercial Effective: 01/01/22
VOCLOSPORIN

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>VOCLOSPORIN</td>
<td>LUPKYNIS</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named VOCLOSPORIN (Lupkynis) requires the following rule(s) be met for approval:
A. You have active lupus nephritis (LN: inflammation of the kidneys caused by lupus when the immune system attacks its own tissues)
B. You are 18 years of age or older
C. Therapy is prescribed by or given in consultation with a rheumatologist (doctor who specializes in conditions that affect the muscles and skeletal system, especially the joints) or nephrologist (doctor who specializes in the kidney)
D. The requested medication will be used in combination with a background immunosuppressive therapy regimen (such as mycophenolate mofetil, corticosteroids)

RENEWAL CRITERIA

Our guideline named VOCLOSPORIN (Lupkynis) requires the following rule(s) be met for renewal:
A. You have active lupus nephritis (LN: inflammation of the kidneys caused by lupus when the immune system attacks its own tissues)
B. You have improvement in renal response from baseline laboratory values (eGFR [measurement of kidney function] or proteinuria [level of protein in urine]) and/or clinical parameters (such as fluid retention, use of rescue drugs, glucocorticoid use)
GUIDELINES FOR USE

Our guideline named VONOPRAZAN (Voquezna) requires the following rule(s) be met for approval:
A. You are being treated for Helicobacter pylori (H. pylori: a type of bacteria) infection
B. You are 18 years of age or older
C. You had a trial of or contraindication (harmful for) to a bismuth-based quadruple regimen (bismuth/tetracycline/metronidazole plus proton pump inhibitor [PPI, such as omeprazole, lansoprazole])

Commercial Effective: 06/15/22
GUIDELINES FOR USE

Our guideline named VOSORITIDE (Voxzogo) requires the following rule(s) be met for approval:

A. You have achondroplasia (a type of bone condition)
B. You are 5 years of age or older
C. You have open epiphyses (the end part of a long bone)

Commercial Effective: 04/01/22
GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

Our guideline named VOXELOTOR (Oxbryta) requires the following rule(s) be met for approval:
A. You have sickle cell disease (a type of blood disorder)
B. You are 4 years of age or older
C. Your hemoglobin (a type of blood cell) is less than 10.5 g/dL
D. Therapy is prescribed by or in consultation with a hematologist (a type of blood doctor)
E. You are having symptoms of anemia (a type of blood condition) which are interfering with activities of daily living
F. You had a trial of or contraindication (harmful for) to hydroxyurea
G. If the request is for the 300 mg tablets for oral suspension, approval also requires ONE of the following:
   1. You weigh less than 40 kilograms
   2. You weigh 40 kilograms or more and meet ALL of the following:
      a. You have tried or have a contraindication (harmful for) to Oxbryta 500mg tablets
      b. You are unable to swallow Oxbryta 500mg tablets

RENEWAL CRITERIA

Our guideline named VOXELOTOR (Oxbryta) requires the following rule(s) be met for renewal:
A. You have sickle cell disease (a type of blood disorder)
B. You have maintained an improvement in symptoms associated with anemia (a type of blood condition)

Commercial Effective: 01/16/23
GUIDELINES FOR USE

Our guideline named ZANUBRUTINIB (Brukinsa) requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:
   1. Mantle cell lymphoma (MCL: type of white blood cell cancer)
   2. Waldenstrom's macroglobulinemia (WM: type of blood cancer)
   3. Relapsed or refractory marginal zone lymphoma (MZL: a type of blood cancer)
   4. Chronic lymphocytic leukemia (CLL: a type of blood cancer)
   5. Small lymphocytic lymphoma (SLL: a type of blood cancer)

B. You are 18 years of age or older

C. If you have Mantel cell lymphoma (MCL), approval also requires:
   1. You have previously received at least ONE prior therapy for mantle cell lymphoma

D. If you have relapsed or refractory marginal zone lymphoma (MZL), approval also requires:
   1. You have received at least ONE anti-CD20-based regimen (a type of blood cancer treatment plan)

Commercial Effective: 02/06/23
ZONISAMIDE

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZONISAMIDE</td>
<td>ZONISADE</td>
</tr>
</tbody>
</table>

GUIDELINES FOR USE

Our guideline named ZONISAMIDE (Zonisade) requires the following rule(s) be met for approval:
A. You have partial-onset seizures (a type of seizure)
B. You are 16 years of age or older
C. Zonisade will be used as adjunctive (add-on) treatment
D. You are unable to swallow to zonisamide capsules

Commercial Effective: 01/01/23
INDEX

A

ABALOPARATIDE ................................................................. 3
ABATACEPT - SQ ......................................................... 5
ABEMACICLIB ................................................................. 8
ABILIFY MYCITE ............................................................. 51
ABIRATERONE ACET, SUBMICRONIZED ....................... 10
ABIRATERONE ACETATE .................................................. 9
ABROCIITIB ................................................................. 11
ABSTRAL ................................................................. 224
ACALABRUTINIB ............................................................ 13
ACCUFER ................................................................. 225
ACETAMINOPHEN DAILY LIMIT OVERRIDE ............ 14
ACNE AGE RESTRICTION OVERRIDE ......................... 15
ACTEMRA - SQ ............................................................. 611
ACTHAR ................................................................. 132
ACTIK ................................................................. 229
ADAGRASTIS .............................................................. 16
ADALIMUMAB .............................................................. 17
ADAPALENE ................................................................. 15
ADAPALENE/BENZOYL PEROXIDE .............................. 15
ADBYR ................................................................. 621
ADCIRCA ................................................................. 574
ADDY ................................................................. 235
ADEMPAS ................................................................. 475
ADLARITY ................................................................. 172
ADLYXIN ................................................................. 255
AFATINIB DIMALEATE .................................................. 21
AFINITOR ................................................................. 213
AFINITOR DISPERZ ....................................................... 212
AFREZZA ................................................................. 283
AIMOVIG ................................................................. 204
AJOY ................................................................. 243
AKLIEF ................................................................. 15
ALEGENSA ................................................................. 22
ALECTINIB HCL .............................................................. 22
ALKINDI SPRINKLE ...................................................... 266
ALLERGEN EXTRACT - MIXED GRASS POLLEN .......... 24
ALLERGEN EXTRACT - SHORT RAGWEED POLLEN ...... 25
ALLERGEN EXTRACT - HOUSE DUST MITE ................. 23
ALLERGEN EXTRACT - TIMOTHY GRASS POLLEN ....... 26
ALPELISIB ................................................................. 27
ALPELISIB (VIJOICE) ....................................................... 28
ALTOPREV ................................................................. 569
ALTRENO ................................................................. 15
ALUNBRIG ................................................................. 91
ALYQ ................................................................. 574
AMANTADINE EXTENDED RELEASE ....................... 29
AMANTADINE HCL ......................................................... 29

AMBRISENTAN ................................................................. 30
AMIFAMPIRDINE .......................................................... 31
AMIKACIN LIPOosomal/NEB. ACCESSR ...................... 32
AMLODIPINE BENZoATE ............................................. 33
AMLODIPINE BESYLAte/CelecoxIB ............................. 34
AMPHETAMINE SULFATE ............................................ 35
AMPHETAMINE SULFATE ODT .................................. 36
AMPYRA ................................................................. 143
ANABOLIC STEROIDS .................................................. 37
ANDROL-50 ............................................................... 37
ANAKINRA ................................................................. 40
ANASTROZOLE ............................................................. 59
ANDRODERM .............................................................. 593
ANDROGEL ................................................................. 593
ANDROID ................................................................. 351
ANTI-OBEsITY AGENTS ................................................ 42
APALUTAMIDE ............................................................. 45
APOKYN ................................................................. 46
APOMORPHINE ............................................................. 46
APOMORPHINE - SL ...................................................... 47
APREMLAST ............................................................... 48
APRETEUD ................................................................. 460
ARANESP ................................................................. 144
ARAZLO ................................................................. 15
ARESTIN (NSA) ............................................................. 360
ARIKAYCE ................................................................. 32
ARIMIDEX ................................................................. 89
ARIPIPRAZOLE TABLETS WITH SENSOR ................. 51
AROMASIN ................................................................. 89
ASCENIV ................................................................. 276
ASCRIMINIB HYDROCHLORide .................................... 52
ASFOTASE ALFA ........................................................ 54
ASPARAGINASE ERWINIA-RYWN ................................ 53
ASPIRIN ................................................................. 58
ASPIRIN EC ................................................................. 58
ASPIRIN ER ................................................................. 56
ASPIRIN ZERO COST SHARE OVERRIDE ............... 58
ASPIRIN-OMEPRAZOLE .............................................. 57
ASPRUZYO SPRINKLE ................................................... 463
ATOGEPANT ............................................................... 59
ATORVALIQ ................................................................. 61
ATORVASTATIN CALCIUM ........................................... 569
ATORVASTATIN CALCIUM (ATORVALIQ) ................... 61
ATRALIN ................................................................. 15
AUBAGIO ................................................................. 590
AUSTEDO ................................................................. 162
AUSTEDO XR ............................................................... 162
AUVELELY ................................................................. 163
AVACOPAN ................................................................. 63
AVAPRITINIB ............................................................. 64
AVATROMBOPAG ........................................................ 65
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

AVITA ........................................... .15
AVONEX ........................................ 287
AVONEX PEN ................................... 287
AXIRON ......................................... 593
AXITINIB ......................................  67
AYYAKIT ........................................  64
AZACITIDINE ..................................  68
AZTREONAM INHALED ..........................  69
AZTREONAM LYSINE ...........................  69

B

BACLOFEN (FLEQSUHY) .......................... 70
BACLOFEN (LYVISPAH) ........................... 70
BACLOFEN (OZOBAX) ............................. 70
BAFIERTAM ................................... 367
BALVERSA ....................................... 203
BARICITINIB ...................................  71
BAXDELA ....................................... 158
BEDAQUILINE FUMARATE ......................... 73
BELIMUMAB - SQ ...............................  74
BELUMOSUDIL MESYLATE ......................... 76
BELVIQ ......................................... 332
BELVIQ XR ...................................... 332
BELZUTIFAN ...................................  77
BENLYSTA - SQ ..................................  74
BENRALIZUMAB (NSA) ..........................  78
BERINERT ......................................  96
BEROTRALSTAT HYDROCHLORIDE .................. 80
BESREMI ....................................... 483
BETaine ..........................................  81
BETASERON ..................................... 288
BETHKIS ........................................  610
BEXAROTENE SOFTGEL ............................ 82
BEXAROTENE TOPICAL GEL ....................... 82
BINIMETINIB ...................................  83
BISACODYL/PEG/ELECTROLYTES .................. 87
BIVIGAM (COMMERCIAL, NSA) .................... 276
BLOOD SUGAR DIAGNOSTIC ....................... 165
BLOOD SUGAR DIAGNOSTIC, DISC .................. 165
BLOOD SUGAR DIAGNOSTIC, DRUM .................. 165
BLOOD-GLUCOSE SENSOR .......................... 128
BLOOD-GLUCOSE SENSOR (CGM STEP) ............... 127
BLOOD-GLUCOSE TRANSMITTER ..................... 128
BLOOD-GLUCOSE TRANSMITTER (CGM STEP) ............ 127
BOLUS INSULIN PUMP, 200 UNIT ....................... 112
BOSENTAN ......................................  84
BOSULIF ........................................  86
BOSUTINIB ......................................  86
BOWEL PREP FOR CRC SCREENING ZERO COST OVERRIDE .......................... 87
BRAFTOVI ....................................... 195

Breast Cancer Prevention Zero Cost Share Override .......................... 89
BREMELANOTIDE ................................  90
BREXAFEMME ................................... 268
BRIGATINIB .....................................  91
BRODALUMAB ...................................  92
BRUKINSA ....................................... 661
BUDESONIDE (ORTIKOS) ........................... 94
BUDESONIDE (TARPEYO) ..........................  95
BUPHENYL ....................................... 528
BUPROPION HCL .................................  518
BYDUREON ...................................... 256
BYDUREON BCISE ................................ 256
BYDUREON PEN ................................ 256
BYETTA .......................................... 256
BYLVAY .......................................... 384
BYNFEZIA ....................................... 382

C

C1 ESTERASE INHIBITOR (BERINERT) .................. 96
C1 ESTERASE INHIBITOR (CINRYZE) .................. 97
C1 ESTERASE INHIBITOR (HAEGARDA) ................. 98
C1 ESTERASE INHIBITOR, RECOMBINANT ................. 99
CABLIVI ......................................... 103
CABOMETYX ..................................... 100
CABOTEGAVIR .................................... 460
CABOZANTINIB S-MALATE ......................... 100
CALQUENCE .....................................  13
CAMZYS ........................................  340
CAPECITABINE ................................... 101
CAPLACIZUMAB-YHDP ............................. 103
CAPMATINIB ...................................  104
CAPRELSA ....................................... 650
CAPSAICIN 8% PATCH ............................ 105
CARAC ......................................... 238
CARBAGLU ....................................... 108
CARBIDOPA/LEVDOPA ............................ 106
CARBOXYMETHYLCELLULOSE-CELLULOSE-CITRIC ACID .................. 107
CARGLUMIC ACID ............................... 108
CARIMUNE NF NANOFILTERED (COMMERCIAL, NSA) ............ 276

CAYSTON ........................................... 69
CELECOXIB (ELYXYB) ............................. 110
CENEGERMIN-BKBJ .............................. 111
CEOUR SIMPLICITY .............................. 112
CEOUR SIMPLICITY INSERTER .................... 112
CERITINIB ....................................... 114
CERTOLIZUMAB PEGOL ............................ 115
CGM STEP OVERRIDE ............................ 127
CHANTIX ........................................  518
CHENODAL ...................................... 120

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/26/2023
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may be based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

CHENODIOL .................................................. 120
CHOLBAM .................................................. 121
CHOLIC ACID ............................................... 121
CIALIS ....................................................... 573
CIBINOQ ...................................................... 11
CIMZIA ....................................................... 115
CINRYZE ...................................................... 97
CLADRIBINE .................................................. 122
CLASCOTERONE .............................................. 123
CLENPIQ ..................................................... 87
CLOBAZAM-SYMPAZAN .................................... 124
CLOVIO ........................................................ 632
COBIMETINIB FUMARATE .................................. 125
COLLAGENASE CLOSTRIDIIUM HIST .................. 126
COMETRIQ .................................................... 100
CONJUPRI ..................................................... 318
CONSENSI ..................................................... 34
CONTINUOUS BLOOD GLUCOSE SENSOR (CGM STEP) ........................................... 127
CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER ...................................................... 128
CONTINUOUS BLOOD-GLUCOSE METER/RECEIVER (CGM STEP) ................................ 127
CONTINUOUS BLOOD-GLUCOSE RECEIVER (CGM STEP) ............................................. 127
CONTINUOUS GLUCOSE MONITORS - STAND-ALONE .................................................... 128
CONTRACEPTIVE ZERO COPAY OVERRIDE ................................................................. 130
CONTRACEPTIVE, INTRAVAGINAL ......................... 130
CONTRACEPTIVES, IMPLANTABLE ......................... 130
CONTRACEPTIVES, INJECTABLE ......................... 130
CONTRACEPTIVES, INTRAVAGINAL, SYSTEMIC .... 130
CONTRACEPTIVES, ORAL .................................... 130
CONTRACEPTIVES, TRANSDERMAL .................... 130
CONTRAVERE .................................................. 42
COPAXONE .................................................... 252
COPIKTRA ...................................................... 179
CORTICOTROPIN .............................................. 132
COSENTYX ..................................................... 494
COTELIC ......................................................... 125
CRESEMBA ..................................................... 293
CRESTOR ......................................................... 569
CRIZOTINIB .................................................... 133
CUPRIMINE .................................................... 440
CUTAQUIG ..................................................... 276
CUVITRU ......................................................... 276
CUVRIOR ......................................................... 633
CYCLOSPORINE (VERKAZIA) .................................. 134
CYSTADANE .................................................... 81
CYSTARAN ...................................................... 136
CYSTEAMINE BITARTRATE .................................... 135
CYSTEAMINE HCL ............................................ 136

D ................................................................. 137
DABIGATRAN ETIXILATE MESALATE ...................... 137
DABRAFENIB MESYLATE .................................... 138
DACLATASVIR DIHYDROCHLORIDE ........................ 140
DACOMITINIB .................................................. 142
DALKINZA ....................................................... 140
DALFAMPRIDINE ............................................. 143
DARAPRIM ...................................................... 461
DARBEPOETIN ALFA IN POLYSORBATE .................... 144
DARIDOREXANT HCL ......................................... 146
DAROLUTAMIDE .............................................. 147
DASATINIB ...................................................... 149
DAURISMO ...................................................... 251
DAYBUE ......................................................... 636
DECITABINE .................................................... 150
DEFERASIROX .................................................. 151
DEFERPROME .................................................. 153
DEFEROXAMINE ............................................... 155
DEFLAZACORT ................................................... 156
DELAFLOXACIN ................................................. 158
DEPEN .......................................................... 440
DEPO-TESTOSTERONE ....................................... 595
DESCOVY ......................................................... 460
DESFERAL ....................................................... 155
DESIURUDIN .................................................... 160
DEUCRACITINIB ............................................... 161
DEUTETRABENAZINE ......................................... 162
DEXCOM G4 ....................................................... 128
DEXCOM G5 ....................................................... 128
DEXCOM G5-G4 SENSOR ................................... 128
DEXCOM G6 ....................................................... 127
DEXCOM G6 TRANSMITTER ................................ 127
DEXTROMETHORPHAN HBR/BUPROPION ................ 163
DEXTROMETHORPHAN HBR ................................ 164
DIABETIC SUPPLIES, MISCELL .................................. 112
DIABETIC TEST STRIPS ....................................... 165
DIACOMIT ......................................................... 571
DIAPHRAGMS/CERVICAL CAP ................................ 130
DIBENZYLINE ..................................................... 445
DICHLORPHENAMIDE ........................................ 166
DICLOFENAC SODIUM (PENNSAID) ......................... 168
DICLOFENAC SODIUM (SOLARAZE) ........................ 167
DIFFERIN ......................................................... 15
DIGOXIN ......................................................... 169
DIMETHYL FUMARATE ....................................... 170
DIROXIMEL FUMARATE ...................................... 171
DOJOLVI ........................................................ 635
DONEPEZIL HCL ................................................. 172
DOPTELET ......................................................... 65
DORNASE ALFA ............................................... 173
D-PENAMINE .................................................... 440
DRIZALMA SPRINKLE ....................................... 175
DROXIDOPA ...................................................... 174

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/26/2023

Page 665 of 675
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>DULAGlutide</td>
<td>256</td>
</tr>
<tr>
<td>DuLOXetine HCl (Drizalma Sprinkle)</td>
<td>175</td>
</tr>
<tr>
<td>DUOPA</td>
<td>106</td>
</tr>
<tr>
<td>DUPlIMAB</td>
<td>176</td>
</tr>
<tr>
<td>DUPIXENT</td>
<td>176</td>
</tr>
<tr>
<td>DURAGESIC</td>
<td>223</td>
</tr>
<tr>
<td>DURLAZA</td>
<td>56</td>
</tr>
<tr>
<td>DUVELISIB</td>
<td>179</td>
</tr>
<tr>
<td>EPronTIA</td>
<td>618</td>
</tr>
<tr>
<td>ERDafitinib</td>
<td>203</td>
</tr>
<tr>
<td>Erenumab-Aooe</td>
<td>204</td>
</tr>
<tr>
<td>Ergotamine TAtrate/Caffeine</td>
<td>206</td>
</tr>
<tr>
<td>Erivedge</td>
<td>656</td>
</tr>
<tr>
<td>ERLeada</td>
<td>45</td>
</tr>
<tr>
<td>Erlotinib HCl</td>
<td>207</td>
</tr>
<tr>
<td>ERMeza</td>
<td>322</td>
</tr>
<tr>
<td>ESBriE</td>
<td>448</td>
</tr>
<tr>
<td>ETanEcept</td>
<td>208</td>
</tr>
<tr>
<td>EthAcrylic ACid</td>
<td>211</td>
</tr>
<tr>
<td>EVEKEO</td>
<td>35</td>
</tr>
<tr>
<td>EVEKEO ODT</td>
<td>36</td>
</tr>
<tr>
<td>EVERolimus (Afinitor Disperz)</td>
<td>212</td>
</tr>
<tr>
<td>EVERolimus (Afinitor)</td>
<td>213</td>
</tr>
<tr>
<td>EVERsense Smart Transmitter</td>
<td>128</td>
</tr>
<tr>
<td>EVista</td>
<td>89</td>
</tr>
<tr>
<td>EVphysical DysFUNCTION</td>
<td>481</td>
</tr>
<tr>
<td>EXAlog</td>
<td>267</td>
</tr>
<tr>
<td>Excluded Formulary Drug Exception Criteria</td>
<td>215</td>
</tr>
<tr>
<td>EXEMestane</td>
<td>89</td>
</tr>
<tr>
<td>EXENatide</td>
<td>256</td>
</tr>
<tr>
<td>EXENatide Microspheres</td>
<td>256</td>
</tr>
<tr>
<td>EXJade</td>
<td>151</td>
</tr>
<tr>
<td>EKkivity</td>
<td>365</td>
</tr>
<tr>
<td>ExServaln</td>
<td>472</td>
</tr>
<tr>
<td>EXTavia</td>
<td>289</td>
</tr>
<tr>
<td>EYSvius</td>
<td>334</td>
</tr>
<tr>
<td>EzETIMibe/Simvastatin</td>
<td>514</td>
</tr>
<tr>
<td>FABIor</td>
<td>15</td>
</tr>
<tr>
<td>Fareston</td>
<td>619</td>
</tr>
<tr>
<td>Farydak</td>
<td>421</td>
</tr>
<tr>
<td>FASEnra (NSA)</td>
<td>78</td>
</tr>
<tr>
<td>Fecal MicroBio Spore, Live-BRpk</td>
<td>217</td>
</tr>
<tr>
<td>Fecal MicroBiota, Live-JSLM</td>
<td>218</td>
</tr>
<tr>
<td>FEdratinib DiHydrochloride</td>
<td>219</td>
</tr>
<tr>
<td>Fenfluramine</td>
<td>220</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>223</td>
</tr>
<tr>
<td>Fentanyl Citrate</td>
<td>224</td>
</tr>
<tr>
<td>Fentanyl Nasal Spray</td>
<td>221</td>
</tr>
<tr>
<td>Fentanyl Sublingual Spray</td>
<td>222</td>
</tr>
<tr>
<td>Fentanyl Transdermal Patch</td>
<td>223</td>
</tr>
<tr>
<td>Fentanyl Transmucosal Agents</td>
<td>224</td>
</tr>
<tr>
<td>Fentora</td>
<td>224</td>
</tr>
<tr>
<td>Ferric Maltol</td>
<td>225</td>
</tr>
<tr>
<td>Ferrprox</td>
<td>153</td>
</tr>
<tr>
<td>FeZolinetant</td>
<td>226</td>
</tr>
<tr>
<td>Filgrastim</td>
<td>227</td>
</tr>
<tr>
<td>Filgrastim-AAfi</td>
<td>228</td>
</tr>
</tbody>
</table>

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

FILGRASTIM-AWY………………………………………………………………………………… 229
FILGRASTIM-SNDZ………………………………………………………………………………… 230
FILSPARI……………………………………………………………………………………………… 568
FINASTERIDE/TADALAFIL…………………………………………………………………………… 231
FINERENONE………………………………………………………………………………………… 232
FINGOLIMOD………………………………………………………………………………………… 233
FINGOLIMOD LAURYL SULFATE………………………………………………………………… 234
FINTEPLA…………………………………………………………………………………………… 220
FIRAZYR…………………………………………………………………………………………… 270
FIRDAPSE…………………………………………………………………………………………… 31
FLASH GLUCOSE SCANNING READER (CGM STEP)………………………………………… 127
FLASH GLUCOSE SENSOR (CGM STEP)…………………………………………………………… 127
FLEBOGAMMA DIF (COMMERCIAL, NSA)……………………………………………………… 276
FLEGSUVY………………………………………………………………………………………… 70
FLIBANSERIN……………………………………………………………………………………… 235
FLOLIPID…………………………………………………………………………………………… 515
FLUORIDE (SODIUM) (FLUORIDE ZERO COST SHARE OVERRIDE)………………………… 237
FLUORIDE ZERO COST SHARE OVERRIDE…………………………………………………… 237
FLUORORPLEX……………………………………………………………………………………… 238
FLUOROURACIL 0.5%………………………………………………………………………………… 238
FLUOROURACIL 1%…………………………………………………………………………………. 238
FLUVASTATIN EXTENDED-RELEASE………………………………………………………… 569
FLUVASTATIN SODIUM…………………………………………………………………………… 569
FOLIC ACID………………………………………………………………………………………… 239
FOLIC ACID ZERO COST SHARE OVERRIDE…………………………………………………… 239
FORTEO……………………………………………………………………………………………… 591
FORTESTA………………………………………………………………………………………… 593
FOSDENOPTERIN HYDROBROMIDE……………………………………………………………… 240
FOSTAMATINIB……………………………………………………………………………………… 241
FOSTEMSAVIR……………………………………………………………………………………… 242
FOTIVDA…………………………………………………………………………………………… 609
FREESTYLE LIBRE 2, 10, & 14 SENSOR…………………………………………………………… 127
FREESTYLE LIBRE 2, 3, 10, & 14 SENSOR……………………………………………………… 127
FREMANEZUMAB-VFRM…………………………………………………………………………… 243
FULPHILA…………………………………………………………………………………………… 434
FUTIBATINIB………………………………………………………………………………………… 245
FYLMETRA…………………………………………………………………………………………… 435
GALAFOLD…………………………………………………………………………………………… 356
GALCANEZUMAB-GNLN………………………………………………………………………………… 246
GAMASTAN S-D (COMMERCIAL, NSA)…………………………………………………………… 276
GAMMAGARD LIQUID (COMMERCIAL, NSA)………………………………………………… 276
GAMMAGARD S-D (COMMERCIAL, NSA)……………………………………………………… 276
GAMMAKED (COMMERCIAL, NSA)……………………………………………………………… 276
GAMMAPLEX (COMMERCIAL, NSA)…………………………………………………………… 276
GAMUNEX-C (COMMERCIAL, NSA)……………………………………………………………… 276
GANAXOLONE……………………………………………………………………………………… 248
GATTLEX…………………………………………………………………………………………… 585
GAVILYTE-C………………………………………………………………………………………… 87
GAVILYTE-G………………………………………………………………………………………… 87
GAVILYTE-N, PEG 3350-ELECTROLYTE…………………………………………………………… 87
GAVRETO…………………………………………………………………………………………… 458
GEFITINIB…………………………………………………………………………………………… 249
GENOTROPIN………………………………………………………………………………………… 538
GILENYA……………………………………………………………………………………………. 233
GLIOTRIF……………………………………………………………………………………………… 21
GILTERNITIB FUMARATE…………………………………………………………………………… 250
GIMOTI………………………………………………………………………………………………… 353
GLASDEGIB MALEATE……………………………………………………………………………… 251
GLATIRAMER ACETATE…………………………………………………………………………… 252
GLATOPA……………………………………………………………………………………………… 252
GLECAPREVIR/PIBRENTASVIR……………………………………………………………………… 253
GLEEVEC…………………………………………………………………………………………… 273
GLEOSTINE………………………………………………………………………………………… 328
GLP-1 AGONIST (ADLYXIN)………………………………………………………………………… 255
GLP-1 STEP OVERRIDE…………………………………………………………………………… 256
GLUTAMINE (L-Glutamine)…………………………………………………………………………… 307
GLYCOLYPHYRON UV 2.4% CLOTH………………………………………………………………… 258
GOCCOFRI…………………………………………………………………………………………… 29
GOLIMUMAB - SQ…………………………………………………………………………………. 259
GOLYTELY…………………………………………………………………………………………… 87
GR POL-ORC/SW VER/RYE/KENT/TIM…………………………………………………………… 24
GRANIX……………………………………………………………………………………………… 584
GRASS POLLEN-TIMOTHY, STD…………………………………………………………………… 26
GRASTEK…………………………………………………………………………………………… 26
GUARDIAN 4 GLUCOSE SENSOR…………………………………………………………………… 128
GUARDIAN 4 TRANSMITTER……………………………………………………………………… 128
GUARDIAN CONNECT TRANSMITTER………………………………………………………… 128
GUARDIAN SENSOR 3……………………………………………………………………………… 128
GUSELKUMAB……………………………………………………………………………………… 263
H
HAEGARDA………………………………………………………………………………………… 98
HARVONI…………………………………………………………………………………………… 308
HEMLIBRA………………………………………………………………………………………… 193
HETLIOZ…………………………………………………………………………………………… 581
HETLIOZ LQ………………………………………………………………………………………… 581
HIZENTRA (COMMERCIAL, NSA)………………………………………………………………… 276
HOUSE DUST MITE………………………………………………………………………………… 23
HUMATROPE………………………………………………………………………………………… 542
HUMIRA……………………………………………………………………………………………… 17
HYDROCORTISONE………………………………………………………………………………… 266
HYDROMORPHONE HCL…………………………………………………………………………… 267
HYFTOR……………………………………………………………………………………………… 517
HYQVIA (COMMERCIAL, NSA)…………………………………………………………………… 276
I
IBRANCE…………………………………………………………………………………………… 420
IBREXAFUNGERP CITRATE………………………………………………………………………… 268
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

I

IBRUTINIB ........................................... 269
IBSRELA ............................................. 588
ICATIBANT ACETATE ........................... 270
ICLUSIG ........................................... 454
IDELALISIB ......................................... 271
IDHIFA ............................................... 194
IGG/HYALURONIDASE, RECOMBINANT
(COMMERCIAL, NSA) ....................... 268
ILOPROST TROMETHAMINE ................. 272
IMATINIB MESYLATE ......................... 273
IMBRUVICA .......................................... 269
IMCIVIRE ........................................... 504
IMMUN GLOB G(IGG)/GLY/IGA OV50 .... 276
IMMUN GLOB G(IGG)-HIPP/MALTOSE ... 276
IMMUN GLOB G(IGG)-IFAS/GLYCINE .... 276
IMMUNE GLOB, GAM CAPRYLATE (COMMERCIAL,
NSA) .................................................. 276
IMMUNE GLOBULIN (HUMAN)-KLHW ...... 276
IMMUNE GLOBULIN (HUMAN)-SLRA ...... 276
IMMUNE GLOBULIN / MALTOSE (COMMERCIAL, NSA)
 ...................................................... 276
IMMUNE GLOBULIN INTRAVENOUS (COMMERCIAL,
NSA) ................................................... 276
IMPAVIDO ............................................. 359
INBRIJA .............................................. 320
INCRELEX .......................................... 343
INDOCIN ............................................ 280
INDOCIN RECAT .................................. 279
INDOMETACIN (SUSPENSION) .............. 280
INDOMETACIN RECAT ......................... 279
INFAGRATIN PHOSPHATE .................... 281
INGENOL MEBATE ................................. 282
INGREZZA .......................................... 649
INHALED INSULIN .............................. 283
INLYTA .............................................. 67
INOTERSEN SODIUM .......................... 284
INQOVI .............................................. 150
INREBIC ............................................ 219
INSULIN REGULAR, HUMAN (AFREZZA) .. 283
INTERFERON ALFA-2B ......................... 285
INTERFERON BETA-1A .......................... 287
INTERFERON BETA-1A/ALBUMIN ........... 291
INTERFERON BETA-1B ......................... 288, 289
INTERFERON GAMMA-1B,RECOMB ......... 292
INTERFERONS FOR MS - AVONEX ........... 287
INTERFERONS FOR MS - BETASERON ... 288
INTERFERONS FOR MS - EXTAVIA ......... 289
INTERFERONS FOR MS - PLEGRIDY ....... 290
INTERFERONS FOR MS - REBIF .......... 291
INTRA-UTERINE DEVICES (IUD’S) ....... 130
INTRON A ........................................... 285
IPRIVASK .......................................... 160
IRESSA ............................................. 249
ISAVUCONAZOLIUM ............................. 293
ISTRADEFYLLINE .................................. 294
ISTURISA ........................................... 413
ITRACONAZOLE-TOLSURA .................. 295
IVACAFTOR ....................................... 296
IVOSIDENIB ....................................... 298
IXAZOMIB CITRATE ............................. 299
IXEKIZUMAB ................................. 300
J

JADENU ........................................... 151
JADENU SPRINKLE ............................... 151
JAKAFI ............................................. 485
JATENZO ........................................... 601
JAYPIRCA .......................................... 449
JOENJA ............................................. 312
JUBLIA ............................................. 181
JUXTAPID ......................................... 326
JYNARQUE ....................................... 617
K

KALYDECO ........................................... 296
KATERZIA .......................................... 33
KERENDIA ......................................... 232
KERYDIN .......................................... 582
KESIMPTA ......................................... 385
KEVEYS ............................................. 166
KEVZARA .......................................... 491
KINERET .......................................... 40
KISQALI ............................................. 468
KISQALI FEMARA CO-PACK ................. 469
KITABIS PAK ...................................... 610
KORLYM ............................................ 355
KOSSELUGO ....................................... 503
KRAZATI ........................................... 16
KYNAMRO ......................................... 361
KYNMOLI .......................................... 47
KYZATREX ....................................... 599, 601
L

LACTIC ACID/CITRIC/ POTASSIUM .......... 302
LANADELUMAB-FLOY .................................. 303
LAPATINIB DITOSYLATED ..................... 304
LAROTRECTINIB .................................... 305
LASMIDITAN SUCINATE ....................... 306
LAZANDA ........................................... 221
LEDIPASVIR/SOFOSBUVIR .................... 308
LEFAMULIN ....................................... 309
LENACAPAVIR SODIUM ........................ 310
LENALIDOMIDE .................................. 311
LENILOISIB PHOSPHATE ..................... 312

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
## STANDARD COMMERCIAL DRUG FORMULARY

**PRIOR AUTHORIZATION GUIDELINES**

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

| LENVATINIB MESYLATE | 313 |
| LENVIMA | 313 |
| LESCOL | 569 |
| LESCOL XL | 569 |
| LETAIRIS | 30 |
| LETERMOVIR PO | 314 |
| LEUKINE | 490 |
| LEUPROLIDE ACETATE (ELIGARD) | 317 |
| LEUPROLIDE ACETATE (GENERIC) | 315 |
| LEVAMLODIPINE MALEATE | 318 |
| LEVETIRACETAM (SPRITAM) | 319 |
| LEVODOPA | 320 |
| LEVOKETOCONAZOLE | 321 |
| LEVOTHYROXINE SODIUM (ERMEZA) | 322 |
| LEVOTHYROXINE SODIUM (TIROSINT-SOL) | 323, 324 |
| LIPITOR | 569 |
| LIXSEDAINE | 339 |
| LIQUID GLYCINE | 519 |
| LORZEPATADINE | 544 |
| LONGAFAAR | 336 |
| LONGAFAAR | 329 |
| LONGAFAAR | 330 |
| LONZURAD | 634 |
| LORBREGA | 333 |
| LORASERIN HCL | 332 |
| LORATEIN | 333 |
| LORATADINE | 334 |
| LORVASTATIN | 569 |
| LORVASTATIN EXTENDED-RELEASE | 569 |
| LUCEMYRA | 325 |
| LUDRENT FLUORIDE (FLUORIDE ZERO COST SHARE OVERRIDE) | 237 |
| LUMACAFTOR/IVACAFTOR | 335 |
| LUMAKRAS | 567 |
| LUMARY | 523 |
| LUPKYNIS | 657 |
| LUSUTROMBOPAG | 336 |
| LYBALVI | 386 |
| LYNPARZA | 387 |
| LYTGOBI | 245 |
| LYVISPAH | 70 |
| LIVARL | 569 |
| LIVMARLI | 338 |
| LIVITENCI | 339 |
| LIXSENATIDE | 255 |
| LOFEPIXIDE | 325 |
| LOMITAPIDE | 326 |
| LOMUSTINE | 328 |
| LONAFARNIB | 329 |
| LONAPGESMATROPIN-TG | 330 |
| LONSURF | 634 |
| LORBRAE | 333 |
| LORCASERIN HCL | 332 |
| LORLATINIB | 333 |
| LOPRENDONOL ETABONATE | 334 |
| LOVASTATIN | 569 |
| LOVASTATIN EXTENDED-RELEASE | 569 |
| LUCEMYRA | 325 |
| LUDRENT FLUORIDE (FLUORIDE ZERO COST SHARE OVERRIDE) | 237 |
| LUMACAFTOR/IVACAFTOR | 335 |
| LUMAKRAS | 567 |
| LUMARY | 523 |
| LUPKYNIS | 657 |
| LUSUTROMBOPAG | 336 |
| LYBALVI | 386 |
| LYNPARZA | 387 |
| LYTGOBI | 245 |
| LYVISPAH | 70 |
| M | 337 |
| MACEST | 338 |
| MABACAR | 339 |
| MAVACAMTN | 340 |
| MAVENCLAD | 122 |
| MAVYRET | 253 |
| MAYZENT | 516 |
| MEBENDAZOLE | 341 |
| MECAMYLAMINE HCL | 342 |
| MECASERMIN | 343 |
| MECHLORETHAMINE HCL | 344 |
| MEKINST | 624 |
| MEKTOVI | 83 |
| MEPOLIZUMAB | 345 |
| METCHET | 351 |
| METHOXO PEG-ETOSEL BETA | 348 |
| METHYLNA FORX BROMIDE | 350 |
| METHYLETOSTOSTERONE | 35 |
| METOCLOPRAMIDE | 353 |
| MIDOSTASURINE | 354 |
| MIFEPRISTONE | 355 |
| N | 356 |
| MIGALASTAT | 356 |
| MIGERGOT | 206 |
| MIGLUSTAT | 358 |
| MILTEFOSINE | 359 |
| MINIMED 670G | 637 |
| MINIMED 770G | 637 |
| MINOCYCLINE HCL MICROSPHERES (NSA) | 360 |
| MIPOMERSEN SODIUM | 361 |
| MIRABEGRON | 363 |
| MIRCERA | 348 |
| MITAPIVAT SULFATE | 364 |
| MOBOCERTINIB SUCCINATE | 365 |
| MOMETASONE FURATE (NSA) | 366 |
| MONOMETHYL FUMARATE | 367 |
| MORPHINE SULFATE | 265 |
| MOUNJARG | 256 |
| MOVIPREP | 87 |
| MULTPLEX | 336 |
| MYCASSA | 381 |
| MYFEMBREE | 466 |
| MYRBITRIQ | 363 |
| NAFARELIN ACETATE | 368 |
| NALTREXONE HCL/BUPROPION HCL | 42 |
| NATESTO | 593 |
| NATPARA | 422 |
| NERATINIB MALEATE | 370 |
| NERLYN | 370 |
| NEULASTA | 429 |
| NEULASTA ONPRO | 429 |
| NEUPOGEN | 227 |
| NEXAVAR | 56 |
| NICODERM CQ | 518 |
| NICORETTE | 518 |

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/26/2023
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>NICOTINE</td>
<td>518</td>
</tr>
<tr>
<td>NICOTINE GUM</td>
<td>518</td>
</tr>
<tr>
<td>NICOTINE LOZENGE</td>
<td>518</td>
</tr>
<tr>
<td>NICOTINE PATCH</td>
<td>518</td>
</tr>
<tr>
<td>NICOTINE POLACRILEX</td>
<td>518</td>
</tr>
<tr>
<td>NICTROL</td>
<td>518</td>
</tr>
<tr>
<td>NICTROL NS</td>
<td>518</td>
</tr>
<tr>
<td>NILOTINIB HCL</td>
<td>371</td>
</tr>
<tr>
<td>NIMODIPINE</td>
<td>372</td>
</tr>
<tr>
<td>NINLARO</td>
<td>299</td>
</tr>
<tr>
<td>NINTEDANIB</td>
<td>373</td>
</tr>
<tr>
<td>NIRAFLIB TOSYLALE</td>
<td>376</td>
</tr>
<tr>
<td>NITISINONE</td>
<td>377</td>
</tr>
<tr>
<td>NITYR</td>
<td>377</td>
</tr>
<tr>
<td>NIVESTYM</td>
<td>228</td>
</tr>
<tr>
<td>NORDITROPIN FLEXPRO</td>
<td>546</td>
</tr>
<tr>
<td>NORTHERA</td>
<td>174</td>
</tr>
<tr>
<td>NOURIAZ</td>
<td>294</td>
</tr>
<tr>
<td>NOXAFIL</td>
<td>456</td>
</tr>
<tr>
<td>NTS</td>
<td>518</td>
</tr>
<tr>
<td>NUBEQ</td>
<td>147</td>
</tr>
<tr>
<td>NUCALA</td>
<td>345</td>
</tr>
<tr>
<td>NUEDEXTA</td>
<td>164</td>
</tr>
<tr>
<td>NULIBRY</td>
<td>240</td>
</tr>
<tr>
<td>NULYTELY</td>
<td>87</td>
</tr>
<tr>
<td>NUPLAZID</td>
<td>447</td>
</tr>
<tr>
<td>NURTEC ODT</td>
<td>473</td>
</tr>
<tr>
<td>NUTROPIN AQ NUSPIN</td>
<td>550</td>
</tr>
<tr>
<td>NUZYRA</td>
<td>392</td>
</tr>
<tr>
<td>NYMALIZE</td>
<td>372</td>
</tr>
<tr>
<td>NYVEPRIA</td>
<td>430</td>
</tr>
<tr>
<td>OMAVELOXOLONE</td>
<td>397</td>
</tr>
<tr>
<td>OMBITASVIR/PARITAPREVIR/RITONAVIR</td>
<td>398</td>
</tr>
<tr>
<td>OMBITASVIR/PARITAPREVIR/RITONAVIR/DASABUVIR</td>
<td>400</td>
</tr>
<tr>
<td>OMNITROPE</td>
<td>553</td>
</tr>
<tr>
<td>ONGENTYS</td>
<td>402</td>
</tr>
<tr>
<td>ONUREG</td>
<td>68</td>
</tr>
<tr>
<td>OPICAPONE</td>
<td>402</td>
</tr>
<tr>
<td>OPIOID CUMULATIVE DOSING OVERRIDE</td>
<td>406</td>
</tr>
<tr>
<td>OPIOID LONG-ACTING DUPLICATIVE THERAPY</td>
<td>407</td>
</tr>
<tr>
<td>OPIOID NAIVE FILL LIMIT</td>
<td>410</td>
</tr>
<tr>
<td>OPIOID SINGLE CLAIM DOSING AT POS (OSCDP)</td>
<td>411</td>
</tr>
<tr>
<td>OPIOID-ANTIPSYCHOTIC CONCURRENT USE</td>
<td>403</td>
</tr>
<tr>
<td>OPIOID-BENZODIAZEPINE CONCURRENT USE</td>
<td>404</td>
</tr>
<tr>
<td>OPIOID-BUPRENORPHINE CONCURRENT USE</td>
<td>405</td>
</tr>
<tr>
<td>OPIOID-NAIVE CUMULATIVE DOSING</td>
<td>408</td>
</tr>
<tr>
<td>OPIOID-NAIVE DAY SUPPLY LIMITATION</td>
<td>409</td>
</tr>
<tr>
<td>OPIOID-SOMA-BENZODIAZEPINE CONCURRENT USE</td>
<td>412</td>
</tr>
<tr>
<td>OPZELURA</td>
<td>487</td>
</tr>
<tr>
<td>ORALAIR</td>
<td>24</td>
</tr>
<tr>
<td>ORENCIA - SQ</td>
<td>5</td>
</tr>
<tr>
<td>ORENCIA CLICKJECT - SQ</td>
<td>5</td>
</tr>
<tr>
<td>ORENITRAM ER</td>
<td>630</td>
</tr>
<tr>
<td>ORFADIN</td>
<td>377</td>
</tr>
<tr>
<td>ORGOVYX</td>
<td>465</td>
</tr>
<tr>
<td>ORIADIN</td>
<td>164</td>
</tr>
<tr>
<td>ORILISSA</td>
<td>183</td>
</tr>
<tr>
<td>ORKAMBI</td>
<td>335</td>
</tr>
<tr>
<td>ORLADEYO</td>
<td>80</td>
</tr>
<tr>
<td>ORLISTAT</td>
<td>42</td>
</tr>
<tr>
<td>ORSEROV</td>
<td>182</td>
</tr>
<tr>
<td>ORTIKOS</td>
<td>94</td>
</tr>
<tr>
<td>OSILODROSTAT</td>
<td>413</td>
</tr>
<tr>
<td>OSIMERTINIB MESYLATE</td>
<td>414</td>
</tr>
<tr>
<td>OSMOLEX ER</td>
<td>29</td>
</tr>
<tr>
<td>OSMOPREP</td>
<td>87</td>
</tr>
<tr>
<td>OTSECONAZOLE</td>
<td>415</td>
</tr>
<tr>
<td>OTEZLA</td>
<td>48</td>
</tr>
<tr>
<td>OXANDRIN</td>
<td>37</td>
</tr>
<tr>
<td>OXANDROLONE</td>
<td>37</td>
</tr>
<tr>
<td>OXABYTA</td>
<td>660</td>
</tr>
<tr>
<td>OXERVATE</td>
<td>111</td>
</tr>
<tr>
<td>OXYCODONE HCL</td>
<td>265</td>
</tr>
<tr>
<td>OXYMETAZOLINE HCL/PF</td>
<td>416</td>
</tr>
<tr>
<td>OXYMETHOLONE</td>
<td>37</td>
</tr>
<tr>
<td>OZANIMOD</td>
<td>417</td>
</tr>
<tr>
<td>OZEMPIC</td>
<td>256</td>
</tr>
<tr>
<td>OZOBAX</td>
<td>70</td>
</tr>
</tbody>
</table>
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

RELTONE ................................................. 646
RELUGOLIX ........................................ 465
RELUGOLIX/ESTRADIOL/NORETHINDRONE ACETATE ............ 466
RELYVRIOS ........................................... 529
REMODULIN ......................................... 628
RETACRIT ............................................ 201
RETEVMO ............................................... 502
RETN ................................................... 15
RETN-A .................................................. 15
RETN-A MICRO ...................................... 15
RETN-A MICRO PUMP ................................ 15
REVATIO (IV) ......................................... 505
REVATIO (SUSPENSION) ................................ 507
REVATIO (TABLET) .................................... 510
REVCovi ............................................... 185
REVLIMID ............................................. 311
REYVOW ............................................... 306
REZLIDIA ............................................. 390
REZUROCK ............................................ 76
RIBOCICLIB SUCCINATE ................................ 468
RIBOCICLIB SUCCINATE/LETRZOLE ......................... 469
RIFAXIMIN ............................................ 470
RILUZOLE SUSPENSION ................................ 472
RIMEPEGANT ......................................... 473
RINVOQ ............................................... 641
RIOCIGUAT ............................................ 475
RIPRETINIB ........................................... 478
RISANKIZUMAB-RZAA ................................ 479
RISDIPLAM ............................................ 481
ROFLUMILAST ....................................... 482
ROPEGINTERFERON ALFA-2B-NJFT ............................... 483
ROSVASTATIN CALCIUM ................................ 569
ROZLYTREK ........................................... 196
RUBRACA .............................................. 484
RUCAPARIB ........................................... 484
RUCONEST ............................................ 99
RUKOBIA ................................................ 242
RUXOLITINIB PHOSPHATE ................................ 485
RUXOLITINIB PHOSPHATE TOPICAL ......................... 487
RUZURGI ............................................... 31
RYDAPT .............................................. 354
RYLAZE ................................................ 53
RYPLAZIM ............................................. 452

S
SABRIL ................................................... 655
SACROSIDASE ........................................ 489
SAIZEN ................................................ 556
SAIZEN-SAIZENPREP ................................. 556
SAJAZIR ............................................... 270
SANDOSTATIN LAR DEPOT .............................. 379
SANTYL ................................................. 126
SARGRAMOSTIM ...................................... 490
SARILUMAB ........................................... 491
SATRALIZUMAB-MWGE ................................. 493
SAXENDA ............................................... 42
SCEMBLIX ............................................ 52
SECUKINUMAB ....................................... 494
SELEXIPAG ............................................ 499
SELINEXOR .......................................... 501
Selpercatinib .......................................... 502
SELUMETINIB ......................................... 503
SEMAGLITIDE ......................................... 42
SEMAGLITIDE (OZEMPIC, RYBELSUS) ...................... 256
SEROSTIM ............................................. 558
SETMELANOTIDE ACETATE ............................ 504
SIGNIFOR ............................................. 423
SILDENAFIL CITRATE (IV)-REVATIO ...................... 505
SILDENAFIL CITRATE (SUSPENSION)-REVATIO ............. 507
SILDENAFIL CITRATE (TABLET)-REVATIO ................ 510
SILIQ .................................................... 92
SIMEPREVIR .......................................... 513
SIMPONI - SQ ....................................... 259
SIMVASTATIN ........................................ 569
SIMVASTATINE 80 ................................... 514
SIMVASTATIN ORAL SUSPENSION ....................... 515
SINUVA (NSA) ........................................ 366
SIPONIMOD ............................................ 516
SIROLIMUS TOPICAL (HYFTOR) ......................... 517
SIRTIURO ............................................... 73
SKYCLARYS .......................................... 397
SKYRIZI .............................................. 479
SKYTOFA ............................................. 330
SMOKING CESSATION ZERO COST SHARE OVERRIDE .... 518
SOAANZ ................................................ 620
SOD PHENYL Butyrat/TAURUSODIOL ......................... 529
SOD PHOSPHATE MBAS/SOD PHOS,DI ...................... 87
SOD PICOSUL/MAG OX/CITRIC AC ........................ 87
SOD SULF/POT CHLORIDE/MAG SULF .................... 87
SODIUM CHLORIDE/NAHCO3/ KCL/PE ....................... 87
SODIUM OXYBATE (LUMRYZ) ............................ 523
SODIUM OXYBATE (XYREM) ............................ 525
SODIUM PHENOL BUTYRATE ...................................... 528
SODIUM, CALCIUM, MAG, POT OXYBATE .................. 520
SODIUM, POTASSIUM,MAG SULFATES ...................... 87
SOFOBUVIR .......................................... 530
SOFOBUVIR/VELPATASVIR ............................ 533
SOFOBUVIR/VELPATASVIR/VOXILAPREVIR ............... 534
SOLARAIZE .......................................... 167
SOLIFENACIN SUCCINATE ............................. 355
SOLRIAMFETOL ...................................... 536
SOMATROPIN .......................................... 542
SOMATROPIN (GENOTROPIN) ............................ 538
SOMATROPIN (NORDITROPIN) ............................ 546
SOMATROPIN (NUTROPIN AQ NUSPIN) ...................... 550

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/26/2023
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page Number</th>
<th>Drug Name</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOMATROPIN (OMNITROPE)</td>
<td>553</td>
<td>TALZOPARIB TOSYLANE</td>
<td>579</td>
</tr>
<tr>
<td>SOMATROPIN (SAIZEN)</td>
<td>556</td>
<td>TALTZ</td>
<td>300</td>
</tr>
<tr>
<td>SOMATROPIN (SEROSTIM)</td>
<td>558</td>
<td>TALZENNA</td>
<td>579</td>
</tr>
<tr>
<td>SOMATROPIN (ZOMACTON)</td>
<td>560</td>
<td>TAMOXIFEN CITRATE</td>
<td>89</td>
</tr>
<tr>
<td>SOMATROPIN (ZORBTIVE)</td>
<td>564</td>
<td>TAPINAROF</td>
<td>580</td>
</tr>
<tr>
<td>SONIDEGIB PHOSPHATE</td>
<td>565</td>
<td>TARCEVA</td>
<td>207</td>
</tr>
<tr>
<td>SORAFENIB TOSYLANE</td>
<td>566</td>
<td>TARGETIN</td>
<td>82</td>
</tr>
<tr>
<td>SOTORASIB</td>
<td>567</td>
<td>TARPEYO</td>
<td>95</td>
</tr>
<tr>
<td>SOTYKTO</td>
<td>161</td>
<td>TASCENSO ODT</td>
<td>234</td>
</tr>
<tr>
<td>SOVALDI</td>
<td>530</td>
<td>TASIGNA</td>
<td>371</td>
</tr>
<tr>
<td>SPARSENTAN</td>
<td>568</td>
<td>TASMELTEON</td>
<td>581</td>
</tr>
<tr>
<td>SPRITAM</td>
<td>319</td>
<td>TAVABOROLE</td>
<td>582</td>
</tr>
<tr>
<td>SPRYCEL</td>
<td>149</td>
<td>TAVALISSE</td>
<td>241</td>
</tr>
<tr>
<td>STATIN ZERO COST SHARE OVERRIDE</td>
<td>569</td>
<td>TAVNEOS</td>
<td>63</td>
</tr>
<tr>
<td>STELARA</td>
<td>647</td>
<td>TAZAROTEONE</td>
<td>15</td>
</tr>
<tr>
<td>STIMUFEND</td>
<td>433</td>
<td>TAZEMETOSTAT</td>
<td>583</td>
</tr>
<tr>
<td>STIRIPENTOL</td>
<td>571</td>
<td>TAZVERIK</td>
<td>583</td>
</tr>
<tr>
<td>STIVARGA</td>
<td>464</td>
<td>TBO-FILGRASTIM</td>
<td>584</td>
</tr>
<tr>
<td>STRESIQ</td>
<td>54</td>
<td>TECFIDERA</td>
<td>170</td>
</tr>
<tr>
<td>STRIANT</td>
<td>593</td>
<td>TECHNIVIE</td>
<td>398</td>
</tr>
<tr>
<td>SUBCUTANEOUS INSULIN PUMP</td>
<td>637</td>
<td>TEDUGLUTIDE</td>
<td>585</td>
</tr>
<tr>
<td>SUBSYS</td>
<td>222</td>
<td>TEGSEDI</td>
<td>284</td>
</tr>
<tr>
<td>SUCRAID</td>
<td>489</td>
<td>TELOTRISTAT</td>
<td>586</td>
</tr>
<tr>
<td>SUNITINIB MALATE</td>
<td>572</td>
<td>TEMODAR</td>
<td>587</td>
</tr>
<tr>
<td>SUNLENCA</td>
<td>310</td>
<td>TEMOZOLOMIDE</td>
<td>587</td>
</tr>
<tr>
<td>SUNOSI</td>
<td>536</td>
<td>TENAPANOR HCL</td>
<td>588</td>
</tr>
<tr>
<td>SUPREP</td>
<td>87</td>
<td>TENOFOVIR DISOPROXIL FUMARATE</td>
<td>460</td>
</tr>
<tr>
<td>SUTAB</td>
<td>87</td>
<td>TIPMETKO</td>
<td>589</td>
</tr>
<tr>
<td>SUTENT</td>
<td>572</td>
<td>TEPOTINIB HCL</td>
<td>589</td>
</tr>
<tr>
<td>SYLATRON</td>
<td>436</td>
<td>TERIFLUNOMIDE</td>
<td>590</td>
</tr>
<tr>
<td>SYLATRON 4-PACK</td>
<td>436</td>
<td>TERIRAPATIDE</td>
<td>591</td>
</tr>
<tr>
<td>SYMDEKO</td>
<td>604</td>
<td>TESAMORELIN</td>
<td>592</td>
</tr>
<tr>
<td>SYMPAZAN</td>
<td>124</td>
<td>TESTIM</td>
<td>593</td>
</tr>
<tr>
<td>SYNAREL</td>
<td>368</td>
<td>TESTOSTERONE</td>
<td>593</td>
</tr>
<tr>
<td>SYNRIBO</td>
<td>391</td>
<td>TESTOSTERONE CYPIONATE</td>
<td>595</td>
</tr>
<tr>
<td>SYPRINE</td>
<td>632</td>
<td>TESTOSTERONE ENANTHATE</td>
<td>597</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TESTOSTERONE UNDECANOATE</td>
<td>599, 601</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TESTOSTERONE UNDECANOATE (TLANDO)</td>
<td>600</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TETRED</td>
<td>351</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TETRABENAZINE</td>
<td>603</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TZACAFTOR/IVACAFTOR</td>
<td>604</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TZEPELUMAB-EKKO (NSA)</td>
<td>606</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TEZSPIRE (NSA)</td>
<td>606</td>
</tr>
<tr>
<td></td>
<td></td>
<td>THALIDOMIDE</td>
<td>608</td>
</tr>
<tr>
<td></td>
<td></td>
<td>THALOMID</td>
<td>608</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIBSOVO</td>
<td>298</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TILGLUTIK</td>
<td>472</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIROSINT</td>
<td>323</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIROSINT-SOL</td>
<td>324</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIZEPATIDE</td>
<td>256</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIVOZANIB HCL</td>
<td>609</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TLANDO</td>
<td>600, 601</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TOBI</td>
<td>610</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TOBI PODHALER</td>
<td>610</td>
</tr>
</tbody>
</table>

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.
STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.

TOBRAMYCIN .......................................................... 610
TOBRAMYCIN IN 0.225% SOD CHLOR .......................... 610
TOBRAMYCIN INHALED ........................................... 610
TOBRAMYCIN/NEBULIZER ........................................ 610
TOCILIZUMAB - SO .................................................. 611
TOFACITINIB CITRATE .............................................. 614
TOLSURA ............................................................... 295
TOLVAPTAN ............................................................ 617
TOPIRAMATE (EPRYPTIA) .......................................... 618
TOREMIFENE CITRATE .............................................. 619
TORSEMIDE ............................................................ 620
TRACLEER ............................................................... 84
TRALOKINUMAB-LDRM ............................................ 621
TRAMADOL HCL ........................................................ 623
TRAMETINIB DIMETHYL SULFOXIDE ............................ 624
TREMFIYA ............................................................... 263
TREPONTINSI ........................................................... 626
TREPONTNIL DIOXAMINE ........................................... 630
TREPONTNIL DPI ....................................................... 626
TREPONTNIL SODIUM ............................................... 628
TRETINOIN ............................................................. 15
TRETINOIN MICROSPHERES ....................................... 15
TRET-X ................................................................. 15
TRIENINE HCL ........................................................ 632
TRIENINE TETRAHYDROCHLORIDE ................................ 633
TRIFAROTENE .......................................................... 15
TRIFLURIDINE/TIPRACLIL ......................................... 634
TRIHEPTANOIN ........................................................ 635
TRIKAFTA ............................................................... 188
TROFINETIDE .......................................................... 636
TRULICITY ............................................................... 256
TRUSELTIQ ............................................................. 281
TRUVADA ............................................................... 460
TUCATINIB ............................................................. 639
TUKYSA ................................................................. 639
TURALIO ................................................................. 444
TYKERA ................................................................. 304
TYMLOS ................................................................. 3
TyrVAYA ................................................................. 651
TYVASO ................................................................. 626

U

UBRELVY ................................................................. 640
UBROGEPAINT ........................................................ 640
UDENYCA ............................................................... 432
UPADACITINIB ......................................................... 641
UPNENQ ................................................................. 416
UPTRAVI ................................................................. 499
URIDINE TRICACETATE ............................................. 645
URSODIOL .............................................................. 646
USTEKINUMAB ........................................................ 647

V

VALBENAZINE .......................................................... 649
VALCHLOR ............................................................. 344
VANDETANIB .......................................................... 650
VARENICLINE TARTRATE ........................................... 651, 651
VECAMYL ............................................................... 342
VELTASSA .............................................................. 424
VEMURAFENIB ........................................................ 652
VENCELEXTA .......................................................... 653
VENETOCLAX .......................................................... 653
VENTAVIS .............................................................. 272
VEOZH ................................................................. 226
VERIGUAT .............................................................. 654
VERKAZIA .............................................................. 134
VERQUO ................................................................. 654
VERZENIO ............................................................... 8
VESICARE LS ............................................................ 535
VIBERI ................................................................. 192
VICTOZA ............................................................... 256
VIEKIRA PAK .......................................................... 400
VIEKIRA XR ............................................................ 400
VIGABATRIN ........................................................... 655
VIGADRONI ............................................................. 655
VIJOICE ................................................................. 28
VIREAD ................................................................. 460
VISMODEGIB .......................................................... 656
VITRAKVI ............................................................... 305
VIVJOA ................................................................. 415
VIZIMPRO .............................................................. 142
VOCLOSPORIN ......................................................... 657
VOGELXO ............................................................... 593
VONJO ................................................................. 419
VONOPIRAZON ........................................................ 656
VOQUEZNA DUAL PAK ............................................ 658
VOQUEZNA TRIPLE PAK ........................................... 658
VOSEVI ................................................................. 534
VOSORITIDE ............................................................ 659
VOTRIENT .............................................................. 425
VOWST ................................................................. 217
VOXELOTOR ............................................................ 660
VOXZOGO ............................................................. 659
VTAMA ................................................................. 580
VITY ................................................................. 446
VUMERITY ............................................................. 171
VYLEESI ............................................................... 90
VYNDAMAX ............................................................ 578
VYNDACEL ............................................................. 578
VYTORIN ............................................................... 514

W

WAKIX ................................................................. 450

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 5/26/2023 Page 674 of 675
Drugs listed in this document does not ensure coverage. Your coverage and/or copayment/coinsurance may vary based on your benefit plan. Please check your plan documents. This document is intended for informational use only and is not intended to replace professional medical advice or treatment, or diagnose, treat, cure, or prevent any disease or medical condition. This document is subject to change.